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ABSTRACT 
 
Unknown mechanisms that cause failures in B cell development can lead to humoral 
immunodeficiencies, autoimmune disorders or B cell malignancies. This thesis 
demonstrates that the endosomal intramembrane cleaving protease signal-peptide-
peptidase-like 2A (SPPL2A) is critical for survival of developing B cells and reveals 
SPPL2A-deficiency as a previously unknown mechanism of B cell loss. Mice with 
an ENU-mutagenesis-induced inactivating mutation in Sppl2a exhibited profound 
humoral immunodeficiency and specifically lacked mature B cells, phenotypically 
mirroring BAFF-deficient mice. Surviving B cells were characterised by abnormal 
endosomal membrane expansions and low surface BAFFR and BCR expression. 
Mature B cells, but not BAFFR and BCR surface levels, could be rescued by over-
expression of the pro-survival protein BCL2, indicating that SPPL2A-deficient B 
cells failed to mature due to a survival defect rather than developmental arrest. 
 
On a molecular level SPPL2A-deficiency blocked the ultimate intramembrane 
proteolytic processing step of CD74 (MHCII invariant chain), causing a dramatic 
build-up of residual 8kD CD74 (p8-CD74) membrane stubs leading to endosomal 
enlargement. The accumulation of p8-CD74 was responsible for the loss of mature B 
cells, as inhibition of p8-CD74 build-up by deletion of CD74 in SPPL2A-deficient 
animals reconstituted mature B cell numbers to levels seen in mice solely deficient in 
CD74, and restored surface BCR and BAFFR expression on B cells. Interestingly, 
endosomal enlargement has been similarly observed in B cells from Cathepsin S-
deficient mice that also accumulate a CD74 degradation product, p10-CD74. Despite 
more severe endosomal expansion in these B cells, they did not exhibit survival 
abnormalities. This finding illustrates the distinct capabilities of p10-CD74 and p8-
CD74 to regulate endosomal biology and B cell survival.  
 
Despite its role in CD74 metabolism, SPPL2A appeared disconnected from the 
classical sequence of endosomal CD74 degradation steps, as p8-CD74 production 
required neither penultimate processing by Cathepsin S nor MHCII-chaperoning. 
Additionally, it was found that p8-CD74 already accumulated in immature B cells 
from the bone marrow of SPPL2A-deficient mice, which contrasted with Cathepsin 
S-deficient mice where CD74 accumulation first occurred in transitional B cells. This 
	   XIII 
indicates that Cathepsin S processes CD74 later than SPPL2A during B cell 
development. 
 
p8-CD74 processing by SPPL2A was logically expected to play a role in other 
CD74-expressing immune cells. However, only CD8- dendritic cell (DC) numbers 
were reduced in SPPL2A-deficient mice, whilst CD8+ DC and pDC subsets, as well 
as macrophages and monocytes, appeared to survive. CD8- DCs showed elevated 
surface MHCII levels, whereas CD8+ DCs were characterised by an MHCII-
chaperoning-dependent 10-fold increase in CD74 surface expression, highlighting 
differences in the wiring of MHCII and CD74 trafficking responses in these DC 
subsets. Functionally, SPPL2A-inactivation interfered with the ability of spleen DCs 
to present antigen on MHCII to CD4+ T cells, but not with MHCI associated cross-
presentation. 
 
In summary, these findings reveal that SPPL2A mediated CD74 intramembrane 
proteolysis is a previously unknown mechanism required for humoral immunity, and 
survival of developing B cells and CD8- DCs. Targeting SPPL2A or CD74 may 
provide new therapeutic avenues for the control of endosome and B cell related 
diseases in the future. 
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1.1 B cell development 
1.1.1 Preamble 
Vaccines effectively safeguard from severe diseases; traditionally by harnessing 
adaptive, humoral B cell immunity (Nutt et al., 2015). Successful development of the 
B lymphoid lineage, antigen recognition and presentation, followed by subsequent 
production of the right type of antibody are absolutely crucial for protection from 
infections. Complex interactions between intrinsic and extrinsic signals normally 
guide B cells through various maturation stages to eventually become functional 
effector cells in peripheral lymphoid organs (Samitas et al., 2010). However, despite 
being one of the most thoroughly studied cell developmental systems (Nutt and Kee, 
2007, Bryder and Sigvardsson, 2010), many steps required for the making of B cells 
are yet to be discovered (LeBien and Tedder, 2008). Numerous failures during B cell 
development we do not understand. They may lead to a lack of immunity in form of 
agammaglobulinaemia, inadvertent self-directed immune responses, or to 
uncontrolled proliferation of B cell precursors during lymphoma genesis (Mackay 
and Rose, 2001, Conley et al., 2009, Rui et al., 2011, Rickert, 2013, Cooper, 2015). 
Mouse ENU mutagenesis is a forward-genetics tool that has been employed in our 
laboratory to discover unidentified genes needed by developing B cells (Nelms and 
Goodnow, 2001). This approach is helping to understand and potentially resolve 
failures in B cell development or to reveal entirely new factors governing the making 
of B lymphocytes.  
 
B cells start their development from pluripotent haematopoietic stem cells (HSC) and 
then advance through defined stages to eventually allow expression of a functional B 
cell antigen receptor in immature B cells, transition into peripheral lymphoid organs 
and eventually join the naïve, mature B cell pool (Figure 1.1). Before birth HSCs 
seed the fetal liver and predominantly turn into slightly self-reactive, innate B1-type 
B cell subsets. Just before birth B cell development commences in the bone marrow 
instead, yielding a differet B2-type of B cell (Li et al., 2015b, Melchers, 2015). The 
significant change in the microenvironment responsible for producing the majority of 
B cell subsets throughout early life indicates that this process is rather flexible in 
general, with drastic environmental changes, such as birth or infection, influencing 
the pathway of becoming a certain type of B cell (Hardy et al., 2007).  
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Figure 1.1: B cell development in mice 
 
Simplified sketch of B cell developmental stages in mice. B 
cells form from common lymphoid progenitors in the bone 
marrow, progressing through their early development as Pre-
Pro, Pro and Pre-B cells, until they express their first B cell 
Receptor (BCR) and exit the marrow as immature cells. In the 
periphery immature B cells complete their development 
through transitional stages (T1 and T2) as they pass through 
the blood, migrate to follicular T cell-B cell borders in the 
spleen and become mature B cells. During development B 
cells are supported through various stimuli to progress, 
needing IL7 signalling in the bone marrow as well as BAFFR 
and BCR signalling in the periphery. 
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For the purpose of this thesis, I focus on B2 B cell development in the bone marrow 
towards naïve, mature follicular type B cells. 
 
1.1.2 Early B cell development 
HSC in the bone marrow are self-renewing and able to differentiate. They form the 
lifelong basis of all haematopoietic cell types, including B cells, as such that mice 
experimentally depleted of all blood cells can be entirely repopulated from a single 
HSC (Spangrude et al., 1988). Progenitor-cell fate tracing experiments show that the 
pathway of differentiation on a single cell level is stochastic (Duffy et al., 2012), yet 
on the level of blood cell population very reproducible subset ratios are generally 
achieved. It was noted that differentiating precursors could randomly loose their 
multi-potency at every step of the way and as a result many lymphoid primed 
multipotent progenitors (LMMP) are committed early to only give rise to one type of 
leukocyte, such as B cells (Naik et al., 2013, Perie et al., 2014). Although we like to 
describe B cell development as regulated and linear process that is guided through 
sequential interplay of transcriptional ‘switches’ and micro-environmental ‘nudges’ 
towards gradual B lineage commitment, the aforementioned implies that the fate of 
an individual developing B cell is directed by a degree of chance, rather than through 
cause and effect. 
 
During haematopoiesis, HSCs differentiate through multiple stages to produce early 
B cell progenitors. HSCs at first develop into multipotent progenitor cells (MPPs), 
then LMMPs, followed by differentiation into common lymphoid progenitors (CLP) 
and eventually reach Pre-Pro and Pro-B cell developmental stages (Nutt and Kee, 
2007, Holmes et al., 2008, Melchers, 2015). At this point the scenes are set for the 
defining steps of early B cell development: Sequential immunoglobulin (Ig) gene 
rearrangement that lead to expression of B cell receptors (BCR) on immature B cells, 
ready to leave their cradle in the bone marrow. 
 
To begin the process of making a functional, non-self reactive and highly specific 
surface bound antigen receptor, developing B cells move along a path of several 
steps or checkpoints, which are each followed by proliferative phases when the 
checkpoints are passed successfully (Clark et al., 2014, Melchers, 2015). 
Differentiating from CLPs, Pre-Pro B cells are the first B lymphoid lineage directed 
precursor, expressing a pan-B cell marker that can be used to select early developing 
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B cells in the bone marrow by flow cytometry, B220 (Hardy et al., 2007). Next, 
further influence of micro-environmental Il-7 signalling and transcriptional feed 
forward regulation through PAX5 and EBF1 largely contribute to suppression of 
alternative lineage fates and promote development to the Pro-B cell stage (Nutt and 
Kee, 2007, Pang et al., 2014). Bias to become a B cell is strong in Pro-B cells, and 
expression of B cell specific surface molecules, such as CD19, CD79a and CD79b 
(Igα and Igβ) and BLNK takes full effect (Hardy et al., 2007, Pang et al., 2014). At 
this stage selected chromatin is opened and increasing protein levels of 
recombination activating gene 1 and 2 (Rag1/2) are expressed to facilitate the first 
step of Ig gene rearrangement (Li et al., 1993, Clark et al., 2014). Early pro-B cells 
join D and J regions of one Ig heavy chain allele first, followed by variable (V) 
region joining to a completed DJ sequence at the late BP-1+ Pro-B cell stage in order 
to successfully transcribe and translate Ig heavy chains (Schatz and Ji, 2011). To 
diversify the BCR repertoire, the creation of Ig-heavy chain is an imprecise process 
that requires quality control of the final product. Late Pro-B cells therefore trial 
assembly of the fresh heavy chain in so called Pre-BCR immunoglobulin-like 
complexes using CD79a, CD79b and surrogate light chains (λ5 and VpreB) as 
preliminary space holder for the actual BCR light chain yet to be made (Clark et al., 
2014, Reth and Nielsen, 2014). The Pre-BCR allows testing of the new heavy chain 
molecule for correct ER-assembly, possibly ligand recognition at the cell surface and 
signal integration downstream of the pre-BCR (Reth and Nielsen, 2014). Success at 
this checkpoint marks the developmental progression to a large, proliferative Pre-B 
cell stage in order to expand cells with useful heavy chain recombination. Following 
cell division large Pre-B cells reach the small Pre-B cell stage and once again 
chromatin is opened and the molecular machinery already employed for heavy chain 
recombination, such as Rag1/2 is produced to allow for rearrangements of the light 
chain gene locus (Clark et al., 2014, Melchers, 2015). V and J light chain regions are 
paired, likely through multiple rounds, until an in-frame product that can translate 
into light chain protein is achieved. Synthesis of Ig-light chain eventually allows 
assembly of a complete B cell receptor complex in the ER, consisting of paired Igµ-
heavy and light chains, as well as CD79a and CD79b (Schatz and Ji, 2011). Finally 
the first IgM B cell receptor is expressed on the cell surface and classifies entry of 
earlier B cell precursors into the immature B cell stage, the final phase of B2 B cell 
development (Chung et al., 2003, Melchers, 2015). 
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1.1.3 Late B cell development 
The newly expressed IgM receptor of immature B cells is tested for self-reactivity 
against antigens present in the bone marrow microenvironment. Immature self-
reactive cells that experience different types of strong BCR signalling and IgM cross-
linking are subjected to various faiths in order to prevent the egression of potentially 
harmful B cell clones from the bone marrow. This process is known as ‘central B cell 
tolerance’ (Goodnow et al., 1990), and mechanisms such as ongoing B cell receptor 
editing of both, Ig-heavy and light chains (Radic et al., 1993, Tiegs et al., 1993, 
Halverson et al., 2004), induction of B cell anergy (Goodnow et al., 1988) or clonal 
deletion through apoptosis (Hartley et al., 1991, Hartley et al., 1993) have been 
described (Manjarrez-Orduno et al., 2009). Anergy is induced in cells that recognise 
low valence antigens (usually small, soluble proteins) with lesser ability to crosslink 
surface IgM, which presumably is analogous to milder auto reactive BCR 
stimulation. This mechanism has been experimentally explored by using transgenic 
mouse models expressing soluble model antigens, such as hen egg lysozyme (HEL), 
and the appropriate model-antigen recognising B cell receptor (i.e. mice hosting 
HEL-transgenic, self-reactive B cells) (Goodnow et al., 2005). At last, mostly non-
self reactive, immature B cells begin to co-express IgD BCR isoforms in the cell 
surface and leave the bone marrow via the blood stream, using S1P1, CXCR5 and 
CCR7 receptors for guidance to reach periarteriolar lymphoid sheaths (PALS) in the 
spleen (Melchers, 2015). 
 
B cells that have just exited the bone marrow are phenotypically distinct from their 
naïve, mature counterparts, and are not yet functionally mature either. These 
immature B cells still undergo a late or transitional phase of development in the 
spleen and are therefore termed transitional B cells. At least two transitional B cell 
stages are recognised, by which the transitional stage 1 (T1) describes B cells that 
almost resemble their immature predecessors from the bone marrow, and the 
transitional stage 2 (T2) designates an intermediate B cell subset ‘en route’ to 
maturity (Loder et al., 1999, Allman et al., 2001). A transitional B cell stage 3 (T3) is 
sometimes proposed as developmental endpoint for B cells that respond poorly to 
antigenic stimulation (Merrell et al., 2006, Teague et al., 2007). Allman and Pillai 
specify one way of experimentally distinguishing transitional and mature B cell 
subsets based on surface expression of various B cell maturation markers, with CD93 
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(AA4.1) expression as transitional B cell hallmark in the periphery (Allman et al., 
2001, Allman and Pillai, 2008). 
 
During transitional B cell development the assembly of pathways associated with 
BCR signalling is gradually achieved, resulting in competence of maturing B cells to 
appropriately respond to encountered antigen in the right microenvironment. This 
process involves increasing protein synthesis of relevant molecules and receptors, as 
well as their posttranslational modification and co-localisation into operative 
signalling complexes, sufficiently stabilising the ‘BCR-signalsome’ in the process 
(Su and Rawlings, 2002, Chung et al., 2003, Cobaleda et al., 2007, Khan, 2009). 
Accordingly, an increasing potency of antigen dependent BCR signalling throughout 
transitional B cell development was observed in mice with a GFP-reporter under the 
control of NUR77, a regulator downstream of the BCR (Zikherman et al., 2012). 
Peripheral T1 B cells tend to respond, similar to immature bone marrow B cells, with 
apoptosis or anergy to strong BCR stimulation (Goodnow et al., 1988, Norvell et al., 
1995, Rolink et al., 1998, Allman et al., 2001, Wang et al., 2007), whereas T2 B cells 
seem to be better at withstanding censoring mechanisms by completing B cell 
maturation, responding to T cell help and up-regulating anti-apoptotic molecules 
(Chung et al., 2002). 
 
These gradual differences between transitional B cell subsets are thought to serve as 
additional selection step (‘peripheral tolerance’) to remove self-reactive B cell clones 
binding to self-antigens that were not displayed in the bone marrow, or cells that for 
other reasons have escaped central tolerance mechanisms (Russell et al., 1991, Su 
and Rawlings, 2002, Petro et al., 2002, Chung et al., 2002, Khan, 2009). The removal 
of self-reactive, transitional B cell clones in the periphery is a major filter in humans 
(Wardemann et al., 2003), but in mice fewer clones are lost from the transitional B 
cell repertoire (Melchers, 2015).  
 
The separate localisation of T1 and T2 B cells in peripheral lymphoid organs also 
seems to fit the notion that T1 B cells are more prone to negative selection than T2 
cells. After T1 B cells arrive in splenic PALS, they are excluded from follicles and 
accumulate at the B cell-T cell border of the white pulp in close proximity to 
phagocytic cells that are well capable of removing larger quantities of apoptotic 
residues. T2 cells on the other hand migrate into B cell follicles due to their gradual 
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up-regulation of CD62L and CXCR5 (Loder et al., 1999), allowing them to access B 
cell survival factors and a new set of follicular dendritic cell associated antigen, 
which is thought to promote positive selection into the mature B cell pool (Su and 
Rawlings, 2002, Chung et al., 2002). Once transitional B cells take up residence 
inside the follicle, their development to become fully-fledged, naïve follicular B cells 
is completed (Rolink et al., 2004, Hardy et al., 2007), and they are ready to 
participate in immune responses to become short-lived plasmablasts, long-lived, 
antibody producing plasma cells (Nutt et al., 2015) or memory B cells (Kurosaki et 
al., 2015). 
 
1.1.4 Survival signals supporting late B cell development 
During development and throughout their life B cells are dependent on external 
signals for survival and maturation. Early B cell precursors in the bone marrow 
already depend on signals through the IL-7R and the pre-BCR for their survival 
(Kitamura et al., 1991, Miller et al., 2002, Reth and Nielsen, 2014). Later, once pre-
B cells make their first functional BCR, they no longer require IL-7 to survive, 
allowing them to migrate to the spleen. Immature B cells are thought to increasingly 
rely on tonic or basal signalling levels through the B cell receptor, which becomes an 
essential lifeline for peripheral B cells as soon as they leave their nursery (Monroe, 
2006). Transitional and mature B cells devoid of the BCR or relevant components of 
its downstream signal transduction pathway, such as CD79a or Syk, fail to survive 
(Cheng et al., 1995, Turner et al., 1995, Turner et al., 1997, Lam et al., 1997, Kraus 
et al., 2004). This means that BCR signal in developing B cells has two contrasting 
effects; it either induces deletion and anergy or is essential for B cell survival and 
their peripheral positive selection into the B cell compartment. In its role as survival 
receptor, tonic BCR signalling is a frequently proposed necessity to B cell life, but 
seems poorly understood (Monroe, 2006). It appears to be unclear what the 
fundamental differences around ‘tonic’ or antigen mediated BCR signal in regards to 
induction and downstream effects on the receiving B cells really are. On one hand it 
is agreed that B cells do not survive transitional maturation in the periphery without a 
basally active BCR (Kraus et al., 2004), yet, too much BCR stimulation by potential 
self-antigens on the other hand induces death (Norvell et al., 1995). ‘Tonic’ BCR 
signal could either be a result of weak interactions and BCR cross-linking with 
encountered self antigen, or be an entirely antigen independent, intrinsic property of 
the BCR and its associated molecules (Monroe, 2006, Schweighoffer et al., 2013). 
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BCR signalling through the antigen receptor-signalling reporter NUR77 was only 
detectable from the T2 stage onwards (Zikherman et al., 2012), indicating that the 
timing of BCR stimulation during B cell development may be decisive for its effect 
on the B cell, rather than the type of BCR stimulation per se. This could possibly be 
due to differences in BCR ‘wiring’ or sequestration at different stages of B cell 
maturity (Chung et al., 2001, Sen, 2006), with BCR signals targeting NUR77 
expression only at a late stage, which coincides with down-regulation of surface IgM 
during transitional B cell development (Zikherman et al., 2012). 
 
BCR activation on the B cell surface is known to induce multiple cytosolic pathways 
in parallel, which include classical or canonical NFκB, PI3K-AKT and RAS-ERK 
signalling (Kurosaki, 1999, Rickert, 2013). In respect of the B cell receptor 
supporting peripheral B cell maturation, the aforementioned tonic signalling through 
PI3K is crucial (Figure 1.2) (Srinivasan et al., 2009). The BCR elicits PI3K activity 
indirectly by phosphorylating CD19 or B cell-PI3K-adaptor protein (BCPA), with 
activated CD19/BCPA then recruiting PI3K. PI3K generates phosphatidylinositol –
triphosphate (PIP3) second messenger molecules from PIP2 precursors, providing a 
pool of PIP3 at the surface membrane. AKT, PDK1 and under certain conditions 
BTK, are important kinases, that bind to PIP3 for activation, with AKT being the 
major downstream mediator of PI3K activity and B cell survival (Werner et al., 
2010, Okkenhaug et al., 2014, Hawkins and Stephens, 2015). Among others, AKT 
keeps the basal levels of pro-apoptotic BCL2-homology domain 3 (BH3-only) 
proteins in check, by controlling their transcription through phosphorylation of 
transcription factors of the FOXO family (Werner et al., 2010). The relevance of 
PI3K mediated FOXO suppression for transitional B cell development was 
confirmed by rescuing BCR-deficient B cell survival either by constitutively 
enforcing PI3K activity or by deleting FOXO1 expression (Srinivasan et al., 2009). 
In the same study BCR deficient B cells could not be rescued by enforcing inhibitory 
NFκB kinase 2 (IKK2) canonical NFκB signalling, indicating that this downstream 
pathway is not sufficient on its own to substitute for the loss of the BCR, despite 
being required for mature B cell survival (Pasparakis et al., 2002a). 
 
Immature B cells in the bone marrow initially express only the IgM isoform of the 
BCR, but then start to co-express IgD on the cell surface as well. IgD up regulation  
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Figure 1.2: BCR and BAFFR crosstalk supports 
transitional B cell development and survival by engaging 
PI3K-AKT and NFκB pathways 
 
Schematic drawing showing how signals from the BCR and 
BAFFR support the survival and development of transitional 
and mature follicular B cells. 
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begins just before immature B cells migrate to the spleen and continues throughout 
transitional development (Chung et al., 2003). The dual expression of IgM and IgD 
on developing B cells is mysterious. Evolutionary preservation of IgD-molecules 
across animal classes strongly advocates the importance of IgD in lymphocyte 
function, but a clear role for IgD in B cell development has been elusive (Geisberger 
et al., 2006, Chen and Cerutti, 2010, Chen and Cerutti, 2011). IgM and IgD are 
translated from the same messenger RNA (mRNA) precursor and the zinc finger 
protein 318 (ZFP318) regulates production of alternative mRNA splice products that 
either code for IgM or IgD (Enders et al., 2014). In the absence of ZFP318 B cells 
cannot express IgD, whereas IgM expression is very high, as all BCR transcripts are 
by default translated into IgM protein. Surprisingly, B cell development in ZFP318 
deficient mice or other mouse models with disrupted IgD expression is normal 
(Nitschke et al., 1993, Roes and Rajewsky, 1993, Enders et al., 2014). Deleting IgM 
and taking the opposite approach to test IgD function, did not provide insight into the 
role of IgD either, as IgD fully substituted for the loss of IgM and allowed IgD-only 
B cells to develop normally (Lutz et al., 1998). Despite compensable roles of IgM 
and IgD in B cell development, it was noted that in IgD-deficient heterozygous mice, 
competitive representation of IgD-lacking B cells was reduced, indicating a survival 
advantage for expressing IgD during B cell development (Nitschke et al., 1993, Roes 
and Rajewsky, 1993), and on a molecular level, that IgD transport to the B cell 
surface seemed to be more efficient than for IgM (Brink et al., 1995). 
 
Tonic BCR signalling is absolutely needed for B cell development and survival in 
the periphery, but does not suffice for this purpose alone: Another crucial factor that 
keeps foremost transitional and mature B cells alive outside the bone marrow is the 
cytokine ‘B cell activating factor’ or BAFF, engaging the BAFF-Receptor (BAFFR) 
on the B cell surface (Schneider et al., 1999, Thompson et al., 2001, Rolink et al., 
2002, Khan, 2009, Tussiwand et al., 2012). BAFF is a tumor necrosis factor (TNF) 
superfamily member cytokine also known as BLyS. BAFF is produced at limiting 
quantities by innate immune cells like neutrophils, monocytes and macrophages, but 
also by dendritic cells (DC) and interestingly follicular dendritic cells, other stromal 
cells and B cells themselves (Mackay et al., 2003). Production of BAFF within the 
the B cell follicle highlights the bolstering cytokine support T2 B cells receive once 
they manage to follicular microenvironment. BAFFR is increasingly expressed on B 
cells from the immature stage in the bone marrow onwards and reaches highest 
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levels on mature follicular B cells (Darce et al., 2007, Rowland et al., 2010). B cells 
compete for access to limited amounts of BAFF, whereby this critical survival factor 
effectively regulates the size of the peripheral B cell pool (Mackay and Schneider, 
2009). Mice deficient of BAFF or BAFFR exhibit a B cell developmental block past 
the T1 transitional stage (Schiemann et al., 2001, Thompson et al., 2001), whereas 
BAFF transgenic mice with elevated circulating BAFF levels have increased 
numbers of mature B cells with a greater proportion of surviving self-reactive clones 
causing systemic lupus like autoimmune pathology in these mice (Mackay et al., 
1999, Khare et al., 2000, Thien et al., 2004). It has been shown that self-reactive B 
cells are more dependent on BAFF for their survival (Lesley et al., 2004), which 
explains why overabundance of BAFF particularly facilitates survival of self-antigen 
reactive B cells and drives autoimmune pathology. This finding also highlights how 
limited availability of BAFF provides a selective mechanism to delete self-reactive B 
cells during development by ‘BAFF-starvation’ of the most susceptible B cell clones. 
 
BAFF cytokine is usually released as a trimer, consequently binding three closely 
approximated BAFFRs on the B cell surface, which in turn recruit downstream 
signalling molecules to the receptor complex (Figure 1.2): TNF receptor associated 
factors 2 and 3 (TRAF2 and TRAF3) bind the NFκB inducing kinase (NIK, more 
recently known as MAP3K14) in the B cell cytoplasm and constantly facilitate NIK 
degradation when BAFF is absent. Upon BAFF to BAFFR binding, TRAF3 is drawn 
to associate with the cytoplasmic BAFFR-tail, which in turn initiates TRAF2 to 
follow and target TRAF3 for degradation, so that BAFFR signalling is ended 
(Mackay and Schneider, 2009). As a result NIK protein perseveres for longer, 
allowing it together with the inhibitory NFκB kinase 1 (IKK1) to induce cleavage of 
p100 (NFκB2). The shortened p100 molecule, now p52, localises as activated 
transcription factor after dimerisation with RELB into the nucleus and thereby 
stimulates target gene expression of the alternative, non-canonical or non-classical 
NFκB pathway (Senftleben et al., 2001, Claudio et al., 2002, Kayagaki et al., 2002, 
Siebenlist et al., 2005, Rickert et al., 2011). BAFFR also signals via the kinases 
PI3K, AKT1 and PDK1 to activate mTOR complexes, which further regulate B cell 
survival and growth (Patke et al., 2006, Woodland et al., 2008, Baracho et al., 2011). 
In combination, B cell survival through BAFFR mediated non-classical NFκB and 
PI3K activation is thought to hinge on sustained expression of the anti-apoptotic 
BCL2-protein family member MCL1, which opposes the effects of BIM, a mediator 
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of intrinsic B cell apoptosis (Opferman et al., 2003, Woodland et al., 2008, Mackay 
and Schneider, 2009). Additional ways through which BAFFR signalling supports 
peripheral B cell survival are reviewed by Ranjan Sen (Sen, 2006). Importantly, 
deletion of IKK1 in CD19 expressing B cells that had not yet commenced 
transitional B cell development, did not block T1 to T2 B cell maturation (Jellusova 
et al., 2013). This was surprising, as IKK1 was regarded as the main signalling factor 
downstream of the BAFFR, and BAFFR signalling was known to be required for 
transitional B cell development. This finding indicated that BAFFR signal could 
sustain B cell maturation through downstream pathways other than IKK1 activation 
(Jellusova et al., 2013). Indeed, the B cell developmental block in BAFF deficient 
mice could be rescued by disrupting function of the PI3K inhibitor PTEN, suggesting 
a role of BAFFR signal for constant PIP3 provision in maturing B cells through 
driving PI3K activity (Jellusova et al., 2013). These findings contradict earlier work 
in which IKK1 deficient fetal liver cells did not support B cell development past the 
T1-T2 stage upon reconstituting of sub-lethally irradiated mice (Kaisho et al., 2001). 
Since Jellusova and co-workers used a CD19-cre system to delete IKK1 in 
developing bone marrow cells, and Kaisho et al. used IKK1-deficient fetal liver cells 
to reconstitute B cell development, differences in BAFFR-signalling between fetal 
liver and normal bone marrow derived B cells may be responsible for this 
discrepancy. 
 
Studies of B cell maturation in mouse models that disrupt one or multiple 
components of the BCR, BAFFR and relevant downstream pathways were 
complemented by more recent ‘adding back’ experiments in attempts to rescue BCR 
or BAFF deficiency. These studies produced a picture of considerable crosstalk 
between signalling pathways of the BCR and BAFFR in supporting mature B cell 
survival and development (Figure 1.2) (Cancro, 2009). Firstly, it appears that both, 
BCR and BAFFR activate PI3K and AKT to reduce the production of pro-apoptotic 
proteins, such as BIM, BAX or BAK by turning off their FOXO driven gene 
transcription. Keeping apoptosis induction at bay seems to be the essential role of 
tonic BCR and BAFFR signal during transitional B cell development. Secondly, 
BCR and BAFFR drive the NFκB facilitated expression of pro-survival proteins, 
such as BCL2 or MCL1, by activating the BCR linked canonical or BAFFR linked 
alternative NFκB pathways. Overall signalling through both, PI3K and NFκB, is 
needed for successful B cell maturation, and one cannot compensate for the other, as 
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loss of relevant PI3K isoforms (Clayton et al., 2002, Okkenhaug et al., 2002, 
Ramadani et al., 2010, Okkenhaug et al., 2014), or canonical and alternative NFκB 
pathway components interfere with late B cell development at varying degrees 
(Gerondakis and Siebenlist, 2010, Kaileh and Sen, 2012, Gardam and Brink, 2014, 
Sasaki and Iwai, 2015). Sufficient activation of PI3K and AKT to prevent B cell 
apoptosis normally requires simultaneous input from the BCR and BAFFR, whereby 
the BAFFR appears to contribute by directly phosphorylating components of the 
BCR complex, possibly upstream of IKK1 mediated NFκB2 processing (Okkenhaug 
et al., 2014). The loss of PI3K signal through removal of the BCR or BAFFR can be 
rescued by adding back tonic PI3K activation, indicating that this pathway requires 
dual survival receptor input (Srinivasan et al., 2009, Jellusova et al., 2013). 
Alternatively, strong canonical NFκB stimulation can compensate for the loss of 
BAFFR-contribution to PI3K activation and the sole PI3K activation from the BCR 
suffices then to achieve B cell survival (Sasaki et al., 2006). In this situation, strong 
canonical NFκB signal also offsets the loss of BAFFR mediated activation of the 
alternative NFκB pathway and B cells developed normally (Sasaki et al., 2006). This 
canonical NFκB driven compensation for the loss of BAFFR can be seen in line with 
the ability of canonical NFκB transcription to arm the alternative NFκB pathway by 
up regulating the expression of p100 (NFκB2) and BAFFR molecules (Smith and 
Cancro, 2003, Stadanlick et al., 2008). Further downstream, missing survival signals 
from the BAFFR can be replaced by transgenic over-expression of the pro-survival 
protein BCL2 (Tardivel et al., 2004, Rahman and Manser, 2004, Sasaki et al., 2004), 
interestingly compensating as well for the concomitant loss of PI3K stimulation in 
BAFFR deficient B cells. This is only partially true for the removal of the BCR, as 
BCL2 overexpression only delayed the loss of BCR deficient B cells in the periphery 
(Strasser et al., 1994, Lam et al., 1997), suggesting that the BCR produces a 
comparably greater proportion of PI3K signal as opposed to the BAFFR. In other 
words, BCL2 overexpression appears to be unable to compensate for the loss of 
BCR-derived PI3K signal. Taken together, a model of joint BCR and BAFFR 
signalling to support peripheral B cell development and survival via PI3K-AKT and 
NFκB is emerging, but despite an increasing interest in B cell survival to discover 
more specific drug targets against B cell malignancies and autoimmunity, our current 
knowledge about these pathways and proteins essential for B cell development 
remains fragmentary (Honigberg et al., 2010, Navarra et al., 2011, Rickert, 2013). 
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1.2 Roles for CD74 in B cells 
1.2.1 A brief introduction to CD74 
CD74, also known as MHC class II invariant chain, Ii or just invariant chain, is a 
type II single pass transmembrane protein with a well established role in MHC class 
II antigen presentation, and an enigmatic influence on B cell development and 
survival. CD74 was discovered in 1979 as third or ‘invariant chain’ across diverse 
genetic backgrounds (hence its name) that is associated with the two polymorphic 
chains, α (35kD) and β (28kD), of MHCII (Jones et al., 1979). In the following 
paragraphs I will give an overview of CD74’s basic molecular characteristics and 
then introduce various functions of CD74. Whilst focussing here on the role of CD74 
in murine B cells, it has to be said that much of what we know about this protein was 
investigated in other types of cells and models that will not be exhaustively 
mentioned here, but certainly lend themselves for reasonable extrapolation to 
understand how CD74 generally behaves in B lymphocytes. 
 
1.2.2 CD74 expression and molecular characteristics 
Due to its intimate relationship with MHC class II in the immune system, CD74 
expression is largely restricted to MHCII expressing professional antigen presenting 
cells, which are B cells, dendritic cells (DC), the monocyte-macrophage lineage and 
thymic epithelial cells (Landsverk et al., 2009). In these cells CD74 and MHCII α 
and β chains are amongst the most abundantly transcribed and translated membrane 
proteins, with CD74 being made even in excess of MHCII (Kvist et al., 1982, 
Machamer and Cresswell, 1982, Machamer and Cresswell, 1984, Lipp and 
Dobberstein, 1986b, Nguyen and Humphreys, 1989, Marks et al., 1990, Kampgen et 
al., 1991, Landsverk et al., 2012). For a simplified comparison, the Immunological 
Genome Project ‘ImmGen’ (immgen.org) reports average mRNA expression levels 
of Cd74 in follicular B cells at around 11800 arbitrary units (A.U.), whereas one of 
the most plentiful lymphocyte surface molecules known, CD45 (Ptprc), scores 5270 
A.U. in follicular B cells and 4600 A.U. in CD4+ T cells from the spleen (Zamoyska, 
2007, Heng et al., 2008). Cd74 expression is also seen in other cells of the body after 
induction by interferon-γ and has been identified as aberrantly expressed survival 
receptor in inflammatory diseases, such as cancers, autoimmune and metabolic 
disorders, as well as chronic infections (Pober et al., 1983, Steimle et al., 1994, Stein 
et al., 2007, Borghese and Clanchy, 2011, Grieb et al., 2014). The master regulator of 
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MHCII gene expression and genes associated with antigen presentation, including 
CD74, is the class II transactivator, CIITA (Reith et al., 2005). The expression of 
MHCII is commonly used as indicator for CIITA activity and expression of MHCII 
related proteins like CD74, despite their gene location on separate chromosomes 
(Collins et al., 1984, Ting and Trowsdale, 2002, Masternak and Reith, 2002, Boss 
and Jensen, 2003, Reith et al., 2005). Nevertheless, situations have been observed 
during which CD74 is continually produced, whereas MHCII expression was shut 
down during DC maturation (Nordeng et al., 1998, Landsverk et al., 2012), 
indicating that CD74 expression can be independently regulated. Developing B cells 
are thought to initiate BAFF mediated expression of MHCII, and presumably CD74, 
at the immature stage, just before leaving the bone marrow (Sproul et al., 2000, 
Bossen et al., 2008). Throughout transitional B cell development MHCII expression 
is continuously increased and B cells gain the ability to present antigen and interact 
with helper T cells (Allman et al., 2001, Chung et al., 2003, Monroe et al., 2003). 
MHCII and associated gene expression is further increased in activated B cells (Reith 
et al., 2005).  
 
Following CIITA induced Cd74 gene transcription, CD74 is synthesised in the ER 
whilst its N-terminal tail is translocated back onto the cytosolic side of the ER 
membrane, and thereby gives CD74 its typical single pass type II transmembrane 
topology (Lipp and Dobberstein, 1986b). Alternative splicing of Cd74 mRNA results 
in the synthesis of two CD74 isoforms in mice, which based on their molecular 
weight are designated as p31 and p41. Compared to p31, p41 is spliced to include an 
additional exon 6b and a resulting cysteine-rich 64 amino acid sequence that has 
been shown to inhibit activity of the endosomal protease Cathepsin L (Koch et al., 
1987, Fineschi et al., 1996, Guncar et al., 1999). In humans two additional CD74 
isoforms exist. Human p33 and p41 are homologous to murine p31 and p41 
respectively. In addition to mice, both isoforms can be generated using an alternative 
initiation site for translation, which adds an RxR ER retention motif containing a 16 
amino-acid extension to their N-terminus (Strubin et al., 1986a, O'Sullivan et al., 
1987). This results in synthesis of four CD74 isoforms in humans, p33, p35, p41 and 
p43, as opposed to two isoforms in mice, p31 and p41. In both mouse and human B 
cells, the corresponding p31 and p33 isoforms are predominantly made and exceed, 
at over 80% production, the protein levels of minor CD74 isoforms by far (Strubin et 
al., 1986b, Strubin et al., 1986a, Yamamoto et al., 1985). High levels of conservation 
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in the additionally spliced exon 6b that distinguishes p41 from p31, indicates that 
expression of p41 is necessary to fulfil an important role (Koch et al., 1987, Fortin et 
al., 2013). However, although different purposes for CD74 isoforms have been 
proposed (Lotteau et al., 1990, Naujokas et al., 1993, Guncar et al., 1999), in vivo 
functions for different mouse and human isoforms have been difficult to establish. 
CD74 deficient mice were used as ideal environment in which CD74 variants, 
including human p35 (Geneve et al., 2012a, Geneve et al., 2012b, Bergmann, 2012), 
have been systematically ‘added back’ to probe for their distinct functions. These 
experiments showed that all CD74 isoforms largely compensate for each other in 
vivo, and that this was independent of the CD74 associated MHCII haplotype 
(Naujokas et al., 1995, Shachar et al., 1995, Takaesu et al., 1995, Takaesu et al., 
1997). 
 
As simple, single pass type II transmembrane protein the CD74 molecule can be 
divided into three parts; a 29 amino acid N-terminal or cytosolic tail (1-29), a 26 
amino acid transmembrane domain (30-55) and a 160/224 residue long luminal 
domain (56-215, p31 or 56-279, p41) (Lipp and Dobberstein, 1986b, Koch et al., 
1987). Use of the highly specific N-terminal CD74 antibody IN1 was instrumental in 
unravelling membrane orientation of CD74 in murine B cells (Koch et al., 1982, 
Lipp and Dobberstein, 1986b). Each of the three CD74 sections contains features that 
are relevant for the function of CD74 (Figure 1.3). The N-terminal cytosolic CD74 
domain includes leucine based endosomal targeting motifs in positions 7 and 17, that 
also facilitate rapid CD74 internalisation from the cell surface (Lotteau et al., 1990, 
Bakke and Dobberstein, 1990, Pieters et al., 1993, Bremnes et al., 1994, Pond et al., 
1995, Zhong et al., 1997), and a single cysteine residue in position 27 as 
palmitoylation site that might facilitate membrane fusion events (Koch and 
Hammerling, 1985, Koch and Hammerling, 1986, Koch, 1988). The transmembrane 
domain resembles an α-helical structure that is thought to facilitate trimerisation of 
CD74 molecules (Marks et al., 1990, Amigorena et al., 1995, Cresswell, 1996, Motta 
et al., 1995, Motta et al., 1997, Ashman and Miller, 1999). The CD74 
transmembrane domain also contains a possible RxxL degradation motif at position 
29 to 32, an endosomal targeting motif and a putative triple-leucine intramembrane 
signal sequence cleavage site at position 42 (Lipp and Dobberstein, 1986a, Odorizzi 
et al., 1994, Frauwirth and Shastri, 2001, Matza et al., 2002a). 
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Figure 1.3: Molecular structure of murine CD74 
 
A. Schematic drawing of murine CD74 molecular structure designating 
functionally relevant motifs, protein segments and posttranslational 
modifications mentioned in the text. B. Illustration of 3-dimensional association 
between the p31 isoform of CD74 and MHCII α and β chains to form 
nonameric transmembrane complexes. Modified from (Cresswell, Cell, 1996). 
C. Schematic diagram of CD74 processing steps and products, showing 
estimated molecular weights of CD74 intermediates and proteases involved. 
TM, Transmembrane domain; CLIP, Class II associated invariant peptide; CS, 
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and 41kD murine CD74 isoforms; p8-p22; ~8-22kD C-terminally degraded N-
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p31 
p22 
C 
103 
Trimer CLIP TM 
p41 Exon 
N 
p18 
p10 
p8 
p41 
Aspartic proteases 
Cysteine proteases 
11.6 kD 
Cysteine proteases 
9.3 kD 
Cat S Cysteine protease 
Lumen 
C CD74 
kD 
B 
α  β  
p31  
TM 
Cytosol 
CLIP  
Trimer 
N N N 
C C C 
Lumen 
Luminal view of 
nonameric complex 
CD74-MHCII complex 
Lumen 
N- -C 
A 
L * RxxL 
C16 
Ψ Ψ CS 
LLL 
P 
L *
30 55 
Ψ Ψ 
86 ~192 215aa 
201 
Trimer CLIP 
Cytosol 
42 
p41 Exon 6b 
104 
TM 
CD74 
~118 
279aa p41 
p31 
	   19 
The luminal or C-terminal CD74 domain is equally rich in functionally important 
features. An amino acid region between position 86 and 104 occupies the peptide-
binding groove formed between the α and β chains of MHCII and is known as the 
class II associated invariant chain peptide or CLIP (Freisewinkel et al., 1993, 
Romagnoli and Germain, 1994, Ghosh et al., 1995, Stumptner and Benaroch, 1997). 
Further along, towards the CD74 C-terminus and flanking the CLIP-region on the 
other side, a luminal α-helical region between amino acids 118 and 191 also 
facilitates trimerisation of CD74, similar to the transmembrane domain on the N-
terminal side of CLIP, thereby giving CD74 two regions that support trimer 
assembly and help structure trimerised CD74 (Bijlmakers et al., 1994, Cresswell, 
1996, Gedde-Dahl et al., 1997, Ashman and Miller, 1999, Landsverk et al., 2009). 
Posttranslational modifications such as N-linked glycosylation in positions 113 and 
119 (Koch et al., 1987), and others have been described (Machamer and Cresswell, 
1982, Machamer and Cresswell, 1984, Cresswell, 1992, Newcomb et al., 1996). 
Inclusive splicing of exon 6b in the p41 isoform adds at position 192 the 
aforementioned 64 ammino acid segment, which is homologous to thyroglobulin 
domains (Koch et al., 1987), contains two more N-linked glycosylation sites and a 
serine residue in position 201 that is an acceptor site for the glycosaminoglycan 
chondroitin sulphate (CS) (Miller et al., 1988, Naujokas et al., 1993, Arneson and 
Miller, 2007). 
 
Much of the interest revolving around the CD74 structural features listed above is 
due to its close relationship with the polymorphic MHCII α and β chains in antigen 
processing and presentation. CD74 trimers non-covalently associate as nonameric 
complexes with three MHCII α and β chain pairs and CD74s described molecular 
features determine how CD74 and MHCII complexes are shaped (Roche et al., 1991, 
Cresswell, 1996). A single CD74 chain associates with a MHCII α and β chain pair 
in two points of contact that are located inside a 10kD N-terminal CD74 fragment 
known as p10 (Blum and Cresswell, 1988). Those two contact points have been 
shown to allow CD74-MHCII association independently of one another; one is the 
transmembrane domain, including possibly the cytosolic tail (Smiley et al., 1996, 
Castellino et al., 2001), and the other is the CLIP region of CD74 (Marks and 
Cresswell, 1986, Park et al., 1995, Newcomb et al., 1996, Landsverk et al., 2009). 
Three CD74-MHCII complexes, each consisting of CD74, α and β chain, are joint 
together using the CD74 transmembrane and C-terminal trimerisation domains as 
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hinges in a backbone. The result is a nonameric CD74-MHCII complex in which 
centrally trimerised CD74 molecules arch across the peripherally arranged MHCII-
peptide binding grooves formed between each α/β chain-pair and re-join in the C-
terminal trimerisation domain much like the closed petals of a tulip (Figure 1.3B) 
(Roche et al., 1991, Cresswell, 1996). The affinity between CD74 and MHCII 
molecules varies greatly depending on polymorphisms in the peptide binding groove 
of the MHCII molecule, which therefore specifically affects the affinity at this CLIP-
MHCII contact point (Avva and Cresswell, 1994, Sette et al., 1995, Malcherek et al., 
1995, Takaesu et al., 1997). Classical MHCII molecules are distinguished as I-A and 
I-E subclasses in mice with different polymorphic haplotypes in different genetic 
backgrounds of inbred mouse strains, and CD74-CLIP binding affinity to MHC class 
II haplotypes can be ranked from high to low in the following order; I-Ad, I-As, I-Ab, 
I-Ek, I-Ed and I-Ak, whereby the range of binding affinity between the strongest and 
weakest CLIP-CD74 binding haplotype or subclass is over 1000-fold (Sette et al., 
1995, Liang et al., 1995, Bikoff et al., 1995). Apart from CD74’s historically 
prominent role in binding MHC class II molecules, it has more recently emerged to 
have an even broader influence in coordinating antigen presentation and related cell 
biology overall, including reports of CD74 chaperoning and association with MHC 
class I (Sugita and Brenner, 1995), CD1 (Kang and Cresswell, 2002), Fc-γ receptors 
(Ye et al., 2008), Toll Like Receptor 7 (Tohme and Manoury, 2015), and the BCR 
(Hauser and Lindner, 2014). 
 
1.2.3 A role for CD74 in B cell antigen presentation 
1.2.3.1 Transport of antigen-cargo into the MIIC 
B cells are professional antigen presenting cells and express high levels of CD74 and 
MHCII to present typically exogenous or extracellularly derived peptides on MHC 
class II molecules to CD4+ T cells, although bi-directional crossover with other 
antigen presentation pathways exists. CD74 plays a central role in MHCII mediated 
antigen presentation, which can be divided into a sequence of steps that follow 
antigen from acquisition, uptake, processing into small immunogenic peptides, 
loading onto MHCII molecules, through to trafficking of MHCII-peptide complexes 
to the cell surface for presentation to CD4+ T cells. Since the discovery of CD74’s 
role in MHCII antigen presentation about 25 years ago (Stockinger et al., 1989), this 
process has been recognised to be at the heart of pathogen recognition and 
discrimination and its current, fundamental relevance for appropriate and long-
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lasting immunity is reflected in numerous excellent reviews on different aspects of 
MHCII antigen presentation and the involvement of CD74 (Chapman, 1998, Vyas et 
al., 2008, Neefjes et al., 2011, Clark et al., 2011, Basha et al., 2012, Yuseff and 
Lennon-Dumenil, 2013, Mantegazza et al., 2013, Blum et al., 2013, Avalos and 
Ploegh, 2014, Schuette and Burgdorf, 2014, Roche and Furuta, 2015). As opposed to 
dendritic cells or macrophages, B cells usually seize antigen that is specifically 
recognised by their BCR in a process referred to as receptor mediated endocytosis 
into clathrin-coated vesicles (Clark et al., 2011), although non-specific antigen 
uptake pathways exist. B cells capture antigen either as a soluble particle or immune 
complex diffusing through the liquid around them, or more often, B cells actively 
extract tethered antigen from the surface of follicular dendritic cells, macrophages 
and dendritic cells associated with B cell follicles during close cell-cell interactions 
referred to as immunological synapses (Batista and Harwood, 2009, Batista et al., 
2001, Kuokkanen et al., 2015).  
 
To produce MHCII-peptide complexes that can be presented to CD4+ T cells, B cells 
have to move MHCII molecules and antigenic peptides into the same cellular 
compartment (Figure 1.4) (Villadangos et al., 1999, Landsverk et al., 2009). On one 
hand antigen is captured by the BCR on the cell surface, and on the other hand 
MHCII molecules are synthetised into the membrane of the endoplasmic reticulum, 
separating BCR-antigen complexes from most MHCII molecules. B cells therefore 
employ a well synchronised mechanism that converges BCR-antigen complexes 
from the cell surface and MHCII molecules from the ER or other sites of the resting 
B cell into specialised vesicles that contain MHCII molecules and are commonly 
identified by the late endosomal membrane protein 1 (LAMP1) (Clark et al., 2011, 
Schnyder et al., 2011). This endosmal compartment is the site of antigen processing 
and loading onto MHCII molecules and is known as the MHC class II compartment 
or MIIC (Pieters et al., 1991, Lamb et al., 1991, Tulp et al., 1994, Amigorena et al., 
1995, Yuseff and Lennon-Dumenil, 2013). The pacemaker of this well aligned 
process is the BCR and signals transmitted into the B cell upon antigen binding 
stimulate clathrin-mediated BCR endocytosis and the formation of late endosomal 
MIIC vesicles in the cytosol, the site of antigen processing and MHCII peptide 
loading (Siemasko et al., 1998, Zimmermann et al., 1999, Lankar et al., 2002). BCR 
signalling and clathrin-mediated endocytosis to engulf antigen are inherently  
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connected processes to activate the B cell and fulfil their role as antigen presenting 
cell en route to humoral immunity. Successful endocytosis depends on surface BCR 
signalling to prepare the endosomal pathway and assemble the endocytic machinery 
(AP2, clathrin and actin) that is thought to remove only the major proportion of non-
phosphorylated antigen-BCR complexes, whereas a small proportion (<10%) of 
phosphorylated BCRs remain at the cell surface for immune synapse stabilisation 
(Hou et al., 2006, Clark et al., 2011). Nevertheless, also internalised antigen-BCR 
complexes aggregate a signalsome and continue to signal and activate the B cell 
from the vesicular membrane until they reach the MIIC (Chaturvedi et al., 2011). 
This shows that BCR endocytosis is not only needed for transport of antigen, but also 
for sustained signals from the BCR (Chaturvedi et al., 2011, Chatterjee et al., 2012, 
Avalos and Ploegh, 2014). Valency of the encountered antigen also greatly 
influences the B cell response, as it essentially determines whether BCR signalling 
has sufficient strength to drive antigen processing and presentation (Kim et al., 2006, 
Avalos et al., 2014, Avalos and Ploegh, 2014). The exact mechanism of how 
internalised BCR-antigen cargo traffics to the MIIC is not known, but BCR 
downstream signals through BTK and SYK seem to facilitate rearrangements of the 
actin-filament cytoskeleton and a general model of ESCRT mediated BCR-CD79β 
ITCH-ubiquitinylation dependent sorting towards the late endosomal pathway might 
apply (Zhang et al., 2007, Clark et al., 2011, Yuseff and Lennon-Dumenil, 2013). It 
has also been observed that some of the internalised antigen-BCR complexes are 
stored in non-terminal lysosomal vesicles, presumably to build an intracellular pool 
of antigen for sustained antigen presentation and to possibly contribute to B cell 
memory (Gondre-Lewis et al., 2001). 
 
1.2.3.2 Transport of CD74-MHCII complexes into the MIIC 
On the opposite end of the B cell MHCII antigen presentation pathway CD74 enters 
the scene, as it guides ER synthesised MHCII molecules to meet the advancing BCR-
antigen complexes in the endosomal MIIC compartment (Figure 1.4) (Rocha and 
Neefjes, 2008, Landsverk et al., 2009, Neefjes et al., 2011, Garstka and Neefjes, 
2013). The mode of antigen acquisition by B cells seems to determine from where in 
the B cell MHCII molecules are sourced for MHCII-peptide loading. As mentioned 
above, in most scenarios B cells capture fixed antigen from the surface of other cells 
via the BCR, but B cells are also capable of taking up soluble particles by 
macropinocytotosis that bypasses the BCR. If the BCR and its downstream signalling 
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pathways are involved freshly synthetised MHCII-CD74 complexes from the ER are 
recruited and loaded with peptides in the MIIC, whereas BCR-independent antigen 
uptake does not trigger synchronised formation of the MIIC compartment and 
MHCII molecules abundantly present on the resting B cell surface are recruited for 
peptide loading, as an exception, likely to a slightly different endosomal 
compartment (Forquet et al., 1999, Zimmermann et al., 1999, Roche and Furuta, 
2015).  
 
CD74 begins its involvement with MHCII molecules in the ER, their birthplace. 
Following synthesis into the ER membrane, three CD74 molecules adopt a trimeric 
conformation and then act as a chaperone to help assemble three MHCII α and β 
chains to adopt the nonameric CD74-MHCII complex described above (Roche and 
Cresswell, 1990, Lamb et al., 1991). The trimeric CD74 scaffold does not necessarily 
need to support three MHCII α and β chain-pairs, but might only associate with one 
or two MHCII molecules (Ashman and Miller, 1999). In fact, reflected by its high 
mRNA expression levels in antigen presenting cells, CD74 is synthetised in greater 
quantities than MHCII α and β chains (Kvist et al., 1982, Machamer and Cresswell, 
1982, Machamer and Cresswell, 1984, Lipp and Dobberstein, 1986b, Nguyen and 
Humphreys, 1989, Marks et al., 1990, Kampgen et al., 1991, Landsverk et al., 2012), 
and as such most auto-trimerised CD74 is likely paired with fewer than three MHCII 
molecules or even none at all (Cloutier et al., 2014, Cresswell and Roche, 2014). 
CD74 associates with MHCII in the ER by occupying and blocking the MHCII 
peptide-binding groove, thereby preventing MHC class II molecules from 
prematurely binding and accidentally presenting peptide sequences that occur as 
intermediates during biosynthesis of other self-proteins in the ER (Germain, 2011). 
MHCII haplotypes with lower binding affinity to CD74 therefore predispose their 
bearer for autoimmunity (Busch et al., 2005).  
 
Following assembly, CD74 guides the CD74-MHCII complexes to leave the ER, by 
entering the secretory pathway for membrane proteins (Elliott et al., 1994). This 
pathway represents a default biosynthetic route via the golgi apparatus and trans-
golgi network (TGN) towards the cell surface membrane and is thought to be the 
way most lyso-endosomal membrane proteins (LMPs) travel initially. From the 
surface membrane LMPs then follow the endocytic pathway to reach their 
destination in endosomal membranes, however direct pathways from the TGN to the 
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endolysosomal membrane system exist as well (Saftig and Klumperman, 2009). For 
CD74-MHCII complexes it is still unclear whether they travel via the surface 
membrane or directly from the TGN to reach the MIIC (Landsverk et al., 2009). The 
endosomal targeting motifs of the CD74 cytoplasmic tail non-covalently bind the 
adaptor proteins 1 or 2 (AP1 or AP2) to facilitated clathrin-mediated vesicle 
budding, either from TGN membranes to endosomes regulated by AP1 or from the 
cell surface along the endocytic pathway, which is controlled by AP2. Yet, it has 
been found that the intracellular MHCII content in B cells could be generated from 
the rate of CD74 surface internalisation alone (Hansen et al., 1996), suggesting that 
CD74-MHCII complexes reach the endosomal compartment via surface membrane 
travel associated with AP2 (Roche et al., 1993, McCormick et al., 2005, Dugast et 
al., 2005, McMahon and Boucrot, 2011). Additionally, it was shown that the CD74-
cytoplasmic tail can bind the actin motor protein myosin II upon BCR activation and 
facilitates transport of MHCII containing vesicles to meet BCR-antigen complexes in 
the MIIC (Vascotto et al., 2007). Collectively, CD74 chaperones MHCII molecules 
and, driven by BCR signals, guides them into the MIIC to encounter endocytosed 
BCR-antigen cargo. 
 
1.2.3.3 Stepwise degradation of CD74 and antigen peptide loading in the MIIC 
As the BCR carries antigen from the cell membrane towards the MIIC compartment 
potentially using similar pathways as surface CD74-MHCII complexes (Hauser and 
Lindner, 2014), it is perceivable that CD74-MHCII complexes meet antigen already 
in earlier endocytic vesicles. Early endosomes progressively mature as they move 
along the endocytic pathway, which means that their luminal and membrane 
composition gradually changes and for instance membrane proton pumps (V-type H+ 
ATPases) lower the luminal pH (Landsverk et al., 2009, Saftig and Klumperman, 
2009, Bird et al., 2009, Saftig et al., 2010). Overall different proteases with varying 
pH requirements for their activity in antigen processing are distributed 
heterogeneously along the endocytic route, or even in entirely different antigen 
uptake pathways such as compartments formed by autophagy. This set up seems to 
allow for a diverse generation of antigen peptides from a broad spectrum of sampled 
antigens that can be presented on MHCII (Chapman, 2006, Bird et al., 2009). Once 
CD74-MHCII complexes and BCR-bound antigen reach the MIIC, a late endosomal 
environment with a pH of 4-5 facilitates full activation of pH-dependent luminal 
aspartic and cysteine proteases thereby creating a proteolytic compartment suitable 
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for processing of arriving antigen (Honey and Rudensky, 2003, Hsing and Rudensky, 
2005, Bird et al., 2009). MHCII molecules cannot be loaded with antigenic peptide 
as long as the CLIP region of CD74 occupies the MHCII peptide-binding groove. 
Therefore, not only antigen is degraded to presentable peptides in the endo-
lysosomal MIIC compartment, but also CD74 is subjected to proteolysis. Since the 
C-terminal tail of CD74 is exposed to the proteolytic MIIC lumen, it is this end of 
the molecule that is targeted by luminal proteases, like asparaginyl endopeptidase 
(AEP) and cathepsin proteases (CTS) (Villadangos et al., 1999, Hsing and Rudensky, 
2005, Bird et al., 2009, Landsverk et al., 2009). As these endo-lysosomal proteases, 
including cathepsins K, B, D, F, L, and S, are therefore involved in liberating MHCII 
from CD74 and randomly breaking up antigen to create presentable MHCII peptides, 
they are intensely investigated as potential drug targets to potentially regulate the 
repertoire of presented antigens and ameliorate autoimmune disorders or fine tune 
immune responses (Villadangos et al., 1999, Honey and Rudensky, 2003, Bird et al., 
2009, van Kasteren and Overkleeft, 2014).  
 
Luminal degradation of CD74 occurs in a step-wise manner, whereby parts of the 
CD74 molecule are sequentially cleaved off (Figure 1.3C) (Villadangos et al., 1999). 
The cleavage sites can vary, possibly depending on accessibility of cleavable motifs 
or on the type of enzyme that is processing CD74, and can be differentiated using 
protease inhibitors, such as the cysteine protease inhibitor leupeptin, or specific 
enzyme gene knockdown approaches (Villadangos et al., 1999). Generally, the non-
cysteine endo-lysosomal protease AEP executes the first degradation step and targets 
CD74 regions surrounding the most exposed trimerisation domain that overarches 
the attached MHCII molecules (Villadangos et al., 1999, Manoury et al., 2003). As 
the major full length CD74 isoform in mice has a molecular weight of about 31kD, 
the AEP cleavage results in a trimerisation domain-pruned CD74 fragment with a 
molecular weight of about 22kD, which is referred to as p22 and extends to about 
amino acid 160 (Amigorena et al., 1995, Villadangos et al., 1997). In following 
degradation steps p22’s most exposed C-terminal end is further targeted by cysteine 
proteases, trimming CD74 to other commonly observed fragments, sized 
approximately 18kD (p18) and 10-12kD (p10), of which the latter extends to about 
amino acid 100 (Blum and Cresswell, 1988, Amigorena et al., 1995, Newcomb and 
Cresswell, 1993, Villadangos et al., 1999). The bulky CD74 carbohydrate chains are 
removed in the process and likely expose the N-terminal CD74-CLIP-end in p10-
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MHCII complexes for proteolytic targeting by Cathepsin S (Villadangos et al., 
1999). A single enzyme that is essential to generate p10, p18 or p22 has not been 
found and the quantities of observed CD74 fragments between 10 and 31kD varies, 
which indicates that luminal trimming of CD74 down to the p10 fragment seems to 
be achieved by redundantly expressed proteases (Bird et al., 2009). The cell specific 
make up of the endo-lysosomal protease network, its activation status, but also the 
paired MHCII haplotype therefore determines which types and quantities of N-
terminal CD74 fragments are generated in a certain type of antigen presenting cell 
(Villadangos et al., 1997, Villadangos et al., 1999, van Kasteren and Overkleeft, 
2014). Degradation of p10 in B cells and dendritic cells from mice with high CD74-
MHCII affinity haplotypes (such as I-Ab) requires the activity of Cathepsine S 
(CTSS), as in CTSS deficient mice these cells accumulate large amounts of p10 
(Riese et al., 1996, Shi et al., 1999, Nakagawa et al., 1999). The C-terminus of p10-
CD74 still includes the CLIP and transmembrane regions, the two contact points 
between CD74 and MHCII, and consequently p10 remains associated with MHCII 
(Boes et al., 2005). Despite loss of the CD74 C-terminal trimerisation domain, it is 
thought that adherence of a nonameric p10-MHCII configuration is maintained 
through interactions in the transmembrane region of CD74 and MHCII alone 
(Newcomb and Cresswell, 1993, Amigorena et al., 1995, Newcomb et al., 1996, 
Villadangos et al., 1999, Ashman and Miller, 1999). Persistent MHCII-p10 
interaction also seems to protect p10 from degradation in CTSS deficient B cells and 
DC and is necessary for accumulation of p10 in the first place. When CTSS was 
removed from mice with MHCII haplotypes that had either a high or low binding 
affinity to CD74-CLIP, p10 accumulated only in cells with MHCII haplotypes of 
high CD74 affinity (Nakagawa et al., 1999, Hsing and Rudensky, 2005). 
Interestingly, Cathepsin L and Cathepsin F are able to compensate for the absence of 
CTSS in macrophages, since macrophages, as opposed to B cells and DC co-express 
Cathepsin L and F with CTSS, and thus are able to process p10 in the absence of 
CTSS and/or Cathepsin L (Shi et al., 1999, Rudensky and Beers, 2006). CTSS 
cleaves p10-CD74 on the transmembrane side of the CLIP region, thereby severing 
this connection point between CD74 and MHCII. As a result CLIP remains inside the 
peptide-binding groove of MHCII and a previously unknown intramembrane 
protease is though to degrade the residual CD74 membrane stub (Lipp and 
Dobberstein, 1986a, Matza et al., 2002a, Becker-Herman et al., 2005). It can 
alternatively be imagined that this small residual CD74 fragment remains in its 
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trimerised conformation and associated with MHCII via the second transmembrane 
connection point with MHCII (Castellino et al., 2001). The findings in this study and 
by others identify the intramembrane protease signal peptide peptidase-like 2A 
(SPPL2A) as the responsible enzyme for processing of residual membrane CD74-
fragments (Beisner et al., 2013, Schneppenheim et al., 2013, Bergmann et al., 2013). 
 
MHCII-CLIP complexes are now ready for loading of appropriate antigenic peptides, 
a process that is facilitated by another MHCII-like molecule called H2-M (HLA-DM 
in humans) and inhibited by yet another MHCII-like molecule known as H2-O 
(HLA-DO in humans). Distribution of H2-O in relation to H2-M within the 
endosomal membrane compartments regulates the ability of MHCII-CLIP to sample 
antigenic peptides for antigen presentation (Avalos and Ploegh, 2014). H2-M helps 
to expel CLIP from the MHCII peptide-binding groove, possibly by inducing a 
conformational change in the MHCII structure, which subsequently binds a high 
affinity peptide from the luminal proteolysed antigen pool. Finally, peptide-MHCII 
complexes are transferred from the MIIC via tubular membrane structures to the cell 
surface for presentation to CD4+ T cells (Roche and Furuta, 2015). 
 
1.2.3.4 Observations in CD74 and MHCII deficient mouse models 
Due to the reliance of MHCII on CD74 for assembly and trafficking into antigen 
processing compartments, it comes to no surprise that the removal of CD74 in mouse 
models has detrimental effects on the antigen presentation process, T cell selection 
and humoral immunity (Anderson and Miller, 1992, Bikoff et al., 1993, Viville et al., 
1993, Elliott et al., 1994). On a molecular level aggregation of MHCII α and β chains 
without the chaperoning help of CD74 in the ER is unstable and ineffective; resulting 
in so called ‘floppy’ MHCII molecules (Bikoff et al., 1993, Viville et al., 1993). The 
importance of CD74’s endosomal targeting motifs also becomes apparent, because 
MHCII molecules in the absence of CD74 are less efficient at exiting the ER and 
tend to accumulate intracellularly, in what is believed to be an ER to cis-Golgi sub-
compartment that captures misfolded membrane proteins bound for degradation 
(Bikoff et al., 1993, Viville et al., 1993, Elliott et al., 1994). Fewer MHCII molecules 
leave the ER, become incompletely glycosylated and reach the cell surface, where 
they display poorly binding peptides, which is concomitant with deficient T cell 
selection in the thymus and reduced CD4+ T cell numbers in the periphery (Bikoff et 
al., 1993, Viville et al., 1993, Elliott et al., 1994, Hegde et al., 2002). Whilst there is 
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much evidence for the requirement of CD74 for supporting MHCII function, there 
are fewer investigations as to whether the relationship between CD74 and MHCII 
goes the other way, too. In the human CD74 system, the ER-retention motif 
containing p35 isoform is non-surprisingly retained in the ER, unless associating 
MHCII conceals its ER-motif (Marks et al., 1990, Lamb et al., 1991, Kuwana et al., 
1998, Anderson et al., 1999, Khalil et al., 2003, Mrowiec and Schwappach, 2006), or 
excess CD74 synthesis potentially forces an ER ‘overflow’ (Henne et al., 1995). For 
every human CD74 isoform p35 around four p33 isoforms are expressed. This makes 
it likely that isoform-heterotrimerisation amongst the ER-available CD74 isoforms 
results in CD74 complexes that include p35 (or p43) isoforms with an ER-retention 
motif. This ensures that CD74-trimer scaffolds are held back in the ER to allow for 
assembly of MHCII α and β chain pairs around them, until the ER-retention motif is 
blocked and a completed CD74-MHCII complex emerges form the ER (Cloutier et 
al., 2014, Cresswell and Roche, 2014). Whereas CD74 egress from the ER in humans 
seems to require MHC class II and is regulated by p35, this MHCII dependence of 
CD74 transport in mice is less clear. Murine CD74 also seems to be ‘poorly’ 
exported from the ER when MHCII is not co-synthetised, but in mice p35 does not 
exist and the p31 or p41 isoforms are not known to contain designated ER retention 
motifs (Simonis et al., 1989, Cresswell, 1992). As opposed to MHCII-paired CD74 
complexes, free CD74 molecules leaving the ER do not seem to follow the secretory 
or biosynthetic pathway via the Golgi and TGN to the cell surface, but rather fail to 
become properly glycosylated and directly traffic from the ER to an endo-lysosomal, 
LAMP1+ membrane compartment, possibly via autophagy pathways (Lotteau et al., 
1990, Sant and Miller, 1994, Chervonsky and Sant, 1995). This observation indicates 
the existence of an alternative fate for CD74 molecules that are not paired with 
MHCII or other putative binding partners targeted to fulfil a role in the periphery. 
Since antigen presenting cells synthetise CD74 in excess of MHCII (Kvist et al., 
1982, Machamer and Cresswell, 1982, Machamer and Cresswell, 1984, Lipp and 
Dobberstein, 1986b, Nguyen and Humphreys, 1989, Marks et al., 1990, Kampgen et 
al., 1991, Landsverk et al., 2012), a pathway for CD74 that is not associated with 
MHCII must exists (Henne et al., 1995). 
 
1.2.4 A role for CD74 in B cell development 
With awareness of the known supportive role for CD74 in the MHC class II antigen 
presentation pathway, the aforementioned effects of CD74 deletion on humoral 
	   30 
immune responses and CD4+ T cell selection in the thymus of mouse models could 
be expected (Bikoff et al., 1993, Viville et al., 1993, Elliott et al., 1994). Later 
however, Idit Shachar and Richard Flavell made an additional unanticipated 
observation. In CD74 deficient H2b mice they found a modest block at the 
transitional stage in B cell development, characterized by a cell intrinsic failure of 
maturing B cells to upregulate IgD and CD23 normally (Shachar and Flavell, 1996). 
Like others, they also noted that low MHCII expression, which is caused by the lack 
of CD74, could not be responsible for this B cell defect in CD74 knockout mice, 
because mice that are deficient for either CIITA or MHCII β chains present with 
normally developing B cell compartments (Cosgrove et al., 1991, Markowitz et al., 
1993, Chang et al., 1996, Shachar and Flavell, 1996). 
 
Since research into any cell developmental roles for MHCII molecules at that time 
had established that MHCII expression seemed unnecessary for B cell development, 
it was particularly exciting to discover a B cell defect in CD74 deficient mice, 
indicating that CD74 might play a role in maturing B cells that is independent of its 
historical connection with MHCII. This view led to a series of experiments by the 
Shacher group, exploring the possibility that CD74 acts as a membrane bound 
signalling molecule, which is necessary to facilitate transitional B cell development 
(Matza et al., 2003). This theory hinged on the long-standing discovery by Lipp and 
Dobberstein (Lipp and Dobberstein, 1986a), that the CD74 transmembrane region is 
cleaved by a signal peptide peptidase with potential regulatory role in antigen 
presentation (Frauwirth and Shastri, 2001), and that the cytosolic CD74-tail, similar 
to Notch (Selkoe and Kopan, 2003), could act as a membrane bound transcription 
factor that would be released to the nucleus by regulated intramembrane proteolysis 
(Matza et al., 2002a, Becker-Herman et al., 2005). To test this intriguing hypothesis, 
the group generated transgenic mice that expressed a murine 1-82 amino acid N-
terminal CD74 fragment, which were crossed back onto the CD74 deficient 
background. The N-terminal CD74 1-82 amino acid fragment includes the cytosolic 
CD74-tail, the transmembrane domain and a small luminal segment, but importantly 
lacked the CLIP region and therefore was believed to act independently of MHCII 
molecules. Interestingly, B cell deficiency in CD74 1-82 transgenic mice, solely 
expressing the CD74 N-terminal fragment, was rescued (Matza et al., 2002b). It was 
concluded, that the N-terminal or cytosolic CD74-tail was directly required for B cell 
development (Matza et al., 2002b, Matza et al., 2003). Encouraged by this finding, 
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the Shachar group set out to further investigate the mechanism by which N-
terminally truncated CD74 promoted B cell maturation and it was found that the 
requirement of CD74 for B cell development appeared independent of CD74’s 
MHCII chaperone activity. Instead it was suggested that intramembrane proteolysis 
of CD74 by an unknown intramembrane-cleaving protease releases a 42 amino acid 
fragment from the CD74 N-terminus into the cytosol, which then travels into the 
nucleus as transcriptional co-activator of NFκB, collectively representing another 
NFκB-activating B cell survival signalling pathway (Matza et al., 2002a, Matza et 
al., 2003, Becker-Herman et al., 2005, Starlets et al., 2006, Lantner et al., 2007, 
Shachar and Haran, 2011, Bucala and Shachar, 2014). 
 
Contrasting the experimental path of the Sachar group, a second unpredicted 
observation provided an alternative interpretation that explained B cell deficiency in 
CD74 knockout mice. Initial characterisation of mice with deletions of the MHCII β 
chain or CIITA had not shown any problems in maturing B cells, albeit very low or 
absent MHCII expression levels (Cosgrove et al., 1991, Markowitz et al., 1993, 
Chang et al., 1996). Surprisingly, Rolink and colleagues found that H2b mice with a 
knockdown of the MHCII α chain did in fact present with a B cell intrinsic defect, 
which was characterised by significantly reduced survival time of mature B cells in 
the periphery and that could be rescued by an I-E α chain transgene (Rolink et al., 
1999). These results indicated that B cells might require MHCII α chains, but not the 
MHCII β chains to develop. To resolve this ambiguity, Madsen and co-workers 
created mice with a large deletion of the entire MHCII region, causing a loss of all 
classical MHCII genes in the mouse, namely I-Aβ, I-Aα, I-Eβ, I-Eβ2 and I-Eα, 
resulting in animals that could not express any type of MHCII α or β chain 
whatsoever  (Madsen et al., 1999). B cells in these mice develop normally, which 
definitely confirms that classical MHCII molecules are not required for B cell 
development, and that the B cell defect seen in MHCII α chain knockout mice is not 
due to a requirement of the α chain itself, but rather demonstrates a role for the α 
chain only in conjunction with the β MHCII chain. Taking experiments into 
consideration, in which MHCII β chain overexpression also caused a B cell defect 
(Gilfillan et al., 1990, Singer et al., 1996), the two groups came to the conclusion that 
the accumulation of unpaired MHCII β chains in the absence of α chains in the ER is 
toxic to B cells, presumably inducing a detrimental ER stress response (Labrecque et 
al., 1999). The paradox that MHCII β chain deficient mice present with a normal B 
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cell compartment whereas α chain deficient mice do not, can be explained by low 
level expression of β chains from the I-E MHCII subclass in the examined mouse 
models, compensating for the loss of I-Aβ. On the other hand I-Aα deficient mice 
were of the H2b background, which do not express any I-Eα, resulting in unpaired I-
Aβ chain accumulation to trigger a B cell defect (Maehr et al., 2004). Notably, the 
presence of CD74 in all of these experiments was not able to neutralise aberrant 
MHCII chain accumulation and stimulation of a putative ER stress response. 
 
Bearing in mind that in CD74 knockout B cells abnormally paired MHCII molecules 
also aggregate in an ER or a cis-golgi compartment (Bikoff et al., 1993, Viville et al., 
1993, Elliott et al., 1994), the concept of ‘toxic MHCII chain aggregation’ can be 
extended to explain defective B cell development in CD74 deficient mice as well; 
CD74 acts as a chaperone for MHCII and in the absence of CD74, MHCII chains do 
not assemble properly, resulting in increased proportions of misfolded MHCII 
dimers with empty peptide binding groove in the ER (Koonce and Bikoff, 2004). If 
the apparent B cell development block in CD74 deficient mice is caused by the loss 
of the CD74 chaperoning function for MHCII molecules, rather than the requirement 
of CD74 itself to deliver a B cell survival signal independently of MHCII, then the 
additional removal of potentially toxic MHCII chains from CD74 deficient B cells 
should rescue their survival. Work from two independent groups, who found that 
mice doubly deficient for CD74 and MHCII have a normal B cell compartment, 
confirmed this hypothesis (Benlagha et al., 2004, Maehr et al., 2004), demonstrating 
that CD74 is required to fulfil its role as MHCII chaperone in B cell development.  
 
This conclusion can also be applied to explain the B cell rescue in CD74 1-82 
transgenic mice that only express an N-terminally truncated CD74 without a CLIP 
region (Matza et al., 2002b). As explained before, CD74 associates with MHCII at 
least through two points of contact, and removing CLIP disrupts only one of them. 
An 82 amino acid N-terminal CD74 fragment therefore still associates with MHCII 
chains through its transmembrane region and possibly through interactions in the 
cytoplasmic domain (Smiley et al., 1996, Castellino et al., 2001). Nevertheless, 
occupation of the MHCII peptide-binding groove by appropriately fitted peptides in 
the presence of H2-M (Germain and Rinker, 1993, Martin et al., 1996, Miyazaki et 
al., 1996, Kenty et al., 1998), or by the surrogate CD74 peptide, CLIP (Koonce and 
Bikoff, 2004), appears to be important for efficient assembly of αβ-dimers and 
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explains the worsened B cell defect observed in mice lacking both, CD74 and H2-M, 
as opposed to CD74 mono-deficient mice (Kenty et al., 1998). The CD74-
synergising contribution of H2-M in stabilising MHCII assembly, likely substitutes 
for the specific loss of CLIP-MHCII binding in CD74 1-82 transgenic B cells. With 
transmembrane interactions between CD74 and MHCII still intact, MHCII 
chaperoning in these mice seems interestingly sufficient to prevent misfolded MHCII 
accumulation in the ER of otherwise CD74 deficient B cells. 
 
Analysis of CD74 deficient mice with different MHCII polymorphisms or haplotypes 
provide an additional hint that CD74 per se is not required for B cell development. 
The haplotype of highly polymorphic MHCII and essentially the shape of the α and β 
chains determine how efficiently dimerisation occurs, how strongly MHCII non-
covalently binds to CD74 and how much MHCII assembly depends on CD74 
chaperoning (Bikoff et al., 1995). In H2b mice the affinity between MHCII chains 
and CD74 is much higher, as for instance in H2k mice, and consequently I-Aαb and I-
Aβb cannot assemble efficiently in the absence of CD74, whereas I-Aαk and I-Aβk 
chains can (Bikoff et al., 1995). This difference is reflected in the effect of CD74 
deletion on B cell maturation in H2b and H2k mice. B cell development in CD74 
deficient H2b mice with poor MHCII assembly is defective (Bikoff et al., 1993, 
Viville et al., 1993, Elliott et al., 1994), whereas B cell development in H2k mice 
lacking CD74 is normal (Zimmermann et al., 1999). This strongly supports the 
current view that CD74 is only required to chaperone MHCII molecules, but does not 
deliver an essential survival signal itself. The fact that follicular B cells mature 
normally in the complete absence of CD74 and all classical MHCII molecules, 
shows irrevocably that CD74 and MHCII are not required for B cell development 
(Maehr et al., 2004). Hence, the proposed requirement for intramembrane CD74 
proteolysis in B cell development appeared up to be relegated. 
 
1.2.5 A role for CD74 in vesicle biogenesis 
CD74’s intricate role in antigen presentation has driven detailed characterisation of 
this rather simple type II transmembrane protein, and has revealed an astonishingly 
feature-rich molecule. It is easy to adopt a CD74-centred perspective in antigen 
presentation and uncover how CD74 pulls multiple strings to synchronise this 
complex process on a molecular, intracellular and intercellular level, making it 
appear that CD74 owes its invariant nature to evolution attempting to unify key 
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regulatory functions of antigen presentation in a single protein. Adding to CD74’s 
ability to chaperone and guide MHC molecules in control of MHCII peptide loading 
and protecting B cells from protein overload (Landsverk et al., 2009, Maehr et al., 
2004), and other previously mentioned functions, CD74 has more roles to play. 
These seem possibly related to antigen presentation and include the regulation of 
dendritic cell migration through sequestration of myosin II (Faure-Andre et al., 
2008), association with CXCR2, CXCR4 and CD44 to act as potential pro-survival 
receptor of the inflammatory cytokine macrophage migration inhibitory factor (MIF) 
(Leng et al., 2003, Shi et al., 1999, Bernhagen et al., 2007, Gore et al., 2008, 
Schwartz et al., 2009), T cell co-stimulation by binding CD44 on T cell surfaces 
(Naujokas et al., 1993), or by delivering CD70 into the T cell synapse of antigen 
presenting cells (Zwart et al., 2010), and potentially modifying NFκB signalling and 
cell survival (Starlets et al., 2006, Sapoznikov et al., 2008, Bucala and Shachar, 
2014). 
 
Yet, another fascinating observation emerged during studies of CD74 and MHCII 
cellular transport: Severe enlargement and delayed maturation of the endosomal 
membrane compartment or ‘macrosomes’ in situations where increased quantities of 
CD74 protein are present, indicating that CD74 is able to drive vesicle biogenesis 
(Romagnoli and Germain, 1994, Pieters et al., 1993, Arunachalam et al., 1994, 
Gorvel et al., 1995, Stang and Bakke, 1997, Bakke and Nordeng, 1999, Boes et al., 
2005). Characterisation of the enlarged endosomes suggested that they were early 
and late compartments in the endocytic pathway, but essentially behaved comparable 
to a normal endosome (Romagnoli and Germain, 1994, Pieters et al., 1993, Stang and 
Bakke, 1997). Delayed endosome maturation in the presence of abundant CD74 
protein, slows transport and processing of antigens and CD74-MHCII complexes 
along the endocytic route (Gorvel et al., 1995, Gregers et al., 2003, Landsverk et al., 
2011). Even under physiological conditions B cells and other antigen presenting cells 
feature a specialised type of endosomal compartment that facilitates diverse antigen 
peptide production and was introduced above as the MIIC (MHCII containing 
endosomal compartment). The MIIC is recognised by LAMP1, CD63, MHCII and 
CD74 containing membranes, but also by its striking vesicular membrane structure 
(Pieters et al., 1991, Siemasko et al., 1998, Garstka and Neefjes, 2013, Roche and 
Furuta, 2015). Early in the formation of the MIIC, it takes the shape of membrane 
protein degrading multivesicular bodies (MVBs), which form by budding of the 
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limiting endosome membrane into its own lumen (Piper and Katzmann, 2007). As 
the MIIC matures and lowers its intraluminal pH further, it takes the shape of onion-
like multilamellar bodies (MLBs), which are known to be enriched for C-terminally 
degraded CD74, indicating that CD74 might play a role in regulating the function 
and membrane structure of the MIIC and late endosomal compartment in antigen 
presenting cells (West et al., 1994, Murk et al., 2004, Stern et al., 2006). The exact 
mechanism by which CD74 is able to exert its apparent effect on the endocytic 
pathway is not entirely clear, but multiple attempts to unravel the molecular basis of 
CD74 driven vesicle biogenesis have brought a string of CD74 features to the 
forefront that likely contribute (Bakke and Nordeng, 1999, Landsverk et al., 2009). 
 
Chemical crosslinking analysis of various CD74 trimer constructs was used to 
differentiate which sections of the CD74 molecule would be required for CD74 
trimerisation and identified the C-terminal CD74-trimerisation domain coded by 
Exon 6. This study also concluded in a COS cell overexpression system, that CD74 
trimerisation was a prerequisite of its ability to enlarge the endosomal compartment, 
as well as to fulfil many of its other functions (Lamb and Cresswell, 1992, Arneson 
and Miller, 1995, Gedde-Dahl et al., 1997). However, as mentioned above, the 
CD74-trimerisation domain alone may not be responsible to trimerise CD74 
(Amigorena et al., 1995, Newcomb et al., 1996), and the triple CD74 confirmation 
likely persists, once C-terminal CD74 degradation initiates in the endosome. Apart 
from forming a trimeric complex, CD74 also requires its most N-terminal leucine-
based endosomel targeting motif in conjunction with negative charges in an acidic 
aspartic residue of the N-terminal cytoplasmic tail to trigger endosome enlargement 
(Pond et al., 1995, Nordeng et al., 2002). Interestingly, CD74 fusion proteins 
harbouring similar aspartic residue motifs from other membrane proteins were able 
to mimic induction of endosomal enlargement, but the donor protein did not, 
indicating that additional CD74 characteristics, such as trimerisation, are indeed 
important to form a functional secondary structure (Pond et al., 1995, Gedde-Dahl et 
al., 1997).  
 
A secondary CD74 structure that might contribute to CD74’s endosome enlarging 
capabilities might have been discovered. Nuclear magnetic resonance spectroscopy 
(NMR) modelling was used to study auto-aggregation of recombinant human CD74 
in water (Motta et al., 1997). Specifically aggregation of 1-27 amino-acid CD74 
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fragments, which resembled the CD74-N-terminal tail that is normally exposed to the 
cytoplasm, were examined (Motta et al., 1997). This approach produced a model, in 
which an α-helical structure situated between the two leucine-based endosomal 
targeting motifs of the cytoplasmic CD74 tail electrostatically interacts with two 
other CD74-tails to form a ‘triple stranded α-helical bundle’ (Motta et al., 1997). In 
this trimeric conformation two parallel CD74 tails protruding from the cytoplasmic 
leaflet of one vesicle membrane might interact with a single cytoplasmic CD74 tail 
from the surface of another vesicle by flanking it in antiparallel fashion between 
them and thereby facilitate a form of membrane tethering that might induce increased 
vesicle membrane fusion (Motta et al., 1997, Bakke and Nordeng, 1999). 
 
The existence of a complex molecular machinery involved in regulating membrane 
budding, scission and fusion (McMahon and Boucrot, 2011), implies that CD74 is 
unlikely to produce large endosomes simply in its own right, even if it did fuse 
membranes in a cell free endosome assay (Nordeng et al., 2002). To fish for 
suspected physiological cytoplasmic CD74 binding partners the Bakke and Ploegh 
laboratories constructed a biotin-tagged trimeric CD74 cytoplasmic tail. This CD74 
trimer was then used as bait to precipitate potential binding partners from NP-40 
lysates of a human B lymphoblastoid cell line, allowing the groups to identify two 
homologue uncoating ATPases of clathrin-coated vesicles that preferentially bound 
to trimeric rather than single CD74 tails: HSC70 and GRP75 (Lagaudriere-Gesbert et 
al., 2002). GRP75 is the mitochondrial counterpart of cytosolic HSC70 and both 
enzymes are involved in removing clathrin triskelia from membrane surfaces of 
freshly budded vesicles at the end of the clathrin-coated vesicle cycle (McMahon and 
Boucrot, 2011). If overly abundant CD74 recruits HSC70 to endosomal membranes, 
it is possible that increased removal of clathrin coats prevents budding and scission 
of vesicles, causing the endosomal compartment to grow in the localised presence of 
CD74 (Lagaudriere-Gesbert et al., 2002). Nevertheless, HSC70 is an abundant 
cytosolic protein with many other roles besides its clathrin uncoating ability (Liu et 
al., 2012), including the targeting of proteins for degradation into lyso-endosomes 
through a process known as chaperone mediated autophagy (CMA) (Zhou et al., 
2005, Cuervo, 2011). The Ploegh and Bakke groups further demonstrated in simian 
fibroblast transfection experiments that CD74 overexpression did not induce an 
endosomal enlargement when a dominant-negative HSC70 mutant was present 
(Lagaudriere-Gesbert et al., 2002), indicating that CD74 requires interaction with 
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functioning HSC70, presumably facilitated by the aforementioned aspartic residue in 
the CD74 cytoplasmic tail (Nordeng et al., 2002), to modify endosomal membranes 
in this system.  
 
MHCII is another often overlooked, but certainly well established binding-partner of 
CD74 involved in vesicle biology. Overexpression of CD74 in cell lines causes 
endosomal enlargement or ‘macrosome’ formation in both the presence or absence of 
MHCII (Pieters et al., 1993, Romagnoli and Germain, 1994, Riberdy et al., 1994, 
Amigorena et al., 1995, Stang and Bakke, 1997, Lagaudriere-Gesbert et al., 2002). 
However, it is not known whether situations of increased CD74 protein accumulation 
in the absence of MHCII increases the size of the endosomal compartment in antigen 
presenting cells in vivo as well, as here endosomal enlargement has only been 
observed in Langerhans cells (Stossel et al., 1990), and Cathepsin S deficient antigen 
presenting cells whilst MHCII was present (Driessen et al., 1999, Boes et al., 2005). 
These cells accumulate MHCII-CD74 complexes in enlarged endosomal 
compartments, with CD74 and MHCII likely remaining in a nonameric conformation 
(Amigorena et al., 1995, Newcomb et al., 1996, Ashman and Miller, 1999). This 
suggests that MHCII is not required as a binding partner for CD74 to exert its vesicle 
enlarging capabilities in the endosomal compartment of antigen presenting cells. 
However this has not been shown yet in vivo. In light of antigen presentation it 
would make biological sense to couple CD74 mediated endosome expansion with 
MHCII-binding, so that swelling and maturational delay is limited to vesicles that 
contain not only CD74 but MHCII molecules as well. 
 
1.3 Intramembrane endopeptidase SPPL2A 
SPPL2A is a transmembrane Signal Peptide Peptidase Like endopeptidases (SPPL) 
and belongs, together with its homologue Signal Peptide Peptidase (SPP), the related 
presenilins, bacterial type IV prepilin peptidases (TFPP) and archaeal preflagellin 
peptidases (PFP) to a small group of intramembrane cleaving aspartyl-proteases (I-
CLiP) with the unifying feature of a GxGD amino acid motif within their active site 
(Voss et al., 2013). Therefore these enzymes are collectively known as GxGD type 
aspartyl I-CliPs, that are perhaps best known from the role of presenilin as active 
subunit of the γ-secretase complex involved in Alzheimer’s disease and in Notch-
signalling for T cell maturation and T-cell leukemia (Aster et al., 2008, Selkoe and 
Kopan, 2003). GxGD type aspartyl I-CliPs are distinguished from other types or 
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intramembrane cleaving proteases, such as intramembrane metalloproteases (S2P), 
serine intramembrane proteases or rhomboid proteases and Caax glutamate proteases 
(Erez et al., 2009, Fluhrer et al., 2009, Wolfe, 2010, Voss et al., 2013, Avci and 
Lemberg, 2015). Most intramembrane proteases share an intriguing and not entirely 
resolved mode of action (Wolfe, 2010); they cleave transmembrane proteins within 
the hydrophobic lipid bilayer environment of cell membranes. The underlying 
chemical reaction that proteases catalyse results in the separation of two amino acids 
by a water requiring process called hydrolysis. Overcoming the hydrophobicity of 
cell membranes to facilitate access of water into the lipid bilayer is therefore of 
paramount importance to intramembrane cleaving enzymes, such as SPPL2A (Erez 
et al., 2009). Different intramembrane proteases complement this core principle of 
intramembrane protein cleavage in various ways to facilitate regulated substrate 
recognition and recruitment throughout the cell environment. These involve 
recognition of specific transmembrane protein classes, substrate transmembrane 
helix domain unwinding, controlled intracellular trafficking to specific subcellular 
compartments, interaction with adaptor proteins and dependence on pre-degradation 
of potential substrates in a two-step process referred to as ‘regulated intramembrane 
proteolysis’ or RIP (Avci and Lemberg, 2015). Since their discovery in 1997 
(Rawson et al., 1997), intramembrane proteases have been found throughout all 
kingdoms of life, broadly distributed within cells, and have emerged to fulfil a range 
of important functions. Interestingly, the protein substrates of intramembrane 
proteases identified to date seem to show little conservation between species and also 
within homologous groups of I-CliPs substrates vary greatly (Erez et al., 2009, Avci 
and Lemberg, 2015). It thus appears that intramembrane proteases per se are rather 
non-selective of their substrates and regulation of substrate recognition occurs mostly 
through the secondary mechanisms mentioned above. The ability of I-CliPs to cut 
proteins within their transmembrane domain, which allows the irreversible and 
energy efficient removal of proteins from the membrane, has fuelled the assumption 
that intramembrane proteases have evolved to offer a general pathway for 
degradation of integral membrane proteins and thereby complement proteasome 
mediated protein turn over and membrane protein degradation in multivesicular 
bodies (Piper and Luzio, 2007, Li et al., 2015a, Babst, 2014, Fleig et al., 2012, 
Kopan and Ilagan, 2004, Lemberg, 2011, Avci and Lemberg, 2015, Strisovsky, 
2015). 
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The small sub-family of SPP and SPPL intramembrane proteases (SPP/SPPL) was 
discovered in 2002 based on similarities to presenilins (Grigorenko et al., 2002, 
Ponting et al., 2002, Weihofen et al., 2002) and consists of currently five known 
members in mammals: SPPL2A, SPPL2B, SPPL2C, SPPL3 and SPP. Some enzymes 
from this family are expressed in all eukaryotes, but similar to the picture seen in 
intramembrane proteases overall, paralogous enzymes often fulfil different tasks in 
different species, indicating that SPP/SPPL expression and activity are generally 
necessary for life, whereas specific cleavage of certain substrates probably is not 
(Voss et al., 2013). SPP and SPPL proteases are ubiquitously expressed in many 
tissues in general (www.biogps.org; as an example, tissue expression of Sppl2a can 
be seen in Figure 1.5), as well as in the immune system in particular, further 
highlighting their importance for cell functioning (Lattin et al., 2008, Heng et al., 
2008). Global gene expression analysis of single immune cell subsets by the 
ImmGen consortium (www.immgen.org) shows that SPP, SPPL2A, SPPL2B, SPPL3 
but not SPPL2C are expressed in most immune cell subsets (Heng et al., 2008). The 
representative mRNA expression profile for Sppl2a in selected immune cell subsets 
is shown in Figure 1.6A (Heng et al., 2008). The initially stated examples of 
intramembrane proteolysis by γ-secretase highlight the importance of recognising 
ubiquitous enzyme expression and different I-CLiP roles in relation to different 
substrates in different tissues. This proves to be the major obstacle in developing 
effective presenilin inhibitors that block cerebral amyloid β-peptide accumulation 
and prevent Alzheimer disease, but at the same time do not interfere with Notch 
signalling to avoid T cell toxicity (Golde et al., 2013). 
 
SPP/SPPLs are integral membrane proteins with typically 9 transmembrane domains 
(Figure 1.6B). With their C-terminus oriented towards the cytosol and a luminal N-
terminus, the orientation of SPP/SPPLs in the membrane is opposite to presenilins 
(Friedmann et al., 2004). This is a key difference that explains why presenilins target 
type I membrane proteins and SPP/SPPLs only cleave type II oriented substrates that 
orientate their N-terminus into the cytoplasm and the C-terminus into the lumen 
(Nyborg et al., 2004, Friedmann et al., 2004, Golde et al., 2009). The N-terminal tails 
of SPPL2A, -B and -C possess a signal sequence, are long, heavily glycosylated and 
thought to aid luminal interaction with putative substrates. Glycosylation sites are 
absent in SPPL3 or rare in SPP, indicating a similarity between these two enzymes 
that is reflected in comparable sequences, too (Friedmann et al., 2004). The active  
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Figure 1.5: Sppl2a mRNA expression in mice 
 
Bar graph showing Sppl2a relative mRNA expression 
(arbitrary units, A.U.) in the indicated murine tissues. Graph 
prepared in public online BioGPS gene annotation portal (Wu 
et al., Genome Biology, 2009, PMID19919682; 
www.biogps.org) from published ‘GNF Mouse GeneAtlas V3’ 
murine gene expression dataset (Lattin et al., Immunome 
Research, 2008, PMID18442421). 
Median 3x 10x 
A.U. Sppl2a 
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Figure 1.6: Immune system expression and molecular 
structure of SPPL2A 
 
A. Bar graph showing Sppl2a relative mRNA expression 
(arbitrary units, A.U.) in the indicated immune cell subsets. 
Graph prepared from published Immunological Genome Project 
database (Heng et al., Nature Immunology, 2008, PMID 
18800157; www.immgen.org). Colours shall help to easily 
distinguish groups of leukocyte subpopulations. 
B. Schematic drawing of the 9-pass intramembrane 
endopeptidase SPPL2A and its orientation towards substrates. 
SPPL2A cleaves single pass, type 2 trans-membrane proteins 
within the hydrophobic domain of the lipid bi-layer by allowing 
access of water to the site of proteolysis.  SPPL2A’s active site 
is located between its 6th and 7th transmembrane domain. The 
active site is characterised by a YD-motif in the 6th and a GxGD- 
motif in the 7th transmembrane domain. 
Active Site 
N&
C&
Cytoplasm 
N&
C&
SPPL2A: 
YD& GxGD&
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site of SPP/SPPL intramembrane proteases is formed by the 6th and 7th 
transmembrane domain and is overarched by a hydrophilic hairpin loop that 
protrudes into the luminal side of the membrane and connects both of those 
enzymatic membrane domains (Figure 1.6B). Interestingly the corresponding loop in 
inversely oriented presenilins contains hydrophobic residues thought to interfere with 
the active site and thus requires autoproteolytical cleavage to activate the enzyme 
within the γ-secretase protein complex. SPP/SPPLs on the other hand do not require 
autoproteolysis, thus operating as a single molecular unit and as opposed to 
presenilins presumably independent of co-factors (Weihofen et al., 2002). However, 
homologous dimerisation of SPP/SPPLs has been observed (Nyborg et al., 2004, 
Nyborg et al., 2006). The 6th and 7th transmembrane domains flanking the active site 
contain highly conserved aspartyl motifs that are absolutely essential for SPP/SPPL 
protealytical activity. Removal or alteration of the active site sequences destroys 
enzyme activity (Fluhrer et al., 2006, Friedmann et al., 2006, Kirkin et al., 2007, 
Wolfe, 2010). Transmembrane domain 6 features a YD-motif, and domain 7 holds 
the designative GxGD aspartyl amino acid pattern. The non specific SPP/SPPL 
family active site inhibitor 1,3-di-(N-carboxybenzoyl-L-leucyl-Lleucyl) amino 
acetone ((Z-LL)2 ketone) has been developed to block signal peptide processing in 
the endoplasmic reticulum (ER) and was instrumental to biochemically identify 
human SPP and the homologous SPPL family members (Weihofen et al., 2000, 
Weihofen et al., 2002, Wolfe, 2010). Besides N-terminal glycosylation and the 
intramembrane active site, the C-terminal or cytoplasmic end of these enzymes is an 
additional modifier of their function, by directing subcellular localisation. Known 
mammalian members of the SPP/SPPL family occupy distinct cellular membrane 
compartments along the secretory route. Sorting motifs present in the C-terminal tail 
of the enzymes determine subcellular positioning of each family member and control 
their biological role by regulating access to substrates within a cell (Behnke et al., 
2011, Morohashi and Tomita, 2013, Strisovsky, 2015). The molecularly similar SPP 
and SPP3, as well as SPPL2C are found in ER and Golgi membranes early along the 
secretory pathway, which is consistent with a KKxx motif in the SPP cytoplasmic 
tail that actively retains SPP in the ER membrane (Krawitz et al., 2005, Friedmann et 
al., 2006). SPPL2A has an endolysosomal YxxØ sorting motif in its C-terminal tail 
and hence is recruited into the endosomal membrane compartment from further 
along the secretory route (Schroder et al., 2007). SPPL2B seems to lack sorting 
motifs and thus localises at the default destination of the secretory pathway; the 
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cellular surface membrane (Friedmann et al., 2006, Behnke et al., 2011). Minor 
deviations from this general subcellular localisation pattern of SPP/SPPL family 
members have been observed (Krawitz et al., 2005, Behnke et al., 2011). 
 
Besides type II orientation of putative SPP/SPPL substrates, other requirements for 
substrate processing by this enzyme family need to be met and the aforementioned 
process of ‘Regulated Intramembrane Proteolysis’ (RIP), that usually involves two 
steps, is one of them (Figure 1.7) (Brown et al., 2000, Lemberg and Martoglio, 2002, 
Kopan and Ilagan, 2004, Lichtenthaler et al., 2011, Urban, 2013, Avci and Lemberg, 
2015). RIP is emerging as a well regulated process to either simply remove 
membrane proteins targeted for degradation or act as a definite signalling step at the 
bordering interface of cell membranes (Lichtenthaler et al., 2011, Lemberg, 2011). In 
the first step of RIP, similar to γ-secretase proteolysis, the luminal tail of the 
transmembrane substrate has to be pre-degraded by other enzymes, typically known 
to act as sheddases, so that the bulk of the C-terminal ectodomain protruding into the 
luminal space is pruned to a short membrane traversing stub. In the second step, an 
intramembrane protease can access the remnant substrate and cleave it within the 
plane of the membrane to release a luminal fragment and an intracytoplasmic domain 
(ICD) or, in case of type II transmembrane substrates, a N-terminal fragment (NTF) 
(Wolfe and Kopan, 2004, Fluhrer et al., 2009). The length of the residual substrate 
stub that is left after sheddase pruning, inversely affects how easily it can be cleaved 
by SPP/SPPLs (Struhl and Adachi, 2000, Martin et al., 2009). Additionally, the 
targeted transmembrane domain needs to be isolated to a single pass configuration, 
which is consistent with practically all identified or artificially constructed 
SPP/SPPL substrates so far, although one exception has been postulated for SPPL3 
(Voss et al., 2012). It can be assumed that trimming and isolating type II 
transmembrane protein domains for SPP/SPPLs processing facilitates close substrate 
approximation and fit into the active site. Nevertheless, selectivity of SPP/SPPLs 
towards certain single-pass type II transmembrane proteins as preferred substrates is 
unclear, as no common sequence motif within the transmembrane domain of known 
substrates is apparent (Voss et al., 2013). This is also true in the other way around, 
since the same SPP/SPPL substrates, can be equally be cleaved by SPPL2A and 
SPPL2B, two different enzymes of the same family (Friedmann et al., 2006, Fluhrer 
et al., 2006, Martin et al., 2008). The large known number of single pass 
transmembrane proteins that is trimmed by sheddases makes it seem likely that many  
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Figure 1.7: SPPL2A proteolytic mechanism of action  
 
The intramembrane endopeptidase SPPL2A is located in 
endosomal membranes and selectively cleaves residual, 
single pass, type 2 trans-membrane protein stumps that have 
been pre-degraded by other luminal proteases (*   ). This two-
step process is referred to as Regulated Intramembrane 
Proteolysis (RIP). 
Lumen 
* 
Cytosol 
SPPL2A 
Type 2 trans-membrane substrate 
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residual protein stubs are further processed by intramembrane cleavage, however, 
experimental proof is still lacking (Lemberg, 2011, Lichtenthaler et al., 2011). 
Interestingly, more detailed investigations of BRI2 substrate recognition by SPPL2B 
for intramembrane cleavage noticed that α-helical instability of the substrate 
transmembrane domain and charged residues in the substrate juxtamembrane domain 
on the C-terminal side of SPPL2B were important for proteolysis (Martin et al., 
2009). Future structural revelations of SPP/SPPLs or closely related enzymes will 
provide deeper insights into the mechanism of substrate recognition and handling, 
which might help to identify key determinants that allow rigorous prediction of 
potential SPP/SPPL substrates (Wolfe, 2013). Despite these clues and some more 
general rules for substrate selection within the framework outlined above, SPP/SPPL 
substrate sequence specificity appears to be relatively lenient. 
 
The key to understanding the biological relevance of intramembrane proteases lies in 
understanding which substrates they target, how they access their substrates and the 
physiological consequences of the substrate intramembrane cleavage (Strisovsky, 
2015). Over the last decade a handful of substrates have been identified for various 
members of the SPP/SPPL family and most of them arose from work surrounding the 
ER resident family founding member SPP (Voss et al., 2013). Among others, SPP is 
involved in immune surveillance by processing MHCI signal peptides for antigen 
presentation to natural killer cells (NK cells) (Lemberg et al., 2001), viral protein 
processing (Weihofen et al., 2000, McLauchlan et al., 2002, Lemberg and Martoglio, 
2002), generation of a lung carcinoma epitope from preprocalcitonin signal peptide 
(El Hage et al., 2008) and ER associated membrane protein degradation (m-ERAD) 
(Loureiro and Ploegh, 2006, Stagg et al., 2009, Chen et al., 2014, Ruggiano et al., 
2014). For SPPL2A, SPPL2B and SPPL3 up until recently, only in vitro studies were 
able to identify a number substrates, such as BRI2 (Martin et al., 2008) and 
membrane TNF-α (Friedmann et al., 2006, Fluhrer et al., 2006) cleavage by both 
SPPL2A and SPPL2B, membrane FASL processing by SPPL2A (Kirkin et al., 
2007), transferrin receptor 1 stub degradation by SPPL2B (Zahn et al., 2013) and 
foamy virus envelop protein cleavage by SPPL3 and SPPL2A (Voss et al., 2012). 
For SPPL2C no substrates are known (Voss et al., 2013). Despite this growing list of 
SPP/SPPL substrates the in vivo role particularly for cleavage of SPPL targets had 
not been investigated. Therefore a biological role for SPP and SPPL intramembrane 
proteases was unknown before the start of this research project. Findings presented 
	   46 
in this thesis and work by others recently identified the MHCII invariant chain CD74 
as a new SPPL2A substrate and demonstrated for the first time that SPPL2A activity 
is relevant for biological processes in vivo (Beisner et al., 2013, Schneppenheim et 
al., 2013, Bergmann et al., 2013). It was found that B cells and CD8- dendritic cell 
survival require CD74 intramembrane processing by SPPL2A, which will be 
described and further discussed in detail throughout the rest of this manuscript. 
 
1.4 Phenotype-driven discovery of SPPL2A relevance for B cell immunity 
With the aim to discover novel proteins that were not previously known to play a 
role in B cell survival and development, the Immunogenomics Laboratory at the 
John Curtain School of Medical Research in Canberra established a phenotype 
focussed mutagenesis screen, which randomly alters single genomic nucleotides in 
mice and subsequently tests the mutations’ effect on B cells in the blood. Since this 
unbiased approach potentially uncovers any single nucleotide change that is relevant 
for B cell biology, chances are high to find unappreciated or entirely novel genes in 
the context of the chosen phenotypical screen, without the need for any candidate 
gene knowledge or limitations of studying null alleles in ‘reverse-genetic’ 
approaches (Nelms and Goodnow, 2001, Papathanasiou and Goodnow, 2005, Hoyne 
and Goodnow, 2006, Cook et al., 2006, Moresco et al., 2013). The generation of 
mice with random homozygous and potentially protein coding mutations that allow 
for flowcytometric screening of aberrant B cell phenotypes in the blood is described 
in detail by Nelms, Cook and their colleagues (Figure 1.8) (Nelms and Goodnow, 
2001, Cook et al., 2006). Briefly, our laboratory uses intraperitoneal injections of the 
potent chemical mutagen N-Ethyl-N-Nitrosourea (ENU) to induce germ line 
transcendent single nucleotide variants or polymorphisms (SNV or SNP) in male 
mice. On average 1-2 variants are induced every million nucleotides and in every 
mouse about 45 coding sequence changing SNVs are present (Andrews et al., 2012, 
Bull et al., 2013). ENU treated males are paired with untreated C57B6 females to 
pass one mutated chromosome set to G1 progeny. Thereafter unrelated G1 mice are 
crossed to generate G2 progeny that each consequently carries about 45 
heterozygous protein-coding SNVs on average. Intercrossing G2 mice brings about 5 
protein coding mutations to homozygosity in each G3 mouse. The G3 progeny are 
then bled and screened for changes of B cell proportions in the blood or alterations of 
the normal B cell phenotype.  
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Figure 1.8: Schematic drawing of N-ethyl-N-nitrosourea 
(ENU) mutated mouse pedigree structure used to 
generate mice with random sets of homozygous, protein 
coding mutations (mod. Andrews et al., Open Biol., 2012). 
 
Treatment of male mice with the chemical mutagen ENU 
induces random single nucleotide substitutions in 
spermatogonial stem cells at a known rate of about 1-2 
variants per million nucleotides, of which about 90 are located 
in Exons. Pairing of ENU treated males with untreated female 
mice passes one mutated chromosome set to G1 progeny 
and subsequent breeding of unrelated G1 mice produces G2 
progeny that collectively carry about 45 protein coding 
variants, all in the heterozygous state. Intercrossing second 
generation animals (G2 progeny) yields G3 progeny that 
carry theoretically 94% of the originally induced mutations. 
On average about 5 protein coding mutations are brought to 
homozygosity in each G3 mouse. At last G3 progeny are 
screened for phenotypic aberrations and affected mutants 
further examined (Mapping, Exome or Genome Sequencing) 
to identify the phenotype causing DNA variant. 
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Once a mouse with a B cell phenotype of interest is identified, it is continuously 
backcrossed with wildtype mice of the C57B6 background. Intercrossing of the 
resulting heterozygotes generates homozygous mutant progeny with the phenotype 
of interest, which are tracked by ongoing flowcytometric phenotyping. 
 
From ENU mutagenesis screening efforts in our laboratory, a mutant mouse pedigree 
(ENU15NIH85a) was identified in 2009 (Figure 1.9A), that yielded mice with a 
reduced percentage of B cells in the blood, and with the remaining B cells in affected 
mice (putant mice) showing a lowered surface expression of IgD (Figure 1.9B). One 
major difficulty with using ENU mutagenesis is the identification of causative 
mutations, once a mouse strain with a desirable phenotype is generated (Bull et al., 
2013). The generation of mapping crosses, which are traditionally used to identify 
causative polymorphisms, is a costly and timely undertaking, and variations of the 
investigated phenotype on different mouse strain backgrounds can make tracking of 
the desired trait difficult. By contrast, recent use of exome and whole genome 
sequencing techniques on ENU mutant mouse samples allows for effective 
identification of candidate SNVs in mutant mice (Andrews et al., 2012, Bull et al., 
2013), yet data handling involved in this approach requires considerable 
bioinformatic efforts (Bull et al., 2013). At the time the ENU15NIH85a pedigree was 
discovered, conventional genomic mapping of the causative trait was undertaken 
initially to identify the causative mutation for the B cell deficient phenotype (Figure 
1.10). Crossing putant B cell deficient mice of the C57B6 background with mice 
from the CBA background allowed for identification of C57B6 genome markers that 
tracked with B cell deficiency in the putant C57B6 x CBA F2 progeny. This 
approach located the causative mutation for B cell deficiency in ENU15NIH85a 
mice into a maximum non-recombinant interval between map positions 121366748 
and 138571943bp (GRCm38.p1), a 17.2Mbp interval on chromosome 2. With the 
ongoing validation to apply whole exome sequencing in finding causative mutations 
in ENU mutant mouse pedigrees, the preliminary mapping of ENU15NIH95a was 
superseded by this technique and later validated further by whole genome 
sequencing as well (not shown). Using both, whole exome (Andrews et al., 2012) 
and whole genome sequencing (Bull et al., 2013), two single variants were identified 
within the mapped interval on chromosome 2.  
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Figure 1.9: Discovery of B cell deficient ENU mouse 
mutants during immune-phenotypic screening of G3 
mice in ENU15NIH85aB6 pedigree 
 
A. ENU15NIH85aB6 pedigree showing third generation mice 
(G3) with wildtype or putant phenotype, normal or reduced 
proportion of B cells with low surface IgD expression 
respectively, based on flow cytometric analysis of blood 
lymphocytes. 
B. Flow cytometric plots and percentages of blood 
lymphocyte (Lympho) with IgM and IgD expression on B220+ 
B cells from putant and wildtype mice derived from G3 
progeny of ENU15NIH85aB6 ENU mutated pedigree. 
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Figure 1.10: Genomic Mapping of the B cell deficiency 
causing ENU mutation in ENU15NIH85aB6 mice to a 
17.2Mb region on chromosome 2 
 
Haplotype matrix representing a part of mouse chromosome 
2 in F2 mice ((CBAxB6mut/+)F1x(CBAxB6mut/+)F1) with low 
(Affected) or normal (Unaffected) B cell numbers. The 
double-headed arrow denotes the maximum non-
recombinant interval between map positions 121366748 and 
138571943bp on Ch2. Black squares indicate C57BL/6 
homozygotes and white squares indicate C57BL/6 and CBA 
heterozygotes or CBA homozygotes. Map positions refer to 
Build GRCm38.p1 of the public mouse genome assembly 
(http://mouse.ensembl.org/). 
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One at the 126622956bp position in a gene called Trpm7, and a second one at 
position 126746052bp, which belongs to the gene sequence coding for Sppl2a 
(Figure 1.11). Both nucleotide positions were altered from an adenine reference base 
to thymine as the variant base. 
 
The Trpm7 gene codes for the Transient Receptor Potential Melastatin 7 cation 
channel (TRPM7), which is an integral membrane protein that structurally resembles, 
a Ca2+ and Mg2+ ion channel, as well as a C-terminal protein kinase (Runnels et al., 
2001). The mutation in Trpm7 was inside exon 36 causing a change of amino acid 
1731 from arginine to lysine within the kinase domain of the protein. The mutation 
in Sppl2a was at the second nucleotide position from the start of intron 7, part of the 
intronic sequence either side of each exon that had still been covered by exome 
sequencing and been confirmed by whole genome sequencing later. The Sppl2a gene 
is translated into Signal Peptide Peptidase Like 2A protease (SPPL2A), also an 
integral, multi-domain membrane protein described in more detail in the previous 
subchapter (1.3), with the +2 mutation in intron 7 possibly disturbing correct splicing 
of required exons, thus introducing a possible frame-shift with premature STOP from 
the third transmembrane domain of the protein onwards (Weihofen et al., 2002, Voss 
et al., 2013). Both, TRPM7 and SPPL2A, were unknown to play a role in B cell 
development or peripheral B cell survival, and as such, at the beginning of this 
project there was the potential for the mutation in either gene to be relevant for the 
observed B cell deficiency in mutant mice from the ENU15NIH85a pedigree. Due to 
close proximity of these two mutations, a separating recombination event was 
unlikely to occur during ongoing breeding and backcrossing of this strain. To help 
resolve the causative mutation for B cell deficiency, the ENU15NIH85a strain was 
crossed to other ENU mouse strains with mutations in Trpm7, producing offspring 
with non-matching SNVs on each Trpm7 allele that did not present with B cell 
deficiency. This hinted that the Sppl2a mutation was likely causative for the B cell 
immunodeficiency, yet further validations were necessary. Nevertheless, the B cell 
deficient ENU15NIH85a mouse strain with a likely causative endopeptidase-
mutation was nicknamed Enid for ‘endopeptidase immunodeficiency’. 
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Figure 1.11: Whole Exome sequencing identifies two 
homozygous mutations in maximal non-recombinant 
interval on chromosome 2 of ENU15NIH85aB6 mutant G3 
mouse with B cell deficiency 
 
Mouse chromosome 2 ideogram showing the maximal non-
recombinant 17.2Mbp interval mapped in B cell deficient 
ENU15NIH85aB6 mutant mice (grey shaded). Whole Exome 
sequencing of a ENU15NIH85aB6 G3 B cell deficient mouse 
identified two homozygous mutations in this interval (red 
lines). The mutations in Trpm7 (reference base is A and 
variant base is T) and Sppl2a (base change from A to T) are 
separated only by 123096 nucleotides. 
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1.5 Rationale and aims of this thesis 
In the preceding review of the current literature, I have outlined how developing B 
cells need survival signals provided by the B cell receptor and BAFFR to reach 
maturity in peripheral lymphoid organs. Tonic signals from surface IgM and IgD, as 
well as engagement of the BAFFR by the circulating B cell activating factor (BAFF) 
stimulate downstream phosphoinositol-3 kinase (PI3K) and pathways that activate 
transcription factors of the NFκB family to mediate survival of transitional B cells. 
This process is one of the most thoroughly investigated cell developmental systems 
in mammals, but our understanding of B cell development and survival is far from 
complete.  
 
CD74, a simple, single pass type II transmembrane protein also known as the MHC 
class II invariant chain or Ii, is one example of a startlingly versatile molecule with 
an enigmatic role in B cell development, but also a well established function in 
antigen presentation. I have given an insight into the structural elements and 
associated functions of the CD74 protein, and how CD74 chaperones the assembly of 
nascent MHCII αβ-dimers, subsequently shields the MHCII peptide binding groove 
from premature peptide binding and finally guides MHCII molecules into specialised 
endosomal MIIC compartments for peptide loading and antigen presentation to CD4+ 
T cells. Once arrived in endosomal vesicles, CD74 is able to regulate the architecture 
of this proteolytic membrane compartment and the luminal CD74 domain undergoes 
a distinct series of enzymatic cleavage steps that produce key-intermediate CD74 
fragments identifiable by immunoblotting. At last the endosomal protease Cathepsin 
S is required in B cells and DCs to execute a penultimate CD74 cut for the release of 
class II associated invariant peptide (CLIP) and an inscrutable transmembrane CD74-
stub that is rapidly degraded by a long sought-after, and prior to this project 
unknown, intramembrane protease. 
 
I have then elaborated how murine CD74 deficiency surprisingly causes a mild block 
in transitional B cell development that is characterised by low IgD and CD23 
expression on surviving B cells. The B cell defect in the absence of CD74 can be 
explained through the loss of CD74’s MHCII chaperoning activity, leading to 
accumulation of poorly folded and therefore ‘toxic’ MHCII protein aggregates that 
prevent B cell survival. However, an alternative hypothesis suggested that CD74 
itself, independent of its MHCII chaperoning activity, might be required for B cell 
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survival. As a result it was further proposed that an unknown intramembrane 
protease liberates a cytosolic CD74-fragment, which then acts as transcriptional 
NFκB co-activator and essential B cell survival factor.  
 
At last, I have given an overview of transmembrane protein degradation and 
‘regulated intramembrane proteolysis’ (RIP) by the intramembrane cleaving protease 
SPPL2A. SPPL2A is an endopeptidase for which our laboratory identified an ENU-
mutagenesis derived, B cell deficient mouse strain that harboured a mutation in the 
7th intron of the Sppl2a gene. Intramembrane proteases similar to SPPL2A are 
renown for their role in Alzheimer’s disease and in T cell Notch-signalling, but the 
SPPL2A-subfamily itself was discovered more recently. SPPL2A is ubiquitously 
expressed in the immune system, localises to endosomal membranes and cleaves 
single pass type II transmembrane proteins after they have been pre-degraded by 
other luminal proteases known as sheddases. Despite a handful of identified 
substrates for the SPPL2A protease family in vitro, a biological role for SPPL2A was 
prior to this study unknown.  
 
Taken together, at the beginning of my PhD project in 2011, nothing was known 
about SPPL2A function in vivo, an SPPL2A mutant mouse model did not exist, and 
the 30-year-old proposition for a role of intramembrane proteolysis in CD74 biology 
or an impending role for this process in B cell development were unresolved. I 
therefore set out to address the following three aims, by employing the Sppl2a-
mutant-B cell deficient ‘Enid’ mouse strain: 
 
1.) Characterise B cell deficiency in Sppl2a-mutant mice 
2.) Discover the causative mechanism responsible for the observed B cell 
deficiency in Sppl2a-mutant mice 
3.) Utilise understanding of SPPL2A function in B cells to provide new insights 
into B cell biology and immunobiology in general. 
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Chapter 2: Materials and Methods 
 
 
 
 
Contributions from others:  
• Flowcytometric cell sorting for most applications was done by Harpreet 
Vohra and Mick Devoy at the Imaging and Cytology Facility, John Curtin 
School of Medical Research, Australian National University, Canberra 
• Mouse husbandry and breeding services were provided by the Australian 
Phenomics Facility (APF) and genotyping services were provided by the APF 
Genomics Facility, both Canberra. 
 
Acknowledgement of laboratories for kindly agreeing to host externally 
performed experiments: 
• Most dendritic cell preparations, immunoprecipitations, confocal microscopy, 
antigen presentation and endocytosis assays were performed in the laboratory 
of Jose A. Villadangos at the Department of Microbiology and Immunology, 
University of Melbourne. Metabolic radiolabelling experiments were done in 
another laboratory of Jose A. Villadangos at the Bio21 Institute, Melbourne. 
• In gel protein digestion in preparation for mass spectrometry was performed 
in the Proteomics Laboratory of Andrew Webb at the Walter and Eliza Hall 
Institute, Melbourne. 
• Transmission electron microscopy sample preparation and imaging were 
performed in the group of Melanie Rug at the Centre for Advanced 
Microscopy, Australian National University, Canberra. 
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2.1 Mice 
2.1.1 Mouse strains 
All mice used in this study were housed and bred in specific pathogen–free 
conditions at the Australian National University Bioscience Research Services 
facility, Australian Phenomics Facility in Canberra, ACT, Australia. All mice were 
cared for and experimentally handled as approved by the Australian National 
University or Melbourne University Animal Ethics and Experimentation Committees 
and by following current guidelines from the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes. 
 
Unless noted specifically, all mice used for experiments were 8-16 weeks old and 
maintained on a C57BL/6 background. Genotyping was performed using a PCR 
based amplification of DNA isolated from mouse ear punch tissue samples. Single 
nucleotide polymorphisms of ENU mouse strains were detected by Amplifluor® 
SNPs Genotyping System from Milipore using a FLUOstar OPTIMA microplate 
reader from BMG Labtech. For most experiments the genotype of mice was 
confirmed by measurements of phenotypic characteristics using flowcytometry. 
 
The following original mouse strains were used for this project and intercrossed as 
indicated throughout the thesis: 
 
B6: This inbred C57BL/6J wiltype mouse strain was originally acquired from the 
Jackson Laboratories, Maine, United States. 
 
B6 Ly5a (Ptprc <a>): This C57BL/6-SJL/J mouse strain carries the Ptprca (Ly5a or 
CD45.1) congenital pan-leukocyte marker used to distinguish leukocytes carrying the 
Ptprcb isoform (Ly5b or Cd45.2) found in many strains including C57BL/6 mice 
used for this project. CD45 isoforms permit differentiation of Ly5a and Ly5b derived 
cells in the same cell suspension or bone marrow recipient by flowcytometry. The 
Mouse Genome Informatics reference ID for this allele is MGI:4819849. 
 
B6 Rag1-/- (Rag1 <tm1Mom>): Mouse strain that lacks B and T lymphocytes due to 
blocked V, D and J recombination in the absence of recombination activating gene 1 
(Mombaerts et al., 1992). The Mouse Genome Informatics reference ID for this 
allele is MGI:1857241. 
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Sppl2a-/- (Sppl2a <enid>): SPPL2A-deficient mouse strain. Inactivating, ENU 
mutagenesis induced single nucleotide variant allele of Sppl2a also known as 
<ENU15NIH85a> or <m1ANU>. Enid stands for endopeptidase immunodeficiency. 
The mutation caused complete skipping of exon 7, introducing a frameshift and 
premature stop codon that deleted most of the protein including 7 of the 9 
transmembrane domains and the protease active site (Bergmann et al., 2013). The 
Mouse Genome Informatics reference ID for this allele is MGI:5432126. 
 
Sppl2ako (Sppl2a <tm1a(EUCOMM)Hmgu>): SPPL2A-deficient mouse strain. 
SPPL2A-deficiency was achieved by insertion of a L1L2_Bact_P vector cassette into 
position 126927473 (Build GRCm38) of Chromosome 2 upstream of the critical 
exon 3. ES cell lines with the “Knockout-first” allele Sppl2a 
<tm1a(EUCOMM)Hmgu> were produced by the EUCOMM consortium (Skarnes et 
al., 2011), and the Monash node of the Australian Phenomics Network (APN; 
http://www.australianphenomics.org.au) established the B6 mouse Sppl2ako strain 
with germline transmission of this allele (Embryonic stem cell to mouse service, 
Monash University, Australia ; http://www.platformtechnologies.org/es-cell-to-
mouse-8142/). The Mouse Genome Informatics reference ID for this allele is 
MGI:4887673 
 
Ctss-/- (Ctss <tm1Hap>): This Cathepsin S-deficient mouse strain was originally 
generated by the group of Harold A. Chapman (Shi et al., 1999), who kindly made 
the strain available for studies in this thesis. This mouse strain was made by 
replacing exon 5, which encodes the active site cysteine residue, with a neomycin 
resistance cassette. Immunoblotting confirmed the absence of Cathepsin S protein in 
splenocytes from these mice (Shi et al., 1999). The Mouse Genome Informatics 
reference ID for this allele is MGI:2182133. 
 
Cd74-/- (B6.129S-Cd74 <tm1Liz/J>): CD74-deficient mouse strain was purchased 
from the Jackson Laboratories (ww.jax.org) and was originally generated by 
replacement of the first intron and 11 nucleotides of the second exon with a 
MC1neopA cassette (Bikoff et al., 1993). The Mouse Genome Informatics reference 
ID for this allele is MGI:1927530. 
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H2-Aa-/- (H2-Aa <tm1Blt>): MHC class II α chain deficient mouse strain that was 
produced by inserting a PGK-neomycin resistance cassette into exon 2, which 
encodes for the α1 domain of the α-chain. Flowcytometric and immunoblot analysis 
showed that MHCII α-β-chain pairing is disrupted resulting in the loss of MHCII 
surface expression (Kontgen et al., 1993, Koonce and Bikoff, 2004). It was also 
shown that insertion of the neomycin cassette into H2-Aa caused in exon skipping 
and resulted in the production of truncated α chian molecules at similar to wildtype 
quantities (Koonce and Bikoff, 2004). The Mouse Genome Informatics reference ID 
for this allele is MGI:2157977. 
 
Baff-/- (Tnfsf13b <m1ANU>): Cytokine BAFF-deficient mouse strain. ENU 
mutagenesis derived mouse strain with nonsense mutation converting Tyrosine 27 
codon (TAT) to STOP (TAA) at position 81 of cDNA cDNA 
(ENSMUST00000033892) in exon 1 (Bergmann et al., 2013). ELISA measurements 
for BAFF cytokine plasma levels confirmed the absence of BAFF in these mice 
(Alanna Short and Anselm Enders, unpublished results). The Mouse Genome 
Informatics reference ID for this allele is MGI:5009047. 
 
B6 Bafftg (Tnfsf13b <1Fma>): Transgenic mouse strain with constitutively 
increased circulating levels of the cytokine BAFF. Murine Tnfsf13b is overexpressed 
under the control of the human liver-specific alpha-1-antitrypsin promoter with an 
apolipoprotein E enhancer (Mackay et al., 1999). The Mouse Genome Informatics 
reference ID for this allele is MGI:2386944. 
 
Vav-Bcl2 transgenic mice (<Tg(Vav-BCL2)1Jad>): Transgenic mouse strain with 
constitutive overexpression of the human pro-survival protein BCL2 under the 
control of the Vav-promoter, which limits BCL2 overexpression to haematopoietic 
tissue (Adams et al., 1999, Ogilvy et al., 1999). The Mouse Genome Informatics 
reference ID for this allele is MGI:2429387. 
 
Atp11c-/- (Atp11c <ambr>): ATP11C-deficient mouse strain. ENU mutagenesis 
derived mouse strain with X-linked single nucleotide polymorphism in the +1 splice-
donor position of intron 27 in the Atp11c gene. The mutation causes a frame shift and 
pre-mature STOP, abolishing the two C-terminal transmembrane domains and 
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cytoplasmic tail of ATP11C (Yabas et al., 2011). The Mouse Genome Informatics 
reference ID for this allele is MGI:4456247. 
 
MD-4 (<Tg(IghelMD4)4Ccg >): HEL (chicken or hen egg lysozyme) BCR 
transgenic mouse strain whose B cells express pre-arranged heavy and light chain 
transgenes that produce a high affinity HEL recognising BCR, resembling the 
monoclonal anti-HEL antibody produced by the hybridoma cell line HyHEL10 
(Goodnow et al., 1988). The Mouse Genome Informatics reference ID for this allele 
is MGI:2384162. 
 
ML-5 (<Tg(ML5sHEL)5Ccg>): Transgenic mouse strain that expresses soluble 
HEL (chicken or hen egg lysozyme) into body fluids under the control of the 
metallothionein I-promoter, which is active during embryonic, fetal, and adult life 
(Goodnow et al., 1988). The Mouse Genome Informatics reference ID for this allele 
is MGI:2384160. 
 
OT-I (<Tg(TcraTcrb)1100Mjb>): OVA TCR transgenic mouse strain whose CD8+ 
T cells express a rearranged transgenic T cell receptor consisting of Tcra-V2, Tcra-
J(α26) and Tcrb-V5, Tcrb-D(β2), Tcrb-J(β2.6) chains that recognise the ovalbumin 
residues 257-264 (SIINFEKL, OT-I peptide) in the context of H-2Kb (Hogquist et 
al., 1994). The Mouse Genome Informatics reference ID for this allele is 
MGI:3054907. 
 
OT-II (<Tg(TcraTcrb)425Cbn>): OVA TCR transgenic mouse strain whose CD4+ 
T cells express a transgenic TCR derived from a CD4+ T cell hypridoma clone 1.1 
and recognises the chicken ovalbumin residues 323-339 (OT-II peptide) in the 
context of H2-Ab1 (I-Ab) (Barnden et al., 1998). The Mouse Genome Informatics 
reference ID for this allele is MGI:3046083. 
 
B6 H2-Ab1-/- (H2-Ab <tm1Doi>): MHC class II β chain deficient mouse strain that 
was produced from ES cell lines carrying a deleted H2-Ea promoter region and 
additional disruption of H2-Ab exon 2 by neomycin resistance cassette insertion. 
Cells from these mice therefore lack surface expression of MHC class II A and E 
proteins (Cosgrove et al., 1991). The Mouse Genome Informatics reference ID for 
this allele is MGI:1927483. 
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B6 H-2bm1 (H-2k <bm1>): MHC class I mutant mouse strain. H-2 <bm1> mice carry 
a 7 nucleotide substituting mutation resulting in amino acid changes in the C1 H-2 
domain at codon 152 (glutamate to alanine), codon 155 (arginine to tyrosine) and 
codon 156 (leucine to tyrosine) (Schulze et al., 1983), rendering <bm1> mutant 
MHC class I bearing cells unable to present the OVA257-264 (SIINFEKL) peptide 
to OT-I CD8+ T cells (Nikolic-Zugic and Bevan, 1990). The Mouse Genome 
Informatics reference ID for this allele is MGI:3618114. 
 
2.1.2 Generation of bone marrow chimeric mice 
For the generation of bone marrow chimeric mice, at least 6-week-old recipient mice 
were irradiated with two doses of 450cGy (for C57BL/6J, B6 Bafftg, ML-5 and B6 
Ly5a mice), or if B6 Rag1-/- mice were used as recipients, only a single dose of 
450cGy was applied. Each irradiated recipient mouse was injected into the tail vein 
with 200µl PBS suspending 2-3x106 freshly prepared and filtered bone marrow cells. 
Bone marrow cells were extracted from femur and tibia bones of donor mice of the 
genotypes indicated in the figures, then counted and flowcytometrically analysed to 
confirm the phenotype and proportional composition of the injected cell mixtures. 
After cell injection all recipient mice were treated prophylactically with neomycin 
and polymyxin B antimicrobial chemotherapy through the drinking water and were 
regularly monitored for body weight, comfort and general condition. 10 to 12 weeks 
of time were allowed for successful haematopoietic reconstitution, which was 
monitored by flowcytometric analysis of recipient blood samples, before collection 
of lymphoid recipient tissues for detailed leukocyte analysis. 
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2.2 Solutions and Antibodies 
2.2.1 Buffers, solutions and media 
Buffer/Solution/Medium Composition 
Phosphate Buffered Saline 
(PBS), ddH2O and culture media 
PBS and ddH2O for flowcytometry applications 
were prepared in-house by the John Curtin 
School of Medical Research Media Preparation 
Unit. PBS, ddH2O, RPMI 1640 and DMEM for 
cell culture usage were purchased from Gibco 
(Life Technologies) 
Lymphocyte culture medium, 
complete RPMI (cRPMI) 
RPMI 1640 medium (Gibco, Life Technologies) 
was supplemented with 10mM HEPES pH 7.4 
(Sigma-Aldrich), 0.1 mM non-essential amino 
acid solution (Gibco, Life Technologies), 1 mM 
sodium-pyruvate (Sigma-Aldrich), 55µM 2-
Mercaptoethanol (Life Technologies), 2mM L-
glutamine, 100U/ml penicillin-100µg/ml 
streptomycin (Life Technologies) and 10% (v/v) 
heat inactivated fetal calf serum (FCS) (Life 
Technologies) 
Cell line culture medium, 
complete DMEM (cDMEM) 
DMEM medium (Gibco, Life Technologies) was 
supplemented with 2mM L-glutamine, 100U/ml 
penicillin-100µg/ml streptomycin (Life 
Technologies) and 10% (v/v) heat inactivated 
fetal calf serum (FCS) (Life Technologies) 
Dendritic cell culture medium 
(DC-media) 
RPMI 1640 medium was supplemented with 
2mM L-glutamine, 55µM 2-Mercaptoethanol 
(Life Technologies), 100U/ml penicillin-
100µg/ml streptomycin (Life Technologies) and 
10% (v/v) heat inactivated fetal calf serum (FCS) 
(Life Technologies) 
Flowcytometric buffer (FACS-
wash) 
PBS supplemented with 2% (v/v) bovine serum 
(BS) (Thermo Fisher Scientific Australia) and 
0.1% (w/v) sodium azide (Australian Chemical 
Reagents) 
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Magnetic cell separation buffer 
(MACS buffer) 
PBS supplemented with 0.5% (w/v) bovine serum 
albumin (BSA, biotin free) and 2mM EDTA 
Red blood cell (RBC) lysis stock 
buffer (10X) 
To make 1l of 10X RBC lysis stock solution, 
82.9g (1.55M) ammonium chloride (NH4Cl), 10g 
(100mM) potassium bicarbonate (KHCO3) and 
0.37g (1mM) sodium-EDTA (or 2ml of 0.5M 
EDTA stock solution) were dissolved in 900ml 
ddH2O and adjusted to 1l volume. 
Red blood cell (RBC) lysis 
working buffer (1X) 
RBC-lysis working solution was made by 
dilution of the 10X RBC-lysis stock to 1X in 
ddH2O and adjusting the pH to 7.3 before use 
EDTA-PBS (Aliberti et al., 
2003) 
To make 500ml of EDTA-PBS, add 500µl of 
0.5M EDTA solution to 500ml PBS 
30% BSA-PBS (Aliberti et al., 
2003) 
To make 10ml of 30% BSA-PBS, dissolve 
exactly 3g of bovine serum albumin (BSA; 
Sigma-Aldrich) in PBS and fill volume to 10ml. 
2ml of 30% BSA-PBS are needed for the gradient 
cut of one mouse spleen cell suspension. Keep at 
4°C to maintain density during use. 
RPMI-HEPES-FCS RPMI 1640 supplemented with 2% (v/v) heat 
inactivated FCS and buffered with HEPES to pH 
7.2 
EDTA-FCS To make 11ml of EDTA-FCS combine 10ml of 
FCS with 1ml of 0.1M EDTA 
EDTA-BSS 5mM EDTA supplemented with NaCl and KCl at 
1:40 ratio to final osmolarity of 308m. osmolar, 
buffered with HEPES to pH 7.2 
EDTA-BSS-FCS 95% EDTA-BSS mixed with 5% EDTA-FCS 
Acetic acid solution for PE 
inactivation 
150mM sodium chloride (NaCl) and 150mM 
acetic acid were dissolved in ddH2O and the pH 
adjusted to 2.7 
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ELISA carbonate coating buffer 0.05M sodium Na2CO3 ((di-)Sodium Carbonate 
anhydrous) (Sigma-Aldrich) dissolved in ddH2O 
and pH adjusted to 9.6 
ELISA BSA blocking buffer 1% (w/v) bovine serum albumin (BSA) dissolved 
in PBS 
ELISA Tween washing buffer 0.05% (v/v) Tween 20 (Sigma-Aldrich) dissolved 
in PBS (pH 7.4) 
ELISA BSA-Tween dilution 
buffer 
1% (w/v) bovine serum albumin (BSA) and 
0.05% (v/v) Tween 20 (Sigma-Aldrich) dissolved 
in PBS 
ELISA developing glycine 
buffer 
0.1M glycine (BioRad), 0.1mM zinc chloride 
(ZnCl2) (Sigma-Aldrich), 1M magnesium 
chloride (MgCl2) (Sigma-Aldrich) were 
dissolved in ddH2O and pH adjusted to 10.4 with 
sodium hydroxide solution 
ELISA phosphatase substrate 
solution 
2 tablets of pNPP phosphatase substrate (Sigma-
Aldrich) were dissolved in 10ml of ELISA 
developing glycine buffer 
Lysis buffer To prepare 50ml of lysis buffer combine 250µl 
IGPAL detergent, 2.5ml 1M Tris-HCl (7.4), 
250µl 1M MgCl2 and fill volume to 50ml with 
ddH2O. Add 1 protease inhibitor table (Roche). 
Store as 1ml aliquots at -20°C until use. 
NET buffer To prepare 50ml of NET buffer combine 5ml 
10% Triton X (Sigma-Aldrich), 100µl of 0.5M 
EDTA (pH8), 1.5ml 5M NaCl, 1ml 1M Tris 
(pH7.4) and fill volume to 50ml with ddH2O. 
Optionally 500ul of 1M NEM (125mg/ml NEM 
in 96% ethanol) can be added to inhibit de-
ubiquitination. Freshly add 1 protease inhibitor 
table (Roche). 
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TNM buffers To prepare 50ml of TNM-buffer combine 1.25ml 
1M Tris-HCl, pH7.4, 7.5ml 1M NaCl solution, 
250µl 1M MgCl2 and fill volume to 50ml with 
ddH2O (41ml). Freshly add 1 protease inhibitor 
table (Roche) and either 0.1% or 2% (w/v) 
Digitonin (Sigma-Aldrich) as needed for either 
washing or lysis TNM buffer. 
SDS-sample buffer (4x) To make immunoblot sample-SDS buffer 4x 
stock combine 2ml of 1M Tris-HCl pH 6.8, 0.8g 
of SDS, 4ml Glycerol, 0.4ml 2-Mercaptoethanol, 
1ml of 0.5M EDTA solution and 8mg of 
Bromophenol Blue and fill to 10ml volume with 
ddH2O. Use by diluting 1 part sample in 3 parts 
sample buffer. 
SDS-sample buffer (2x) for 
detection of small peptides by 
Tricine-SDS-PAGE (Schagger, 
2006) 
To make 20ml of 2x SDS-sample buffer combine 
12ml of 10% SDS solution, 3ml Glycerol, 1.82ml 
of 1M Tris solution adjusted to pH6.8, 0.6ml of 
2-Mercaptoethanol, 5µl of saturated 
Bromophenol Blue solution and fill volume to 
20ml with ddH2O (2.575ml) 
Anode running buffer (10x; 
outer chamber) for detection of 
small peptides by Tricine-SDS-
PAGE (Schagger, 2006) 
To make 500ml of anode running buffer 10x 
stock, dissolve 60.6g of alkaline Tris (1M) in 
ddH2O, adjust pH to 8.9 and fill volume with 
ddH2O to 500ml 
Cathode running buffer (10x; 
inner chamber) for detection of 
small peptides by Tricine-SDS-
PAGE (Schagger, 2006) 
To make 200ml of cathode running buffer 10x 
stock dissolve 24.23g alkaline Tris (1M), 35.82g 
Tricine (1M) 2g of SDS (1%) in ddH2O and fill 
with ddH2O to 200ml. Solution should have ~pH 
8.25. 
Gel Buffer (3x) To make 500ml of Gel buffer 3x stock, dissolve 
181.6g alkaline Tris (3M) and 1.5g SDS (0.3%) 
in ddH2O, titrate with 37% conc. HCl solution to 
pH 8.45 (~12.5ml) and fill volume with ddH2O to 
500ml 
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16% Lower gels with 6% 
crosslinking (volume enough for 
two 0.07x8x5cm Minigels) 
To make two lower gels combine 4ml of 40% 
19:1 Acrylamide/Bisacrylamide (BioRad), 
3.33ml of 3x Gel buffer, 793µl Glycerol and fill 
volume to 10ml with ddH2O (~1.874ml). Add 
33µl of freshly in ddH2O dissolved 10% 
ammonium persulfate (APS; Sigma-Aldrich) and 
10µl of tetramethylethylenediamine (TEMED; 
BioRad) just before casting the gel. 
4% Upper gels with 6% 
crosslinking (volume enough for 
two 0.07x8x5cm Minigels) 
To make two upper gels combine 0.4ml of 40% 
19:1 Acrylamide/Bisacrylamide (BioRad), 1ml of 
3x Gel buffer and fill volume to 4ml with ddH2O 
(~2.6ml). Add 30µl of freshly in ddH2O dissolved 
10% ammonium persulfate (APS; Sigma-Aldrich) 
and 3µl of tetramethylethylenediamine (TEMED; 
BioRad) just before casting the gel. 
 
 
 
 
 
 
2.2.2 Antibodies 
Antibodies, cell dyes and membrane reagents used in this study are summarised in 
tables: Primary anti-mouse antibodies and sera for flowcytometry and microscopy 
are shown in Table 2.1. Secondary reagents to detect biotinylated or non-conjugated 
antibodies by fowcytometry or microscopy are shown in Table 2.2. Flowcytometry 
antibodies against human markers are shown in Table 2.3 and cell dyes in Table 2.4. 
Table 2.5 lists antibodies and sera that were used to detect proteins by immunoblot or 
immunoprecipitation. 
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Target Clone Conjugate Source 
CD103 M2/69 PE J. A. Villadangos 
CD11b M1/70 Biotin BD 
CD11b M1/70 APC Cy7 BioLegend 
CD11b M1/70 Biotin BioLegend 
CD11b M1/70 APC eBioscience 
CD11b M1/70 FITC eBioscience 
CD11c HL3 Biotin BD 
CD11c HL3 Biotin BD 
CD11c N418 PE eBioscience 
CD11c N418 PE Cy7 eBioscience 
CD16/CD32 (Fc-Block) 2.4G2 none BD 
CD172a (SIRPα) P84 FITC BD 
CD172a (SIRPα) P84 AF594 J. A. Villadangos 
CD172a (SIRPα) P84 AF633 J. A. Villadangos 
CD19 1D3 APC BD 
CD19 1D3 PE BD 
CD19 6D5 Brilliant Violet 510 BioLegend 
CD19 1D3 AF700 eBioscience 
CD19 1D3 Biotin eBioscience 
CD21/35 7G6 FITC BD 
CD21/35 7G6 PE BD 
CD21/35 7E9 FITC BioLegend 
CD23 B3B4 PE BD 
CD23 B3B4 Pacific Blue BioLegend 
CD23 B3B4 PE Cy7 eBioscience 
CD24 M1/69 Pacific Blue BioLegend 
CD24 M1/69 PE BioLegend 
CD24 M1/69 PE eBioscience 
CD24 91 Biotin SouthernBiotech 
CD25 PC61 APC BD 
CD25 7D4 Biotin BD 
CD25 7D4 FITC BD 
CD25 PC61 PE Cy7 BioLegend 
CD268 (BAFFR) 7H22-E16 PE BioLegend 
CD3 145-2C11 PerCP BD 
CD3 17A2 PerCP Cy5.5 BioLegend 
CD3 145-2C11 AF700 eBioscience 
CD3 145-2C11 FITC eBioscience 
CD317 (BST-2) 120G8 AF680 J. A. Villadangos 
CD4 RM4-5 AF700 BD 
CD4 GK1.5 Biotin BD 
CD4 RM4-5 AF700 BioLegend 
CD4 GK1.5 APC eBioscience 
CD4 GK1.5 PE eBioscience 
CD43 S7 FITC BD 
CD43 S7 PE BD 
CD43 1B11 Biotin BioLegend 
Table 2.1: List of primary flowcytometry antibodies  
 
Primary antibodies and conjugates used for flowcytometry. 
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Target Clone Conjugate Source 
CD44 IM7 APC BD 
CD44 IM7 Pacific Blue BioLegend 
CD44 IM7 FITC eBioscience 
CD45 30-F11 FITC BD 
CD45.1 (Ly5a) A20 FITC BD 
CD45.1 (Ly5a) A20 PE BD 
CD45.1 (Ly5a) A20 AF700 BioLegend 
CD45.2 (Ly5b) 104 PerCP Cy5.5 BD 
CD45.2 (Ly5b) 104 Pacific Blue BioLegend 
CD45.2 (Ly5b) 104 APC eBioscience 
CD45R (B220) RA3-6B2 A700 BD 
CD45R (B220) RA3-6B2 APC BD 
CD45R (B220) RA3-6B2 APC Cy7 BD 
CD45R (B220) RA3-6B2 Biotin BD 
CD45R (B220) RA3-6B2 FITC BD 
CD45R (B220) RA3-6B2 PerCP BD 
CD45R (B220) RA3-6B2 Brilliant Violet 605 BioLegend 
CD45R (B220) RA3-6B2 PE eBioscience 
CD45RA 14.8 APC J. A. Villadangos 
CD45RA 14.8 PerCP Cy5.5 J. A. Villadangos 
CD5 53-7.3 Biotin BD 
CD5 53-7.3 APC eBioscience 
CD62L MEL-14 APC eBioscience 
CD62L MEL-14 FITC eBioscience 
CD62L MEL-14 PE eBioscience 
CD69 H1.2F3 PE Cy7 BioLegend 
CD69 H1.2F3 FITC eBioscience 
CD71 (Transferrin R.) C2 Biotin BD 
CD71 (Transferrin R.) C2 PE BD 
CD74 C-terminus JV11 (rabbit serum) none J. A. Villadangos 
CD74 N-terminus IN1 FITC BD 
CD74 N-terminus JV5 (rabbit serum) none J. A. Villadangos 
CD8 53-6.7 eF450 eBioscience 
CD8 53-6.7 Biotin BD 
CD8 53-6.7 PE Cy7 BioLegend 
CD8 YTS169.4 APC eBioscience 
CD8 53-6.7 APC Cy7 eBioscience 
CD90.2 53-2.1 Biotin BD 
CD93 AA4.1 APC BD 
CD93 AA4.1 Biotin eBioscience 
CD95 Jo2 PE Cy7 BD 
CD95 15A7 PE eBioscience 
CXCR5 2G8 Biotin BD 
GL-7 GL7 FITC BD 
Gr-1 RB6-8C5 APC Cy7 BD 
Gr-1 RB6-8C5 Biotin BD 
Table 2.1 continued: List of primary flowcytometry 
antibodies 
 
Primary antibodies and conjugates used for flowcytometry. 
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Target Clone Conjugate Source 
IA/IE αβ-dimers M5/114.5.2 eF450 eBioscience 
IA/IE αβ-dimers M5/114.15.2 Brilliant Violet 421 BioLegend 
IgD 11-26c.2a PerCP Cy5.5 BioLegend 
IgD 11-26c Biotin eBioscience 
IgD 11-26c FITC eBioscience 
IgD 11-26c.2a PE BioLegend 
IgDa AMS-9.1 FITC BioLegend 
IgM II/41 APC BD 
IgM II/41 Biotin BD 
IgM II/41 PE eBioscience 
IgM II/41 PE Cy7 eBioscience 
IgMa DS-1 PE BD 
IgMb AF6-78 PE BD 
Lamp1 1D4B eF660 eBioscience 
Ly6C HK1.4 Biotin BioLegend 
NK1.1 PK136 APC BD 
NK1.1 PK136 Biotin BD 
NK1.1 PK136 PE eBioscience 
PD-1 J43 PE eBioscience 
TCR-Vα2 B20.1 PE eBioscience 
TCRβ H57-597 Biotin BD 
TCRβ H57-597 APC Cy7 BioLegend 
TCRγ/δ GL3 Biotin BD 
Ter119 TER-119 Biotin BD 
Target Reagent/Clone Conjugate Source 
Biotin Streptavidin APC BD 
Biotin Streptavidin Brilliant Violet 605 BioLegend 
Biotin Streptavidin Qdot605 Invitrogen 
Biotin Streptavidin PE Cy7 eBioscience 
IgG (rabbit) polyclonal AF647 Invitrogen 
Table 2.2: List of secondary flowcytometry reagents 
 
Secondary reagents and conjugates used for flowcytometry 
or as indicated in the text. 
Table 2.1 continued: List of primary flowcytometry 
antibodies 
 
Primary antibodies and conjugates used for flowcytometry. 
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Target Clone Conjugate Source 
CD19 HIB19 PE Cy7 eBioscience 
CD3 SP34-2 AF700 BD 
HLA-DR G46-6 PE BD 
IgD IA6-2 PE BD 
IgM G20-127 FITC BD 
N-terminal CD74 Pin.1 PE BioLegend 
Target Reagent Emission/Conjugate Source 
Protein Zombie NIR Live/Dead Far red BioLegend 
Protein Fixable Viability Dye eF780 eBioscience 
DNA Chemical 7-AAD Invitrogen 
Phosphatidylserine Annexin-V Pacific Blue BioLegend 
Plasmamembrane C6-NBD-PS FITC Avanti Polar Lipids, Inc. 
Protein Chemical Cell Trace Violet Invitrogen 
Protein Chemical CFSE Molecular Probes 
Target Purification/Clone Conjugate Source 
I-A α chain JV1 (rabbit serum) none J. A. Villadangos 
CD74 N-terminus JV5 (rabbit serum) none J. A. Villadangos 
IgM affinity purified (goat) none Jackson 
CD74 N-terminus IN1 (rat) none BD 
α/β-Tubulin affinity purified (rabbit) none Cell Signalling Technology 
IgG (rabbit) affinity purified HRP Cell Signalling Technology 
IgG (rat) affinity purified HRP Cell Signalling Technology 
Table 2.4: List of cell dyes and membrane reagents 
 
Cell and membrane dyes used to measure proliferation, 
apoptotic or dead cells and membrane composition. 
Table 2.5: List of immunoblot antibodies 
 
Antibodies used for immunoblotting and immunoprecipitation 
as indicated in the text. 
Table 2.3: List of human flowcytometry antibodies 
 
Primary antibodies and conjugates used for flowcytometric 
analysis of human samples. 
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2.3 Cell isolation 
2.3.1 Isolation of lymphocytes 
Unless stated otherwise all direct cell handling environments were carefully kept at 
0-4°C by generally performing cell work on a bed of ice, cooling centrifuges to 4°C 
and using ice-cold cell solutions and buffers. Cells were generally centrifuged at 
350-400g, whilst centrifugation time was dependent on the size of the liquid column. 
Typically, 96-well U-bottom FACS-plates with up to 350µl of cell suspension per 
well were centrifuged for 2min to form an adherent cell pellet. 
 
Mouse tissues, such as spleens, thymi, lymphnodes, femur and tibia bones were 
dissected from mice sacrificed by cervical dislocation and collected in ice-cold 
FACS-wash or sterile cRPMI for cell culture or cell transfer experiments. Whilst 
syringes and 35G needles were used to pressurise FACS-wash or cRPMI liquid to 
first flush cells out scissor-cut opened bone cavities, single cell suspensions from soft 
tissues were prepared directly by passing through a 70µm nylon mesh filter (BD). 
Filtered cell suspensions were subjected to less than 3min (typically 1-2min), 
agitated incubation in red cell lysis buffer (RBC-lysis) at room temperature, before 
stopping RBC-lysis by at least 2-fold dilution of the RBC-lysis buffer with ice-cold 
FACS-wash or cRPMI, followed by immediate centrifugation and resuspension in 
fresh FACS-wash or cRPMI, followed by a second centrifugation. After discarding 
the supernatant, the resulting cell pellet was resuspended to an appropriate volume 
suitable, based on expected cell numbers and intended cell usage. As described 
elsewhere in this chapter, viable cells where then counted either manually on a 
haemocytometer or automatically on a ViCell Counter (Beckham Coulter) by using 
the trypan-blue exclusion method. For further flowcytometric antibody staining 
typically 2x106 cells were transferred from tissue cell suspensions per well of a 96-
well U-bottom FACS-plate. Once all samples were transferred into wells, FACS-
plates were centrifuged to pellet cell suspensions, flicked to discard supernatant and 
exposed cell pellets were subsequently resuspended in antibody mixtures for staining 
as outlined below. 
 
To isolate lymphocytes for flowcytometric analysis from ~200µl mouse blood 
samples collected by retro-orbital bleeding into 20µl of 1000U/ml heparin containing 
cluster tubes by trained animal technicians at the Australian Phenomics Facility, 
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freshly collected blood was usually allowed to rest at room temperature for 2-3 hours 
before further processing to improve red cell lysis. 70µl blood aliquots for each 
sample were typically transferred into 96-well U-bottom 350µl FACS-plates and 
incubated with ~220µl RBC-lysis buffer for 3min at room temperature, followed by 
centrifugation and a second resuspension in 250µl RBC-lysis buffer for 3min. At the 
end of the second incubation time, cells were centrifuged, from then on kept on ice 
and resuspendend in cold FACS-wash for washing followed by centrifugation to 
pellet cells ready for receiving antibody staining mixtures and flowcytometric 
analysis. 
 
2.3.2 Isolation of DCs and macrophages 
DCs and Macrophages were generally isolated from mouse spleens for 
flowcytometric analysis of their phenotype by following previously described 
protocols based on collagenase tissue digestion and using concentrated bovine serum 
albumin (BSA) in PBS as density gradient (Aliberti et al., 2003). For high purity 
isolation of DCs from spleens intended to be used for confocal microscopy, 
endocytosis or antigen presentation assays and for immunoblot analysis, more 
elaborate pre-enrichment of DCs from tissue preparations was employed using 
protocols described extensively by David Vremec and colleagues (Vremec et al., 
1992, Vremec et al., 2000, Vremec and Shortman, 2008). 
 
DCs and Macrophages were isolated for flowcytometric phenotyping from spleens 
by injecting about 2ml freshly prepared and pre-warmed to 37°C FCS-free RPMI-
Collagenase mix (2mg/ml; has to be trypsin-free; Roche) into the organ, followed by 
artificial mastication using scissors and agitated incubation of mashed spleen tissue 
in the resulting ~2ml suspension for 30min at 37°C. Digested spleen tissue fragments 
were passed and washed through 70µm nylon mesh filter whilst adding up to 12ml of 
ice-cold EDTA-PBS to stop collagenase and break up DC-T cell rosettes. From here 
on, cell processing continued on ice. The resulting cell suspension was centrifuged to 
pellet and washed by resuspending in EDTA-PBS, followed by centrifugation and 
resuspension of the pellet in 2ml of 4°C cold PBS. The 2ml PBS-spleen suspension 
was then carefully layered onto a column of 2ml, 4°C 30% PBS-BSA, prepared in a 
15ml Falcon tube (BD). The resulting two-phase liquid column was centrifuged 
(with brakes turned off) at 500g for 15min and at 4°C. After centrifugation the PBS-
spleen cell suspension separates into a high-density pellet at the bottom of the tube 
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and a light density cell fraction, which floats at the interface between 30% BSA-PBS 
and PBS. The light density cell fraction was collected carefully using a Pasteur 
pipette and transferred to a fresh tube, followed by adding ~12ml of cold EDTA-PBS 
to resuspend and wash the collected fraction. The suspension was centrifuged and 
resuspended in 3ml room temperature RBC-lysis buffer for 1min, then 14ml cold 
EDTA-PBS were added and the suspension centrifuged. After discarding the 
resulting supernatant, the light density spleen cell pellet was resuspended in 1ml of 
FACS-wash, counted and transferred in adequate cell numbers into 96-well U-
bottom FACS plates for flowcytometric antibody staining and analysis. Typically, 
this 30% BSA-PBS gradient cut spleen preparation yielded a light density fraction of 
6x106 cells, of which 1.5-2x106 cells were CD11c+ DCs. For flowcytometric analysis 
of macrophages and monocytes from the spleen the density gradient centrifugation 
was omitted and cells were analysed after collagenase digest and RBC-lysis. 
 
DCs were isolated from spleens using the protocol of David Vremec and co-workers 
by dissecting up to 8 spleens per preparation into small pieces with scissors and 
collecting tissue pieces in 6ml of RPMI-HEPES-FCS, to which 1 ml of pre-prepared 
DNAse (0.01%; Boehringer-Mannheim) and collagenase (1mg/ml; Worthington 
Biochemicals) were added to the indicated final concentrations and incubated under 
agitation for 20-30min at room temperature. Then, addition of 0.6ml 0.1M EDTA at 
pH 7.2 breaks up DC-T cell interactions and mixing with a Pasteur pipette is 
continued for 5min. The cell-tissue digestion was then passed through a nylon mesh 
cell filter and the flow-through volume was adjusted to ~9ml volume by adding and 
washing with RPMI-HEPES-FCS. 2-3ml Cold EDTA-FCS were layered underneath 
the cell suspension and cells were centrifuged to pellet into the lower EDTA-FCS 
phase and the supernatant discarded. For every 4 organs that were pooled into the 
preparation the pellet was then mixed with 5ml of Nycodenz medium (Nycomed 
Pharma, Oslo, Norway), prepared at 1.077g/cm3 density (kindly supplied by K. 
Shortman laboratory, Walter and Eliza Hall Institute, Melbourne, Australia). The 
cell-Nycodenz mixture was then overlayed onto 5ml of Nycodenz in another tube 
and then itself overlayed with 1-2ml EDTA-FCS to create a three-phase column in a 
15ml Falcon tube. The phases were broken by inserting a glass Pasteur pipette, 
followed by centrifugation at 1700g for 10-15min at 4°C. The upper zone of the 
centrifuged gradient cut, which included the light-density cell fraction, was collected 
and transferred to a clean 50ml Falcon tube, leaving about 4ml with the high-density 
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cell fraction pellet behind. The light density fraction was then resuspended with 30-
40ml EDTA-BSS-FCS for washing and centrifuged to form a pellet, from which the 
supernatant was removed. The cells in the pellet were counted to determine adequate 
antibody concentrations for the following magnetic bead depletion step of non-DC 
cell types. 10µl of monoclonal non-DC-depletion antibody cocktail (kindly supplied 
titrated and diluted to work optimally at 10µl/106 cells by K. Shortman laboratory, 
Walter and Eliza Hall Institute, Melbourne, Australia; anti-CD3, (clone KT3-1.1) + 
anti-Thy1, (clone T24/31.7) + anti-Ly6G/Ly6C, (clone 1A8) + anti-CD19, (clone 
ID3) + anti-Ter119, (clone TER-119)) was added to the pellet for every 106 cells, 
then mixed and incubated on ice for 30min. To wash the labelled cells, EDTA-BSS-
FCS was added to a volume of ~9ml and the resulting suspension underlayed with 
1ml of EDTA-FCS. Centrifugation pelleted the cells into the bottom layer of the 
liquid column and excess antibody cocktail could be removed by discarding the 
upper layer. EDTA-BSS-FCS pre-washed BioMag goat-anti-IgG coated magnetic 
beads (Qiagen) were prepared at 10 beads per cell and mixed with the washed cell 
pellets in 300-400µl of EDTA-BSS-FCS in a 6ml polypropylene round bottom tube 
and incubated under rotating agitation for 20min at 4°C. Then the cell-bead mix was 
diluted with 4ml EDTA-BSS-FCS and attached to appropriate magnets (Thermo 
Fisher Scientific, Dynabeads MPC-S Magnetic Particle Concentrator, or similar) to 
adhere magnet-beads to the tube wall and allow the collection of bead-free 
supernatant with a Pasteur pipette, transferring the supernatant to a fresh tube and 
repeating the magnetic depletion of beads. The collected supernatant was then 
underlayed with 1-2ml EDTA-FCS to wash cells into the bottem layer by 
centrifugation and recover a final light-density, DC enriched cell population that was 
further flowcytometrically analysed or FACS sorted for the aforementioned 
experiments. This DC isolation procedure was less susceptible to cell loss than the 
DC isolation method described in the preceding paragraph, and normally yielded 
about 2.5-4x106 light density cells per spleen, of which around 90% were DCs. 
 
2.3.3 PBMC isolation from human blood 
Human blood samples were aliquoted at 15ml volumes into 50ml Falcon tubes (BD) 
and mixed with 15ml PBS, all at room temperature. A fine glass Pasteur-Pipette was 
used to underlay the blood-PBS suspension with 15ml of the density adjusted, highly 
branched polysaccharide solution Ficoll (GE Healthcare) before centrifugation at 
400g for 40min. Centrifugation separated the gradient mixture into several distinct 
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phases, of which the layer of peripheral blood mononuclear cells between the Ficoll 
and serum phase was collected by careful aspiration using a fine glass Pasteur-
Pipette and transferring PBMCs to a fresh 50ml Falcon tube. Subsequent washing of 
the pipette with PBS minimised PBMC losses. Collected PBMCs were then washed 
twice by re-suspension into 50ml of PBS, centrifugation and discarding of 
supernatant. Washed PBMCs were counted on haemocytometer by trypan blue 
exclusion and used fresh for flowcytometric analysis. 
 
2.4 Cell culture 
2.4.1 Cell cultures for treatments with mitogens, staurosporine or 3-
methyladenine 
B cell activation with mitogens was tested by isolation of spleen cells into cRPMI 
suspensions, followed by brief RBC lysis. When proliferation was assessed, cells 
were labelled with Cell Trace Violet (CTV; Invitrogen), by incubation in cRPMI 
supplemented with 200µM CTV at 37°C for 20min in the dark. CTV-labelled cells 
were then washed by resuspension in cRPMI, counted and, alike to non-CTV 
labelled splenocytes, plated in cRPMI for cell culture at 1x106 cells/ml in 37°C and 
5% CO2. As mitogens anti-IgM (10µg/ml; Jackson ImmunoResearch Laboratories, 
Inc.), anti-IgM plus anti-CD40 (10µg/ml; FGK4.5, BioXCell), lipopolysaccharides 
(LPS; 10µg/ml; Sigma-Aldrich), CpG (1µg/ml; GeneWorks, Hindmarsh, Australia), 
IgM plus LPS or Macrophage Migration Inhibitory Factor (MIF; 25, 100 and 
200ng/ml; R&D systems) were added to cultures in the indicated final 
concentrations. Stimulated cells were cultured for 24 hours to assess B cell activation 
by flowcytometric analysis after staining with live-dead discrimination dye 7AAD, 
anti-CD25-APC, anti-CD69-PE Cy7, anti-CD44-FITC, anti-CD19-AF700 and anti-
B220-APC Cy7 (see Table 2.1). After 96 hours of culture B cell proliferation was 
flowcytometrically analysed by staining with 7AAD, anti-CD19-AF700 and anti-
B220-APC Cy7 to measure CTV fluorescence dilution in B cells.  
 
To assess susceptibility of B cells to apoptosis, splenocytes were isolated and 
cultured for 0.5 or 3 hours in cRPMI in the presence of 1µg/ml of the protein kinase 
inhibitor staurosporine (Sigma-Aldrich) or not. After culture, cells were moved onto 
ice until staining with 7AAD, Annexin V and B cell surface markers for 
flowcytometric analysis of apoptosis and cell death as shown in Figure 3.25.  
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To measure the effect of the PI3-Kinase and autophagy inhibitor 3-methyladenine (3-
MA) on surface expression of IgM and IgD in B cells, isolated splenocytes were 
cultured in cRPMI at 1x106 cells/ml supplemented with 10µg/ml LPS and in the 
presence of titrated concentrations of 3-MA (Sigma-Aldrich). Cells were treated with 
0, 0.5, 1, 5, 10, 20 or 40 mM of 3-MA and cultured for 8 hours before 
flowcytometric analysis for B cell surface expression of IgM and IgD. Cells were 
also stained and analysed for Annexin V binding and 7AAD in order to control for 
toxic effects of 3-MA during the culture period. 
 
FL-DCs were activated in culture for 24 hours by adding GM-CSF (10ng/ml; Pepro 
Tech), LPS (1µg/ml) or CpG (0.5nMol) to pre-established day 9 Flt3-Ligand 
supplemented bone marrow cultures that were originally plated at 1.5x106 bone 
marrow cells per ml of DC-media on day 0, as described in subchapter 2.4.3. After 
24 hours of treatment, FL-DCs were harvested from cultures and flowcytometrically 
analysed for surface expression of CD69, CD103 and MHCII (see Table 2.1) on live 
CD24+ or Sirpα+ CD11c+ FL-DC. 
 
2.4.2 Retroviral transductions 
For retroviral transduction of bone marrow B cells (see Figure 3.2), mouse Sppl2a 
cDNA was cloned into pMX-IRES-EGFP (Sppl2a-pMX-IRES-EGFP was kindly 
provided by Keisuke Horikawa, John Curtin School of Medical Research) and 
transduced into retroviral producer cell line GP+E86 (a kind gift from Dario Vignali, 
St. Jude Children's Research Hospital). MACS purified B220+ B cells from bone 
marrow were cultured in 10 ng/ml IL-7 (R&D Systems) for 2 days, and co-cultured 
with retroviral producer cells for 48h in the presence of IL-7 and Polybrene (Sigma-
Aldrich). The cells were washed, cultured for 8 days with 10 ng/ml BAFF (R&D 
Systems) without IL-7 to facilitate survival of maturing B cells, and analysed by flow 
cytometry. Splenocyte transduction with retroviral empty vector EGFP+ (EV) or 
constitutively active IkkB EGFP+ construct (Ikk*, kindly provided by James Wang 
and Keisuke Horikawa, John Curtin School of Medical Research) was done similar 
to previous descriptions (Jeelall et al., 2012, Wang et al., 2014). In brief, mouse 
splenocytes were activated in culture for 24h with 10µg/ml LPS and 10µg/ml α-IgM 
(both Jackson ImmunoResearch Laboratories, Inc.), spinocculated at room 
temperature with retroviral packaging cell line supernatants containing DOTAB 
(Roche) by centrifuging at 920 g for 90 min. Thereafter, transduced cells were 
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cultured for another 36h with mitogens, before LPS and α-IgM were washed off the 
cells (the experimental time point designated as day 0). Transduced splenocytes were 
then analysed for surface phenotype and changes in live and GFP positive or 
negative cell numbers on days 1 and 3. 
 
2.4.3 FL-DC cultures 
Generation of ‘FL-DCs’ from murine FMS-Like Tyrosine Kinase 3 Ligand (Flt3-
Ligand or FL; produced as in-house stock by Walter and Eliza Hall Institute, 
Melbourne, Australia or R&D Systems) supplemented bone marrow bulk cultures 
was done as described previously (Brasel et al., 2000, Naik et al., 2005). In brief, 
bone marrow was isolated in sterile environment into cell suspensions from mouse 
femur and tibial bones. Isolated bone marrow cells were re-suspended at 1.5x106 
cells per ml in DC-media supplemented with Flt3-Ligand (300ng/ml or optimally 
titrated concentration, depending on stock to ensure optimal development of 
CD11c+MHCII+ cells over 9 days) and cultured for 8-10 days at 37°C and 10% CO2. 
After 9 days of culture or else as indicated in the results, FL-DCs were harvested and 
used for experiments, whilst CD8+, CD8- and pDC equivalent subsets could be 
distinguished in day 9 cultures by flowcytometric staining for anti-CD11c, anti-
MHCII, anti-B220 or anti-CD45RA, anti-CD24, anti-SIRPα or anti-CD11b (see 
Table 2.1) (Naik et al., 2005). 
 
2.4.4 DC in vitro antigen presentation assays 
As depicted in Figure 5.21 and similar to previous descriptions (Schnorrer et al., 
2006), DC exogenous antigen presentation on MHC class I or II to antigen specific 
CD4+ or CD8+ T cells was tested in vitro cultures and thus required the preparation 
of the three ingoing components: DCs, antigen and T cells. DCs were FACS sorted 
from mouse spleens and plated in DC-media at 1x104 cells per well into U-bottom 
96-well plates. For presentation of soluble OVA (sOVA; Worthington) and OVA257-
264 peptide (SIINFEKL, OT-I; Auspep, Melbourne, Australia), DCs were then pulsed 
by incubation in titrated final culture amounts of sOVA (0.5, 0.25, 0.125, 0.0625, 
0.03125mg/ml) and OT-I-SIINFEKL peptide (0.1, 0.01, 0.001, 0.0001, 
0.00001ug/ml) for 1 hour at 37°C, followed by three washes in DC-media to remove 
any excess antigen. OVA323-339 synthetic peptide (OT-II; Auspep, Melbourne, 
Australia) was directly added to DCs for presentation at titrated final concentrations 
of 1, 0.1, 0.01, 0.001, 0.0001ug/ml.  
	   77 
 
As a model for cell associated antigen OVA coated splenocytes (OCS) were used in 
these assays. In cultures that tested the ability of DCs to present cell associated 
antigen to CD8+ T cells, OCS were prepared from B6 H-2bm1 mice that are unable to 
present OT-I-OVA257-264 peptide and in cultures that tested the ability of DCs to 
present cell associated antigen to CD4+ T cells, OCS were isolated from B6 H2-Ab1-
/- mice, which are unable to present MHCII-associated OT-II-OVA323-339 peptides. 
This strategy ensures, that in OCS-containing DC-cultures only DCs were able to 
present antigen to co-cultured T cells, but not any unwanted cells contained in the 
OCS preparation, which used as a source of antigen only. To prepare OCS, isolated 
splenocytes were briefly RBC-lysed and washed in RPMI supplemented with 3% 
FCS, before irradiation (1500cGy) and washing in RPMI-3%FCS. Irradiated 
splenocytes were then pulsed with sOVA by incubation in RPMI-3%FCS with 
10mg/ml sOVA for 10min at 37°C, followed by three washes in RPMI-3%FCS. 
OCS were added to 1x104 DC cultures at titrated quantities of 50000, 16666, 5555, 
1851, 617 OCS per culture well. For all types of antigen, antigen-free wells 
containing only media were included to control for unspecific, non-antigen 
dependent readouts.  
 
I-Ab restricted anti-OVA323-339 CD4+ (OT-II) and H-2Kb restricted anti-OVA257-264 
CD8+ T cells (OT-I) were prepared from pooled mesenteric lymphnodes of OT-II 
and OT-I mice, by magnetic depletion (MACS sorting) of non-CD4+ or non-CD8+ T 
cells respectively. Isolated CD4+ or CD8+ T cells were first confirmed by 
flowcytometry to be >85% pure and then labelled with carboxyfluorescein 
succinimidyl ester (CFSE; Molecular Probes) by incubation in 0.1% BSA 
supplemented PBS with 2.5µM CFSE for 10min at 37°C, followed by three washes 
in RPMI with 3%FCS. 5x104 CFSE labelled T cells resuspended in DC-media were 
added to each antigen and 1x104 DCs containing culture well, using OT-I or OT-II T 
cells depending on whether MHC class I cross presentation or MHC class II 
presentation was assessed.  
 
Each culture was established in dublicates under addition of 10ng/ml GM-CSF 
(Pepro Tech) and 10nM CpG (GeneWorks, Hindmarsh, Australia), before incubation 
at 37°C and 10% CO2 for 60 hours. Proliferation of T cells in cultures was measured 
flowcytometrically after 60 hours, by staining cultures with live-dead dye, anti-CD4 
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or anti-CD8 and anti-TCR-Vα2 (B20.1; see Table 2.1) and resuspension in FACS-
wash with 2.5x104 blank, flowcytometric calibration particles (BD). The total 
number of live, proliferated T cells in each culture well as shown in the results was 
calculated from the number of CFSE-diluted, TCR-Vα2+ T cells per 5x103 analysed 
calibration particles. 
 
In this in vitro assay, the type of antigen chosen allows examination of different 
antigen acquisition pathways. Unspecific uptake of soluble antigen by DCs requires 
macropinocytosis, whereas uptake of particulate antigen, or apoptotic cells, uses 
unspecific or receptor mediated phagocytosis (Roche and Furuta, 2015). To assess 
the ability of SPPL2A-deficient DC to phagocytose and present cell membrane 
associated antigen, OVA was coated onto irradiated spleen cells from MHCI (H-
2bm1/bm1) or MHCII deficient mice (H2-Ab-/-). Depending on whether 
presentation on MHCI or MHCII was assessed, OVA coated splenocytes (OCS) from 
a source that would not be able to contribute to MHCI or MHCII antigen 
presentation were chosen. To circumvent internalisation and OVA processing by 
DCs, and to solely test their ability to directly induce T cell proliferation SIINFEKL 
OT-I or OT-II peptides instead of OVA-protein were added to the cultures. These 
peptides are thought to directly bind surface MHC on DCs and provide a way to 
differentiate whether DCs are unable to process antigen or are unable to provide 
appropriate co-stimulation to T cells in the presence of surface peptide-MHC (De 
Bruijn et al., 1991, Santambrogio et al., 1999). 
 
2.4.5 Human B cell and T cell line cultures and transfection 
Raji, Ramos, Daudi and Jurkat cell lines (American Type Culture Collection) were 
maintained in complete cell line culture medium in a 37°C and 5% CO2 incubator. 
Cell line suspensions were transfected by electroporation with U6gRNA-Sppl2a-
Cas9-2A-GFP vector (vector map in Figure 2.1, vector was constructed and supplied 
by Sigma Aldrich, St. Louis, MO, United States to requested specifications) using 
the Neon Transfection System (Invitrogen) according to the manufacturer’s protocol. 
The AGTAGGGCGGCCCCGGCAGGGG target sequence of the U6gRNA-Sppl2a-
Cas9-2A-GFP vector guides Cas9 cutting to Sppl2a exon 1, relying on non-
homologous end joining DNA repair (Yang et al., 2013, Mali et al., 2013, Mei et al., 
2016) to produce insertions or deletions that result in a reading frame-shift and 
premature STOP to inactivate SPPL2A in cell lines. CMV promoter driven Cas9  
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Figure 2.1: Sppl2a CRISPR/Cas9 plasmid 
 
Vector map of the U6gRNA-Sppl2a-pCMV-Cas9-GFP 
plasmid (Sigma-Aldrich) to target Cas9 cleavage to exon 1 of 
Sppl2a. 
pUC ori Kanr 
Sppl2a  
target 
region 
Hpal Hpal 
Xpal GFP 2A Cas9 
T7 CMV gRNA U6 
U6gRNA-Sppl2a-pCMV-Cas9-GFP 
(8229bp + 22bp Sppl2a target) 
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expression is coupled by an intra-ribosomal transcription entry site (A2) to the 
expression of a GFP fluorescent reporter protein, which was used to 
flowcytometrically assess successful electroporation, transfection and Cas9 
expression. GFP+ Raji, Ramos and Daudi cells were FACS sorted to grow SPPL2A-
deficient lines from a single GFP+ cell clones, which were subsequently analysed by 
flowcytometry for total CD74 expression and phenotype changes as shown in the 
results. 
 
2.5 Analysis of B cell responses 
2.5.1 Immunisation and enzyme-linked immunosorbent assay (ELISA) 
To measure humoral immune responses, mice were immunised and serum samples 
analysed by ELISA for specific antibody production as described previously 
(Randall et al., 2009) and depicted in Figure 3.15B. In brief, immunisations with 
50µg azobenzenearsonate hapten (Biosearch) coupled to chicken gamma globulin 
(Jackson) (ABA-CGG) and 108 formalin fixed Bordetella pertussis bacteria (Lee 
Laboratories) precipitated together in alumn and PBS to a total volume of 300µl per 
mouse. Mice were injected intraperitoneally (i.p.) as split doses of 150µl on either 
side of the abdomen to avoid false-negative antibody responses. After 2 and 4 weeks 
serum was collected for analysis of primary T cell dependent immune responses to 
CGG, B. pertussis and the hapten ABA respectively. 7 weeks after the first 
immunisation, mice were injected i.p. with 25µg of the T-independent polymeric 
sugar BCR cross-linking antigen nitrophenyl-Ficoll41 (NP-Ficoll41) (Biosearch) and 
ABA-CGG in 300µl per mouse, again delivered as split dosage on either side of the 
abdomen. To measure T cell independent B cell antibody responses to NP-Ficoll41 
serum was again collected 6 days later, at week 8 of the immunisation trail. Serum 
was obtained by centrifugation of mouse blood samples, subsequent aspiration of 
supernatant serum and dilution at 1 part serum and 4 parts PBS to be stored at -20°C. 
Antigen specific serum antibody concentrations were measured on 96 well flat 
bottom high binding ELISA microplates coated over night at 4°C with CGG, BSA-
ABA, B. pertussis or BSA-NP2 diluted in coating buffer and washed with washing 
buffer to remove excess antigen. Coated microplates were incubated for 1.5 hours 
with blocking buffer at 37°C, followed by three washes with washing buffer. Sera 
were prepared by appropriate dilution in dilution buffer and incubated in microplates 
at 37°C for 1 hour. Then sera were removed, microplates again washed three times in 
washing buffer and incubated with alkaline phosphatase (AP) conjugated secondary 
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antibodies against mouse IgG1 (Southern Biotech) and IgG2 (BD) or IgM (Southern 
Biotech) for 1 hour at 37°C, before washing again three times. ELISA phosphatase 
substrate solution was then added to each well of microplate and incubated at 37°C 
until adequate strength of reagent colour has developed. The developed plate was 
read at 405 and 650nm absorbance in each well using a ThermoMax plate reader. 
Absolute serum IgM and IgG concentrations of unimmunised mice were determined 
in comparison to murine MOPC21 hybridoma derived IgG1-kappa standard (Sigma-
Aldrich) at a known prepared concentration of 5mg/µl for IgG or 2mg/µl for IgM 
measurements (Popov et al., 1999). 
 
2.5.2 Sheep Red Blood Cell immunisation to induce germinal centre formation 
Sterile sheep red blood cells (SRBC) were washed multiple times in cold PBS by 
consecutive rounds of re-suspension, centrifugation and removal of supernatant until 
all haemolytic residues were removed. Then SRBCs were counted using a 
haemocytometer and re-suspended in PBS to achieve a concentration of 2x108 
SRBCs per 200µl. Each mouse was injected i.p. with 100µl of the SRBC-PBS 
suspension on either side of the abdomen to receive a total of 2x108 SRBCs. The 
frequency and absolute number of germinal centre and T follicular helper T cells in 
spleens was determined 7 days after SRBC injection by flowcytometric analysis. 
 
2.6 Flowcytometry 
2.6.1 Surface antibody staining 
Pelleted cells were resuspended at equal cell to volume ratios in a first staining layer 
of FACS-wash containing unconjugated anti-CD16/CD32 (Fcγ II and III receptor-
block) before or, if applicable, in combination with biotinylated or other primary 
antibodies at pre-determined optimal concentrations and incubated at 4°C for 15-
30min in the dark. Afterwards cells were washed by adding FACS-wash, at least 3-
times the volume of the original antibody cocktail, followed by centrifugation and 
discarding the supernatant. A second antibody-FACS-wash cocktail layer of primary, 
fluorochrome conjugated antibodies, 7AAD viability dye (Invitrogen) and secondary 
reagents (such as streptavidin-fluorochromes) at pre-determined optimal 
concentrations was used to resuspend the resulting cell pellet. Cells were stained by 
incubation at 4°C for 15-30min in the dark, followed by another round of washing 
through addition of FACS-wash, centrifugation and discarding of supernatant. For 
flowcytometric analysis, the surface stained cell pellet was washed once again in the 
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same way to remove any unbound flurochromes and then resuspended in an 
appropriate volume of FACS-wash and transferred into cluster tubes. Fluorescent 
cell labels were measured on BD CellQuest Pro or FACSDiva software operated BD 
FACS Calibur, Canto, LSR I, LSR II or LSR Fortessa cell analysers and the acquired 
data was analysed using FlowJo software for MACS version 8.8.7 (Tree Star). 
 
2.6.2 Intracellular staining 
Intracellular staining of cells was performed following the surface antibody staining 
procedure. For live-dead cell discrimination of fixed and permeabilised cells a PBS 
wash and staining step with a fixable live-dead dye in PBS (eBioscience Fixable 
Viability Dye eFluor 780NIR Live or BioLegend Zombie NIR Fixable Viability Kit), 
followed by washes in PBS and FACS-wash were included before cell fixation. For 
fixation, pelleted cells were resuspended in a paraformaldehyde-based fixation buffer 
(typically 2x106 cells in 150µl; Buffer was made from 3 parts 
Fixation/Permeabilisation 4x concentrate and 1 part Fixation/Permeabilisation 
Diluent, both eBioscience) and incubated in the dark at room temperature for 30min. 
Then, cells were centrifuged and resuspended in FACS-wash to remove fixative, 
followed by resuspension of the fixed pellet in permeabilisation buffer (1 part 
Permeabilisation Buffer 10x from eBioscience diluted in 9 parts of ddH2O) and 
incubation in the dark at 4°C for 20min. Permeabilised cells were centrifuged and 
resuspended in permeabilisation buffer containing intracellular antigen targeting, 
fluorochrome labelled antibodies at pre-determined optimal concentrations and were 
incubated in the dark at 4°C for 30min. To wash intracellularly stained cells, 
permeabilisation buffer at a volume of at least 3-times the volume of the intracellular 
antibody cocktail was added, following centrifugation and resuspension in 
permeabilisation buffer for another washing step. Centrifugation and discarding the 
supernatant produced a pellet that was at last resuspended in an appropriate volume 
of FACS-wash to be transferred to cluster tubes and to be flowcytometrically 
analysed using cell analysers indicated above. 
 
2.6.3 Annexin V staining 
Staining for Annexin V was done on washed and pelleted cells after surface antibody 
staining, excluding 7AAD. Cells were washed by resuspension in calcium-free 
Annexin V binding buffer (BioLegend, BD), centrifuged and the supernatant 
discarded. For Annexin V and 7AAD labelling, cells were resuspended and 
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incubated in Annexin V binding buffer containing fluorochrome labelled Annexin V 
(BioLegend) and 7AAD at pre-determined optimal concentrations for 20min in the 
dark at room temperature. After staining, cells were washed twice in Annexin V 
binding buffer and transferred, still in Annexin V binding buffer, into cluster tubes 
for immediate flowcytometric analysis. 
 
2.6.4 Cell sorting 
Most flowcytometric cell sorting work was done as a service by Harpreet Vohra and 
Mick Devoy at the John Curtin School of Medical Research Imaging and Cytology 
Facility, Australian National University, Canberra, using BD FACS ARIA I or ARIA 
II cell sorters. Some flowcytometric cell sorting was performed on a BD FACS 
ARIA III cell sorter at the ImmunoID Flow Cytometry Facility, Depertment of 
Microbiology and Immunology, University of Melbourne. For flowcytometric 
sorting, cells intended for subsequent culture experiment were sterilely surface 
stained as described, at last resuspended in PBS supplemented with 3% FCS, clumps 
and debris removed by passing through a 70µm nylon mesh filter and sorted through 
100µm nozzles for DC or 70/80µm nozzles for B cells into sterile FCS or cRPMI 
with 20% FCS. 
 
 MACS cell sorting of all B cells was done using positively selecting anti-CD19 or 
anti-B220 conjugated MicroBeads (Miltenyi Biotech) or negatively selecting only 
mature B cells through CD43+ cell depletion (S7) with anti-CD43 MicroBeads 
(Miltenyi Biotech), according to the manufacturer’s product protocol instructions. 
 
2.6.5 Viable cell counting 
Cell suspensions were counted and assessed for cell viability either manually using a 
haemocytometer, or automatically using a ViCell Viability Analyzer (Beckman & 
Coulter). Both systems apply the trypan blue dye (Thermo Fisher Scientific) 
exclusion method described previously (Strober, 2001), by appropriately diluting cell 
suspensions directly in trypan blue dye for counting microscopically over a 
haemocytometer grid, or in cell buffer to be mixed with dye and automatically 
counted by the ViCell Analyzer. 
 
2.6.6 Haematology 
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For haematological analysis of murine blood leukocyte subsets and erythrocytes, 
EDTA blood samples were collected by retro-orbital bleed and diluted at 1:1 ratio 
with FACS wash buffer before automated flowcytometry based analysis in ADVIA 
2120i Hematology System (Siemens Healthcare Diagnostics). 
 
2.7 Protein analysis 
2.7.1 Immunoblot 
Single cell suspensions from spleens were prepared as described in this chapter and 
sorted to desired cell subsets by the method indicated in figure legends. Sorted cell 
fractions were counted and resuspended at equal cell numbers in 2-Mercaptoethanol 
containing SDS sample buffer, subsequently incubated at either 37° C for 60min, 70° 
C for 10min or 95° C for 5 min and sonicated on ice at intervals to achieve sufficient 
breakdown of DNA slurry if needed, depending on sample concentration and 
denaturing conditions. Samples were lysed in reducing LDS buffer (Invitrogen) 
when NuPAGE electrophoresis system was used (Invitrogen). Protein samples were 
submitted to Tricine SDS PAGE on 16% acrylamide gel with 6% crosslinking as 
described previously by Schaegger (Schagger, 2006) for best resolution of small 
protein bands, or 8-12% Tris-Glycine precast gels (NuPAGE Bis-Tris Pre-Cast gels, 
Invitrogen) and transferred onto nitrocellulose membrane. For Immunoblotting and 
detection of N-terminal CD74 and α/β-Tubulin, antibodies by BD Pharmingen (IN1) 
and Cell Signalling were used in a skim-milk (IN1) or BSA (Tubulin)-PBST block to 
avoid unspecific binding, with antibody incubation either at 4° C over night or at 
room temperature for 2 hours. All washing of membranes to remove antibodies was 
done by submerging, at least three times in fresh PBST for 5 min on a shaker. 
Western blot recycling stripping buffer kit (Alpha Diagnostics) was used to strip 
bound antibodies from nitrocellulose membranes before blocking and re-incubation 
for subsequent immunoblotting. Revealing of bands on nitrocellulose membranes 
was done after application of secondary antibody and washing in PBST by 
incubation in Western Lightning™ Chemiluminescence Reagent Plus (Perkin Elmer) 
as per instruction and detection of chemilumiescence on Kodak BioMax Light Film 
or per CCD camera system (ImageQuant LAS 4000, GE Healthcare Life Sciences). 
 
2.7.2 Metabolic radiolabeling and immunoprecipitation 
Metabolic radiolabeling, immunoprecipitations and SDS-polyacryl gel 
electrophoresis were performed as previously described (Villadangos et al., 1997). 2-
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10x106 freshly FACS-sorted CD11c+MHCII+ dendritic cells or whole splenocyte 
preparations were starved for 30-45min at 37°C in cysteine or methionine free RPMI 
starvation media (Gibco) with 10% FCS, 2mM glutamine and 100U/ml penicillin-
100µg/ml streptomycin. Starvation was followed by pulse incubation in fresh 
starvation media supplemented with 500 µCi/ml [35S]-L-methionine and L-cysteine 
(Perkin Elmer) for the time periods as indicated in the figures. Aliquots to be 
analysed after pulse were washed in cold PBS and lysed in 1ml of lysis buffer. 
Aliquots for further chase cultures were resuspended in DC-media or cRPMI and 
cultured for the indicated chase time periods before washing and lysis. 
Trichloroacetic acid (TCA) precipitation of the lysates was used to measure 
incorporated radioactivity in each lysate and was used to normalise radioactivity 
between samples by adjusting the lysate volume used to precipitate the protein of 
interest. Lysed samples could be stored at -80°C. All manipulations for 
immunoprecipitations (IP) were performed on ice or at 4°C. Approximately 150µl of 
sepharose protein G IP-beads (GE Healthcare) per 1ml of lysate sample were 
prepared by three rounds of washing, centrifugation and re-suspension in NET 
buffer. Lysates were pre-cleared by combining with 50ul of protein G beads and 
incubation with 5µl of normal mouse serum and 5µl of normal rabbit serum under 
agitation for 1 hour. Then beads were centrifuged, supernatant lysate recovered and 
transferred to fresh tube of 50µl beads to be agitatedly incubated for 1 hour and 
subsequent pre-cleared lysate recovery by centrifugation. IP was performed with pre-
cleared lysates combined with fresh 50µl of protein G beads and the addition of 
antibody or serum that precipitates the protein of interest, here IN1, JV1, JV5 
(Driessen et al., 1999) or anti-mouse IgM (see Table 2.5), as mentioned in the 
results. The IP was incubated under agitation for 2 hours or over night. After IP, 
beads precipitated protein of interest and are centrifuged to remove lysates. Then 
beads were washed three times in NET buffer before re-suspension in 20-60µl of 
SDS-immunoblot buffer and incubation at room temperature for 15min. Beads were 
then boiled at 100°C for 3min, centrifuged again and the supernatant buffer aspirated 
for PAGE on a large ~20x20cm gel, with protein separation at low voltages slowly 
over night. Radioactivity containing gels were developed at room temperature by two 
20min washes in DMSO followed by 40min incubation in PPO (Sigma-Aldrich) 
scintillation liquid containing PPO-DMSO. Then gels were washed three times in 
water and sandwich-dried between transparent and Whatman-filter paper. Dried gels 
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were eventually exposed to G&E Healthcare phosphoimager plates or X-ray films to 
read radioactivity and to produce gel-images as shown in the results. 
 
2.7.3 Proteomics 
For proteomic analysis of CD74 binding partners all procedures were performed in 
sterile and skin-covered environments to minimise foreign protein contamination. To 
immunoprecipitate CD74 and potential CD74-binding partners equal numbers of B 
cells (10-30x106 per sample) were washed in cold PBS and lysed in 2% Digitonin 
containing TMN buffer by agitated incubation for 1 hour at 4°C. Lysate debris was 
centrifuged to bottom of tube and supernatant aspirated for incubation in two pre-
clearing steps with 0.1% Digitonin TMN buffer-washed protein G beads and only 
1µl of normal rabbit serum to limit foreign protein input, but otherwise as described 
for normal immunoprecipitations. Pre-cleared lysate supernatant and fresh 0.1% 
Digitonin TMN buffer-washed protein G beads were incubated with anti-N-terminal 
CD74 antibody (IN1) for 2 hours or over night under agitation at 4°C. After 
centrifugation, supernatant lysates were removed and beads with precipitated protein 
were washed in 0.1% Digitonin TMN buffer by two rounds of re-suspension, 
centrifugation and supernatant aspiration. Washed beads were resuspended in ~40µl 
of SDS-sample buffer containing DDT as reducing agent (Thermo Fisher Scientific), 
boiled at 95°C for 5min and transferred with fine needle Hamilton syringe for 
maximum buffer recovery to 4-12% Tris-Glycine precast gels (NuPAGE Bis-Tris 
Pre-Cast gels, Invitrogen) for PAGE to separate precipitated protein by size. Small 
aliquots of each sample were also run on separate gels, transferred to nitrocellulose 
gels and immunoblotted for N-terminal CD74 (IN1) to confirm precipitation of N-
terminal CD74 fragments in wildtype and Sppl2a-/-, but not in Cd74-/- or Sppl2a-/-
Cd74-/- B cell samples. PAGE separated IP-gels were washed two times for 3min in 
ddH2O followed by 1 hour incubation in Imperial Protein Stain (Invitrogen, Thermo 
Fisher Scientific) and briefly rinsed a few times in ddH2O followed by overnight de-
staining in ddH2O at room temperature. This visualised protein bands inside the gel 
and allowed excision of each sample lane in 25 sections using a cutting tool for size 
ordered identification of unknown protein by mass spectrometry. Size ordered gel 
sections were transferred to V-bottom polypropylene 96 well plate for in gel protein 
digestion and peptide elution for subsequent analysis was done as described before 
(Shevchenko et al., 2006) and by following the Walter and Eliza Hall Institute 
(WEHI) Proteomic Laboratory, Melbourne, Australia, Standard Operating Procedure 
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for manual in-gel reduction, alkylation and digestion of gel resolved proteins (SOP-
01, 14/10/2011). In brief, gels were de-stained of coomassie blue, proteins reduced 
using dithiothreitol (DDT), then alkylated with iodoacetamide (IAM) and trypsin in-
gel digested for 16 hours under agitation at 37°C. Trypsin digested peptides were 
extracted from gels with formic acid acetonitrile extraction buffer, lyophilised and 
stored in 1% formic acid at -80°C for analysis. Mass spectrometry of peptide 
samples was performed as a service by the WEHI Proteomic Laboratory, Melbourne, 
Australia and provided Mascot-based search result files for size and frequency of 
identified proteins in each sample. 
 
2.8 Nucleic acid analysis 
2.8.1 PCR and cDNA sequencing 
Total RNA was isolated from splenic lymphocytes using the mirVana micro RNA 
isolation Kit (Ambion) according to the manufacturers instruction. cDNA was 
synthesised using the SuperScript First Strand Synthesis System (Invitrogen) with 
Oligo-dT primers. PCR amplification of parts of the Sppl2a cDNA was performed 
with primers located in Exon 5 (CCATCCTGGCCTAACTTTGA) and Exon 9 
(CATGAAATTGGGTAACTTCATTGT) using AccuPrime High Fidelity Taq 
(Invitrogen) and products visualised by gel electrophoresis and excised from the gel 
for cDNA sequencing. After gel purification, PCR products were sequenced on an 
ABI 3730 Sequencer (Applied Biosystems) at the ACRF Biomolecular Resource 
Facility (JCSMR, ANU) according to the manufacturer’s protocol. 
 
2.8.2 Microarray 
For microarray analysis, aliquots of 105 selected cells were sorted into 15 ml Falcon 
tubes containing 2 ml fetal calf serum, on ice. The cells were washed in PBS, 
resuspended in 700 ul PBS, transferred to 1.5 ml Eppendorf tubes, centrifuged at 900 
g for 6 min at 4˚C, supernatants removed, and tubes with cell pellets snap frozen in 
liquid nitrogen, stored at -80˚C. All tubes were shipped together on dry ice to 
Miltenyi Biotech, Germany. Miltenyi Biotech GmbH were contracted to perform B 
cell sample RNA extractions, T7-based RNA amplification and Cy3-single colour 
labelling, hybridisation on 8x60K Agilent Whole Mouse Genome Oligo Microarray, 
scanning and feature extraction to normalised gene expression values. In brief, 
Miltenyi Biotech lysed and isolated RNA using NucleoSpin RNA II kits (Macherey-
Nagel) using manufacturers protocols. RNA quality was confirmed on Agilent 21 
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Bioanalyzer before Cy3 labelling and linear T7-based amplification using the Agilent 
Low Input Quick Amp Labelling Kit following the manufacturer’s protocol, and 
yields measured with a Nanodrop ND-1000 Spectrophotometer. 600ng of Cy3-
labelled and fragmented cRNA was hybridised at 65°C for 17 hours to the 8x60K 
Agilent Whole Mouse Genome Oligo Microarray following the Agilent 60-mer 
microarray processing protocol. The hybridised array was then washed, scanned on 
Agilent Microarray Scanner System and the G2567AA Agilent Feature Extraction 
Software version 9.1 to analysed the individual feature signal intensities of the 
microarray Cy3-images. Individual feature reads were normalised by dividing them 
by the median signal of all features on the same array. The resulting relative mRNA 
expression values are shown for each gene-probe and sample in the results and were 
analysed in an excel table and Graph Pad Prism 5.0f for Mac OS X to fit linear 
regression. Genes on heatmaps were clustered horizontally by average linkage. 
Heatmaps were generated using the NIH data-mining tool CIMminer developed by 
the Genomics and Bioinformatics Group, Developmental Therapeutics Branch 
(DTB), Developmental Therapeutics Program (DTP), Center for Cancer Research 
(CCR), National Cancer Institute (NCI) 
(http://discover.nci.nih.gov/cimminer/oneMatrix.do). 
 
2.9 Microscopy 
2.9.1 Immunofluorescence microscopy 
10-µm spleen cryosections were fixed in acetone and blocked with 5% pig serum, 
before detecting B cell follicles and T cell zones with anti–mouse CD19-PE (1D3) 
and anti–mouse CD3-FITC (145-2C11) antibodies from BD. Slides were analyzed 
on an IX 71 fluorescence microscope (Olympus). 
 
2.9.2 Confocal microscopy 
Confocal microscopy of FACS-sorted B cells and DC was performed similar to 
previous descriptions (Wilson et al., 2003). In brief, 50 000 cells were cultured in 
50µl drops of PBS with 2% FCS on anti-MHCII (N22) coated round coverslips 
(1cm/170µm; coated with a 50µl drop of 10µg/ml N22 in PBS for 2 hours at 37°C in 
cell incubator) in 24-well plates for surface adherence and spreading of cells.  
 
Sufficient attachment of cells on the coverslips required about 2 hours of culture and 
morphological cell changes during that time could be observed under microscope. 
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Once cells were adhered to coverslips, they were subjected to two rounds of washing 
by emergence in PBS, which was followed by fixation of cells in situ using 4% 
paraformaldehyde for 10min at room temperature. Fixed cells were then washed 
three times with PBS substituted with 5% FCS and permeabilised with 
permeabilisation buffer (PBS containing 0.05% saponine and 10% normal goat 
serum or other species that does not lead to cross-reactivity with secondary reagents) 
for 15min at room temperature and stained with LAMP1-eF660 (1D4B), MHCII-
Biotin (N22) or N-terminal CD74-FITC (IN1) primary antibodies diluted in 
permeabilisation buffer for 30min in the dark at room temperature and washed three 
times in the same buffer. For MHCII staining cells were then stained with 
streptavidin conjugated to AF488 or AF647 (Invitrogen) in permeabilisation buffer 
for 30min and washed again. To stain nuclei, cells were then incubated with 5µg/ml 
DAPI (4’,6-diamidino-2-phenyindole; Sigma-Aldrich) in PBS-5% FCS and washed 
again before mounting of the coverslips upside down onto drops of fluorescence 
mounting medium (DAKO) containing 100 mg/ml DABCO (Sigma-Aldrich) or 
Prolong Gold Antifade Reagent (Life Technologies) on objective slides, whilst 
avoiding inclusion of air bubbles. After mounting solution had set, coverslip edges 
were sealed with nail polish and stored at 4°C in the dark until acquisition of 
confocal images with LSM700 confocal microscope (Zeiss, Jena, Germany) and 
image analysis using Image J software version 1.47 (Rasband WS. ImageJ, U.S. 
National Institutes of Health, Bethesda, Maryland, USA, imagej.nih.gov/ij/, 1997-
2012). 
 
2.9.3 Transmission electron microscopy (TEM) 
Live CD19+ B cells were flowcytometrically sorted from mouse spleen suspensions, 
cultured at 37°C in cRPMI for 1 hour to allow for equilibration of membrane 
ultrastructures that had been disturbed during the sorting procedure, washed in PBS 
and fixed by incubation in freshly prepared PBS with 4% paraformaldehyde and 2% 
glutaraldehyde (both E.M. grade ProSciTech) for 30min under gentle agitation at 
room temperature. Then fixed B cells were centrifuged, supernatant discarded and 
washed by resuspending cells in 1ml PBS and transferring the cell suspension into 
1.5ml Eppendorf tubes for further processing. The PBS wash was followed by 
centrifugation, removal of 0.5ml of the supernatant and a second, osmium-fixation 
step by adding 1ml of ddH2O with 1% osmium oxide (ProSciTech; final 
concentration in tube to be 0.75% OsO4) and 20-60min incubation until sufficient 
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osmium deposition inside cells had occurred and the cell pellet appeared dark grey. 
Through sequential centrifugations and resuspending washes osmium-fixed cell 
pellets were gradually transferred into clean ddH2O: First resuspension in PBS: 
ddH2O at 1:1 ratio, second resuspension in PBS: ddH2O at 1:2 ratio and last 
resuspension in 100% ddH2O. Then cells were centrifuged again, supernatant 
removed and cells resuspended in residual ddH2O volume of ~25µl liquid. 50µl of 
1.2% low melting point analytical DNA grade agerose in ddH2O kept at 58°C was 
placed into 150µl PCR-Eppendorf tubes and 5µl aliquots of the osmium-fixed B cells 
suspension was carefully pipetted and centrifuged into the cooling agerose gel to 
create a clearly visible and appropriately distributed B cell cluster to one side of the 
gel. Cell embedded gels were allowed to set on ice for 1 hour, then cut out of the 
tube with a razor blade and cell containing gel pieces stained ‘en-bloc’ by 
transferring into aqueous 2% uranyl-acetate (Sigma-Aldrich) and incubated in the 
dark for 16 hours at 4°C. Gel pellets were washed once with ddH2O after removing 
the uranyl solution, followed by dehydrating the gels in 1 hour incubation steps by 
sequential washes in ethanol-ddH2O mixtures with gradually increasing ethanol 
content: 30%-50%-70%-80%-90% and three times 100% ethanol, whereby the last 
100% ethanol incubation was done for 16 hours, all under gentle agitation. 
Deydrated gel pellets were then resin infiltrated in a similar manner, by 1 hour 
incubations in ethanol-resin mixtures with gradually increasing concentrations of 
resin: 10%-25%-50%-75% and three times 100% resin. After complete resin 
infiltration the cell containing gel blocks were placed ‘cells-down’ into the bottom of 
No. 00 gelatin capsules (Ted Pella, Redding, CA, USA), filled with resin and baked 
at 70°C under nitrogen atmosphere for at least 16 hours to polymerise resin 
embedded B cell blocks. Resin cell blocks were freed from the gelatin capsule cover 
and a sectioning plane in close proximity to the embedded B cells was exposed by 
trimming the resin blocks with razor blades and ultramicrotome. Intact morphology 
of exposed B cells on the sectioning surface was confirmed by microscopy of 
toluidine resin sections, before using the ultramicrotome to prepare ultrathin 40-
70nm B cell resin sections that were mounted onto microfilm coated copper or gold 
TEM grids. Grid mounted B cell sections were post stained by incubating the grids 
upside down for 5-10min on aqueous 2% uranyl acetate and 2% lead citrate drops 
surrounded by NaOH pellets to reduce localised air humidity and unwanted crystal 
formation. Between stains and afterwards the grids were washed by submerging 
three times in ddH2O and air dried. Post stained B cell grids were TEM imaged using 
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a Hitachi H7100FA with 125kV acceleration voltage. For semi-quantitive 
measurement of B cell vesicle numbers with and without internal membrane sheets, 
vacuoles ≥200nm were counted per B cell cross section. 
 
2.10 Endocytosis and membrane PS-flipping analysis 
2.10.1 Internalisation assays 
Measurement of surface molecule internalisation rates over time was performed 
similar to previous descriptions (Blery et al., 2006, Gazumyan et al., 2006). It was 
assumed that all endocytic processes which cause surface molecule internalisation 
are temperature dependent and do not occur at 0°C, whilst a temperatures of 37°C 
allow normal membrane protein internalisation. As internalisation was measured 
during timed incubation periods, great care was taken to perform all other cell 
handling on ice, including the chilling of centrifuges and keeping all reagents ice 
cold. Mouse spleen cells were isolated into suspension of RPMI with 10% FCS, 
briefly RBC lysed and resuspended in RPMI-FCS. Spleen cells were then antibody 
labelled for the surface molecule of interest for internalisation rate measurements 
(IgM, IgD, BAFFR, CD71, CD74 and MHCII) and incubated in a 37°C water bath to 
allow usually 0, 0.5, 1, 2, 3, 5, 10, 20, 30, and 50min time for internalisation of the 
antibody labelled surface molecule cohort over time. A sufficient number of cells 
were included at the beginning of the assay to allow at least 2x106 cells per analysed 
time point. At each time point one aliquot of cells was moved onto ice to stop any 
internalisation processes. SPPL2A-deficient and wildtype samples were handled in 
separate tubes and two-handedly transferred at exactly the same times. Once all time 
points were collected on ice and depending on the surface molecule of interest and 
reagent availability, treatments or additional surface antibody staining was carried 
out to allow differentiation of internalised molecules and cell types within the cell 
suspension and are described in the following text.  
 
Acid treatment: The outgoing surface IgM, IgD, BAFFR and CD71 cohorts were 
labelled with anti-IgMb-PE (AF6-78), anti-IgD-PE (11-26a.2a), anti-BAFFR-PE 
(7H22-E16) or anti-CD71-PE (C2) and after allowing various times at 37°C for 
internalisation, remaining surface PE fluorescence was inactivated by two rounds 
acetic acid treatment: 2x106 cells were resuspended in 100µl of acetic acid and 
incubated for 1min, followed by addition of 100µl FCS (Life Technologies) to stop 
the acid treatment. Then cells were centrifuged and the acid treatment repeated. 
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Controls for cells that were not acid treated at all, or treated in the same manner as 
described, but with PBS instead of acid were always prepared as controls to establish 
background treatment effects. Overall, this method of measuring surface molecule 
internalisation inactivated all surface exposed PE molecules and only internalised PE 
molecules that were protected intracellularly emitted flowcytometrically measurable 
fluorescence (see Figure 4.33A). Thus in this system, PE-fluorescence increased over 
time with increasing internalisation. Usage of the IgMb specific AF6-78 antibody for 
marking the outgoing surface IgM cohort, allowed counterstaining of total surface 
IgM for each time point using a different epitope binding IgM antibody (II/41) and 
confirmed that the total surface IgM levels on SPPL2A-deficient and wildtype B 
cells did not change, regardless of incubation time at 37°C.  
 
Secondary counter staining: Surface CD74 and MHCII internalisation was discerned 
by labelling the surface cohort of these molecules with the rabbit sera JV11 (anti-C-
terminal CD74) and JV1 (anti-I-A α chain; see Table 2.5). After internalisation at 
37°C, remaining surface molecules that were labelled with JV11 or JV1 were 
detected with secondary anti-rabbit-IgG staining (rabbit-IgG-AF647; Invitrogen), so 
that all non-internalised surface remaining molecules were flowcytometrically 
measured, and thus fluorescence for these molecules decreased over time, as shown 
in the results. 
 
2.10.2 Flippase assay 
B cell membrane flippase activity was assessed similar to previous descriptions 
(Yabas et al., 2016). Spleen cell suspensions were prepared from Sppl2a-/- Ly5b and 
B6 Ly5a mice, briefly RBC lysed, counted and sufficient numbers of cells from both 
spleeocyte genotypes mixed in one tube to allow collection of at least 2x106 cells at 7 
time points. Mixing of Ly5a-wildtype and Sppl2a-/- cells in one tube permited equal 
staining and treatment conditions, but still allowed differentiation of both cell type 
during analysis later based on congenital Ly5a and Ly5b differences. Splenocytes 
from mice deficient for the phosphatidylserine (PS) flippase ATP11C (Atp11c-/-) 
were included into the experiment as flippase defective control. The splenocyte 
mixture was then washed with to 15°C pre-warmed ‘pH 6.0-solution’, which 
consisted of Hank’s Balanced Salt Solution (HBBS; Gibco, Life Technologies) 
supplemented with 5.5 mM D-glucose and 20mM HEPES and was adjusted to pH 6. 
After washing, the cell mixture was from thereon kept in a waterbath at 15°C, 
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resuspended in 200µl of fresh ‘pH 6.0 solution’ and the flippase assay was started by 
adding 10µl of pre-diluted C6-NBD-PS analogue (1-palmitoyl-2-{6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphoserine (ammonium salt); 
Avanti Polar Lipids, Inc.) to achieve a final analogue concentration of 5µM. After 1, 
2, 3, 5, 10, 20 and 30min ~35µl aliquots were removed from the 15°C incubation 
with C6-NBD-PS analogue and transferred into ice-cold, pre-prepared vials with 
500µl of ‘pH 6.0 solution’ supplemented with 1% lipid-free bovine serum albumin 
(BSA; Sigma-Aldrich) to stop membrane incorporation and flipping of C6-NBD-PS 
analogues. Then collected cells from each time point were centrifuged and washed 
once by resuspending in 500µl of ice-cold ‘pH 6.0 solution’ with 1% BSA, then 
centrifuged and washed twice by resuspending in 500µl of ice-cold ‘pH 6.0 solution’ 
without BSA. After final wash, cells were stained for anti-Ly5a-AF700, anti-Ly5b-
Pacific Blue and anti-B220-APC Cy7 (see Table 2.1) for flowcytometrical analysis 
and to measure C6-NBD-PS analogue membrane integration levels on B cells by 
fluorescence the analogue emitted in a wavelength comparable to FITC. Figure 
3.25E in this thesis shows only C6-NBD-PS fluorescence for samples collected after 
1 min of analogue incubation, as other time points provided similar results. 
 
2.10.3 Endocytosis, acidification and proteolysis of soluble antigen in DC 
To test whether DC could execute soluble antigen uptake and proteolysis, FACS 
sorted DC were incubated in DC-media with either OVA-AF488 or OVA-DQ 
conjugates (both Molecular Probes) at 37°C and 10% CO2 for generally 0.5, 1, 2 and 
4 hours or as indicated in the results, before being moved onto ice to stop antigen 
uptake from the culture medium. To assess the ability to acidify endosomal content, 
FACS sorted DCs were pulsed with pH sensitive OVA-FITC conjugates by 
incubation in DC-media with OVA-FITC (Molecular Probes) for 30min, followed by 
washing of cells and ongoing culture in fresh DC-media for 1, 2 or 4 hours, before 
moving cells from each time point onto ice to stop further endosome maturation and 
acidification. For all OVA-conjugates aliquots of cells were incubated on ice to 
control for background fluorescence caused by the conjugates that was not due to 
endocytic processes. The OVA-conjugates provided different types of information 
about soluble antigen uptake and processing of DCs. AF488 is pH stable and 
therefore allows tracking and quantification of endocytosed soluble antigen over 
time, indicated by increasing AF488 fluoresence of the cells. DQ is a self-quenching 
fluorophore-protein complex that emits fluorescence upon proteolytical degradation 
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and thus increasing fluorescence over time provided a measure of endosomal content 
proteolysis. FITC is pH sensitive and with decreasing pH of the maturing endosomal 
environment, fluorescence of the pulsed OVA-FITC cohort is lost over time, thus 
decreasing FITC fluorescence provided a measure of endosomal acidification. Once 
DC samples from all time points had been collected on ice, DCs were washed, 
stained with anti-CD11c, anti-MHCII and anti-CD45RA (see Table 2.1) for 
flowcytometric analysis of OVA-conjugate fluorescence over time as shown in the 
results. 
 
2.11 Statistics 
As indicated in figures, data was statistically analysed as described in figure legends 
using Graph Pad Prism 5.0f for Mac OS X. Two experimental groups were usually 
compared using a two-tailed students t test unless otherwise specified. Multiple 
groups were compared by One-Way Analysis of Variance (ANOVA) unless 
mentioned otherwise. P-values of p<0.05 were deemed significant and differences in 
figures marked with increasing numbers of asterisks or as non-significant if p was 
>0.05: **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05, n.s. p>0.05. Open source 
FlowPy software, (developed by Revanth Sai Kumar, Tejas Mehta and Biplab Bose 
from the Department of Biotechnology in the Indian Institute of Technology 
Guwahati, 2015; http://flowpy.wikidot.com) was used for extraction of raw data 
from flow cytometry standard files type 3 in order to fit a linear regression model to 
intracellular CD74 and MHCII fluorescence (see Chapter 4) of all events in a single 
sample. Goodness of fit and slope of the model were calculated with GraphPad Prism 
5.0f. 
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Chapter 3: SPPL2A mediated 
degradation of CD74 is essential 
for B cell survival and humoral 
immunity 
 
Contributions from others: 
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• Keisuke Horikawa kindly provided the wiltype-Sppl2a retroviral vector 
producing GP+E86 cell line for data in Figure 3.3 and Ikk*-pMX-IRES-GFP 
vector for the experiments in Figure 3.24. 
• James Wang helped with retroviral transductions and analysis for data in 
Figure 3.24, and cell culture for data in Figure 3.31. 
• Michelle Townsend performed spleen cryosectioning for data in Figure 3.7C. 
• Debbie Howard and Charis Teh provided technical assistance with 
intravenous injections and irradiations, whilst Mehmet Yabas helped with 
donor cell preparations and sample processing for bone marrow chimera 
experiments in Figure 3.12 and 3.14. 
• Nadine Barthel, Heather Domaschenz and Anselm Enders did most of the 
ELISA analysis repeats for data in Figure 3.15. 
• Mehmet Yabas helped with flippase experiments for data in Figure 3.25E. 
• Vicky Cho and Daniel Andrews provided technical help towards database 
mining in search of SPPL2A-substrates that resulted in Table 3.1. 
• Christopher Goodnow made schematic drawing of CD74 degradation 
products in Figures 3.27C. 
• Mehmet Yabas, Nadine Barthel, Yogesh Jeelall, James Wang, Alanna Short, 
Samantha Lambe, Anselm Enders and Stephen Daley provided some 
technical help towards flowcytometric sample preparation. 
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3.1 Sppl2a mutation is inactivating and causative of B cell deficiency in ENU-
mutagenesis derived ‘Enid’ mouse strain 
Flow cytometric screening of peripheral blood leukocyte subsets in ENU-
mutagenised mouse pedigrees has identified the aforementioned B cell deficient 
‘Enid’ mouse strain (ENU15NIH85a) with mutations in Sppl2a and Trpm7. The B 
cell compartment in mice homozygous for the mutated alleles (enid/enid) were 
characterised by reduced percentages of CD19+ B cells in the blood, with the 
remaining B cells exhibiting a distinctive, lowered IgD surface expression profile on 
the IgMlow B cell subset (Figure 3.1). This B cell defect was not observed in blood 
samples collected from heterozygous mutant mice (enid/+), which were 
indistinguishable from non-mutant littermates (+/+). Overall, in a large cohort of 
mice (n=24 in Figure 3.1B) B cell deficiency tracked with a homozygous Sppl2a and 
Trpm7 genotype-detecting amplifluor genotyping of the continuously C57B6-
backcrossed Enid mouse colony. This indicated that the Sppl2a and Trpm7 ENU-
mutations, neither by themselves nor in combination, were having a negative 
dominant effect or haploinsufficiency and required homozygosity to cause B cell 
deficiency. 
 
Due to close proximity of 123kbp between the SNVs in Sppl2a and Trpm7 on 
chromosome 2 in Enid mice (Figure 1.11), continuous breeding of this strain was 
unlikely to produce a recombination event that separated both mutations in progeny 
mice within reasonable timeframes and mouse numbers used for breeding. With an 
average recombination rate of 0.528 cM/Mb in the murine genome and ignoring 
chromosomal variation, a recombination event to separate the mutations can be 
expected only in 0.065% of offspring, or once every 1600 mice born (Jensen-Seaman 
et al., 2004). To resolve whether the ENU-induced mutations in Sppl2a or Trpm7 
were causing the B cell defect in homozygously mutant Enid mice, two approaches 
were taken. Firstly, retroviral transduction experiments to rescue one of the two 
mutations in cultured B cells in vitro (Figure 3.2 and 3.3), and secondly, 
interbreeding of the mutant Enid-allele with a complementary allele that solely 
inactivates only one of the affected genes in mice (Figure 3.4). For the retroviral 
rescue, bone marrow cells from homozygous mutants (enid/enid) and wildtype 
controls (+/+) were isolated and subsequently cultured on a layer of a fibroblast 
retroviral producer cell line, to transduce Enid-mutant B cells with a wildtype-Sppl2a 
expressing or empty vector (EV) as shown schematically in Figure 3.2. 
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Figure 3.1: Enid mice (ENU15NIH85aB6) with 
homozygous ENU mutations in Sppl2a and Trpm7 have a 
reduced proportion of B cells circulating in the blood and 
their residual B cells exhibit lowered surface expression 
of IgD. 
 
A. Representative flow cytometric plots of B cell subsets and 
percentages in the blood from a larger cohort of interbred 
wildtype mice (Sppl2a+/+) or mice with the Enid-ENU-mutation 
on either one allele (Sppl2aenid/+) or both (Sppl2aenid/enid) 
alleles, tracking the B cell phenotype with the ENU mutation. 
Numbers in the top left corner of the plots in the right column 
are geometric mean fluorescent intensity (MFI) of surface IgD 
on CD19+ B cells and other numbers are percentages of cells 
in each gate. 
B. Bar graphs showing percentage of CD19+ B cells among 
blood lymphocytes from mice of the indicated genotypes and 
the geo. MFI of surface IgD staining on these B cells form the 
blood. One Way ANOVA with Bonferroni’s Multiple 
Comparison post test, **** p<0.0001, n.s. p>0.05. Data are 
representative of more than three independent experiments 
with more than three mice per genotype. 
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Figure 3.2: Experimental approach for transducing mutant 
Pre-B cells with a retroviral vector encoding either wildtype 
Sppl2a and GFP or empty vector encoding GFP alone in vitro. 
 
Magnetic bead sorted B220+ bone marrow cells are cultured in 
IL-7 (Day 0) for two days and are then, in the presence of 
polybrene (on Day 2), plated over the top of adherent, irradiated 
GP+E86 retroviral producer cells that either make an empty GFP 
vector or a vector coding for GFP and wildtype Sppl2a cDNA. Co-
culture is maintained with IL-7 for two days, before bone marrow 
cells are harvested (Day 4) and re-plated again with IL-7 for 
another two days. From then onwards BAFF cytokine is also 
added to the culture (Day 6), providing fresh media and cytokines 
every two days thereafter. At last IL-7 is withdrawn on day 12 and 
the transduced cells are plated in BAFF alone for two days before 
flow cytometric measurement of GFP expression and surface IgD 
on day 14. 
IL-7 
B220+ BM cells 
Irrad. retroviral 
producer cells 
B220+ BM cells 
IL-7 
Polybrene 
2 days co-culture 
B220+ BM cells 
BAFF 
Il-7 
IL-7 
FACS analysis 
Day 0 
Day 2 
Day 4 
Day 6 
Day 14 
Day 12 
B220+ BM cells 
BAFF 
no Il-7 
	   99 
The transduced day 14-B cell cultures were fluorescently labelled with the viability 
dye 7AAD, and antibodies against B cell markers and surface IgD for analysis by 
flowcytometry (FACS) (Figure 3.3A). Retroviral over-expression of the wildtype 
Sppl2a gene in Enid-mutant B cells (enid/enid) rescued lowered surface IgD 
expression to levels seen in wildtype B cells (+/+) transduced with the empty vector, 
whereas treatment of mutant B cells with the empty vector did not (Figure 3.3B). 
This suggests that compensating for the Sppl2a SNV in homozygous mutant Enid-B 
cells is sufficient to correct the B cell defect, whereas the mutation in Trpm7 appears 
to be irrelevant, at least for surface IgD expression. 
 
To confirm whether the Sppl2a ENU-mutation was causative of the IgD-low B cell 
defect in Enid-mice, the ENU-mutant strain was crossed with an Sppl2a deficient 
mouse strain (Sppl2ako/ko), resulting in progeny with the known Sppl2a inactivation 
on one allele and the Enid-allele containing SNVs in Sppl2a and Trpm7 on the other. 
Since a single mutant Enid-allele is unable to cause the B cell defect in heterozygous 
mutants (Figure 3.1), it would be decisive to see if Sppl2aenid/ko mice present with B 
cell deficiency or not. Flowcytometric analysis of blood derived B cells from these 
mice with one Sppl2a-Enid allele and one Sppl2a-knock out allele revealed reduced 
proportions of B cells with lowered surface IgD expression on the IgMlow subset 
(Figure 3.4). B cell deficiency in Sppl2aenid/ko mice was indistinguishable from the B 
cell phenotype seen in homozygous Enid-mutant mice (Sppl2aenid/enid), whereas 
heterozygous control samples (Sppl2aenid/+) did not show a B cell defect at all. This 
demonstrates that the ENU-induced mutation at the +2 position in intron 7 of Sppl2a 
is causative for the observed B cell deficiency and low surface IgD expression in 
homozygous Enid mutant mice. 
 
This result further suggests that the intronic mutation in Sppl2a is causing a loss of 
Sppl2a function, as a single intact allele in heterozygote mutants is capable of 
maintaining the gene’s function, whereas an allele deletion in combination with the 
mutated allele is not (Figure 3.4). The first two bases at the 5’-end of most introns 
are highly conserved and are essential as spliceosome acceptor site for the splicing 
reaction, during which the 3’-end of the intron loops back across itself to attach to its 
5’-end and form a ‘RNA-lariat’ intermediate that is then removed and splices the 
beginning of the 3’-exon to the end of the preceding 5’-exon (Papasaikas and 
Valcarcel, 2016).  
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Figure 3.3: Retroviral introduction of wildtype Sppl2a 
cDNA into mutant IL-7-cultured Pre-B cells restores 
normal IgD surface expression on B cells maturing in 
vitro. 
 
A. FACS plots from day 14 bone marrow derived B cell 
cultures that have been transduced with the indicated 
retroviruses by co-culture with viral GP+E86 producer cell 
lines as per previous figure. 
B. Flow cytometric histogram showing surface IgD on GFP
+IgM+ Sppl2aenid/enid B cells from IL-7 bone marrow cultures 
transduced with a retroviral vector encoding wildtype SPPL2A 
and GFP (dotted red line) or empty vector encoding GFP 
alone (green line), compared with Sppl2a+/+ B cells 
transduced with empty GFP vector (shaded gray). 
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Figure 3.4: Co-expression of the inactivating Enid-Sppl2a 
ENU-mutation on one allele and Sppl2a deletion on the 
other allele phenocopies the Sppl2aenid/enid B cell defect 
observed in homozygous Sppl2a ENU-mutants. 
 
A. Representative flow cytometric plots and percentatges of 
blood B cell subsets in mice of the indicated genotypes, pre-
gated on 7AAD- lymphocytes.  
Sppl2aenid/enid mice were crossed to Sppl2ako/ko to generate 
Sppl2aenid/ko offspring. The offspring inherited one Sppl2a 
gene copy deleted by the known knock out allele, whilst 
carrying the ENU-Sppl2aenid mutation, along with the point 
mutation in Trpm7 on the other allele (Sppl2aenid/ko). 
B. Bar graph quantifying surface IgD expression as geometric 
mean fluorescent intensity on CD19+ B cells from the blood of 
a larger cohort of mice with the indicated genotypes. One 
Way ANOVA with Bonferroni’s Multiple Comparison post test, 
**** p<0.0001, n.s. p>0.05. 
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To investigate potential effects of the +2 intronic Sppl2a mutation on mRNA 
splicing, complementary DNA from splenocyte lysates of Enid-homozygous and 
heterozygous mice was reverse transcribed and the cDNA subjected to PCR analysis, 
using PCR-primers targeting Sppl2a exon 5 and 9. These primers were expected to 
produce an approximately 500bp PCR product upon amplification. Agarose gel 
electrophoresis revealed a smaller than expected PCR product in homozygous 
samples, about 350bp in size, and the heterozygous sample produced two PCR 
products, one of the expected 500bp size and the smaller 350bp product, presumably 
one from each Sppl2 allele (Figure 3.5A). This indicated that the Sppl2a mutation at 
the start of intron 7 disrupts the splice-site recognition site at the 5’-end of intron 7 
and likely causes skipping of exon 7 resulting in a shortened mRNA between exon 5 
and 9. Excising, digesting and Sanger sequencing the questionable shortened PCR 
product of the homozygous sample confirmed this interpretation of the PCR result. 
The sequence of the Sppl2a mutant PCR product showed a loss of the entire exon 7 
and splicing of exon 6 to exon 8, inducing a reading frame-shift that resulted in a 
premature STOP-codon at the beginning of exon 8 (Figure 3.5B). Therefore Enid-
mutant cells will only be able to translate SPPL2A protein from mRNA code of exon 
1 to exon 6, which resembles the first two of the nine transmembrane domains of the 
protein, producing a truncated SPPL2A protein that is devoid of its active site 
between transmembrane domains 6 and 7 (Figure 3.5B).  
 
Therefore, the Enid-mutation in Sppl2a is an intronic splice-site mutation that causes 
spleiceosome skipping of exon 7, which leads to a frame-shift and emergence of a 
premature STOP codon in the mutant mRNA, which therefore at the most gives rise 
to a heavily truncated SPPL2A protease lacking its active site. 
 
Taken together, these findings showed that the Sppl2a mutation in the Enid mouse 
strain is an inactivating splice-site mutation and causative of the B cell defect in this 
ENU-mutagenesis derived mouse pedigree, whereas the mutation in Trpm7 appears 
to be irrelevant for B cells. The Enid mouse strain therefore resembles an Sppl2a-
knock out mouse model, and for simplicity, I will refer to this ENU-mouse strain 
throughout the rest of this thesis as Sppl2a-/-, Sppl2+/- or Sppl2a+/+ genotype, when 
homozygous, heterozygous or no mutant Enid-alleles are present. 
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Figure 3.5: Sppl2a-ENU mutation in ENU15NIH85a mouse 
strain causes skipping of Exon 7 during splicing 
 
A. Electrophoretic agerose gel image of PCR products that 
were generated by amplifying approx. 500bp sequence 
intervals surrounding the Sppl2a-ENU mutation in cDNA 
samples prepared from either ENU15NIH85a homozygous or 
heterozygous mutant mouse spleenocyte samples. 
B. PCR products from homozygous mutants were isolated 
from the gel and their sequence determined by Sanger 
sequencing. The schematic drawing illustrates the nucleotide 
sequence of the splice acceptor-site mutation in intron 7 of 
the Sppl2a gene and its effect on mRNA splicing. 
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3.2 Sppl2a deficiency causes block in transitional B cell development 
The ENU-mutagenesis derived Sppl2a-deficient Enid mouse strain was discovered 
due to its lack of B cells in the peripheral blood. To determine why B cells were 
missing in the periphery, I set out to undertake a systematic analysis of B cell 
development, starting by analysing early B cell precursors in the bone marrow 
(Figure 3.6). As mentioned before, B cell development proceeds through distinct 
stages that can be separated by flowcytometry through the use of fluorescently 
labelled antibodies that visualise characteristic B cell surface markers (Allman and 
Pillai, 2008). After isolating bone marrow cells from Sppl2a-deficient and wildtype 
mice, B220 expression was used to identify members of the B cell lineage, which 
were then further divided into IgM-IgD- early B cell precursor, immature IgM+ and 
mature recirculating IgD+IgMint B cells (2nd column, Figure 3.6A). Early BCR 
lacking B cell precursors were subdivided into CD43+CD24low Pre-Pro-B cells, 
CD24+CD43+ Pro-B cells and CD24+CD43low Pre-B cell subsets (3rd column, Figure 
3.6A). Percentages and absolute cell numbers of early B cell developmental subsets 
in the bone marrow of Sppl2a-/- mice were normal, whereas proportions and numbers 
of mature B cells that are normally found in the bone marrow after recirculation from 
the periphery, were reduced and marked by the characteristic low surface IgD 
expression profile already seen on B cells in the blood (Figure 3.6 A and B). 
Induction of BCR and BAFFR surface expression in IgM+ immature Sppl2a-/- B cells 
occurred at normal levels (Figure 3.6C). Thus, in the absence of SPPL2A, B cells 
were able to develop normally in the bone marrow up until the immature stage. 
 
The observed reduction in recirculating mature B cells in the bone marrow in the 
presence of normally developing B cell precursors, suggested that Sppl2a-deficiency 
interferes with later, peripheral stages of B cell maturation. Therefore peripheral 
CD19+ B cell subsets in spleens from Sppl2a-/- mice and Sppl2a+/+ controls were 
flowcytometrically analysed. CD19+ B cells were differentiated into CD93high 
immature and CD93low mature B cells (2nd column, Figure 3.7A). Immature B cells 
were further resolved into the IgMhighCD23- transitional stage 1 (T1), the 
IgMhighCD23+ transitional stage 2 (T2) and the IgMlowCD23+ transitional stage 3 
(T3) B cells (3rd column, Figure 3.7A). The mature B cell population was subdivided 
into IgMintCD21int follicular and IgMhighCD21high marginal zone B cells (4th column, 
Figure 3.7A).  
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Figure 3.6: Early B cell precursors in the bone marrow of 
Sppl2a-/- mice develop normally 
 
A. Flow cytometric plots and percentages of B cell and precursor 
subsets in the bone marrow of Sppl2a+/+ and Sppl2a-/- mice. 
B. Bar graph of absolute cell numbers for B cell and precursor 
subsets as indicated in the bone marrow from Sppl2a+/+ and 
Sppl2a-/- mice. Numbers shown represent cellularity in bone 
marrow samples that were collected from a single mouse femur 
and tibia per animal. Bars represent mean. 
C. Geometric MFI graphs quantifying surface expression of IgM 
and BAFFR on the indicated B cell subsets in the bone marrow, 
gated as in second column in A. Ends of dotted lines indicate the 
mean of multiple mice. Data are representative of more than three 
independent experiments with three to 5 mice per genotype. 
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Figure 3.7: SPPL2A is required for B cell development in the 
periphery past the transitional stage T1 
 
A. Flow cytometric plots and percentages of B cell subsets in the spleen of 
Sppl2a+/+, Sppl2a-/- and Baff-/- mice. 
B. Bar graph of absolute cell numbers for B cell subsets spleens from 
mice with the indicated genotypes. Lympho, lymphocytes; Foll, follicular B 
cells; MZ, marginal zone B cells. Bars show mean, and each symbol is a 
single mouse. 
C. Spleen cryosections from Sppl2a+/+ and Sppl2a-/- mice were stained 
with fluorescently labeled antibodies to microscopically detect B cells 
(CD19) and T cells (CD3). White arrow heads point out marginal zone. 
Bars, 200 µm. Data are representative of more than three (A and B)  or 
two (C) independent experiments with three to 5 mice per genotype. 
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The most recent bone marrow emigrants, T1 B cells in Sppl2a-/- spleens were present 
in normal numbers with surface IgM expression levels comparable to wildtype 
controls (Figure 3.7A). However, subsequent developmental stages of T2, T3 and 
CD93low mature follicular B cells were about 20-fold reduced in Sppl2a-/- spleens, 
and marginal zone B cells appear to be about 200-fold down in numbers in these 
mice (Figure 3.7B). Interestingly, immunofluorescent imaging of spleen cryo-
sections from Sppl2a-deficient mice showed that the remaining B cells seemed to 
normally localise into primary B cell follicles and marginal zone architecture (see 
white arrow heads, Figure 3.7C). These observations pinpoint a B cell developmental 
block at the T1/T2 stage in SPPL2A-deficient mice, causing a reduction of B cell 
numbers that was apparent macroscopically. SPPL2A-lacking mice were 
characterised by slightly smaller spleen sizes (Figure 3.8A) and viewing of spleens 
against backlighting revealed reduced mottling of the organ, an indication of fewer B 
cell follicles. 
 
SPPL2A-deficiency caused a B cell phenotype that is closely resembled by mice 
deficient for BAFFR or BAFF cytokine. To help resolve specific B cell defects 
caused by SPPL2A-deficiency that are not induced by the loss of mature B cells, 
peripheral B cell development in Sppl2a-/- mice was therefore directly compared with 
developing cells from mice lacking BAFF (Figure 3.7 and 3.8C). Based on absolute 
cell numbers of developmental B cell subsets in the spleen, the absence of SPPL2A 
or BAFF-signalling appeared cause a block at the same T1/T2 stage in SPPL2A- and 
BAFF-deficient mice (Figure 3.7B). However, induction of CD23 expression, which 
is an indication of NFκB signalling (Sasaki et al., 2006), was lower in remaining T2 
cells from Sppl2a-/- mice compared to Baff-/- mice (3rd column, Figure 3.7A). This 
indicated that B cell deficiency in the absence of SPPL2A occurred at a slightly 
earlier developmental stage than B cell loss caused by the absence of BAFF. 
 
Normally, on developing wiltype B cells (Sppl2a+/+), BAFFR surface expression is 
first induced at the immature B cell stage in the bone marrow and receptor levels 
further increase as immature B cells exit the bone marrow and progress from T1 to 
T2 (Figure 3.8B). In Baff-/- animals induction of BAFFR expression and up-
regulation at the T1 stage occurred comparable to wiltype cells, but in B cells from 
mice lacking SPPL2A there was almost no up-regulation of surface BAFFR during 
transitional development (Figure 3.8B).  
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Figure 3.8: Sppl2a-/- B cells do not up-regulate surface expression 
of B cell and BAFF receptors during their development 
 
A. Photograph of spleens from Sppl2a+/+ and Sppl2a-/- mice. Facies 
parietalis facing up. 
B. Geometric mean fluorescence intensity (MFI) of staining for BAFFR, 
IgD, and IgM on the indicated B cell developmental subsets in spleens 
from Sppl2a+/+, Sppl2a-/- and Baff-/- mice. 
C. Schematic of late B cell development in mice. Sppl2a-/- mice revealed 
a maturation block at the T1 to T2 transitional stage, phenotypically 
mirroring BAFF deficient mice (Tnfsf13b-/-). During maturation in the 
periphery B cells rely on signals such as BAFF and BCR-stimulation for 
survival. Data are representative of more than three independent 
experiments with three to 5 mice per genotype. 
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This resulted in mature Sppl2a-/- B cells, that expressed only about 25% of BAFFR 
levels compared to wildtype CD93low mature B cells (Figure 3.8B). Up-regulation of 
surface BAFFR also ceased in Baff-/- animals from the T2 stage onwards, indicative 
of the loss of survival signalling at that stage of development, and further suggesting 
that in the absence of SPPL2A surface BAFFR expression and blockage of 
transitional B cell development occurs before BAFF-signalling is required. Figure 
3.8B also shows that expression of IgD followed the same pattern as BAFFR during 
transitional B cell development in SPPL2A deficient, failing to up-regulate and 
leaving mature B cells with about 12% of normal surface IgD. Conversely IgM is 
progressively down regulated in developing wildtype B cells from T1 to the mature 
stage, and this measure of B cell maturation was not disrupted in the absence of 
BAFF, but was even more pronounced when SPPL2A was absent. Surface IgM 
levels were around 30% of normal levels, leading to a profound decrease of the total 
surface BCR pool on SPPL2A-deficient B cells overall (Figure 3.8B). The same 
results were obtained when mature splenic B cells were resolved from immature cells 
in SPPL2A and BAFF-deficient mice by additionally using CD62L (L-Selectin) 
expression (Figure 3.9). CD62L is a functionally relevant marker for maturing B 
cells that home to lymphoid organs (Gallatin et al., 1983, Arbones et al., 1994). 
 
The ability of follicular B cells to reach maturity in the absence of SPPL2A was 
assessed not only by measuring up-regulation of surface CD62L and identification of 
splenic B cell follicles, but also by detecting SPPL2A-deficient B cells in peripheral 
lymph nodes (Figure 3.10A). Once transitional B cell development is completed, 
naïve mature cells start to circulate through the body and seed other secondary 
lymphoid organs, such as the lymphnodes (Allman and Pillai, 2008). Flowcytometric 
analysis of axillary and subiliac lymphnodes from Sppl2a-/- mice, again in direct 
comparison to Baff-/- animals with a known block in transitional B cell development, 
showed that mature Sppl2a-/- B cells do reach this organ despite a similar reduction 
of surface BAFFR, IgD, IgM, CD23 as seen on mature B cells in the spleen (Figure 
3.10B, Figure 3.8B and Figure 3.9C and D). Normally B cells represent about 40-
50% of cells in the examined lymphnodes, but in lymphnodes from Sppl2a-/- mice 
only about 2-3% of cells are mature B cells. At 1-2% the proportion of mature B 
cells was even lower in Baff-/- mice (Figure 3.10A).  
 
 
	   110  
Figure 3.9: Resolving mature B cells in the spleen using CD62L and 
CD93 confirms that SPPL2A is required for their peripheral 
accumulation 
 
A. Flow cytometric plots of B220+ B cells isolated from Sppl2a+/+ and 
Sppl2a-/- mouse spleens, showing CD62L and CD93 based gating 
strategy to distinguish immature (T1, T2) and mature B cells. 
B. Bar graph of absolute splenic CD62LlowCD93high and CD62LhighCD93low 
B cell numbers in mice with the indicated genotype. 
C. Representative flow cytometric staining presented as overlay 
histograms for B220, IgM, IgD, BAFFR, and CD23 on Sppl2a+/+ (shaded 
gray) and Sppl2a-/- (black line) immature (CD62LlowCD93high) or mature 
(CD62LhighCD93low) splenic 
B cells as per A. The numbers show the MFI for Sppl2a+/+ (gray; top) and 
Sppl2a-/- cells (black; bottom). 
D. Geometric MFI graphs quantifying surface expression of the B cell 
markers in immature and mature B cells, as shown in C. Dotted lines 
indicate mean. Data are representative of more than three independent 
experiments with three to 5 mice per genotype. 
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Figure 3.10: SPPL2A is required for mature B cells to 
accumulate in lymphnodes 
 
A. Flow cytometric plots and percentages of B cell subsets in 
lymphnode preparations pooled from Lnn. axillares and Lnn. 
subiliaci of Sppl2a+/+, Sppl2a-/- and Baff-/- mice. 
B. Column dot graphs showing geometric mean fluorescent 
intensity for IgD, IgM, B220, CD21 and CD23 on the surface 
of CD19+ B cells in lymphnodes as indicated for panel A. 
Data are representative of three independent experiments 
with three to 5 mice per genotype. 
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This observation in lymph nodes was similar to what was seen in the spleen (Figure 
3.3.7B), showing that the loss of mature B cells in the absence of BAFF was more 
severe than in the absence of SPPL2A. 
 
SPPL2A was required for conventional recirculating B2 B cell development, but was 
SPPL2A activity also important for natural antibody producing, innate-type B1 B 
cells? B1 B cells develop earlier during ontogeny than B2 B cells, and are thought to 
either emerge from distinct B1 B cell precursors or from common B cell precursors, 
but have received different signals to B2 cells during development and selection 
(Baumgarth, 2011). B1 B cells are found most abundantly in the peritoneal and 
pleural cavity in mice, but are scarce in typical secondary lymphoid organs. Since B1 
B cells might take a different maturation path to B2 B cells, they may not require 
SPPL2A to develop, and a difference in phenotype between B1 and B2 B cells could 
provide a clue to find out why SPPL2A is required by B2 B cells to accumulate in 
peripheral lymphoid organs. To investigate B1 B cells, the peritoneal cavities of 
Sppl2a-/-, Baff-/- and wildtype mice were flushed with PBS to isolate cells in this 
body compartment with the wash fluid for flowcytometric analysis. Figure 3.11 
shows that SPPL2A-deficient CD5+ B1a and CD5- B1b B cell subsets in the 
peritoneal cavity were reduced in numbers and were unable to maintain normal 
surface IgM and CD11b levels, whereas B1 B cells in BAFF-deficient mice appeared 
normal, confirming that B1 B cell deficiency in Sppl2a-/- mice was not a secondary 
effect of a small B cell compartment. Non-surprisingly B2 B cells in the peritoneal 
cavity were around 4-5-fold reduced in numbers in the absence of SPPL2A and 
BAFF. SPPL2A thus appears to interfere with factors that are required for maturation 
by both, B1 and B2 B cells. 
 
To test whether the B cell defect in mice lacking SPPL2A was caused extrinsically 
by detrimental changes in the B cell environment, such as the loss of BAFF, or was 
due to a B cell intrinsic problem, 100% and mixed wildtype and Sppl2a-/- bone 
marrow chimeric mice were generated. For the mixed chimeras, T and B lymphocyte 
deficient Rag1-/- recipient mice were sub-lethally irradiated with a 450cGy dose and 
then intravenously reconstituted with a Ly5a and Ly5b congenitally marked bone 
marrow mixture made up of 70% Ly5b-Sppl2a-/- and 30% Ly5a-wildtype marrow. 
As controls, mixed chimeras reconstituted with mixtures of Ly5a and Ly5b wildtype 
marrows were generated as well (not shown).  
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Figure 3.11: SPPL2A is needed for B1 B cell formation in the 
peritoneal cavity 
 
A. Flow cytometric plots and percentages of B2 and B1 B cells in the 
peritoneal cavity of Sppl2a+/+, Sppl2a-/- and Baff-/- mice. 
B. Bar graph showing absolute cell numbers of the indicated B cell 
subsets in the peritoneal cavity of Sppl2a+/+, Sppl2a-/- and Baff-/- mice. 
C. Overlay FACS histograms and bar graphs presenting IgM and 
CD11b surface expression on peritoneal B1a and B1b B cell subsets in 
mice with the indicated genotype. Data are representative of three 
independent experiments with three mice per genotype. 
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After allowing about 12 weeks for the donor bone marrow to populate the recipient 
environment, bone marrow, spleens, lymphnodes and washes form the peritoneal 
cavity were collected from the chimeras to asses the Sppl2a-/- bone marrow derived B 
cell phenotype and relative reconstitution rates in comparison to wildtype marrow 
derived B cells (Figure 3.12). Recipients that were reconstituted with 100% Sppl2a-/- 
bone marrow still presented with reduced percentages of peripheral B cells that had 
lowered surface IgD expression, whereas recipients reconstituted with 100% 
wildtype marrow had a normal B cell compartment, demonstrating that the lack of 
SPPL2A causes a B cell intrinsic defect that can not be rescued by factors in the non-
hematopoietic environment (Figure 3.12A). This was consistent with BAFF-
transgenic recipients that produce excess amounts of BAFF failing to rescue the 
Sppl2a-/- B cell defect when receiving SPPL2A-deficient bone marrow (Figure 
3.12A). Despite a block in B cell development at the T1/T2 stage in Sppl2a-/- mice 
that mirrored BAFF-deficiency, oversupply of BAFF did not overcome this block. 
This expectantly confirmed the non-responsiveness of surface BAFFR devoid 
SPPL2A-deficient B cells to overabundant supply of BAFF. Relative reconstitution 
in mixed chimeras was used as a measure of the ability of various Sppl2a-/- B cell 
subsets to develop in the presence of wildtype (Sppl2a+/+) competition for survival 
niches. Whereas immature B cells in the bone marrow and T1 cells in the spleen 
emerged at the ratio of the donor marrows, the outgoing ratio of 70% Sppl2a-/- cells 
reduced at the T2/T3 stage to around 40% and mature follicular Sppl2a-/- B cells 
were only represented at 2.7% in the spleen, indicating that SPPL2A-deficient B cell 
precursors can competitively develop up to the T1 stage, but contesting survival 
alongside wildtype developing B cells highlights the Sppl2a-/- B cell deficiency 
observed in a non-competitive environment even further (Figure 3.12B). In mixed 
chimeras, Sppl2a-/- B cells in peripheral lymphnodes, Sppl2a-/- B2 and B1b B cells in 
the peritoneal cavity and flowcytometrically detectable Sppl2a-/- marginal zone (MZ) 
B cells were all represented at less than 1%, which demonstrated the requirement for 
SPPL2A in the competitive and cell autonomous development of these B cell subsets 
(Figure 3.12C). Interestingly, Sppl2a-/- myeloid cell compartment in the peritoneal 
cavity was underrepresented at 26.9% instead of the expected 70%, suggesting an 
intrinsic role for SPPL2A in the development of peritoneal myeloid cells as well 
(Figure 3.12C). 
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Figure 3.12: B cell deficiency caused by the lack of SPPL2A is cell 
intrinsic 
 
A. FACS plots of blood derived B cells from 100% hematopoietic mouse 
chimera of the indicated genotypes. Baff tg (transgenic) recipients provide 
an environment of increased BAFF levels (Mackay et al., JExpMed., 1999). 
B and C. Stacked bar graphs showing proportions of reconstitution for B 
cell developmental subsets in the bone marrow and spleen (A and B) or B 
cell subsets in the peritoneal cavity and lymphnodes (B) in sub-lethally 
irradiated Rag1 deficient host B6 mice that have been injected with a 
~70%-30% mixture of congenitally marked Ly5a-Sppl2a+/+ (white bars) and 
Ly5b-Sppl2a-/- (black bars) donor bone marrow to generate mixed 
hematopoietic mouse chimera. 12 weeks were allowed for reconstitution 
before FACS analysis. Numbers above columns are mean percentages 
and standard deviation of Sppl2a-/- derived cell proportion. Data are 
representative of two independent experiments with 5 to 10 recipient mice 
per group. 
A 
0 102 103 104 105 
IgM 
Ig
D
 
Host: 
100% Donor: 
B6 Rag1-/- B6 Baff tg B6 Rag1-/- 
Sppl2a-/- Sppl2a-/- Sppl2a+/+ 
Blood 
CD19+ 
Enid BMCs
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
0
20
40
60
80
100
R
ec
on
st
itu
tio
n 
(%
) 
Immature 
B cells 
Recipient # 
T1 T2 T3 Follicular 
B cells 
Bone marrow Spleen 
Sppl2a-/- 
Sppl2a+/+ 
B 
85.5% ± 3.1 79.6% ± 4.2 43.4% ± 11.1 36.6% ± 9.3 2.7% ± 0.4 
Enid BMCs
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
0
50
100
R
ec
on
st
itu
tio
n 
(%
) 
Recipient # 
Marginal Zone 
B cells 
Myeloid 
cells 
Spleen 
0.05% ± 0.01 26.9% ± 11.5 
Sppl2a-/- 
Sppl2a+/+ 
C Peritoneal cavity Lympnodes 
B2-B cells B1b-B cells B cells 
0.24% ± 0.04 1.03% ± 0.24 1.21% ± 0.23 
	   116 
To test whether SPPL2A-deficiency solely interferes with B cell development, or 
whether T lymphocyte also rely on SPPL2A for their maturation, thymic T cell 
development was flowcytometrically analysed in more detail. As previous results of 
normal T cell percentages in the periphery might have already implied (Figure 3.4A 
and 3.7A), development of Sppl2a-/- thymocytes through early double negative (DN) 
stages 1, 2, 3 and 4, resolvable by surface CD25 and CD44 expression, and later 
double positive (DP), CD4+CD8dim and CD4+, as well as CD8+ thymocyte 
development appears comparable to wildtype controls (Figure 3.13A and B) (Koch 
and Radtke, 2011). This is reflected in normal numbers of thymocyte subsets (Figure 
3.13C) and normal total T cell numbers in the spleen (Figure 3.14A). Analysis of the 
same mixed bone marrow chimeras already described for Figure 3.12 (70% Ly5b-
Sppl2a-/- and 30% Ly5a- Sppl2a+/+ donor marrow), showed that SPPL2A-deficient 
CD4+ and CD8+ T cells reconstitute recipient Rag1-/- mice competitively at the 
expected ratio in the periphery (Figure 3.14B). Surprisingly, the splenic Sppl2a-/- 
myeloid compartment was overrepresented.  
 
To screen for SPPL2A-dependent major defects of other hematopoietic peripheral 
cell types, blood samples from Sppl2a-/-, Sppl2a+/- and Sppl2a-/- mutant mice were 
analysed with fluorescent antibodies by flowcytometry and by a flowcytometry 
based diagnostic haematology system (ADVIA 2120 Siemens Healthcare-
Diagnostics) that measured forward and side scatter of laser light to discern blood 
leukocyte subsets. Combination of these two types of data revealed normal numbers 
of erythrocytes, T cells, neutrophils and monocytes, but reduced numbers of B cells 
in the peripheral blood of Sppl2a-/- mice (Figure 3.14C). 
 
In conclusion these findings show that SPPL2A is cell intrinsically required for B 
cell development past the T1 transitional stage and for B cell surface expression of 
BCRs and BAFFRs. T cells, lymphocyte lineage relatives of B cells, interestingly did 
not depend on SPPL2A for normal development. Thus, apart from some 
inconsistencies in chimeric myeloid cell reconstitution, SPPL2A-deficiency caused a 
B cell defect in the immune system, which implied an essential role for SPPL2A 
specifically in B cells.	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Figure 3.13: SPPL2A is not necessary for T cell 
development in the thymus 
 
A. Flow cytometric plots and percentages of thymocyte 
subsets in thymi from Sppl2a+/+ and Sppl2a-/- mice. 
B. Geometric MFI graphs quantifying surface expression of 
thymocyte markers on developing T cell subsets in the 
thymus, as shown in A. Dotted lines indicate mean of the 
respective thymocyte subset MFI from multiple Sppl2a+/+ 
(white circles) and Sppl2a-/- (green circles) mice. 
C. Bar graph showing absolute cell numbers of the indicated 
thymocyte subsets in thymi from Sppl2a+/+ and Sppl2a-/- mice, 
gated according to plots in panel A. DN1-4, CD4 and CD8 
double negative, stage 1-4; DP, CD4 and CD8 double 
positive. Data are representative of two independent 
experiments with three mice per genotype. 
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Figure 3.14: Number of T cells in the spleen and number of 
Monocytes, Neutrophils and Eosinophils in the blood of Sppl2a-/- 
mice is normal 
 
A. Bar graph displaying absolute T cell numbers in spleens of Sppl2a+/+ 
and Sppl2a-/- mice. Data is pooled from four separate experiments. Bars 
represent median. Two tailed t-test; n.s. p>0.05. 
B. Stacked bar graph showing proportions of reconstitution for T cells 
and Myeloid cells in the spleen of sub-lethally irradiated Rag1 deficient 
mice that have been injected with a ~70%-30% mixture of Ly5a-Sppl2a+/
+ (white bars) and Ly5b-Sppl2a-/- (black bars) donor bone marrow to 
generate mixed hematopoietic chimera. 12 weeks were allowed for 
reconstitution. Numbers above columns are mean percentages and SD 
of Sppl2a-/- derived cell proportion.  
C. Bar graphs showing cell counts of the indicated leukocyte subsets in 
peripheral blood collected from Sppl2a+/+, Sppl2a+/- and Sppl2a-/- mice 
by retro-orbital sampling. Analysis was done by FACS based 
flowcytometry in combination with a flowcytometric diagnostic 
heamatology system (ADVIA 2120, Siemens Healthcare Diagnostics). 
One-Way ANOVA followed by Bonferroni’s Multiple Comparison post 
test; **** p<0.001, *** p<0.01, n.s. p>0.05. 
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3.3 SPPL2A is necessary for antibody production and normal B cell function 
Follicular B cells form the basis of humoral immunity and they function to recognise 
antigen, by cell activation, recruitment of T cell help and terminal differentiation into 
long-lived antibody secreting plasma cells (Nutt et al., 2015). SPPL2A was essential 
for B cells to develop normally and in the absence of SPPL2A mature follicular B 
cell numbers were about 20-fold reduced. Yet, residual mature CD93-CD62L+ B 
cells localised to B cell follicles in the spleen of Sppl2a-/- mice, and could potentially 
partake in humoral immune responses.  
 
Therefore it was tested next, whether SPPL2A-deficiency only interferes with B cell 
development, or whether SPPL2A is also required for normal B cell function. The 
ultimate outcome of a successful B cell response is the secretion and maintenance of 
specific antibody levels in the body. To see if B cells made any antibodies in Sppl2a-
/- mice, blood was collected from unimmunised 6-8 week old mice and the total 
serum IgM and IgG1 antibody concentrations were measured by ELISA. Compared 
to wildtype control mice, Sppl2a-/- animals had about 25-fold less IgM and 6-fold 
less IgG1 antibody base levels in the blood (Figure 3.15A). To test whether Sppl2a-/- 
B cells could mount antibody responses to specific antigens, Sppl2a-/- and control 
mice were immunised with various model antigens. After the time periods indicated 
in Figure 3.15B to allow for a humoral immune response to occur, serum samples 
were collected for detection of antibodies against the employed antigens by ELISA. 
The immunisation strategy is depicted in Figure 3.15B. Almost no specific antibody 
was made in SPPL2A-deficient mice after immunization with formalin-inactivated 
and heat-killed Bordetella pertussis and alum-precipitated chicken gamma globulin 
(CGG) coupled to p-azobenzenearsonate (ABA) hapten or after immunization with 
the T-independent antigen 4-hydroxy-3-nitrophenylacetyl-Ficoll (NP-Ficoll) (Figure 
3.15C). Antibody responses to these model antigens normally elicit production of 
specific IgG2c (B. pertussis) and IgG1 (CGG), demonstrate hapten recognition 
(ABA) or extra-follicular T cell help-independent B cell IgM secretion (NP-Ficoll). 
Therefore, SPPL2A is not only required for normal B cell maturation, but also 
essential for humoral immunity, as the absence of SPPL2A completely blocked 
specific antibody production to a variety of model antigens. 
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Figure 3.15: SPPL2A is essential to mount a humoral 
immune response 
 
A. ELISA analysis of total serum IgM and IgG1 concentration 
in unimmunized 6-8 week old mice of the indicated genotype, 
kept under specific pathogen free condition. 
B. Schematic illustrating mouse immunisation strategy 
employed to test humoral B cell responses to various model 
antigens. CGG, chicken gamma globulin; ABA, p-
azobenzenearsonate; NP, 4-Hydroxy-3-nitrophenylacetyl. 
C. ELISA analysis of serum antibodies to B. pertussis and 
CGG 2 weeks after immunization, against the hapten ABA 4 
weeks after immunization, and against NP-Ficoll 6 days after 
booster immunization. Bars represent mean, and each 
symbol a single mouse of the indicated genotype. Data are 
representative of one experiment with 5 to 7 mice per 
genotype. 
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The production of high-affinity antibodies by follicular B cells in response to 
immunisation or infection is a multistep process that relies on interactions between B 
cells and follicular T helper cells (TFH), an essential CD4+ T helper cell subset, in a 
specialised microenvironment that is known as germinal centre (GC) (Vinuesa et al., 
2010, Nutt and Tarlinton, 2011, Victora and Nussenzweig, 2012). The lack of 
antibody production in SPPL2A-deficient mice could be due to the inability to form 
germinal centres or due to a block in post-germinal centre differentiation of antigen 
secreting plasma cells. To measure the differentiation of B cells into CD95+GL-7+ 
germinal centre B cells, as well as co-development of the essential 
CD4+PD1highCXCR5high TFH cells (Crotty, 2011), Sppl2a-/- and Sppl2a+/+ mice were 
immunised with sheep red blood cells (SRBC) as foreign antigen to trigger germinal 
centre formation (Brink et al., 2008).  
 
After allowing 7 days for differentiation of B and T cell subsets in germinal centres, 
spleens of the immunised mice were flowcytometrically analysed. As can be seen in 
Figure 3.16A and B, no CD95+GL-7+ germinal centre B cells were detectable in 
SPPL2A-deficient mice. The differentiation of TFH cells and germinal centre B cells 
is interdependent, and so it comes to no surprise that almost no Sppl2a-/- TFH cells 
were detected either. CD44 surface was comparable between wildtype and Sppl2a-/- 
TFH cells, indicating that TFH cells became normally activated, but did not develop in 
greater numbers due to the absence of GC-B cells in Sppl2a-/- mice (Figure 3.16C). 
Therefore, follicular B cells appeared unable to differentiate into germinal centre B 
cells in the absence of SPPL2A, explaining why long lived antibody production is 
blocked in Sppl2a-/- mice. 
 
Preceding the germinal centre reaction mature B cells are required to activate and 
proliferate following stimulation of their BCR or non-specific pattern recognition 
receptors, such as Toll Like Receptors (TLR) (De Silva and Klein, 2015). To test the 
isolated ability of Sppl2a-/- B cells to activate and proliferate following stimulation in 
vitro, splenocyte cultures from wildytpe and SPPL2A-deficient mice were prepared. 
The splenocytes were either labelled with the amine-binding cell proliferation dye 
cell-trace-violet (CTV) and stimulated with anti-IgM, the surface TLR-4 ligand LPS, 
the endosomal TLR-9 ligand CpG, and with combinations of anti-IgM and anti-
CD40, or anti-IgM and LPS (Figure 3.17). After 24 hours B cells from the  
	   122  
0
10
20
30
40
50
# 
G
C
 c
el
ls
 (x
10
4 )
# 
G
C
 B
 c
el
ls
 (x
10
4 )
 
0
10
20
30
# 
Tf
h 
ce
lls
 (x
10
4 )
# 
T F
H
 c
el
ls
 (x
10
4 )
 Sppl2a+/+  
 Sppl2a-/- 
B 
0
103
104
105 40.8
30.7
42.8
31.8
0 103 104 105 
0
102
103
104
105 2.37
6.24
CXCR5 
P
D
1 
CD4+ 
CD8 
C
D
4 
Non B cells 
Sppl2a+/+ 
A 
Sppl2a-/- 
010
2
103
104
105 0.075
6.53
CD19+ 
CD95 
G
L7
 
0 102 103 104 105 
Figure 3.16: Sppl2a-/- mice  cannot form germinal centre 
B cells 
 
A. Flow cytometric plots and percentages of T cell and B cell  
subsets in spleens of Sppl2a+/+ and Sppl2a-/- mice, 7 days 
after intraperitoneal injection with 2x108 sheep red blood cells 
(SRBC). Pregating is shown above columns. 
B. Bar graphs of absolute germinal centre B cell (GC) and 
Tfh numbers in spleens from from SRBC injected Sppl2a+/+ 
and Sppl2a-/- mice; analysed 7 days after injection. Bars 
represent mean. 
C. FACS overlay histogram of CD44 expression on 
PD1highCXCR5high T follicular helper cells (TFH), shown in 
subgate of the second column in A. 
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Figure 3.17: SPPL2A is required for normal B cell 
activation and proliferation 
 
A. Overlay FACS histograms presenting representative 
staining for activation markers on Sppl2a+/+ (black line) and 
Sppl2a-/- (green line) B cells after 24 hour of culture in the 
presence of the indicated stimuli. 
B. Overlay histograms showing Cell Trace Violet (CTV) 
fluorescence dilution of B cells that have initially been CTV 
labelled and cultured for 96 hours in the presence of the 
indicated B stimulating agents. Dilution of the chromatin 
integrating CTV label is a measure of cell proliferation, as the 
CTV fluorescence is shared between progeny with every cell 
division. Sppl2a+/+ (black line), Sppl2a-/- (green line) and non-
dividing, unstimulated (shaded grey) cells are shown. Data is 
representative of 3 independent experiments 
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splenocyte cultures were analysed by flowcytometry for up-regulation of surface 
activation markers. SPPL2A-deficient B cells appeared to be able to normally up-
regulate CD44 and CD69, whereas CD25 expression, which is thought to be NFκB 
signalling dependent (Wang et al., 2014), did not occur (Column 1,2 and 3 in Figure 
3.17). This was regardless of the type of stimulation. After 96 hours of culture 
dilution of the cell proliferation dye showed that Sppl2a-/- B220+ B cells overall did 
not proliferate as much as wildtype B220+ cells, and that there are gradual 
differences between the different stimuli (Figure 3.17). Taken together, SPPL2A-
deficient B cells exhibit reduced responses to BCR and TLR stimulation in vitro. 
This observation might help to explain the inability of Sppl2a-/- B cells to form 
germinal centres. 
 
During B cell development the response to antigenic stimulation changes. To prevent 
inappropriate maturation of self-reactive immature and early transitional B cells, 
strong BCR stimulation by BCR crosslinking with membrane bound antigen induces 
B cell apoptosis (Hartley et al., 1991, Hartley et al., 1993), whereas milder BCR 
signals by soluble self-antigens trigger down-regulation of surface IgM and a 
changeover into an anergic state (Goodnow et al., 1988, Goodnow et al., 2005). 
Since mature SPPL2A-deficient B cells appeared non-responsive to antigenic and 
‘pathogen-associated-molecular-pattern’ (PAMP) stimulation, a B cell anergy 
inducing mouse model was used to also test B cell responsiveness to self-antigen 
stimulation (Goodnow et al., 1988, Adams et al., 1990). In this model BCR-
transgenic B cells recognise a soluble model self-antigen. In this system hen-egg 
lysozyme (HEL) acts as model antigen, which is systemically expressed as a soluble 
protein in a HEL-transgenic mouse strain known as ML-5. The matching, pre-
arranged transgenic BCR in this model recognises only HEL with high affinity and is 
constitutively expressed on B cells of the HEL-BCR transgenic mouse strain referred 
to as MD-4. Crossing MD-4 and ML-5 mice creates double-transgenic mice that 
harbour large quantities of circulating soluble HEL and only produce HEL-
recognising BCR-transgenic B cells. In these double-transgenic mice, developing B 
cells encounter HEL and as a result respond to self-antigen stimulation with down-
regulation of surface IgM to become anergic.  
 
Testing the response of SPPL2A-deficient developing B cells to self-antigen in this 
model by using mixed bone marrow chimeric mice has added benefits. B cell 
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responsiveness can be compared between homologous wildtype and Sppl2a-/- 
immature and transitional B cell populations in vivo within the same recipient mouse, 
at an early stage in development that is not yet affected by SPPL2A-deficiency. 
Hereafter results in mixed bone marrow chimeric mice will be described, although 
similar results were also obtained from the analysis of Sppl2a-/- mice crossed onto the 
MD-4 or MD-4 ML-5 double transgenic backgrounds. 
 
In order to assess B cell responsiveness in immature B cells in vivo, mixed bone 
marrow chimeric mice as depicted in Figure 3.18A were generated. Bone marrow 
donors were progeny of Sppl2a-/- mice that interbred with the HEL-recognising 
transgenic BCR MD-4 mouse strain, resulting in offspring that were SPPL2A-
deficient and only yielded B cells with the pre-arranged HEL-transgenic BCR (MD-4 
Sppl2a-/-). To congenitally differentiate SPPL2A-deficient B cells from wildtype B 
cells in mixed bone marrow chimeric mice, the CD45 isoform Ly5a (CD45.1) was 
used as pan-leukocyte marker.  Sppl2a-/- donor marrow was Ly5a-negative, therefore 
HEL-BCR transgenic, SPPL2A-deficient and Ly5a- donor marrow is designated as 
MD-4 Ly5a- Sppl2a-/- (Figure 3.18A). 
 
Wildtype control bone marrow donors were analogous MD-4 Sppl2a+/+ mice, but 
congenitally marked with Ly5a+ surface expression. Thus they are labelled as MD-4 
Ly5a+ Sppl2a+/+. As recipients for a 60% Sppl2a-/- MD-4 Ly5a- to 40% Sppl2a+/+ 
MD-4 Ly5a+ bone marrow mixture, either C57B6 wildtype mice (B6) or ML-5 HEL-
transgenic mice (ML-5 HELtg) that secrete the model self-antigen as soluble HEL 
into the bloodstream were used. After reconstitution, B cell development was 
analysed in the bone marrow and spleen by FACS. The upper panel in Figure 3.18B 
shows that SPPL2A-deficient B cells with a pre-arranged HEL-transgenic BCR 
normally express IgM and develop to the immature stage. Similar to the non-BCR-
transgenic Sppl2a-/- bone marrow samples (Figure 3.6), reduced proportions of 
mature B cells re-circulate back into this compartment (Figure 3.18B). In the 
presence of soluble HEL as self-antigen recognised by all BCRs in this system, both 
Sppl2a-/- and Sppl2a+/+ immature IgD- B cells respond with down-regulation of 
surface IgM expression (lower panel in Figure 3.18B). For comparison, the same 
immature B cells that were not exposed to soluble self-antigen in B6 recipients 
maintained higher IgM expression (Figure 3.18C).  
 
	   126  
Recipient 
ML-5 
HELtg 
B6 
.:.
:. 
A Donor 
MD-4 Ly5a- 
Sppl2a-/-  
MD-4 Ly5a+ 
Sppl2a+/+  40% 
60% 
ML-5 
HELtg 
.:.:.  
B6 
Ly
5a
 
FSC 
0
102
103
104
105
68.9
29.5
50 150 250 
0
102
103
104
105 26.9
58.2
10.7
54.6
25.4
16.4
14.3
74.6
8.22
59.3
23.6
12.7
Ig
D
a 
IgMa 
0 102 103 104 105 
Sppl2a+/+  
(Ly5a+) 
Sppl2a-/-  
(Ly5a-) 
Sppl2a+/+  
(Ly5a+) 
Sppl2a-/-  
(Ly5a-) 
Ly5a+/Ly5a- 
MD-4 
MD-4 
B 
0
102
103
104
105
58.7
39.7
MD-4 B220+ 
B6 recipient 
FSC 
50 150 250 
Ly
5a
 
Ig
D
a 
MD-4 B220+ 
ML-5 HELtg  
recipient 
Ly5a+ 
Ly5a- 
Ly5a+ 
Ly5a- 
Figure 3.18: Sppl2a-/- immature B cells in the bone 
marrow normally respond to autoantigen  
 
A. Schematic illustration of mixed hematopoietic chimera set 
up to test Sppl2a-/- B cell response to autoantigen. 
Congenitally marked (Ly5a) HEL-recognising-BCR-transgenic 
(MD-4) B cells of the indicated genotype were reconstituted in 
either B6 or systemically HEL expressing (ML-5 HELtg) 
recipient mice and analysed by FACS after 11 weeks. 
B. FACS plots showing Ly5a+ Sppl2a+/+ or Ly5a- Sppl2a-/- B 
cells in the bone marrow of B6 (top) or ML-5 HELtg (bottom) 
chimeric mice. Pregating indicated above columns. 
C. MFI graph displaying IgMa expression on Ly5a+ Sppl2a+/+ 
or Ly5a- Sppl2a-/- immature bone marrow B cells from either 
B6 or ML-5 HELtg chimeric mice. Dashed line is mean. 
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This shows that Sppl2a-/- immature B cells, which developed without obvious 
phenotypic defects in the absence of SPPL2A (Figure 3.6), also were able to respond 
normally to self-antigen BCR stimulation at this earlier stage of maturation, before B 
cell development is blocked from T2 onwards. SPPL2A therefore appeared to be 
required for B cell responsiveness only from the T2 stage of B cell development 
onwards. 
 
Analysis of spleen B cells in the same chimeras shows that SPPL2A-deficient total 
B220+ B cell accumulation in recipients 11 weeks post bone marrow transplantation 
is around 7-fold reduced at 9% rather than the 60% outgoing representation of 
Sppl2a-/- donor marrow (Figure 3.19A). This was regardless of self-antigenic BCR 
stimulation through presence or absence of soluble HEL in B6 or ML-5 HELtg 
recipient mice. Sppl2a-/- B cell loss in this system was similar to what I saw in non-
BCR transgenic mixed bone marrow chimera experiments (Figure 3.12). The 
increased ratio of Sppl2a-/- bone marrow derived CD93high immature to CD93low 
mature B cells also indicated the previously observed loss of mature B cells. This 
was again regardless of Sppl2a-/- B cells receiving an inappropriate BCR signal 
through “self”-HEL binding or not in B6 or ML-5 HELtg recipient mice respectively. 
However, as already seen in bone marrow samples, SPPL2A-deficient B cells did 
respond normally to HEL-BCR binding with down-regulation of surface IgM (Figure 
3.19B). This demonstrates that the loss of SPPL2A does not interfere with the type of 
BCR signalling needed to induce and maintain B cell anergy, and that SPPL2A-
deficient B cells are responsive to at least some type of BCR signal. It was 
interesting to observe that Sppl2a-/- MD-4 B cells in the absence of HEL-binding in 
B6 recipient mice also down-regulated surface IgM, although to a much lesser 
degree than in the presence of HEL-binding. This indicated that weak, tonic BCR 
stimulation in the absence of a soluble BCR ligand was sufficient to induce IgM 
down-regulation in Sppl2a-/- MD-4 B cells, which further suggests that IgM 
internalisation mechanisms might be abnormally ‘hyper-sensitised’ or activated. 
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Figure 3.19: SPPL2A is not necessary for B cell anergy 
 
A. FACS plots showing Ly5a+ Sppl2a+/+ or Ly5a- Sppl2a-/- B 
cells in the spleen of B6 (top) or ML-5 HELtg (bottom) 
chimeric mice. See previous figure. Pre ting indicated. 
B. MFI graphs of B cell markers on immature (CD93high) and 
mature (CD93low) D-4 B cells of the indicated genotype, 
reconstituting spleens of either B6 (left column) or ML-5 
HELtg (right column) chimeric mice. 
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3.4 B cell survival requires SPPL2A 
Sppl2a-/- B cells are characterised by low surface expression of BCRs and BAFFRs. 
As both of these receptors are important regulators for peripheral B cell survival, it 
was tested whether SPPL2A deficient B cells are unable to mature due to a survival 
defect or due to developmental arrest. Low BCR and BAFFR surface expression 
could prevent that transitional B cells and CD93low mature B cells in the periphery 
receive survival signals needed to block FOXO mediated transcription of pro-
apoptotic proteins, such as BCL2-associated X protein (BAX) and BCL2 antagonist 
killer (BAK), or to produce anti-apoptotic proteins that inhibit BAX and BAK in 
order to block the mitochondrial apoptosis pathway, such as BCL2 (Figure 1.2) 
(Youle and Strasser, 2008, Tait and Green, 2010). Conversely, the absence of 
SPPL2A might directly activate apoptosis and synthesis of pro-apoptotic proteins, 
which could subsequently prevent the surface expression of BCRs and BAFFRs. To 
block or at least delay potential apoptosis in SPPL2A-deficient B cells, the Sppl2a-/- 
mutant mouse strain was crossed with transgenic mice that overexpress the anti-
apoptotic BAX/BAK-inhibitor BCL2 in hematopoietic tissues under the control of 
Vav-promotor elements (Ogilvy et al., 1999). From the resulting Sppl2a-/- Vav-Bcl2 
offspring blood samples were collected to asses whether BCL2 overexpression and 
inhibition of intrinsic apoptosis is able to rectify the loss of surface BCR and BAFFR 
expression. The flowcytometric data in Figure 3.20 shows that overexpression of 
BCL2 did not rescue surface BCR and BAFFR expression in SPPL2A-deficient B 
cells. Sppl2a-/- Vav-Bcl2 and Sppl2a-/- non-transgenic B cells in the blood present 
with a similarly reduced surface expression of IgD, IgM and BAFFR, as well as 
CD23 and CD21. This was also true for splenic B cells in these mice (Figure 3.21A 
and Figure 3.23B), indicating that the failure of SPPL2A-deficient B cells to display 
BCRs and BAFFRs on the cell surface is not secondary to apoptosis. Nevertheless, 
enforced BCL2 expression in Sppl2a-/- Vav-Bcl2 mice did increase the total number 
of splenic B cells to 32.2 ± 15 × 106 (mean and SD), which was greater than the total 
B cell number in wildtype (19.5 ± 4.6 × 106) or in Sppl2a-/- non-transgenic mice 
(9.4 ± 3.7 × 106), but still lower than in Vav-Bcl2-transgenic mice with wild-type 
SPPL2A (107 ± 42 × 106), suggesting that BCL2 overexpression does not render 
Sppl2a-/- B cells independent of the need for SPPL2A, yet was able to increase 
survival of cells that would have otherwise died.  
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Figure 3.20: Overexpression of anti-apoptotic BCL2 does 
not rescue low surface BCR and BAFFR levels on 
Sppl2a-/- B cells in the blood 
 
A. FACS plots and percentages showing Sppl2a+/+ or 
Sppl2a-/- B cell subsets in the blood, either expressing a Bcl2 
transgene or not, as indicated. 
B. Overlay historgrams of CD19+ B cells form the blood of 
Bcl2-transgenic Sppl2a+/+ or Sppl2a-/- mice showing surface 
BAFFR expression. Data are representative of at least three 
independent experiments with three or more mice per 
genotype. 
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Figure 3.21: Overexpression of anti-apoptotic BCL2 rescues 
mature B cell accumulation, but does not render them 
independent for the need of SPPL2A 
 
A. FACS plots and percentages of the B cell subsets in spleens from 
mice with the indicated genotype, either expressing a Bcl2 transgene or 
not. 
B. Bar graphs showing Number of B cells of the indicated subsets (as 
gated in A, 3rd column) in spleens from Sppl2a+/+ and Sppl2a-/- mice, 
either transgenic for Vav-Bcl2 or not. Bars show mean, and each 
symbol is a single mouse. Data are representative of at least three 
independent experiments with three to four mice per genotype (A) or 
data were combined from four experiments (B). 
 
B 
0.25
0.5
1
2
4
8
16
32
64
128
# 
ce
lls
 (x
10
6 )
C
D
93
-  I
gM
lo
w
 c
el
ls
 (x
10
6 )
 
+ + - - 
0.25
0.5
1
2
4
8
16
32
64
128
# 
ce
lls
 (x
10
6 )
C
D
93
+  
Ig
M
lo
w
 c
el
ls
 (x
10
6 )
 
+ + - - 
0.25
0.5
1
2
4
8
16
32
64
128
# 
ce
lls
 (x
10
6 )
C
D
93
+  
Ig
M
hi
 c
el
ls
 (x
10
6 )
 
Vav-Bcl2 
Sppl2a+/+  
 Sppl2a-/- 
+ + - - 
	   132 
It has been shown in other BCR or BAFFR deficient systems that BCL2 
overexpression does not entirely substitute for the loss of BCR or BAFFR survival 
signalling (Lam et al., 1997, Rahman and Manser, 2004, Tardivel et al., 2004, 
Takeuchi et al., 2005), and so the absence of BCRs and BAFFRs could explain the 
reduced proportions of mature CD93lowCD62+ B cells in Sppl2a-/- Vav-Bcl2 
transgenic mice compared to wildtype transgenic mice (Figure 3.21A). However, the 
BCL2 transgene specifically increased the numbers of mature CD93-IgMlow B cells 
in spleens of Sppl2a-/- mice by about 6.5-fold, whereas BCL2 overexpression did not 
alter the numbers of CD93+IgMhigh splenic T1 B cells (Figure 3.21A and B), and as 
such BCL2 increased the ratio of mature to immature B cells in Sppl2a-/- mice.  
 
The B cell phenotype and absolute cell numbers in peripheral lymphnodes were 
examined to obtain an additional measure of mature B cell survival in secondary 
lymphoid organs (Figure 3.22). In lymphnodes from Sppl2a-/- Vav-Bcl2 transgenic 
mice the proportion of B cells with a CD62L+CD93- mature phenotype was doubled 
compared to non-transgenic mice (Figure 3.22A). This was reflected in specifically 
increased absolute numbers of mature CD62L+CD93- B cells compared to non-
transgenic Sppl2a-/- mice (Figure 3.22B). As seen in the spleen (Figure 3.23A and B), 
surface expression of IgD, IgM, BAFFR and CD23 on BCL2 transgenic B cells in 
lymphnodes remained largely comparable to their non-transgenic counterparts, even 
when comparing only surface expression on mature CD62L+CD93- B cell subsets 
(Figure 3.23A and C). Taken together, overexpression of the anti-apoptotic protein 
BCL2 rescues accumulation of Sppl2a-/- mature B cells in peripheral lymphoid 
tissues, but does not correct the SPPL2A-deficiency induced loss of surface BCR and 
BAFFR. This indicates that the block in transitional B cell development of Sppl2a-/- 
mice is due to a B cell survival defect, rather than a programmed developmental 
arrest. 
 
The above findings impose a simple explanation of the B cell developmental block at 
the T1/T2 stage in Sppl2a-/- mutant mice. Since transitional B cells rely on survival 
signals from tonic BCR signalling and binding of the cytokine BAFF to the BAFFR, 
it comes to no surprise that Sppl2a-/- B cells with virtually no surface BCR or 
BAFFR levels succumb to a survival defect, that nevertheless can be overridden by 
enforcing BCL2 expression. It could be hypothesised that the loss of SPPL2A  
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Figure 3.22: Overexpression of anti-apoptotic BCL2 rescues 
accumulation of mature Sppl2a deficient B cells in lymphnodes 
 
A. Flow cytometric plots and percentages of B cell subsets in 
lymphnode preparations pooled from Lnn. axillares and Lnn. subiliaci of 
Sppl2a+/+ and Sppl2a-/- mice, either expressing a Bcl2 transgene or not. 
B. Bar graphs showing Number of CD62L+CD93- B cells (as gated in A, 
3rd column), T cells and total lymphocytes (Lympho) in lymphnodes from 
Sppl2a+/+ and Sppl2a-/- mice, either transgenic for Vav-Bcl2 or not. Bars 
show mean, and each symbol is a single mouse. Data are 
representative of two independent experiments with three mice per 
genotype. 
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Figure 3.23: The inability of mature Sppl2a-/- B cells to up-regulate 
BCRs and BAFFR is not the result of a survival defect 
 
A. Representative flow cytometric plots of CD62L and CD93 expression 
on B cells from subcutaneous LNs in Vav-Bcl2 transgenic mice of the 
indicated genotype. Overlay of flow cytometric histograms for B220, IgM, 
IgD, BAFFR, and CD23 cell surface expression on CD62LhighCD93low 
mature B cells in spleen (top) or LNs (bottom) from Sppl2a+/+ (shaded 
gray) and Sppl2a-/- (green line) mice. Numbers in the plots indicate 
geometric mean fluorescence intensity for Sppl2a+/+ (gray; top) and 
Sppl2a-/- cells (black; bottom). 
B and C. Column graphs quantifying surface expression of the indicated 
surface markers on mature CD62LhighCD93low B cells in spleens (B) and 
lymphnodes (C) of Sppl2a+/+ and Sppl2a-/- Bcl2 transgenic or non-
transgenic mice. Data are representative of at least three (A and B) or 
two (C) independent experiments with three or more mice per genotype. 
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somehow causes reduced surface BCR and BAFFR levels, which then in turn render 
Sppl2a-/- B cells devoid of survival signals and lead to their death by apoptosis.  
 
To test this assumption the retroviral gene transfer system already mentioned above 
was used to artificially restore at least parts of the survival signal perceived by B 
cells through the BCR and BAFFR. BCL2 expression is induced by BAFFR and 
BCR supported signalling through the NFκB-pathway (Figure 1.2) (Rahman and 
Manser, 2004, Tardivel et al., 2004, Takeuchi et al., 2005). By retrovirally 
transducing Sppl2a-/- B cells with a mutant Ikbkb allele (K171E) (Rossi et al., 2011), 
that enforces expression of constitutively active IKK*, the NFκB-pathway can be 
directly activated (Mercurio et al., 1997), whilst bypassing the need for BCR and 
BAFFR stimulation. Thus wildtype B cells transduced with Ikk* in vitro display 
increased CD69, CD95, CD25 and CD23 expression, confirming these surface 
molecules as NFκB-targets, and are able to survive and proliferate in culture upon 
withdrawal of B cell stimulating factors, such as anti-IgM (Wang et al., 2014). 
 
To reinstitute NFκB mediated B cell survival signal in Sppl2a-/- B cells that is not 
dependent on surface BAFFR or BCR expression, retroviral gene transfer was used 
to introduce the constitutively active Ikk* vector into SPPL2A-deficient, activated 
splenic B cells (Jeelall et al., 2012, Wang et al., 2014). The schematic drawing in 
Figure 3.24A illustrates how Sppl2a-/- and Sppl2a+/+ splenocytes were cultured and 
activated with anti-IgM and LPS for one day, before spinocculation to transduce the 
activated cells with the Ikk* or empty (EV) retroviral vectors. Successful B cell 
transduction could be monitored through EGFP-reporter expression. The following 
day, removal of anti-IgM and LPS ceased B cell stimulation. From this ‘day 0’ 
onwards Sppl2a-/- and Sppl2a+/+ B cells, either transduced with EV or Ikk*, were 
followed by cell counting, flowcytometrically measuring EGFP+ B cell proportions 
and surface expression of CD25, CD69 and CD44 (Figure 3.24B and C). Against 
expectation, Sppl2a-/- B cells transduced with constitutively active IKK* did not 
proliferate and increase in numbers, and NFκB-mediated induction of surface CD25 
expression did not occur (Figure 3.24B and C). The latter finding is consistent with 
the previously presented inability of activated Sppl2a-/- B cells to up-regulate CD25 
surface expression (Figure 3.17). This suggests that SPPL2A is required to facilitate 
NFκB signalling, presumably downstream of IKK, or responsiveness to NFκB 
mediated transcription. As mentioned in the introduction, constitutively active IKK  
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Figure 3.24: Constitutively active IKK* driven NFkB 
signal is blocked in Sppl2a-/- B cells 
 
A. Schematic drawing of experimental approach to enforce 
IKK (Inhibitor of κ-B Kinase) signal in in Sppl2a-/- B cells 
despite the lack of B cell receptors on the cell surface. 
Splenocytes were harvested from either Sppl2a+/+ or Sppl2a-/- 
mice, cultured with LPS and α-IgM for 24h, before 
spinoculation with depicted retroviruses expressing either 
constitutively active IKK (IKK*) or an empty vector (EV). 36h 
after retroviral transduction, LPS and α-IgM are washed off 
cultures (day 0) and B cells analysed by flowcytometry for 
activation markers, GFP expression and cell enumeration. 
B. X-Y-plots showing the rate of change in absolute cell 
numbers, relative to the starting number of cell on day 0. 
C. MFI graphs summarising surface expression of activation 
markers on GFP+ B cells measured by FACS on day 1, as 
per experiment described in panel A. 
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in vivo is able to compensate for the loss of BAFFR signalling, but not the loss of 
BCR signal (Sasaki et al., 2006, Srinivasan et al., 2009). Since the retroviral 
approach in this experiment ignored PI3-Kinase signalling downstream of the BCR 
and BAFFR (Srinivasan et al., 2009) and SPPL2A-deficient B cells lack both of 
these surface receptors, constitutively active IKK alone may not be sufficient to 
compensate for this. Nevertheless, Sppl2a-/- B cells failed to respond to enforced 
canonical NFκB signal, which ultimately implies that NFκB signal from the BCR or 
BAFFR would be ineffective, even if they would be expressed on the cell surface of 
Sppl2a-/- B cells. Thus, the absence of surface BCRs and BAFFRs, appears to be 
symptomatic, but not causative of the SPPL2A-deficient B cell survival problem. 
 
SPPL2A is necessary for B cell survival in the periphery, and in the absence of 
SPPL2A late transitional and mature B cells are lost, presumably by increased 
apoptosis. In apoptotic cells excessive amounts of phosphatidylserine (PS), a 
phospholipid that is normally restricted to the cytoplasmic leaflet of the plasma 
membrane, becomes exposed to the outer membrane leaflet, as membrane 
asymmetry is no longer maintained (Fadok et al., 1998, Daleke, 2003). Therefore 
fluorescently labelled Annexin V binding to surface exposed PS can be used as a 
flowcytometric tool to identify apoptotic cells. To test whether SPPL2A-deficient 
mice harbour increased levels of circulating apoptotic B cells, blood samples from 
Sppl2a-/-, Sppl2a+/- and Sppl2a+/+ mutant mice were collected to determine Annexin 
V surface staining on B cells. Figure 3.25A shows the FACS histogram overlay for 
Annexin V surface labelling on CD19+ B cells from the blood, indicating the gating 
strategy to select the percentage of Annexin V+ apoptotic cells, which are 
enumerated for multiple animals in the adjacent graph. Surprisingly proportions of 
apoptotic B cells in the blood were lower than normal in SPPL2A-deficient mice 
(Figure 3.25A). It was also apparent that the Annexin V staining levels on non-
apoptotic Sppl2a-/- B cells were reduced, whereas Annexin V surface binding and 
therefore surface emergence of PS on apoptotic B cells occurred at normal levels. 
The blood stream may not be the ideal compartment to search for increased B cell 
apoptosis in SPPL2A-deficient mice, as the survival defect takes effect in T2 and 
mature follicular B cells, the majority of which resides in splenic follicles. Therefore 
splenocytes from Sppl2a-/- and Sppl2a+/+ mice were isolated to examine apoptosis in 
B cell subsets from the spleen (Figure 3.25B, C and D). To ameliorate any effects of 
the cell isolation process on membrane lipid distribution,  
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Figure 3.25: Apoptotic B cell proportions in Sppl2a-/- mice  are not 
increased and SPPL2A is needed to maintain phosphatidylserine 
surface membrane levels in B cells 
 
A. Overlay FACS histogram of Annexin V staining on B cells from the blood 
from Sppl2a+/+ (shaded grey) and Sppl2a-/- (green line) mice. Column graph 
quantifying proportion of  Annexin V+ B cells in the blood. One Way ANOVA 
with Bonferroni’s Multiple Comparison post test, * p<0.05, n.s. p>0.05. 
B and C. FACS plots and x-y-graphs (percentages and absolute cell 
numbers) showing 7AAD and Annexin V labelling on splenic B cell subsets 
with the indicated genotypes cultured for 0.5 or 3 hours in either RPMI 
media alone (B) or treated with 1µg/ml Staurosporine. 
D. Histogram of Annexin V staining on splenic B cells. 
E. FACS histograms showing membrane integration levels of fluorescently 
labeled phasphatidylserine analogue C6-NBD-PS after incubating 
congenitally marked Ly5a-wildtype B cells (shaded grey) and the indicated 
Ly5b cells in the same tube for 1 min in media with the PS analogue.  
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the splenocytes were allowed to rest in RPMI culture medium at 37°C for 30min 
before flowcytometric staining on ice and subsequent analysis (Figure 3.25B).  
 
Spleen B cell labelling with Annexin V and the cell viability dye 7AAD showed that 
proportions of pre-apoptotoic Annexin V+ 7AAD- B cells were comparable between 
wildtype and SPPL2A-deficient B cells, whereas the proportions of Annexin V+ 
7AAD+ G0 and G1 apoptotic cells, that had lost membrane integrity, were reduced in 
Sppl2a-/- B cells. Differentiation of developmental B cell subsets gated on all 
Annexin V+ cells as shown in panel A, revealed that SPPL2A-deficient mice had 
about 3-fold fewer numbers of mature apoptotic cells than expected, whilst the 
number and frequency of apoptotic cells among transitional B cell subsets was 
normal. This observation was independent of the time that isolated splenocytes spent 
in RPMI culture; 3 hour cultures produced comparable results. Exposure of cultured 
splenocytes to 1 µg/ml of the promiscuous inhibitor of protein kinases staurosporine 
(Bertrand et al., 1994, Boix et al., 1997) did not elicit a differential apoptotic effect 
on wiltype and SPPL2A-deficient B cells in 30min or 3hour cultures (Figure 3.25C), 
suggesting that Sppl2a-/- B cells are not increasingly susceptible to apoptosis in this 
system. The histogram in Figure 3.25D shows the same reduction of Annexin V 
surface labelling on non-apoptotic Sppl2a-/- B cells in the spleen, already seen in the 
blood. This observation was B cell specific, as Sppl2a-/- T cells had normal Annexin 
V+ staining levels (Figure 3.25D).  
 
Annexin V binds PS on the outer membrane leaflet of cells that cannot maintain 
asymmetric distribution of higher concentrations of PS on the cytoplasmic leaflet of 
the plasma membrane. ‘Flipping’ and ‘scrambling’ are the two enzymatic processes 
that regulate PS membrane asymmetry (Daleke, 2008, Panatala et al., 2015, 
Montigny et al., 2015, Williamson, 2015): Firstly, scrambleases homogenise the 
distribution of phospholipids across both membrane leaflets, a Ca2+-dependent 
process. Secondly, flippases transport and concentrate PS from the outer leaflet into 
the cytoplasmic leaflet, a process that requires ATP. Our laboratory has recently 
discovered that activity of the ATP11C flippase is essential for B cell maturation, 
presumable by regulating membrane-bound signalling complexes. Atp11camb/- or 
ATP11C-deficient mice present with a block in B cell development past the Pro-B 
cell stage (Yabas et al., 2011). Reduced basal Annexin V staining on SPPL2A-
deficient B cells suggests that either flippase activity is increased or that scramblease 
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activity is decreased. To test if flippase activity is abnormal in Sppl2a-/- B cells 
splenocytes from wildtype, Sppl2a-/- and Atp11camb/- mice were incubated in C6-
NBD-PS (a fluorescently labelled PS-homologue) and measured its flippase 
dependent incorporation into the inner membrane leaflet over time. Histograms in 
Figure 3.25E show that C6-NBD-PS incorporation levels in B220+IgM+ Sppl2a-/- B 
cells after 1 minute were comparable to wildtype cells, and ATP11C-deficient cells 
expectantly had incorporated less PS-homologue. Consequently, SPPL2A-lacking B 
cells have potentially reduced PS externalising scramblease activity and present with 
abnormal phospholipid distribution across the membrane lipid bilayer. 
 
3.5 CD74 degradation by SPPL2A is essential for B cell survival 
SPPL2A-deficiency in mice is characterised by a loss of transitional and mature B 
cells, whereas T lymphocytes and most other peripheral blood leukocyte subsets 
seem to develop and survive normally. This observation suggests a specific role for 
the intramembrane protease SPPL2A only in B cells. The graph in Figure 1.6 shows 
that according to mRNA expression measurements by the ImmGen consortium 
(www.immgen.org), Sppl2a, as well as most other SPP/SPPL family members are 
ubiquitously expressed in many different immune cell subsets, including T cells 
(Heng et al., 2008). This suggests that SPPL2A fulfils an important role in most 
leukocytes, but to the contrary, removal of SPPL2A only seems to be relevant for B 
cells. So how could the absence of SPPL2A cause a specific B cell defect and how 
does SPPL2A normally ensure surface expression of BCRs and BAFFRs? It seems 
most plausible that the physiological relevance of SPPL2A in B cells is not 
dependent on SPPL2A per se, but rather linked to a specific transmembrane protein 
substrate this intramembrane protease targets in B cells, but not in T cells. Therefore 
SPPL2A must process a protein substrate that is only expressed in B cells. In the 
absence of SPPL2A this substrate is not processed adequately and then causes B cell 
deficiency. To test this hypothesis, I set out to search for a potential SPPL2A 
substrate, which I knew had to be a single-pass, type II transmembrane protein and 
needed to be expressed in B cells, but not in T cells. Since SPPL2A-deficiency 
causes a B cell defect during transitional B cell development, the putative SPPL2A-
substrate should be increasingly expressed during the late phase of B cell maturation.  
 
Applying these search criteria, a list of all murine type II and single-pass 
transmembrane proteins was extracted from the UniProt protein database 
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(www.uniprot.org) (UniProt, 2015) and narrowed it to all proteins that had higher 
mRNA expression in mature follicular B cells than in T1 B cells, based on 
expression values from the aforementioned ImmGen mRNA database (Heng et al., 
2008). At last the remaining proteins were ranked by their mRNA expression ratio 
between follicular B cells and average expression in CD4+ and CD8+ spleen T cells. 
This approach should allow identification of potential SPPL2A substrates that were 
highly expressed in B cells, but not T cells. Table 3.1 shows the first 27 proteins in 
the resulting list, which is headed by Cd74. Cd74 has by far the highest absolute and 
relative follicular B cell specific expression levels in this ranking. At 20-fold higher 
expression in B cells than T cells Cd38, Xylt1 (3.38-fold), Enpp1 (3.3-fold) and 
Lpcat1 (2.2-fold) follow Cd74 expression at 36-fold by a wide margin to round out 
the top 5 SPPL2A substrate candidates in B cells. CD74, also referred to as MHCII 
invariant chain or Ii, is renown for its role in MHCII chaperoning and antigen 
presentation (Landsverk et al., 2009). B cells are one of the professional antigen 
presenting cell types, and so it is not surprising to see high expression levels of Cd74 
in this cell type, but not in T cells. A handful of in vitro SPPL2A substrates, such as 
BRI2, TNF-α, FASL and foamy virus envelope protein are known (Voss et al., 
2013). Interestingly those proteins did not emerge from the here employed search 
strategy, as these SPPL2A substrates are expressed similarly in B and T 
lymphocytes. This means that deficient processing of any of these SPPL2A 
substrates would not be able to explain the B cell specific defect observed in 
SPPL2A-deficient mice, but the broader expression pattern of the known SPPL2A-
substrates certainly does not rule out their ability to contribute to B cell deficiency. 
 
CD74 as a top candidate for B cell specific SPPL2A cleavage was further 
investigated by looking at Cd74 and Sppl2a mRNA expression throughout B cell 
development (Figure 3.26) (www.immgen.org). As expected Cd74 expression is 
induced at the Pre-B cell stage and then about 24-fold up-regulated throughout 
subsequent B cell maturation stages (Figure 3.26A). Notably, Cd74 reaches its 
highest expression in transitional B cells, and is also expressed in B1 B cells, thus 
correlating with Sppl2a-/- B cell defects in those B cell subsets. Contrastingly, Sppl2a 
does not follow a similarly drastic expression pattern with about 1.3-fold increasing 
expression in developing B cells. This Sppl2a expression profile in developing B 
cells is consistent with the assumption that SPPL2A mediated B cell deficiency is  
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Gene Relative gene 
expression: 
B cells/T cells 
T1 B cells 
A.U. mean gene 
expression  
(ImmGen) 
Follicular B cells 
A.U. mean gene 
expression  
(ImmGen) 
 
Likely subcellular 
location 
(UniProt) 
Cd74 36.298 9405 10205 Membranes 
Cd38 20.123 2108 2205 Membranes 
Xylt1 3.380 717 1280 ER 
Enpp1 3.302 184 464 Membranes 
Lpcat1 2.246 496 1069 ER, Golgi, Lipid-droplet 
Manea 2.162 456 545 Golgi 
Tpst1 2.144 265 291 Golgi 
Mgat4a 1.878 201 474 Golgi 
Clec2i 1.755 341 1255 Cell surface 
St8sia4 1.697 695 887 Golgi 
B3gnt2 1.659 723 834 Golgi 
Btnl2 1.647 125 171 Membranes 
St14 1.564 173 193 Golgi 
Galnt1 1.346 538 708 Golgi 
B3galt2 1.220 43 54 Golgi 
Fut11 1.177 88 119 Golgi 
Fam69a 1.169 611 1011 ER 
Galnt11 1.153 331 380 Golgi 
C1galt1c1 1.141 129 156 Membranes 
B4galt5 1.128 457 501 Golgi 
Erlin2 1.096 226 282 ER 
St3gal5 1.086 78 97 Golgi 
St6gal1 1.082 1000 1060 Golgi 
Csgalnact2 1.072 235 338 Golgi 
Fam20b 1.045 414 442 Golgi 
St6galnac3 1.042 49 98 Golgi 
Glt8d1 1.036 115 139 Membranes 
Table 3.1: List of murine, single-pass type 2 trans-membrane 
protein coding mRNA that is expressed at higher levels in B cells 
than in T cells, and is up-regulated during late B cell 
development 
 
Table listing 27 UniProt (UniProt Consortium, Nucleic Acids Research, 
2015, www.uniprot.org) annotated murine single-pass type 2 trans-
membrane protein coding genes that have been selected based on 
their gene expression profiles published in the Immunological 
Genome Project database (Heng et al., Nature Immunology, 2008, 
PMID 18800157; www.immgen.org). All listed genes are expressed at 
higher levels in splenic follicular B cells than in CD4+ and CD8+ T 
cells, and are up-regulated during late B cell development from 
transitional T1 to the follicular mature B cell stage. The second 
column shows relative gene expression levels in follicular B cells over 
average expression in CD4+ and CD8+ T cells. The likely subcellular 
location for each gene product is taken from UniProt. A.U., arbitrary 
units. 
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Figure 3.26: Cd74 mRNA is up-regulated during late B 
cell development, whilst Sppl2a mRNA is expressed in all 
B cell developmental stages 
 
A and B. Bar graphs showing Cd74 (A) and Sppl2a (B) 
relative mRNA expression (arbitrary units, A.U.) in the 
indicated B cell developmental cell subsets.  
Both graphs are prepared from public Immunological 
Genome Project database (Heng, Nature Immunology, 2008; 
www.immgen.org) 
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linked to the lack of processing of a specifically expressed substrate, rather than 
targeting of Sppl2a expression to a certain B cell subset (Figure 3.26B). 
 
The schematic drawing of Figure 3.27A illustrates the MHCII antigen presentation 
pathway and shows how CD74 aids chaperoning and trafficking of MHCII 
molecules into endosomal antigen presentation compartment referred to as MIIC 
(MHCII containing compartment). Once CD74-MHCII complexes reach the MIIC, 
luminal proteases degrade the C-terminal CD74 domain. A penultimate CD74-
cleavage step by Cathepsin S releases MHCII-CLIP complexes for peptide loading 
and subsequent presentation to CD4+ T cells on one hand, and on the other hand a 
residual CD74-membrane stub is liberated. SPPL2A localises to the endosomal 
membrane as well and requires type II transmembrane substrates that have been pre-
degraded. Therefore, our current understanding of luminal CD74 trimming in 
endosomes was consistent with the assumption that CD74 could be a highly suitable 
and B cell specific SPPL2A substrate. As shown in Figure 3.27A, I hypothesised that 
SPPL2A normally degrades CD74-membrane fragments that have been released 
from Cathepsin S cleavage in B cells. 
 
To test this theory, CD74 degradation fragments in FACS single cell sorted spleen B 
cell lysates from Sppl2a-/-, Sppl2a+/- and Sppl2a+/+ mice were biochemically tracked 
by immunoblotting (Figure 3.27B and C). The monoclonal IN1 antibody is directed 
against an N-terminal epitope of murine CD74, and if short C-terminally degraded 
CD74 membrane stubs are not cleaved in SPPL2A-deficient B cells, then IN1 
immunoblotting of the B cell lysates should detect any accumulating N-terminal 
CD74 fragments. The IN1 N-terminal CD74 immunoblot of Sppl2a-/-, Sppl2a+/- and 
Sppl2a+/+ B cell lysates in Figure 3.27B shows accumulation of about 10- and 8-kD 
CD74 fragments in Sppl2a-/- samples and a small accumulation in heterozygous 
Sppl2a+/- mutant B cells. Interestingly there was no reduction, or perhaps only a 
small decrease of the p31 and p41 full length CD74 isoforms. The schematic drawing 
adjacent to the IN1-blot in Figure 3.27C explains the stepwise degradation of CD74 
in the endosome. It shows how the accumulating CD74 fragments correlate to 
predicted sizes for the penultimate p8-CD74 cleavage products produced by 
Cathepsin S. This extraordinary accumulation of penultimate p8-CD74 N-terminal 
fragments in Sppl2a-/- B cells revealed SPPL2A as the previously unknown  
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Figure 3.27: Proteolytic processing of CD74 in B cells requires 
SPPL2A 
 
A. Illustration of CD74’s role in MHCII antigen presentation, and 
depiction of a hypothesised requirement for SPPL2A in removing pre-
degraded residual CD74 fragments from endosomal membranes. 
(Modified after Neefjes at al., 2011) 
B. Immunoblot analysis of FACS sorted splenic B cells from Sppl2a+/+, 
Sppl2a+/- and Sppl2a-/- mice. Blots were probed with In-1 antibody 
against the CD74 N-terminal tail and then stripped and re-probed with 
antibody to α/β-Tubulin. p41 and p31 isoforms of CD74 are indicated. 
About 75 000 cells were loaded per lane. 
C. Schematic diagram of CD74 processing steps and products, showing 
estimated molecular weights and proteases involved. TM, 
transmembrane. Data are representative of more than three 
independent experiments. 
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intramembrane endopeptidase responsible for this final CD74 cleavage step (Lipp 
and Dobberstein, 1986a). 
 
How could the lack of p8-CD74 cleavage in SPPL2A-deficient B cells cause a 
transitional B cell defect? It has been suggested previously that CD74 intramembrane 
cleavage and the subsequent release of a small p4 N-terminal CD74 fragment into 
the cytosol would be necessary to induce a NFκB-mediated B cell survival signal. 
The absence of such a CD74-signal in Cd74-/- mice was thought to be the reason for 
a block in transitional B cell development in CD74-deficient mice (Matza	   et	   al.,	  2002b,	  Becker-­‐Herman	  et	  al.,	  2005). Therefore it could be possible, that SPPL2A-
deficiency prevents the release of p4-CD74 into the cytosol and induction of the 
CD74 survival signal. If this would be true, then the phenotype of B cell deficiency 
in Cd74-/- mice should be comparable to Sppl2a-/- mice. However, the B cell defect in 
the absence of CD74 is less severe than in the absence of SPPL2A, particularly T2 
transitional B cells seem to develop better in Cd74-/- mice as opposed to Sppl2a-/- 
mice (Shachar and Flavell, 1996, Maehr et al., 2004). Since enforced NFkB 
induction could not compensate for a putative CD74 mediated survival signal in 
SPPL2A-deficient B cells in vitro (Figure 3.24), it appeared more likely that the lack 
of CD74-fragment removal was causal for the B cell deficiency in Sppl2a-/- mice. 
Analogous to the concept of lyso-endosomal storage diseases and the B cell defect 
seen in I-Aα chain deficient mice (Rolink et al., 1999, Labrecque et al., 1999), the 
excessive accumulation of p8-CD74 transmembrane stubs could be the reason for 
severe disturbances of Sppl2a-/- transitional B cell homeostasis.  
 
To test whether excessive CD74-fragment accumulation is responsible for B cell 
deficiency in Sppl2a-/- mice, CD74-deficient mice were crossed with the Sppl2a-/- 
mutant mouse strain. If CD74 accumulation causes the Sppl2a-/--B cell defect, then 
additional removal of CD74 in Sppl2a-/- Cd74-/- doubly deficient mice should rescue 
B cell survival, at least to levels seen in singly CD74-deficient mice. Thus splenocyte 
suspensions from Sppl2a+/+, Sppl2a-/-, Cd74-/- and Sppl2a-/- Cd74-/- mice were 
prepared for flowcytometric analysis of late B cell development side by side. The 
plots in Figure 3.28 show that additional removal of CD74 from Sppl2a-/- B cells 
phenotypically rendered Sppl2a-/- Cd74-/- B cells indistinguishable from Cd74-/- B 
cells. The proportion of CD93low mature B cells in Sppl2a-/- Cd74-/- mice was almost  
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Figure 3.28: Removal of CD74 rescues developmental defect in 
Sppl2a deficient B cells 
 
A. Representative flow cytometric plots and percentages of B cell 
subsets in spleens from Sppl2a+/+, Sppl2a-/-, CD74-/- and Sppl2a-/-CD74-/- 
double deficient mice. 
B. FACS overlay histogram of surface IgD expression on CD19+ B cells 
in spleens from mice with the indicated genotypes. 
C. Bar graph presenting absolute cell numbers of the indicated subsets 
in spleens from Sppl2a+/+, Sppl2a-/-, CD74-/- and Sppl2a-/-CD74-/- mice: 
Lympho, lymphocytes; Foll, follicular B cells; T1, 2, 3, transitional stage 
1, 2 or 3 B cells. Bars show mean, and each symbol is a single mouse. 
Data are representative of at least three independent experiments with 
three or more mice per genotype. 
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doubled compared to SPPL2A singly deficient B cells (Figure 3.29A), as was the 
CD93highIgM+CD23+ transitional T2 compartment (Figure 3.28A).  
 
Cellularity of spleen B cell subsets in Sppl2a-/- Cd74-/- mice was also 
indistinguishable from CD74 singly deficient mice. Compared to reduced T2 and 
mature B cell numbers in Sppl2a-/- mice, SPPL2A-CD74-double deficient mice had 
normal numbers of T2 cells and increased to about twice as many mature follicular B 
cells (Figure 3.28C). Surface expression of IgD, IgM and CD23 on Sppl2a-/- Cd74-/- 
B cells were corrected to Cd74-/- B cell levels, whereas expression of BAFFR and 
B220 were comparable to levels seen in wildtype cells (Figure 3.28B and Figure 
3.29A). It is interesting to notice that low CD23 expression in Sppl2a-/- B cells 
increases when CD74 is also deleted. Since CD23 expression is thought to be NFκB 
regulated during transitional B cell development (Chung et al., 2002, Sasaki et al., 
2006), this observation firstly confirms that SPPL2A-deficiency might block NFκB 
activity in a CD74 dependent way. It secondly shows that in the absence of CD74 
this block is less severe, which opposes a proposed role for CD74 as potential NFκB 
activating pro-survival factor (Becker-Herman et al., 2005).  
 
The graphs in Figure 3.29B compare the up regulation of surface BAFFR, IgD and 
IgM in developing T1, T2 and mature CD93low B cells. Double deficient Sppl2a-/- 
Cd74-/- B cells had normal induction of BAFFR and IgD, with BAFFR surface 
expression reaching wildtype levels specifically in mature B cells. IgD did not fully 
up regulate to levels seen in mature Sppl2a+/+ B cells, as conversely IgM expression 
was not lost in mature Cd74-/- and Sppl2a-/- Cd74-/- B cells, indicating that this was 
caused by the lack of CD74. Taken together these data demonstrate that removal of 
CD74 from SPPL2A-deficient mice completely rescues the B cell defect in these 
animals, as Sppl2a-/- Cd74-/- double deficient B cells become indistinguishable from 
Cd74-/- B cells. This observation strongly suggests that SPPL2A is not required to 
cleave other putative substrates, such as TNF-α, FASL or other substrate candidates 
in Table 3.1, to facilitate B cell survival. The rescue of Sppl2a-/- B cell deficiency 
through CD74 removal demonstrates that the excessive accumulation of p8-CD74 
fragments in Sppl2a-/- B cells is responsible for the B cell developmental defect 
caused by the lack of SPPL2A, thus confirming that SPPL2A is required in 
developing B cells to degrade the N-terminal, residual p8-CD74 fragments. 
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Figure 3.29: Low surface expression of BCR and BAFFR in 
Sppl2a-/- B cells is caused by accumulating CD74 
 
A. Column graphs quantifying flowcytometric surface measurements of 
the indicated B cell markers as geometric mean fluorescent intensity 
(MFI) on splenic B cells isolated from wildtype (Sppl2a+/+), Sppl2a-/-, 
CD74-/- and Sppl2a-/-CD74-/- mice. 
B. MFI of staining for BAFFR, IgD and IgM on the indicated 
developmental B cell subsets in spleens from Sppl2a-/-, CD74-/-, 
Sppl2a-/-CD74-/- and Sppl2a+/+ mice. Data are representative of at least 
three independent experiments with three or more mice per genotype. 
0
200
400
600
0
5000
10000
15000
0
5000
10000
15000
B 
B
A
FF
-R
 (M
FI
) 
Ig
D
 (M
FI
) 
Ig
M
 (M
FI
) 
mat T1 T2 
Sppl2a+/+ 
mat T1 T2 
Sppl2a-/- 
mat T1 T2 
Cd74-/- 
mat T1 T2 
Sppl2a-/- 
Cd74-/- 
	   150 
The results presented so far showed that SPPL2A is the long sought-after 
intramembrane protease responsible for the ultimate cleavage step in the well 
studied, sequential process of CD74 degradation (Lipp and Dobberstein, 1986a), and 
CD74 emerged as a new SPPL2A substrate with in vivo relevance that requires 
SPPL2A-mediated processing to allow normal B cell development and BCR and 
BAFFR expression on the B cell surface. This finding resolved by which mechanism 
the Enid mutation in Sppl2a-/- mice causes B cell deficiency. Nonetheless, revealing 
this mechanism immediately raises a following question: How does the dramatic 
accumulation of p8-CD74 N-terminal fragments actually trigger a B cell defect? 
Apparently SPPL2A-mediated B cell deficiency hinges on CD74 metabolism and the 
review of this intensely studied molecule in the introduction (Chapter 1) highlighted 
the versatility of effects CD74 might have on B cell biology.  
 
Considering the ability of overly abundant CD74 to drive vesicle biogenesis and 
distort the endsomal system	   by inducing large intracellular early endosomes with 
delayed maturation into late endosomes and lysosomes (Lagaudriere-Gesbert et al., 
2002), the working hypothesis schematically depicted in Figure 3.30A was 
developed: The absence of SPPL2A in B cells causes the built up of p8-CD74 
fragments (a), which subsequently induce vesicle biogenesis and lead to an 
enlargement of the endosomal compartment (b). Disturbance of the endocytic 
pathway could block trafficking of BCRs and BAFFRs to the B cell surface and 
interfere with the downstream pathways of these survival receptors (c), thereby 
preventing the inhibition of intrinsic apoptosis. To see whether intracellular 
vacuolation is a defining feature of SPPL2A-deficiency in B cells, flowcytometry 
was used to measure the side scatter (SSC) of laser light as an objective measure of 
granularity in peripheral blood B cells. SSC was significantly increased selectively in 
mature IgD+IgMlow B cells from Sppl2a-/- mice compared with wildtype littermate 
controls (Figure 3.30B). This was not observed in BAFF-deficient controls (not 
shown), indicating that the increase in granularity was not due to a defect in 
transitional B cell survival. Perhaps surprisingly, SSC in Sppl2a-/- Cd74-/- double 
deficient IgD+ B cells from the blood was not significantly lower than SSC in 
SPPL2A-deficient cells and indistinguishable from Cd74-/- B cells (Figure 3.30C). 
Thus CD74 removal from SPPL2A-deficient B cells might not represent the 
expected rescue in SSC phenotype. However, this could be explained with  
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Figure 3.30: Maturing SPPL2A deficient B cells have increased 
granularity 
 
A. Illustration summarising how the lack of SPPL2A in B cells might 
causes accumulation of p8-CD74 fragments (a), leading to CD74-
induced vesicle biogenesis (b) and subsequent disturbances in protein 
synthesis and/or trafficking (c). 
B and C. Bar graphs quantifying flowcytometric light SSC as a relative 
measure of cell vesicle content, gated on IgM+ immature and IgD+ 
mature B cells in the blood as shown in the left panel of plots (in B) from 
mice with the indicated genotypes. Bars show mean, and each symbol 
is data from one mouse. One Way ANOVA with Bonferroni’s Multiple 
Comparison post test;  **** p<0.001, n.s. p>0.05. Data are 
representative of at least three independent experiments with at least 
four mice per genotype. 
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‘toxic MHCII chain aggregation’ in abnormal vacuoles when CD74 is absent	  (Bikoff	  et	   al.,	   1993,	   Viville	   et	   al.,	   1993,	   Elliott	   et	   al.,	   1994), suggesting that increased 
vacuolation could be a common symptom in situations of undue membrane protein 
accumulation in B cells. The here presented SSC measurements seemed to support 
the working hypothesis outlined above: SPPL2A is required to degrade CD74 in 
developing B cells to ensure their survival. There seems to be no redundancy of 
SPPL2A function to remove residual CD74 membrane fragments in B cells and 
inadequate accumulation of p8-CD74 stubs coincides with increased B cell 
granularity, which might conceivably interfere with B cell survival. 
 
The involvement of CD74 with reduced Sppl2a-/- B cell survival instigates the distant 
possibility of disturbed pro-survival signalling by the inflammatory cytokine 
macrophage migration inhibitory factor (MIF). As mentioned in Chapter 1, CD74 is 
known to form a receptor complex with CXCR2, CXCR4 and CD44 at the surface of 
immune cells to bind the MIF cytokine (Leng et al., 2003, Shi et al., 1999, 
Bernhagen et al., 2007, Gore et al., 2008, Schwartz et al., 2009). It was trialled 
whether SPPL2A deficient B cells show altered responses to different levels of MIF 
stimulation in vitro. No obvious changes in surface expression of the activation 
markers CD69 and CD25 after 24 hours of MIF stimulation could be detected, 
neither in Sppl2a-/- nor wildtype control B cells (Figure 3.31). Mild CD44 up-
regulation appeared to be specifically induced in Sppl2a-/- B cells by MIF treatments. 
However, this preliminary measurement was not MIF dose-dependent and requires 
experimental validation. B cell stimulation with anti-IgM and LPS was performed in 
parallel and as opposed to MIF did elicit B cell activation. From this one off 
experiment it was concluded that SPPL2A-deficiency induced changes in CD74 
homeostasis do not obviously alter the responsiveness of B cells to MIF. However 
repeated and more detailed investigations of this aspect in the future might reveal a 
role for MIF-CD74 signalling in SPPL2A-deficient B cells. 
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Figure 3.31: The inflammatory cytokine Macrophage 
migration inhibitory factor (MIF) does not activate B cells 
in the absence of SPPL2A 
 
Overlay flow cytomertic histograms showing activation 
marker surface expression on B cells after 24 hours culture 
with either 25, 100 or 200ng/ml Macrophage migration 
inhibitory factor (MIF) cytokine. Untreated wildtype B cells 
(shaded grey, Sppl2a+/+) are overlaid by MIF treated wildtype 
Sppl2a+/+ (black line) or Sppl2a-/- (green line) B cells. 
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3.6 Normal regulation of gene transcription profiles in maturing Sppl2a-/- B 
cells 
SPPL2A-deficiency and subsequent accumulation of p8-CD74 membrane fragments 
has detrimental effects on immature and mature B cell survival in peripheral 
lymphoid organs. Sppl2a-/- B cells are hallmarked by lowered surface expression of 
most typical mature B cell markers, including BCRs, BAFFR, CD23, B220, CD19 
and CD21. SPPL2A’s role in B cells to ultimately degrade CD74, a central player in 
MHC class II antigen presentation, also implies disturbances in this pathway. To 
understand whether the stark pathophysiological effects of SPPL2A-deficiency are 
reflected in altered gene transcription, 7AAD-CD19+B220+ CD93highIgMhigh 
immature and CD93lowIgMlow50% mature B cells from spleens of Sppl2a-/-, Baff -/- and 
wildtype mice were flowcytometrically sorted for global gene expression analysis by 
Agilent whole mouse genome oligo-microarray. BAFF-deficient B cell samples were 
included to help differentiate gene expression changes that would be caused not 
specifically by the loss of SPPL2A, but rather be secondary to transitional B cell 
loss. To compare mature B cells from each genotype that likely receive a similar 
relative dose of BCR signal, as indicated by down-regulation of surface IgM 
(Zikherman et al., 2012), half of the mature CD93low B cell populations with the 
lowest IgM surface levels were isolated. The flowcytometric sorting strategy is 
shown in Figure 3.32A.  
 
B cell sample RNA extraction, T7-based RNA amplification and Cy3-single colour 
labelling, array hybridization, microarray scanning and feature extraction were 
contracted to be done externally by Miltenyi Biotech GmbH in Germany. Raw gene 
signal intensity data from each array were normalised by dividing the intensity 
values by their median, resulting in the gene expression values presented hereafter. 
 
Since BCL2 overexpression could rescue mature B cell accumulation in SPPL2A-
deficient mice (Figure 3.21 and 3.22), the block in transitional Sppl2a-/- B cell 
development seemed to be due to a survival defect, rather than a genetically 
programmed developmental arrest. Nevertheless, global gene expression profiling in 
immature and mature Sppl2a-/- B cells provided the opportunity to look at 
transcriptional regulation of transitional B cell development in SPPL2A deficient 
mice. To visualise how the B cell transcriptional program changes in maturing 
Sppl2a-/- B cells, a list of genes normally regulated during transitional B cell  
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Figure 3.32: Regulation of mRNA expression in maturing splenic 
Sppl2a-/- B cells is normal 
 
A. FACS plots illustrating sorting strategy for immature (CD93high IgMhigh) and 
mature (CD93low IgMlow50%) B cells from mouse spleens with the indicated 
genotypes, used for gene expression analysis by microarray. B cell 
populations from three mice per genotype were analysed and presented as 
average values in B. B. Heat map showing average RNA expression of a 
selected gene set normally regulated during late B cell development in 
indicated spleen B cell subsets; immat, immature; mat, mature; see A. 
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development was generated. The list was based on Zfp318 (ZFP318), Fcer2a 
(CD23), Cr2 (CD21) and Tnfrsf13c (BAFFR) correlating gene clusters. As 
mentioned in the introduction, ZFP318 is a highly conserved mRNA splice factor 
that regulates increasing IgD expression during transitional B cell development and 
has recently been identified as key B cell lineage regulator that is up-regulated 
during transitional B cell development (Jojic et al., 2013, Enders et al., 2014). CD23, 
CD21 and BAFFR are also key transitional B cell markers (Chung et al., 2003). 
Using Pearson’s correlation of these B cell candidate genes with global gene 
expression pattern of developing B cell subsets in the ImmGen mRNA database 
(www.immgen.org) (Heng et al., 2008). The identified list of genes is shown in 
Figure 3.32B, which had a highly correlating B cell developmental expression 
pattern when compared with the seeded candidate genes mentioned above (r>0.85). 
The heat map in Figure 3.32B was produced using the ‘One Matrix CIMminer’ tool 
maintained by Yves Pommier and colleagues of the Genomics and Bioinformatics 
Group at the National Cancer Institute (Weinstein et al., 1997). It visualises changes 
in expression levels for this gene set of transitional B cell development in Sppl2a-/-, 
Baff -/- and wildtype immature and mature spleen B cells. Most genes, including 
Zfp318, Cr2 and Tnfrsf13c, regulated between immature and mature Sppl2a-/- B cells 
were expressed comparably to wildtype maturing cells. Notably, Fcer2a specifically 
did not up regulate in mature SPPL2A-deficient cells, which was consistent with the 
lack of CD23 expression in mature Sppl2a-/- B cells (Figure 3.9).  
 
On the other hand, Nfkb2 expression in mature B cells from BAFF-deficient mice 
was low, reflecting the absence of BAFF-signalling. Nfkb2 expression was 
surprisingly not reduced in Sppl2a-/- B cells. Quantitative representation of Zfp318, 
Cr2, Tnfrsf13c and Nfkb2 gene expression in all microarray samples is presented in 
Figure 3.33, and confirms the trends observable in the gene set overview of the heat 
map in Figure 3.32B. Interestingly transcript levels for IgM and IgD are regulated 
normally, as is the BAFFR transcript. Other B cell marker transcripts, like Cd93 and 
Cd19 are also regulated comparable to immature and mature wildtype B cells (Figure 
3.33). Similar to normal expression levels of Nfkb2 in Sppl2a-/- B cells, Foxo1 was 
also down regulated normally as immature Sppl2a-/- B cells progress to maturity. 
This suggests that despite reduced surface measurements of BAFFR and BCRs, 
downstream signalling of these receptors still occurs at least to some degree. Aicda 
transcript was detected at reduced levels in mature Sppl2a-/- B cells compared to  
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Figure 3.33: Transcriptional regulation of late B cell 
development is normal 
 
Column graphs quantifying mRNA expression for the indicated late B 
cell development markers in immature (i) and mature (m) B cells from 
Sppl2a+/+, Sppl2a-/- and Baff-/- mouse spleens. Paired immature and 
mature samples were sorted from the same three mice as shown in 
Figure 3.32 and analysed by Agilent microarray. A.U., arbitrary units. 
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immature cells and at overall lower quantities when compared to wildtype B cells, 
which seems consistent with the inability of Sppl2a-/- B cells to form germinal 
centres (Figure 3.16). Taken together, transcriptional regulation of key transitional B 
cell maturation genes occurs normally in SPPL2A-deficient B cells, supporting the 
understanding that the absence of SPPL2A does not block a genetic development 
program, but rather interferes with B cell survival. 
 
SPPL2A degrades CD74 and thus is connected with MHCII antigen presentation. 
Therefore transcript levels of proteins that play a role in this pathway were examined 
next (Figure 3.34). Graphs in Figure 3.34 show first of all that Sppl2a expression in 
Sppl2a-/- mutant B cells is reduced to about 30% of normal levels, indicating that the 
intronic splice site mutation not only induces a premature STOP codon to hinder full 
SPPL2A protein expression, but seems to reduce transcript stability as well. 
Quantification of Cd74 transcripts revealed that accumulation of p8-CD74 
membrane stubs in Sppl2a-/- mature B cells appears to negatively regulate Cd74 gene 
expression. Nevertheless overall Cd74 expression levels were very high at about 
9000 to 16000 A.U. when compared to other proteins, even the normally regulated 
transcript levels for MHCII α chains (H2-Aa) at 1200 to 3500 A.U. and β chains (H2-
Ab1) at 8000 to 12000 A.U.. Ciita expression in Sppl2a-/- mutant B cells was just 
above background and transcript levels for Cathepsin S, the endosomal protease 
responsible for the penultimate CD74 cleavage step, presumably resulting in p8-
CD74 production, were regulated similarly to wildtype B cells (Ctss).  
 
Expression of the transcriptional master regulator for one branch of the unfolded 
protein response (UPR), XBP1 (Cao and Kaufman, 2012), was reduced to about 60% 
of normal levels in Sppl2a-/- B cells, contradicting the possibility that excessive 
CD74 protein accumulation might trigger XBP1 activity. 
 
To further explore potential cellular pathways that might be disturbed by SPPL2A-
deficiency, I set out to compare differential expression levels of selected pathway 
target genes between Sppl2a-/- and wildtype Sppl2a+/+ B cells in immature and 
mature subsets. However, regulation of the following pathways appeared 
surprisingly normal in Sppl2a-/- B cells.  
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Figure 3.34: SPPL2A deficiency has only mild effects on MHCII-
pathway gene expression 
 
Column graphs quantifying mRNA expression for the indicated MHCII-
pathway markers in immature (i) and mature (m) B cells from Sppl2a+/+, 
Sppl2a-/- and Baff-/- mouse spleens. Paired immature and mature 
samples were sorted from the same three mice as shown in Figure 3.32 
and analysed by Agilent microarray. A.U., arbitrary units. 
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SPPL2A-deficieny causes the loss of surface BCR and BAFFR expression, which 
implies that signalling through these crucial B cell survival receptors should be 
impaired. Therefore Sppl2a-/- B cell expression levels of genes that are known to be 
transcriptionally regulated by BCR signalling were examined (Figure 3.35C) 
(Shaffer et al., 2008), as well as genes known to be regulated by NFκB stimulation 
(Figure 3.36C) (Lam et al., 2005), as BCR and BAFFR both activate this 
transcription factor family. Double-log scatter plots in Figure 3.35 for BCR genes 
and in Figure 3.36 for NFκB genes visualise comparative target gene expression 
(black dots) between wildtype and SPPL2A-deficient immature (Figure 3.35A and 
Figure 3.36A) and mature B cells (Figure 3.35B and Figure 3.36B). Target gene 
scatters are underlayed with expression values for all measured gene transcripts (grey 
circles) and proximity of any dots to a linear regression fitted to all expression values 
(dotted line), indicates low differential gene expression between wildtype and 
Sppl2a-/- samples, whereas remotely positioned values from the regression line 
indicate that genes are either up- or down-regulated in Sppl2a-/- B cells. Overall BCR 
and NFκB target gene scatters exhibited a shape reminiscent of the regression line, 
suggesting that neither BCR nor NFκB signals lacked or altered downstream 
transcripts in Sppl2a-/- B cells. These findings seem consistent with normal Nfkb2 
and Foxo1 expression shown in Figure 3.33 and the ability of Sppl2a-/- B cells to 
normally respond to self-antigenic BCR stimulation with IgM-down-regulation and 
anergy (Figure 3.18 and 3.19). Whilst changes in BCR and NFκB target gene 
expression profiles would have been expected due to reduced surface BCR and 
BAFFR levels, it has to be considered, that the microarray expression data presented 
here was acquired from resting B cell populations. It is possible that resting B cells 
receive only relatively weak BCR and BAFFR signals, which cause very similar 
gene expression profiles to situations of reduced BCR and BAFFR expression 
examined here. A repeat of this experiment with anti-BCR and anti-BAFFR 
stimulated B cells should reveal differences in BCR and NFκB target gene 
expression between wildtype and SPPL2A-deficient B cells. 
 
In the absence of SPPL2A B cells accumulate membrane CD74 fragments, which 
coincides with increased cell vacuolation and negative feedback of CD74 
transcription. This suggests that Sppl2a-/- B cells activate pathways to manage the 
pathological abundance of CD74-membrane fragments and related MHCII 
molecules. One such process eukaryotic cells employ to cope with severe changes in  
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Figure 3.35: Genes induced by BCR signaling are expressed 
normally in Sppl2a-/- mature and immature B cells 
 
A and B. X-Y-plots showing global gene expression (grey circles) from 
immature (A) and mature (B) B cells from either wildtype, plotted on 
the X-axis, or Sppl2a-/- mice, plotted on the Y-axis. Differential gene 
expression of BCR target genes (C) are highlighted as black dots. A 
first order polynomial (straight line) model was fitted to all gene 
expression values (dotted line). Each dot represents the average gene 
probe expression value from triplicate samples sorted as shown in 
Figure 3.32 and analysed by Agilent microarray. 
C. BCR target genes were identified by Shaffer et al. (Shaffer, 2008, 
Nature) through treatment of human blood B cells with α-IgM and 
measurement of subsequently up-regulated genes. 
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Figure 3.36: NFκB target gene expression in Sppl2a-/- mature and 
immature B cells is normal 
 
A and B. X-Y-plots showing global gene expression (grey circles) from 
immature (A) and mature (B) B cells of either wildtype genotype plotted 
on the X-axis or Sppl2a-/- genotype plotted on the Y-axis. Differential 
gene expression of NfκB target genes (C) are highlighted as black dots. 
A first order polynomial (straight line) model was fitted to all gene 
expression values (dotted line). Each dot represents the average gene 
probe expression value from triplicate samples sorted as shown in 
Figure 3.32 and analysed by Agilent microarray. 
C. NfκB target genes were identified by Lam et al. (Lam, 2005, Clin. 
Cancer Res.) through treatment of human DLBCL cell lines with 
MLX105 IKKβ-inhibitor and measurement of subsequently down-
regulated genes. 
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protein homeostasis is the aforementioned unfolded protein response (UPR). The 
UPR is normally induced due to endoplasmatic reticulum stress that results from the 
accumulation of unfolded protein (Cao and Kaufman, 2012). B cells typically 
activate this system by inducing XBP1 transcription factor activity to accommodate 
increased immunoglobulin synthesis in the rough ER during their transformation into 
antibody secreting plasma cells (Nutt et al., 2015). Autophagy is another means by 
which B cells cope with ER stress during immunoglobulin production (Pengo et al., 
2013). Since adequate CD74 chaperoning in the ER is required to prevent toxic 
MHCII chain aggregation and excessive CD74 accumulation highlights disturbed 
CD74 metabolism in Sppl2a-/- B cells, it was hypothesised that SPPL2A-deficiency 
might trigger an unfolded protein response as well as autophagy pathways to manage 
aberrant protein build-up. Analogous to examining transcriptional activity of the 
BCR and NFκB pathways, differential expression of XBP1 target genes (Figure 
3.37) (Shaffer et al., 2004), genes coding for UPR related proteins (Figure 3.38) 
(Todd et al., 2008, Takayanagi et al., 2013), glutamine starvation response genes 
(Figure 3.39 and Table 3.2) (Peng et al., 2002), glucose starvation response genes 
(Figure 3.40C) (Peng et al., 2002) and selected genes relevant for classical macro-
autophagy (Figure 3.41) (Moussay et al., 2011) were visualised by using x-y-double-
log scatter plot overlays as shown in each respective figure. The x-y-scatter plots in 
Figures 3.37 to 3.41 show that XBP1 target genes, UPR genes and metabolic stress 
gene clusters anticipated to collectively regulate changes in autophagy were 
expressed at comparable levels in Sppl2a-/- and Sppl2a+/+ B cells, regardless of their 
maturation status. As shown by the heat map in Figure 3.41B, selected classical 
macro-autophagy pathway genes, such as Atg12 and Map1lc3b (LC3) were normally 
up- or down-regulated in maturing SPPL2A-deficient B cells.  
 
Although transcriptional measurements for the purpose of monitoring autophagy 
have to be interpreted with caution (Klionsky et al., 2016), this simple screen for 
alterations of gene expression related to ER stress, the unfolded protein response, 
XBP1 mediated transcription, metabolic stress and at least classical forms of 
autophagy did not suggest that SPPL2A-deficiency and CD74-membrane fragment 
accumulation in B cells engages ER-stress and autophagy responses. 
 
Since pathway exploration did not yield any insights into how the loss of SPPL2A 
and subsequent accumulation of p8-CD74 causes a transitional B cell defect, it was  
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Figure 3.37: Expression of Xbp1 target genes in Sppl2a-/- mature 
and immature B cells is normal 
 
A and B. X-Y-plots showing global gene expression (grey circles) from 
immature (A) and mature (B) B cells of either wildtype genotype plotted 
on the X-axis or Sppl2a-/- genotype plotted on the Y-axis. Differential 
gene expression of XBP1 target genes (C) are highlighted as black dots. 
A first order polynomial (straight line) model was fitted to all gene 
expression values (dotted line). Each dot represents the average gene 
probe expression value from triplicate samples sorted as shown in 
Figure 3.32 and analysed by Agilent microarray. 
C. XBP1 target genes were suggested by Shaffer et al. (Shaffer, 
Immunity, 2004) based on gene expression profiling of developing 
plasma cells in BLIMP1 and XBP1 deficient mouse strains. 
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Figure 3.38: SPPL2A deficiency does not induce expression of 
unfolded protein response genes 
 
A and B. X-Y-plots showing global gene expression (grey circles) from 
immature (A) and mature (B) B cells of either wildtype genotype plotted 
on the X-axis or Sppl2a-/- genotype plotted on the Y-axis. Differential 
gene expression of unfolded protein response (UPR) target genes (C) 
are highlighted as black dots. A first order polynomial (straight line) 
model was fitted to all gene expression values (dotted line). Each dot 
represents the average gene probe expression value from triplicate 
samples sorted as shown in Figure 3.32 and analysed by Agilent 
microarray. 
C. Non extensive selection of genes coding for proteins involved in the 
unfolded protein responses (UPR, Todd et al., Nat. Rev. Immunol., 
2008, Takayanagi et al., Cell Stress Chaperones, 2013). 
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Figure 3.39: Genes up-regulated during glutamine 
starvation are normally expressed in Sppl2a-/- B cells 
 
A and B. X-Y-plots showing global gene expression (grey 
circles) from immature (A) and mature (B) B cells of either 
wildtype genotype plotted on the X-axis or Sppl2a-/- genotype 
plotted on the Y-axis. Genes normally induced in B cell lines 
starved of Glutamine (Peng et al. Mol. Cell Biol., 2002) are 
highlighted as black dots. A first order polynomial (straight 
line) model was fitted to all gene expression values (dotted 
line). Each dot represents the average gene probe 
expression value from triplicate samples sorted as shown in 
Figure 3.32 and analysed by Agilent microarray. 
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Glutamine starvation induced genes 
Aars Cadm1 Drap1 Katnb1 Phgdh Smtn 
Abcb9 Calcoco2 Dvl1 Kdelr1 Pja2 Snph 
Abi1 Camk1 Eapp Kdm4a Plcl2 Sp2 
Acadvl Cars Eif1 Kiaa0141 Plxnb2 Spag9 
Acp1 Cbfa2t3 Eif3J Kiaa0355 Pmaip1 Spg11 
Acta1 Cblb Eno2 Kiaa0430 Pnoc Spint2 
Ada Ccdc28a Enosf1 Kiaa0652 Pold4 Spon1 
Add3 Ccng1 Entpd4 Kiaa0907 Polr2c Stc2 
Aim1 Ccng2 Eps15 Kifap3 Ppp1r15a Stk19 
Akr7a2 Cd27 Ergic3 Klk3 Ppp2r5a Stxbp2 
Aldh2 Cd52 Ethe1 Laptm5 Ppp2r5c Surf1 
Aldh6a1 Cdc25c Fam49a Lgals3bp Ppp3r1 Tars 
Apbb3 Cdc2l6 Fbxo46 Mef2b Pqbp1 Tbc1d2b 
Arid3a Cdkn1b Fcgrt Lpp Prkci Tcf12 
Arl2bp Cdkn1c Flot1 Lrp10 Prmt2 Terf2 
Arrb2 Cds2 Foxo1 Lta Prtn3 Tes 
Asmtl Cebpb Fuca1 Ly86 Ptpra Tm9sf1 
Asns Cep135 Gabarap Ly96 Ptprc Tmem131 
Ass1 Cep350 Gchfr Map1lc3b Ptprt Top2a 
Asxl1 Chmp2a Ggt1 Map2k3 Pycr1 Top3b 
Atf4 Chrna5 Glb1 Map4k2 Pygb Tor1aip1 
Atf5 Cirbp Gnb3 Mapk13 Rab3gap1 Tpp1 
Atp5s Clasp1 Gns Mars Rasa1 Trank1 
Atp6v0a1 Clasp2 Gpld1 Masp2 Rasgrp2 Trappc6a 
Atpaf2 Clic4 Grhpr Med13L Rasgrp3 Trio 
Atrx Cln3 Gsn Mef2a Rbck1 Trrap 
Bach1 Cnih Gstt1 Megf9 Rbm39 Tsc2 
Bai2 Col9a2 Gstz1 Mmp15 Rbm5 Tsc22d3 
Bard1 Cpne1 Hadh Mthfd2 Rdbp Tspan31 
Bcat2 Creg1 Hagh Nadk Rnf103 Txn2 
Bckdha Csdc2 Hax1 Nans S100A11 Tyk2 
Bckdhb Csnk1g2 Hdac5 Ncf4 Sars Ube2J1 
Bcl7a Ctage5 Hexa Ncor1 Sec14L1 Uqcr 
Bcl9 Ctdsp2 Hist2h2aa3 Ndc80 Sel1L3 Vamp3 
Birc5 Cul4b Hmgb2 Nfe2L1 Serpini1 Vapb 
Blk Cux1 Hnrnpa3 Nfic Setd1a Vegfa 
Bloc1s1 Cyth1 Hoxc5 Nfix Sf4 Vezf1 
Bmi1 Cyth2 Hsf1 Nit1 Siah1 Vps45 
Bmp7 Cytsa Iars Notch4 Slc16a3 Wars 
Bnip3l Daam1 Idh2 Nr3c1 Slc1a4 Wdtc1 
Brd8 Ddb2 Ifrd1 Ogt Slc1a5 Wipf2 
Btg1 Ddhd2 Igbp1 P4ha2 Slc30a9 Wipi2 
Btg2 Ddit4 Ighg3 Pck2 Slc35e2 Wrb 
Bud31 Ddx23 Ighm Pex10 Slc3a2 Xpc 
C1orf77 Ddx46 Igl Pex11b Slc43a1 Xpot 
C21orf33 Decr1 Iglj3 Pex5 Slc7a5 Yars 
C2Cd3 Dennd5a Il4r Pgap2 Slit1 Zbtb22 
C6orf130 Dkfzp586I1420 Itpr2 Phf2 Smad5 Zc3h11a 
Cabin1 Dok4 Itpr3 Phf21a Smarcb1 Zkscan1 
Table 3.2: List of genes induced in glutamine starved human 
BJAB Burkitt lymphoma cell line 
 
Gene list taken from gene profiling work done on glutamine starved 
human BJAB Burkitt lymphoma cells (Peng et al. Mol. Cell Biol., 2002). 
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Figure 3.40: Genes up-regulated during glucose starvation are 
normally expressed in Sppl2a-/- B cells 
 
A and B. X-Y-plots showing global gene expression (grey circles) from 
immature (A) and mature (B) B cells of either wildtype genotype plotted 
on the X-axis or Sppl2a-/- genotype plotted on the Y-axis. Genes 
normally induced in B cell lines starved of Glucose (C) are highlighted 
as black dots. A first order polynomial (straight line) model was fitted to 
all gene expression values (dotted line). Each dot represents the 
average gene probe expression value from triplicate samples sorted as 
shown in Figure 3.32 and analysed by Agilent microarray. 
C. Gene list taken from gene profiling work done by Peng et al. on 
glucose starved human BJAB Burkitt lymphoma cells, starved from 
Glutamine (Peng et al. Mol. Cell Biol., 2002). 
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Figure 3.41: Classical autophagy pathway is regulated normally 
during late B cell development in Sppl2a-/- mice 
 
A. X-Y plots of Sppl2a-/- (y-axis) and wildtype (Sppl2a+/+, x-axis) 
differential autophagy pathway gene probe (black dots, C) expression 
in immature (left graph) and mature spleen B cells (right), overlaying 
global gene expression (grey circles) of all genes. Each dot represents 
the average gene probe expression value from triplicate samples 
sorted as shown in Figure 3.32 and analysed by Agilent microarray. 
B. Heat map showing average relative RNA expression from three 
samples of the selected autophagy gene set (C) side by side in 
immature and mature spleen B cells from mice with the indicated 
genotypes; immat, immature; mat, mature. 
C. List of selected genes relevant for classical macro-autophagy. 
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of interest which genes were up- or down-regulated in mature SPPL2A-deficient B 
cells the most. Thus global gene expression profiles of mature Sppl2a-/- and wildtype 
B cell samples were compared (see gating strategy for microarray samples in Figure 
3.32A), to identify microarray probes that precipitated the most and the least amount 
of transcript in mature Sppl2a-/- relative to wildtype samples. The x-y-plot in Figure 
3.42A shows 500 gene transcripts that were most up-regulated in mature Sppl2a-/- B 
cells compared to wildtype cells, plotting fold-up-regulation on the x-axis and 
absolute gene expression levels on the y-axis. Conversely the 500 most down-
regulated transcripts in mature Sppl2a-/- B cells compared to wildtype cells are 
shown in Figure 3.42B, accordingly. The plots in Figure 3.42 give an impression of 
the general density and grouping of transcripts expressed at the extremes of 
detection. The fold-change of 100 most up-regulated or down-regulated genes was 
similar and ranged between 8 to 64-fold changes. It was also apparent that genes 
with increased expression in SPPL2A-deficient B cells had non-surprisingly much 
greater absolute expression values than genes with lowered expression in Sppl2a-/- 
cells, which mostly ranged just above background level. Interestingly, Fcer2a 
emerged in this segregation of the microarray data set as one of the 500 most down-
regulated genes in mature Sppl2a-/- B cells. Tables 3.3 and 3.4 list the 100 most up- 
or 100 most down-regulated microarray probes, indicated in Figure 3.42, that were 
detected in mature Sppl2a-/- B cell samples compared to wildtype samples. Selected 
candidates, some of them from these lists, are quantified and presented as sample-
pair-linked column graphs in Figure 3.43. Myb, Bcar3, Wnt10a, Adm, Ahr and 
Myo1e were highly expressed genes in mature Sppl2a-/- B cells when compared to 
wildtype and Baffr -/- cells.  
 
However, Wnt10a was the only transcript that was specifically up-regulated in 
maturing SPPL2A-deficient B cells, whereas most other transcripts were also up-
regulated in B cells from control BAFF-deficient mice, if not at the same rate, but 
with a similar trend. Tendency of genes with increased expression in Sppl2a-/- B cell 
to be als up-regulated in mature Baff -/- B cells, suggests that regulation of these 
genes might be secondary to transitional B cell loss, rather than providing a clue for 
the underlying cellular process that drives SPPL2A-mediated B cell deficiency. 
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Figure 3.42: Most up- and down-regulated genes in mature 
Sppl2a-/- B cells 
 
A. 500 up-regulated gene probes in mature Sppl2a-/- B cells plotted for 
fold up-regulation versus gene expression levels. Global gene 
expression was measured by Agilent Microarray in FACS sorted mature 
B cells from Sppl2a+/+ (wildtype) and Sppl2a-/- mice. All gene probes 
were ranked by calculating the fold increase of gene expression in 
mature Sppl2a-/- B cells over the mean gene expression in 
corresponding wildtype samples. Probes with the 500 highest fold 
increase expression are shown in this plot. Dashed line represents cut 
of for top 100 gene probes displayed in following Table 3.3.  
B. 500 most down-regulated gene probes in mature Sppl2a-/- B cells 
relative to mature wildtype B cells. 100 most down-regulated probes 
with more than  7.38-fold lowered expression (dashed line) are listed in 
Table 3.4. Each dot represents the average gene probe expression 
value from triplicate samples sorted as shown in Figure 3.32 and 
analysed by Agilent microarray. 
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Gene probe name Fold 
in- 
crease 
A.U. 
expres
-sion 
(mean) 
 
P Gene probe name Fold 
in-
crease 
 
A.U. 
expres-
sion 
(mean) 
P 
Cxcr7 71.88 44.82 0.0486 Ak8 8.54 13.72 0.0143 
chr8:131178212-131180657_F 29.81 10.85 0.0355 Cmtm8 8.54 39.96 0.0021 
Gpr56 29.21 9.20 0.0331 chr10:62267317-62269871_R 8.48 1.90 0.0120 
Adm 20.40 293.75 0.0308 6720422M22Rik 8.43 9.30 0.0342 
Kifc3 19.98 17.98 0.0040 Ahr 8.33 2.84 0.0226 
Myb 19.49 367.81 0.0051 Ak8 8.31 13.79 0.0060 
Wnt10a 18.65 229.74 0.0122 Echdc3 8.08 88.77 0.0017 
Cblc 17.69 106.60 0.0340 Bhlhe41 8.07 12.73 0.0259 
Dnase1l3 16.92 55.20 0.0121 Bhlhe41 8.04 15.14 0.0411 
Nrxn1 16.74 4.47 0.0170 Mar-08 7.97 5.23 0.0225 
Gfi1 16.04 255.04 0.0011 Ms4a4a 7.88 68.07 0.0017 
Mt1 15.55 54.23 0.0209 Rnf208 7.87 1.96 0.0106 
Tmem151b 15.47 78.78 0.0319 Ak8 7.85 13.35 0.0105 
Capsl 15.05 3.83 0.0179 Spef2 7.82 3.46 0.0077 
Col5a3 14.64 3.86 0.0465 Man1c1 7.82 2.59 0.0146 
Agbl1 13.85 11.07 0.0001 Wnk2 7.74 4.64 0.0373 
AF067061 13.71 79.34 0.0257 Cplx2 7.55 17.55 0.0177 
Trpm5 13.51 25.81 0.0198 chr4:149445201-149445902_F 7.54 5.02 0.0357 
Ak8 13.45 13.42 0.0161 Fxyd4 7.51 1.91 0.0237 
Nrxn1 12.97 4.71 0.0114 Serpinf2 7.47 2.71 0.0188 
Gm20767 12.82 20.11 0.0298 1700026L06Rik 7.35 39.42 0.0109 
chr8:129336539-129400338_R 12.56 49.12 0.0405 chr7:111530578-111539097_R 7.35 2.42 0.0495 
Ptpn5 12.55 2.66 0.0486 Vwf 7.31 14.23 0.0321 
1500012K07Rik 12.52 3.35 0.0488 A_55_P2059283 7.28 1.65 0.0251 
Ak8 12.17 14.06 0.0166 Uaca 7.25 2.81 0.0043 
Ak8 11.77 14.07 0.0072 Mgst1 7.16 25.04 0.0296 
AK137313 11.58 3.30 0.0123 Epb4.1l4b 7.14 12.68 0.0011 
D13Ertd608e 11.46 8.38 0.0044 Prdm1 7.10 21.56 0.0159 
chr8:129336539-129400338_R 11.44 18.99 0.0364 Thbd 7.05 2.68 0.0061 
Sv2b 11.29 2.53 0.0032 1700026L06Rik 7.01 131.57 0.0118 
Ccr9 11.21 3.45 0.0250 Tnfsf18 6.90 12.33 0.0471 
BM941693 11.15 2.58 0.0338 Col4a5 6.89 3.70 0.0198 
Rasgef1a 11.09 65.42 0.0134 Cd80 6.87 4.79 0.0319 
Ahr 10.95 213.70 0.0206 Prickle1 6.79 3.43 0.0440 
Ak8 10.87 14.08 0.0116 Il18r1 6.77 4.48 0.0104 
Rilpl1 10.34 3.12 0.0065 4930458D05Rik 6.70 6.69 0.0122 
chr8:129336539-129400338_R 10.33 29.46 0.0444 Dhrs3 6.58 60.41 0.0192 
A_55_P2143081 10.32 18.31 0.0424 LOC101055828 6.52 1.53 0.0465 
Ak8 10.05 13.07 0.0122 Rilpl1 6.51 4.98 0.0241 
Fzd6 10.00 2.77 0.0339 Ms4a6d 6.49 1.54 0.0283 
Ccr9 9.96 48.04 0.0131 Fam92a 6.47 8.63 0.0042 
Mgst1 9.86 39.34 0.0144 chr2:180161459-180189542_R 6.39 10.86 0.0324 
Echdc3 9.78 52.95 0.0018 chr10:62267317-62269871_R 6.37 5.37 0.0020 
Csf2rb2 9.48 5.28 0.0095 9630013D21Rik 6.33 3.38 0.0387 
Ak8 9.29 13.59 0.0223 Nat8l 6.26 1.88 0.0460 
Nyx 9.07 34.24 0.0004 Lgalsl 6.22 3.68 0.0499 
Ifng 9.02 7.12 0.0039 Dlk1 6.22 1.70 0.0321 
Ak8 8.90 13.39 0.0106 chr2:180161459-180189542_R 6.20 10.25 0.0256 
Rab3b 8.88 25.94 0.0341 ENSMUST00000103589 6.18 1.76 0.0483 
Esr1 8.62 2.48 0.0247 Lzts2 6.16 25.51 0.0077 
Table 3.3: List of 100 most up-regulated gene probes in Sppl2a-/- 
mature B cells 
 
Top 100 significantly (p<0.05) up-regulated gene probes in mature 
Sppl2a-/- B cells compared to expression levels in mature wildtype B 
cells. CD93lowIgMlow50% B cells were FACS sorted as per Figure 3.32 and 
RNA analysed by microarray. The list shows array probe names, the fold 
increase of average probe intensity values from three Sppl2a-/- 
compared to three wildtype samples and the relative mean expression 
value in Sppl2a-/- mature B cells (sorted as shown in Figure 3.32) for 
each probe; P-value for unpaired, 2-tailed t-test between Sppl2a-/- and 
Sppl2a+/+ samples; A.U., arbitrary unit. 
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Gene probe name Fold 
de- 
crease 
A.U. 
expres
-sion 
(mean) 
 
P Gene probe name Fold 
de-
crease 
 
A.U. 
expres-
sion 
(mean) 
P 
Aicda 117.38 0.18 0.0316 Aif1l 7.34 0.19 0.0005 
Prss12 55.07 0.70 0.0373 Ngfr 7.23 3.97 0.0032 
ENSMUST00000103416 49.21 0.20 0.0297 Amz1 7.13 2.35 0.0152 
Gcsam 41.91 0.18 0.0264 Ppap2a 7.11 0.47 0.0082 
Fam101b 34.28 0.30 0.0360 Ngfr 6.90 4.23 0.0006 
Tmem51 30.72 0.76 0.0080 Amz1 6.84 2.49 0.0174 
Cyp27a1 25.66 0.25 0.0430 Ngfr 6.82 4.35 0.0002 
Nuggc 24.76 0.17 0.0483 A_55_P2052709 6.76 0.75 0.0079 
Tmprss13 24.16 0.47 0.0126 chr4:8865575-8899400_F 6.72 0.20 0.0139 
S1pr2 22.76 0.31 0.0365 Spin2 6.59 0.33 0.0372 
Ccr6 20.24 76.58 0.0351 Hip1 6.46 1.17 0.0018 
Lfng 18.29 1.17 0.0026 Ada 6.40 6.75 0.0420 
Cdkl1 16.29 0.80 0.0222 Ngfr 6.39 4.53 0.0050 
A_55_P2124065 15.79 0.42 0.0007 Dll1 6.36 0.45 0.0253 
Efna1 15.08 0.22 0.0066 Cd59a 6.31 0.21 0.0053 
Ttbk1 13.52 0.71 0.0012 Icosl 6.27 0.28 0.0062 
Ildr1 12.67 0.39 0.0002 Ngfr 6.26 4.36 0.0117 
Qrfp 12.45 0.36 0.0005 Ngfr 6.25 4.71 0.0000 
Parm1 12.14 0.67 0.0376 Apof 6.25 1.03 0.0227 
Fam101b 11.05 0.32 0.0040 Amz1 6.19 2.44 0.0394 
Wfdc17 10.90 6.05 0.0238 Ngfr 6.16 4.54 0.0108 
Amz1 10.89 1.53 0.0299 Galnt6 6.09 49.15 0.0030 
Cd209a 10.55 0.29 0.0303 Amz1 6.07 3.02 0.0100 
chr16:59557120-59602070_R 10.14 0.20 0.0245 Zdhhc2 6.05 0.36 0.0156 
Gpsm2 10.07 0.25 0.0455 chr15:73231192-73231819_R 6.03 0.82 0.0197 
Zdhhc2 9.65 0.20 0.0447 Ngfr 5.99 4.79 0.0058 
Parm1 9.43 0.80 0.0352 Slc16a10 5.95 0.73 0.0231 
Sema5a 9.16 0.75 0.0029 Amz1 5.94 2.81 0.0003 
Zdhhc2 9.14 0.26 0.0066 Map3k19 5.83 3.17 0.0327 
chr18:79286360-79304510_F 8.81 0.20 0.0312 Epb4.1 5.78 1.20 0.0070 
Parm1 8.78 0.87 0.0458 A_55_P2014315 5.77 0.74 0.0005 
Myo1f 8.72 12.38 0.0253 Map3k19 5.74 3.35 0.0311 
Gsn 8.54 13.34 0.0122 Slc16a10 5.72 0.21 0.0094 
Ccdc92 8.50 1.21 0.0036 Asb2 5.59 0.37 0.0241 
Myo1f 8.44 8.32 0.0074 Ngfr 5.56 5.01 0.0109 
Rnft2 8.38 0.53 0.0171 H1fx 5.53 0.34 0.0084 
chr13:34693404-34717987_R 8.34 9.30 0.0268 chr4:8865575-8899400_F 5.46 0.51 0.0082 
Gsn 8.21 24.14 0.0188 Artn 5.42 0.33 0.0044 
Hip1 8.14 1.63 0.0021 Stat4 5.39 31.88 0.0150 
chr13:34693404-34717987_R 8.01 4.36 0.0316 A630081J09Rik 5.39 6.22 0.0168 
Amz1 7.87 2.19 0.0287 Srgap3 5.37 0.22 0.0442 
chr13:34693404-34717987_R 7.86 7.35 0.0390 Abhd15 5.31 0.21 0.0000 
Pltp 7.76 1.68 0.0153 Lefty1 5.29 0.48 0.0173 
Fam212a 7.66 0.33 0.0061 chr13:34693404-34717987_R 5.28 9.21 0.0192 
Slfn5 7.64 0.38 0.0156 Akap2 5.27 13.32 0.0406 
A_55_P2126557 7.61 8.57 0.0178 Dll1 5.26 0.66 0.0044 
chr13:34693404-34717987_R 7.58 4.92 0.0300 Amz1 5.22 2.93 0.0433 
chr12:33604247-33638654_R 7.52 0.24 0.0216 Hsd11b1 5.21 7.77 0.0207 
Amz1 7.46 2.17 0.0162 Akap2 5.16 2.17 0.0419 
Ngfr 7.45 3.89 0.0043 chr16:59556175-59603176_R 5.10 0.75 0.0007 
Table 3.4: List of 100 most down-regulated gene probes in Sppl2a-/- 
mature B cells 
 
List of top 100 significantly (p<0.05) down-regulated gene probes in 
mature Sppl2a-/- B cells when compared to expression levels in mature 
wildtype (Sppl2a+/+) B cells. The list shows array probe names, the fold 
decrease of average probe intensity values from three Sppl2a-/- 
compared to three wildtype samples and the relative mean expression 
value in Sppl2a-/- mature B cells (sorted as shown in Figure 3.32) for 
each probe; P-value for unpaired, 2-tailed t-test between Sppl2a-/- and 
Sppl2a+/+ samples; A.U., arbitrary unit. 
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Figure 3.43: Selection of gene-probes with increased expression in 
mature Sppl2a-/- B cells 
 
Column graphs quantifying mRNA expression of selected gene probes 
that are expressed at higher levels in mature Sppl2a-/- than in mature 
wildtype B cells (Sppl2a+/+) or mature B cells from spleens of mice 
lacking BAFF (Baff-/-). Paired immature (i) and mature (m) samples 
were sorted from the same three mice as per sorting strategy shown in 
Figure 3.32 and analysed by Agilent microarray. A.U., arbitrary units. 
i m i m i m 
i m i m i m i m i m i m 
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3.7 Chapter summary  
In this chapter I showed that mice with an inactivating mutation in the 
intramembrane endopeptidase SPPL2A exhibited profound humoral 
immunodeficiency and specifically lacked mature B cells, phenotypically mirroring 
BAFF deficient mice. Surviving B cells were characterized by low surface BAFFR 
and BCR expression. BCR and BAFFR are important regulators for peripheral B cell 
survival, and I therefore tested whether SPPL2A deficient B cells are unable to 
mature due to a survival defect or developmental arrest. Mature B cell accumulation, 
but not BAFFR and BCR expression, could be rescued by over-expression of the 
BAFF-induced pro-apoptotic protein BCL2, indicating a survival defect of mature 
Sppl2a-/- B cells. On a molecular level I discovered that SPPL2A is the long sought-
after, final enzyme in the sequence of CD74 cleaving proteases. SPPL2A deficiency 
blocked the ultimate step of CD74 degradation, causing a dramatic build-up of p8-
CD74 membrane-peptide, the product of Cathepsin S processing. Accumulation of 
p8-CD74 was responsible for the cellular phenotype as deletion of CD74 in SPPL2A 
deficient animals reconstituted mature B cell numbers to levels seen in mice solely 
deficient in CD74, and also restored surface BCR and BAFFR expression. I thus 
defined a non-redundant in vivo function for SPPL2A in CD74 processing and the 
expression of survival receptors on B cells, revealing a critical role for regulated 
intramembrane proteolysis in B cells. 
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Chapter 4: SPPL2A processes 
CD74 in B cells independent of 
Cathepsin S and MHCII 
chaperoning 
 
 
Contributions from others:  
• Javier Vega Ramos supervised and helped with the confocal microscopy and 
metabolic labelling experiments performed for the data shown in Figures 4.2, 
4.13, 4.23, 4.24, 4.28 and 4.36. The experiments performed for these data 
where all done under the general supervision and expertise of Jose A. 
Villadangos, in his laboratories at the Department of Microbiology and 
Immunology as well as the Bio21 Institute, both University of Melbourne. 
• Linda Wakim supervised the immunoprecipitations and in-gel protein 
digestion of sample preparations for the proteomic analysis shown in Figure 
4.12. Giuseppe Infusini in Andrew Webb’s Proteomics Laboratory at the 
Walter and Eliza Hall Institute performed the actual mass spectrometry. 
• Joanne Lee helped with the sample preparation and imaging for transmission 
electron microscopy shown in Figure 4.29 and 4.30, which was performed 
under the general supervision and expertise of Melanie Rug at the Centre for 
Advanced Microscopy, Australian National University, Canberra. 
• Vicky Athanasopoulos and Mehmet Yabas performed the electroporation of 
cells for the experiments shown in Figure 4.40. 
• Mehmet Yabas, Nadine Barthel, and Anselm Enders provided some technical 
help towards flowcytometric sample preparation.  
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4.1 Despite similar CD74-fragment accumulation in SPPL2A- and Cathepsin 
S-deficient B cells, endosomal expansion in the absence of Cathepsin S is 
more severe 
In the previous chapter I characterised the B cell defect in SPPL2A-deficient mice 
and discovered that the absence of the intramembrane protease SPPL2A causes an 
excessive accumulation of p8-CD74 membrane fragments, demonstrating that 
SPPL2A normally cleaves CD74 stubs inside the membrane. The accumulation of 
CD74 was responsible for B cell deficiency in Sppl2a-/- mice, because additional 
removal of CD74 in doubly SPPL2A-CD74-knock out mice completely rescued the 
B cell defect, rendering double deficient mice indistinguishable from Cd74-/- mice. I 
concluded that SPPL2A ensures B cell survival and surface molecule expression 
through simply removing excessive p8-CD74 membrane fragments. Understanding 
abnormalities in SPPL2A-deficient B cells therefore hinges on understanding CD74 
metabolism, and further provides an opportunity to learn about general B cell 
biology and the MHCII trafficking pathway schematically depicted in Figure 4.1. As 
explained in the introduction, our current understanding of CD74 processing is 
intimately linked to MHCII chaperoning and trafficking. CD74 is synthesised in the 
ER, and associates with MHCII α and β chains in nonameric complexes to allow exit 
from the ER and trafficking along the secretory route into the endosomal 
compartment. Once in the endosome, the proteolytic environment facilitates luminal 
degradation of CD74, until Cathepsin S in a penultimate cleavage step releases 
CLIP-MHCII complexes for peptide loading and p8-CD74 membrane stubs, which 
are ultimately cleaved by SPPL2A. Based on this model I hypothesised that CD74 
metabolism follows the same pathway in SPPL2A-deficient B cells. It is consistent 
with the endosomal localisation of SPPL2A that CD74 trafficking to the endosome 
and penultimate cleavage by Cathepsin S results in the p8-CD74-membrane fragment 
that acts as substrate for SPPL2A in the endosomal membrane compartment. 
Accordingly, I further hypothesised that in the absence of SPPL2A, large quantities 
of p8-CD74 accumulate within endosomal membranes. p8-CD74 accumulation 
coincided with increased B cell granularity, which could be due to endosomal 
enlargement observed by others in situations of overly abundant CD74 (Romagnoli 
and Germain, 1994, Pieters et al., 1993, Arunachalam et al., 1994, Gorvel et al., 
1995, Stang and Bakke, 1997, Bakke and Nordeng, 1999, Boes et al., 2005). 
Intriguingly, this view on SPPL2A processing of CD74 in endosomes makes  
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SPPL2A functionally very similar to the well-characterised CD74 cleaving enzyme 
Cathepsin S.  
 
Both Cathepsin S and SPPL2A are required in H2b mice to cleave small CD74 
membrane fragments, and in their absence p10-CD74 or p8-CD74 (respectively) 
excessively accumulate. This is biochemically detectable by immunoblotting of 
SPPL2A- or Cathepsin S-deficient B cells (see Figure 3.27) (Riese et al., 1996, Shi et 
al., 1999, Nakagawa et al., 1999). In Cathepsin S deficient B cells p10-CD74 
accumulation has been shown to induce an abnormally enlarged endosomal 
compartment (Boes et al., 2005), which supports the assumption that p8-CD74 
accumulation in SPPL2A-deficient B cells would have a similar effect. The striking 
biochemical and mechanistic similarities in CD74 degradation between SPPL2A and 
Cathepsin S strongly suggest that B cells deficient in either endosomal enzyme will 
have a similar phenotype. Thus, Cathepsin S-deficient B cells are ideal controls to 
further unravel the role of SPPL2A in B cell biology. 
 
To get a better understanding on the localisation of accumulating CD74 in Sppl2a-/- 
B cells,splenic B cells from wildtype, Sppl2a-/- and Ctss-/- mice were 
flowcytometrically sorted, adhered to anti-MHCII coated glass cover slips, and  
analysed by confocal microscopy Figure 4.2. Distribution of CD74 staining in 
Sppl2a-/- B cells was distributed in the slim cytoplasmic margin featuring a 
characteristic blotchy pattern. By comparison, in wildtype B cells CD74 staining was 
homogenous throughout the cytoplasm, with a single larger speckle on one pole of 
the cell. The pole speck was a likely representation of the ER and appeared to 
localise in a groove formed by the nucleus that was visible in many cells imaged in 
the right plane to reveal this feature. Although CD74 distribution in Cathepsin S-
deficient B cells looked somewhat similar to the disrupted distribution in Sppl2a-/- B 
cells, CD74 stained areas and even the relative size of the Cathepsin S-deficient B 
cells seemed larger. MHCII staining distribution was entirely eclipsed by CD74 
fluorescence in all genotypes, indicating that MHCII usually localises to the same 
areas as CD74, but CD74 also resides in subcellular compartments that are not 
accessed by MHCII (Figure 4.2A). In relation to endosomal LAMP1 staining, 
subcellular CD74 staining patterns seemed to match the labelling pattern of LAMP1 
in B cells lacking SPPL2A and Cathepsin S (Figure 4.2B).  
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Sppl2a-/- 
Sppl2a+/+ 
Ctss-/- 
A CD74 MHCII Merge 
Figure 4.2: Subcellular localisation of accumulating CD74  
in B cells that lack either SPPL2A or Cathepsin S 
 
A. Confocal images of FACS-sorted B cells from Sppl2a-/-, 
Ctss-/-, and Sppl2a+/+ mice, labelled with antibodies against 
MHCII (red) and the N-terminus of CD74 (green). 
B. B cells as per panel A labelled with antibodies against the 
late endosomal marker LAMP1 (red) and N-terminal CD74 
(green). The scale bar is 5µm in both panels. 
CD74 LAMP1 Merge 
Sppl2a-/- 
Sppl2a+/+ 
Ctss-/- 
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In wildtype B cells LAMP1 staining was confined to smaller areas than CD74 
labelled regions. Taken together, it was concluded from these observations that 
SPPL2A and Cathepsin S deficiency changes the subcellular distribution of CD74 
molecules in relation to MHCII and LAMP1. In Sppl2a-/- B cells CD74 seemed to 
only localise in subcellular compartments that also contain LAMP1 and MHCII. 
However, it needs to be considered that the N-terminal CD74 staining does not 
distinguish between the fragment lengths. As can be seen from the immunoblot in 
Figure 3.27, most CD74 in wildtype B cells is full length p31 and p41, whereas in 
SPPL2A-deficient B cells the majority is of the accumulating smaller CD74 
fragments, as appears to be the case in Cathepsin S deficiency as well (Shi et al., 
1999). 
 
To more objectively quantify the total amount of CD74 protein in Sppl2a-/- B cells by 
flowcytometry, CD74 was labelled in permeabilised and fixed cells, using the 
fluorochrome-tagged IN1 antibody that is directed against the CD74 N-terminus 
(Figure 4.3A). Similar to CD74 staining for confocal microscopy mentioned above, 
this approach detects all CD74 molecules, regardless ofdegradation status. 
Exemplary flowcytometric plots of blood samples from wildtype, heterozygous and 
homozygous SPPL2A-deficient mice stained for CD19+ B cells and intracellular N-
terminal CD74 are presented in Figure 4.3B. It was apparent that flowcytomertic N-
terminal CD74 labelling could resolve CD74 expressing B cells from non-CD74 
expressing T cells in the blood. 
 
Confocal microscopy of Sppl2a-/- B cellsrevealed that accumulating p8-CD74 
fragments seemed confined to a LAMP1+ and MHCII+ subcellular compartment. To 
test thehypothesis that increased granularity in Sppl2a-/- B cells is due to CD74-
driven enlargement of the endosomal MIIC compartment, intracellular 
flowcytometry was employed to quantify total protein amounts of LAMP1 and 
MHCII as an objective measure of the endosomal MIIC compartment size. Figure 
4.4A shows representative flowcytometric plots of blood samples from Sppl2a+/+, 
Sppl2a+/- and Sppl2a-/- mice that were stained for intracellular MHCII (M5/114) and 
LAMP1 (1D4B). MHCII expressing B cells could be resolved from MHCII- T cells 
and LAMP1high myeloid cells in the blood. Intracellular flowcytometric staining of 
these blood samples for N-terminal CD74, LAMP1 and total MHCII demonstrated a  
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Figure 4.3: Quantification of total CD74 expression in B 
cells by flow cytometry 
 
A. Illustration of CD74 molecules in B cells and their 
detection by intracellular FACS staining. Since CD74 is 
degraded by starting from the C-terminus of the molecule,  
permeabilisation of cellular membranes and CD74 labelling 
with a fluorochrome bound antibody (red-Y) directed against 
the CD74 N-terminus will quantify the total amount of CD74 
per cell. This is irrespective of size or location of the CD74 
molecules detected. 
B. Flow cytometric plots showing total N-terminal-CD74 
staining in blood derived B cells from wildtype (Sppl2a+/+), 
Sppl2a heterozygous (Sppl2a+/-) or Sppl2a deficient 
(Sppl2a-/-) mice. 
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Figure 4.4: Size measurements of the endosomal compartment by 
intracellular flow cytometry of LAMP1 and MHCII 
 
A. FACS dot plots from blood analysis of wildtype (Sppl2a+/+), Sppl2a 
heterozygous (Sppl2a+/-) or Sppl2a deficient (Sppl2a-/-) mice showing 
total intracellular staining for the late endosomal marker LAMP1 and 
MHC class II. Plots are pregated to exclude doublets, showing all white 
blood cell populations, such as B cells (B), T cells (T), Macrophages 
and MCHII positive or negative Monocytes (not marked). The latter are 
characterised by high LAMP1 expression. 
B. Flowcytometric overlay histograms of B220+IgM+ blood derived B 
cells from mice of the indicated genotypes showing intracellular staining 
levels for N-terminal-CD74, MHCII and LAMP1.  
C. Bar graphs quantifying N-terminal-CD74, MHCII, LAMP1 and SSC 
geometric mean fluorescent intensity on a larger cohort of mice of the 
indicated genotypes. One Way ANOVA with Bonferroni’s Multiple 
Comparison post test, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05, 
n.s. p>0.05. 
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5-fold increase in CD74 protein levels and a marginal but consistent increase in 
LAMP1 and MHCII levels in Sppl2a-/- B cells (Figure 4.4B and C).  
 
This method of quantifying CD74 accumulation in the absence of SPPL2A was 
sensitive enough to reveal a small increase of CD74 protein in Sppl2a+/- 
heterozygous B cells as well (Figure 4.4C). Increased N-terminal CD74, LAMP1 and 
MHCII staining in Sppl2a-/- B cells correlated with increased B cell granularity 
measured by SSC overall (Figure 4.4C), confirming that increased vacuolation in 
Sppl2a-/- B cells is due to enlargement of the endosomal MIIC compartment. 
 
CD74 accumulation in Sppl2a-/- B cells presumably resembles the endosomal 
phenotype of Cathepsin S-deficient B cells, which are known to also have an 
expansion of the endosomal MIIC compartment, driven by p10-CD74 accumulation 
in the absence of Cathepsin S (Boes et al., 2005). To verify the approach of 
measuring the size of the MIIC compartment in B cells using flowcytometric 
intracellular quantification of MHCII and LAMP1, and to also put the endosomal 
phenotype in Sppl2a-/- B cells into perspective, the previous analysis was extended to 
include Cathepsin S-deficient B cells (Figure 4.5). Figure 4.5A,B and D show that 
total intracellular N-terminal CD74 staining was comparably increased in Cathepsin 
S- and SPPL2A-deficinet B cells from the blood, yet mean fluorescent intensity of 
CD74 fluorescence was slightly greater in Sppl2a-/- B cells. Surprisingly, LAMP1 
and MHCII measurements returned much greater levels in Cathepsin S-deficient B 
cells compared to B cells lacking SPPL2A, despite relatively similar levels of CD74 
accumulating in both (Figure 4.5A). The same was true for SSC measurements of B 
cell granularity (Figure 4.5B). Thus, the endosomal MIIC expansion in Cathepsin S 
deficient B cells is relatively more severe than in Sppl2a-/- B cells.  
 
As suggested by the microscopic images described above, the endosomal alterations 
in Cathepsin S-B cells resulted in increased cell size overall, that could be measured 
by an increase in forward scatter (FSC) as shown in Figure 4.5C. Sppl2a-/- B cell size 
by comparison was normal. Consistent with these observations in B cells from the 
blood, similar relative increases of N-terminal CD74, LAMP1 and total MHCII 
levels in Sppl2a-/- and Ctss-/- B cells were also seen in B cells from the spleen (Figure 
4.5D). It was therefore concluded that the biochemical and mechanistic similarities 
of CD74-fragment accumulation in B cells lacking SPPL2A or Cathpesin S  
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Figure 4.5: Similar accumulation of CD74 in Cathepsin S and 
SPPL2A deficient B cells is contrasted by severe endosome 
enlargement in B cells without Cathepsin S 
 
A. Flowcytometric overlay histograms of B220+IgM+ blood derived 
B cells from wildtype (Sppl2a+/+), Sppl2a deficient (Sppl2a-/-) and 
Cathepsin S knock out mice (Ctss-/-) showing intracellular staining 
levels for N-terminal-CD74, MHCII and LAMP1. 
B. X-Y-plots showing geometric mean fluorescent staining (MFI) 
on B cells from the blood of Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice 
for N-terminal CD74 (X-axis) against total MHCII and LAMP1 
expression levels as well as side scatter signal plotted on the Y-
axis. Each dot represents the B cell MFI of a single mouse in the 
experiment. 
C. B cell size as measured by flow cytometric forward scatter 
(MFI-FSC) on cells from the blood of Sppl2a-/-, Ctss-/-, and Sppl2a
+/+ mice. 
D. Bar graphs displaying total expression levels of N-term. CD74, 
MHCII and LAMP1 in B cells from the spleen. One Way ANOVA 
with Bonferroni’s Multiple Comparison post test, **** p<0.0001, *** 
p<0.001, ** p<0.01, * p<0.05, n.s. p>0.05. 
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resulted in potentially similar types of endosomal MIIC expansion, although  the 
expansions were unexpectedly more severe in Ctss-/- B cells. 
 
If the levels of CD74-fragment accumulation in both SPPL2A and Cathepsin S-
deficient B cells are similar, with more severe endosomal changes in Ctss-/- B cells, 
and the understanding that excessive CD74 accumulation is responsible for the 
defect observed in Sppl2a-/- B cells, then one would expect, that mice lacking 
Cathepsin S exhibit a similar, if not worse, B cell deficiency to the one seen in 
Sppl2a-/- mice. On the contrary, original reports that examined Ctss-/- mice on H2b 
backgrounds briefly mention that B cells developed normally in the absence of 
Cathepsin S (Shi et al., 1999, Nakagawa et al., 1999). To verify this claim, B cell 
development was flowcytometrically analysed in Cathepsin S and SPPL2A deficient 
mice side by side. Figure 4.6 shows early developmental B cell subsets in the bone 
marrow. Proportions of Pro-Pre-, Pre- and immature B cells, surface IgM and onset 
of IgD expression were normal in both, Sppl2a-/- and Ctss-/- mice, indicating that 
early B cell development is not defective in the absence of Cathepsin S or SSPL2A. 
Mature IgD+IgMint recirculating B cells in the bone marrow of Sppl2a-/- mice were 
reduced in percentages and had lowered surface IgD expression (consistent with 
previous findings), whereas recirculating mature bone marrow B cells in Ctss-/- mice 
were present at normal proportions and expressed normal IgD levels. Since SPPL2A-
deficient mice present with a defect in transitional B cell survival, late B cell 
development in the spleen was then investigated. Percentages and cellularity of T1, 
T2, T3 and follicular mature B cells in spleens of Ctss-/- mice were normal, as 
already indicated by a normal recirculating B cell compartment in the bone marrow 
(Figure 4.7A and B). Ctss-/- B cells in the spleen expressed lower levels of IgM and 
CD23 (Figure 4.8A), whereas subtle increases in surface IgD expression and the 
proportion of CD93low mature B cells were only significant in experiments with 
larger sample numbers, as shown for B cells from the blood in Figure 4.8B. 
Differentiation of surface IgM and CD23 levels on immature CD93high and mature 
CD93low spleen B cells revealed that particularly mature Ctss-/- B cells had reduced 
surface CD23 expression overall and contained an increased fraction of IgMlow cells 
(Figure 4.8C). When following surface levels of IgD and IgM on developing 
transitional B cells, stepwise up-regulation of IgD and down-regulation of IgM in T1, 
T2 to mature B cells from Ctss-/- mice was comparable to wildtype cells and  
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Figure 4.6: B cell development in the bone marrow of  
Cathepsin S deficient mice is normal 
 
Representative flow cytometric plots and percentages of 
bone marrow B cell subsets isolated from Sppl2a+/+, Ctss-/- 
and Sppl2a-/- mice. Data are representative of at least two 
independent experiments with 3 to 5 mice per group. 
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Figure 4.7: Late B cell development in Cathepsin S 
deficient mice is almost normal 
 
A. Representative flow cytometric plots and percentages of 
spleen B cell subsets from Sppl2a-/-, Ctss-/-, and wild-type 
(Sppl2a+/+) mice. 
B. Number of cells of the indicated subsets in spleens from 
Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice: Lympho, lymphocytes; 
T1 and T2, transitional B cells stage 1 and 2; Foll, follicular B 
cells. Bars show mean, and Each dot is a single mouse. Data 
are representative of at least two independent experiments 
with 3 to 5 mice per group. 
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Figure 4.8: Surface expression of selected B cell markers 
on Cathepsin S deficient B cells  
 
A. Geometric mean fluorescent intensity (MFI) of staining for 
surface IgD, IgM, BAFFR and CD23 on total B220+ B cells as 
well as the proportion of mature CD93low B cells in spleens 
from Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice. Data taken from 
same experiment as presented in previous figure. 
B. Bar graphs showing surface expression of IgD as MFI and 
the proportion of CD93low mature B cells in blood samples 
from Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice.  
C. Representative flow cytometric staining shown as overlay 
histograms for surface IgM and CD23 in immature CD93high 
and mature CD93low splenic B cells from Sppl2a-/- (green 
line), Ctss-/- (purple line), and Sppl2a+/+ (shaded grey) mice. 
One Way ANOVA with Bonferroni’s Multiple Comparison post 
test, **** p<0.0001, *** p<0.001, * p<0.05, n.s. p>0.5. Data 
are representative of at least two independent experiments 
with 3 to 5 mice per group. 
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contrasted the lack of IgD up-regulation as well as the more pronounced IgM drop in 
these cell subsets from Sppl2a-/- mice (Figure 4.9A).  
 
Since the surface Ctss-/- B cell phenotype appeared surprisingly normal, but both 
Sppl2a-/- and Ctss-/- B cells were characterised by changes in MHCII and CD74 
homeostasis, effects on surface expression of MHCII and full-length CD74 
molecules was tested. Surface CD74 expression was measured using a polyclonal 
rabbit serum directed against an epitope in the luminal C-terminus of CD74 (JV11), 
which is exposed on the cell surface. Expression of surface MHCII was detected 
using the same broadly I-A and I-E reactive monoclonal antibody used for 
intracellular MHCII quantification shown above (M5/114). Surface MHCII 
expression was up regulated in a stepwise manner in wildtype, Sppl2a-/- and Ctss-/- B 
cells as they developmentally progressed from CD93high T1 and T2 to CD93low 
mature cells (Figure 4.9B). The same was true for full-length surface CD74 
expression detected by flowcytometric anti-C-terminal CD74 staining. The variation 
of CD74 surface levels was large in wildtype and Sppl2a-/- B cells, but was not the 
case in cells lacking Cathepsin S. MHCII surface levels in SPPL2A-deficient T1, T2 
and mature B cells were increased about 1.5 to 2-fold, whereas Cathepsin S-
deficiency halved surface MHCII expression specifically in T2 B cells, which 
seemed to recover to normal levels in CD93low mature B cells (Figure 4.9B and C). 
From this examination of B cell development in Ctss-/- mice in comparison to Sppl2a-
/- animals it was concluded that increased surface IgD and CD93low B cell 
proportions, as well as reduced surface IgM levels could suggest a possible 
hypermature phenotype in B cells lacking Cathepsin S. However, as opposed to 
SPPL2A-deficient B cells, lack of Cathepsin S does not seem to interfere with 
normal accumulation of mature B cells in peripheral lymphoid organs. This suggests 
that CD74 induced endosomal changes cause a B cell defect in Sppl2a-/- B cells but 
not in Ctss-/- cells and therefore the effects of excessive of CD74 and its degradation 
products  in the absence of SPPL2A or Cathepsins S must be different. 
 
4.2 Free p8-CD74 fragments induce endosome enlargement without MHCII 
association 
The discrepancy between similarities of excessive CD74-fragment accumulation in 
Sppl2a-/- and Ctss-/- B cells on one hand, but differences in survival of these enzyme-
lacking B cells on the other was puzzling and led to the question, ‘What is different  
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Figure 4.9: Cathepsin S deficient B cells almost normally up-
regulate their B cell receptors during development and also bring 
CD74 and MHCII to the cell surface 
 
A. Mean fluorescent intensity (MFI) of staining for IgD and IgM on the 
indicated developmental B cell subsets in spleens from Sppl2a-/-, 
Ctss-/-, and wild-type (Sppl2a+/+) mice. 
B. Mean fluorescent intensity (MFI) of staining for surface MHCII and 
surface C-terminal CD74 using the JV11 rabbit serum on the indicated 
developmental B cell subsets in spleens from the same mice as in 
panel A. 
C. Representative overlay histograms of flowcytometric staining for 
surface MHCII on splenic B cells of the indicated developmental 
subsets from Sppl2a-/- (green line), Ctss-/- (purple line), and Sppl2a+/+ 
(shaded grey) mice.  
T1 and T2, transitional B cells stage 1 and 2; mat, CD93low mature B 
cells. One Way ANOVA with Bonferroni’s Multiple Comparison post test, 
*** p<0.001, ** p<0.01, n.s. p>0.5. Data are representative of at least 
two independent experiments with 3 to 5 mice per group. 
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about CD74-fragment accumulation in B cells lacking SPPL2A as opposed to 
Cathepsin S that might be responsible for this disparity?’  
 
One possible difference appeared to be most obvious: that the N-terminal p8-CD74 
fragment accumulating in SPPL2A-deficeint B cells is devoid of the CLIP-peptide 
(see Figure 1.3). Side-by-side immunoblotting of Sppl2a-/- and Ctss-/- B cell lysates 
using the anti-N-terminal CD74 antibody IN1 confirmed that p8-CD74 is slightly 
shorter than the p10-CD74 peptide, which accumulates in the absence of Cathepsin S 
(Figure 4.10A). p8-CD74 is therefore lacking one of the two contact points for 
association with MHCII and has a lower affinity to bind MHCII molecules than p10-
CD74, which is known to remain associated with MHCII (Boes et al., 2005). To test 
whether the p8-CD74 fragments accumulating in SPPL2A-deficient B cells are also 
associated with MHCII molecules, splenocyte lysates were prepared from wildtype 
or Sppl2a-/- mice using the detergent NP-40. Immunoprecipitation of MHCII using 
an anti-I-Ab α chain serum (JV1), co-precipitated p10-CD74 peptides, but not p8-
CD74 peptides in Sppl2a-/- samples, which was detectable on IN1 immunoblots of 
the precipitates (Figure 4.10B). p8-CD74 could be precipitated from these lysates 
using anti-N-terminal CD74 serum (JV5). Co-precipitation of p10-CD74, but not p8-
CD74 from Sppl2a-/- splenocyte NP-40 lysates suggested that p8-CD74 fragments 
indeed accumulate in SPPL2A-deficient B cells as ‘free’- p8, whereas p10-CD74 in 
Cathepsin S-deficient cells remains associated with MHCII. 
 
Co-accumulation of intracellular MHCII in Cathepsin S-, but not in SPPL2A-
deficient B cells was also detectable by flowcytometry (Figure 4.11). Whenthe mean 
fluorescent intensity (MFI) of N-terminal-CD74 staining was plotted against total 
MHCII or LAMP1 signal in B cells from the blood of wildtype,    Sppl2a-/- or Ctss-/- 
mice, then only Cathepsin S-deficient samples were CD74 signal levels proportional 
to MHCII or LAMP1 (fell onto a diagonal) (Figure 4.11A). This meant that Ctss-/- 
blood samples with B cells accumulating large quantities of CD74-peptides also 
produced a correlating strong MHCII and LAMP1 signal. A diagonal line was also 
formed by data points, when N-terminal CD74 staining was plotted against total 
MHCII expression within splenic Ctss-/- B cell populations from individual mice, 
indicating that B cells with low intracellular CD74 levels have also lower MHCII 
levels and vice versa (Figure 4.11B). Linear correlation of the relationship between 
CD74 accumulation and MHCII expression levels was increased about 3-fold among  
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Figure 4.10: Accumulating p8-CD74 fragments in Sppl2a-/- 
B cells are slightly smaller than p10-CD74 fragments that 
accumulate in Ctss-/- and are not associated with MHC 
class II molecules 
 
A. Immunoblot analysis of MACS sorted splenic B cells from 
Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice. Blots were probed with 
IN1 antibody against the CD74 N-terminal tail and then 
stripped and re-probed with antibody to α/β-Tubulin.  
B. Immunoblot analysis of MHC class II serum (JV1) and N-
terminal-CD74 rabbit serum (JV5) immunoprecipitates from 
splenocte lysates isolated from Sppl2a-/- and Sppl2a+/+ mice. 
Immunoprecipitates were probed with IN1 antibody against 
the CD74 N-terminal tail. p41 and p31 CD74 isoforms as well 
as p10 and p8 fragments of CD74 are indicated in panels A 
and B.  
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Figure 4.11: Accumulating p10-CD74 fragments in B cells lacking 
Cathepsin S is closely correlated with intracellular levels of MHCII 
 
A. X-Y-graphs plotting the geometric MFI on B cells from the blood from 
mice of the indicated genotypes for N-terminal intracellular CD74 
staining (X-axis) against total intracellular MHCII and Lamp1 staining 
levels on the Y-axis. Each dot represents the B cell MFI of a single 
mouse in the experiment. Linear regression models are fitted as lines 
with indicated correlation coefficient r2 to describe relation between 
MHCII, Lamp1 and CD74 staining in Cathepsin S deficient mice. 
B. Representative FACS plots from splenic B cells of Sppl2a-/- (green 
dots), Ctss-/- (purple dots), and Sppl2a+/+ (grey dots) mice showing total 
MHCII and N-terminal-CD74 staining presented as overlay dot plots.  
C. Bar graphs showing the correlation coefficient r2 (goodness of fit) and 
the slope of linear regression models fitted for the relation between total 
MHCII and N-terminal-CD74 staining on B cell events within 
flowcytometric samples from spleens of Sppl2a-/-, Ctss-/-, and Sppl2a+/+ 
mice.  
D. Representative MFI graph showing total N-terminal-CD74 expression 
levels on Sppl2a-/-, Ctss-/-, and Sppl2a+/+ splenic B cell populations 
subgated according to their total MHCII expression. Gating strategy is 
shown. One Way ANOVA with Bonferroni’s Multiple Comparison post 
test, . **** p<0.0001, *** p<0.001, * p<0.05, n.s. p>0.05. Data 
representative of three experiments with at least 3 mice per genotype. 
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Sppl2a-/- B cells and 4-fold among Ctss-/- B cells. The slopes for linear correlations 
fitted to describe the relationship between CD74 accumulation and MHCII 
expression were steepest among SPPL2A-deficient B cells, compared to being less 
steep among Ctss-/- and wildtype B cells (Figure 4.11C).  
 
This relationship is visualised in a different way in Figure 4.11D, which shows that 
Sppl2a-/- B cells with low total MHCII levels possess greater quantities of CD74 
protein than Ctss-/- B cells. Cathepsin S-deficient B cells accumulate CD74 
molecules only when MHCII amasses alongside. 
 
‘Free’-p8-CD74 accumulating SPPL2A-deficient B cells are characterised by 
reduced surface expression of BCRs, BAFFRs and other B cell markers. p10-CD74 
accumulation in Ctss-/- B cells exerts morphological effects on the endosomal 
compartment in association with MHCII, but as mentioned in the introduction, CD74 
has been proposed to interact with many molecules other than MHCII, including the 
BCR. p8-CD74 does not seem to persist as a complex with MHCII, so I hypothesised 
that p8-CD74 might interfere with surface molecule expression and B cell survival 
by directly attaching to an unknown binding partner. For example, p8-CD74 could 
directly associate with the BCR and block its expression on the cell surface by 
encapsulating it in endosomes, or bind to an unknown protein that indirectly disrupts 
protein homeostasis in SPPL2A-deficient B cells. If the excessively accumulating 
p8-CD74 associates with an unknown molecule, it is likely that an equally large 
protein pool of the potential p8-binding partner exists in  Sppl2a-/- B cells. To screen 
for a large pool of p8-associated proteins in SPPL2A-deficient B cells, B cells were 
sorted from spleens of Sppl2a+/+, Sppl2a-/-, Cd74-/- and Sppl2a-/- Cd74-/- mice to 
identify CD74-bound proteins by mass spectrometry. B cells were lysed in a buffer 
containing the mild detergent digitoxin, in order to minimise disruption of protein-
protein interactions. From lysates N-terminal CD74 was immunoprecipitated using 
the IN1 antibody and resulting precipitates were subjected to mass spectrometry to 
identify any CD74-co-precipitated proteins. Inclusion of CD74 and SPPL2A-CD74 
doubly deficient control B cell samples allowed differentiation of non-specific 
CD74-independently precipitated protein, which could be excluded from mass 
spectrometrically detected proteins in the precipitates. The venn diagram in Figure 
4.12 shows the number of individual proteins that were identified in N-terminal 
CD74 precipitates from digitoxin Sppl2a+/+, Sppl2a-/-, Cd74-/- and Sppl2a-/- Cd74-/- B  
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cell lysates or any combination thereof. Of a total 189 (78%) identified proteins, 147 
were found in precipitates from all four sampled genotypes, indicating that most 
proteins precipitated not because they were bound to CD74. In total only 8 of the 
identified proteins (4.2%) co-precipitated specifically from lysates containing CD74, 
but not from Cd74-/- or Sppl2a-/- Cd74-/- B cell lysates.  
 
As indicated by the arrowed explosions of the venn diagram, the pie diagrams in 
Figure 4.12 detail which proteins were found in CD74-precipitates from wildtype or 
SPPL2A-deficient B cells. The numbers in each pie chart represent mass 
spectrometry counts that indicate protein abundance in the precipitates. As well as 
the expected CD74 and MHCII, the ER-chaperone Calnexin was also predominantly 
found in both wildtype and SPPL2A-deficient B cell lysates. CD180 (TLR4 
accessory molecule RP105) and HBA (haemoglobin α chain complex) were the only 
two proteins found to co-precipitate specifically with CD74 from SPPL2A-deficient 
B cell lysates, but not from wildtype lysates, and therefore, CD180 and HBA could 
theoretically be associated with p8-CD74 and play a role in the SPPL2A-deficient 
pathophysiology. However, based on their known functions and low quantity of 
precipitate this seemed unlikely. MYH11 (Mysosin heavy chain 11), HSP90AB1 
(Heat shock protein 90 α class B member 1) and PREX2 (phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac exchange factor 2) were specifically co-precipitated 
with CD74 only from wildtype B cell lysates, where these three proteins collectively 
comprised 4.7% of all specifically precipitated proteins. Collectively the data of this 
proteomic screen did not seem to support the existence of a potentially abundant p8-
CD74 binding partner that could explain how p8-CD74 accumulation in SPPL2A-
deficient B cells interferes with cell survival and surface molecule expression. 
 
From these observations I concluded that p8-CD74 is able to accumulate in Sppl2a-/- 
B cells without concomitant increase of MHCII levels, whereas in contrast Cathepsin 
S-deficiency causing p10-CD74 accumulation is known to depend on MHCII 
association (Nakagawa and Rudensky, 1999, Hsing and Rudensky, 2005). If binding 
of CD74 with MHCII in nonameric complexes is required for overly abundant CD74 
to expand the endosomal compartment, then MHCII binding could be the key 
difference between p8 and p10-CD74 that explains why similar levels of CD74 
accumulation elicits pronounced endosomal enlargement in Cathepsin S deficient B 
cells, but only relatively small changes in B cells lacking SPPL2A. 
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4.3 SPPL2A-mediated B cell deficiency is independent of CD74 cleavage by 
Cathepsin S and MHCII chaperoning 
CD74 chaperones MHCII in the ER, and together they travel as nonameric CD74-
MHCII complex along the secretory route through the Golgi to the cell surface and 
then follow the endocytic pathway to reach the endosomal compartment (Figure 4.1). 
Here, stepwise luminal CD74 proteolysis produces p10-MHCII complexes, which 
are processed by Cathpesin S to release MHCII-CLIP and p8-CD74 fragments. Thus, 
Cathepsin S turns endosomal p10-MHCII complexes into SPPL2A-intramembrane 
substrates. Since p10-MHCII complexes only form in the presence of MHCII 
(Nakagawa and Rudensky, 1999, Hsing and Rudensky, 2005), I hypothesised that 
disruption of CD74’s ability to chaperone MHCII αβ-dimers interferes with the 
production of p8-CD74 in SPPL2A-deficient B cells. To test this hypothesis the 
MHCII α-chain was removed from Sppl2a-/- B cells by crossing Sppl2a-/- mice with 
H2-Aa-/- animals that harbour a disrupted MHCII α chain gene (Kontgen et al., 
1993). H2-Aa-/- B cells lack full length MHCII α chains, leaving orphan β chains 
trapped in the ER, as they are unable to form MHCII-CD74 complexes that travel 
into the endosome (Bonnerot et al., 1994, Koonce and Bikoff, 2004). Consequently, 
CD74-MHCII complexes are disrupted in Sppl2a-/-H2-Aa-/- doubly deficient B cells 
and CD74 is unable to fulfil its MHCII chaperoning function. At first the effect of 
blockage of CD74-MHCII chaperoning on the distribution of CD74 in B cells was 
visualised by confocal microscopy (see Figure 4.13). N-terminal CD74 staining in 
Sppl2a+/+ B cells produced a pattern of relatively homogenous CD74 distribution 
throughout the narrow cytoplasmic seam. Focal areas of apparent CD74 
concentration co-labelled with the endosomal membrane protein LAMP1. Depending 
on the confocal imaging plane, a kidney shaped nucleus was visible. The ‘pelvis’ or 
groove of the nucleus likely resembles the peri-centriolar region containing ER and 
trans-Golgi network (TGN) (Elliott et al., 1994). Wildtype B cells generally 
displayed a strong CD74 staining pattern throughout this region unlike SPPL2A-
deficient B cells. As described above, SPPL2A-deficient B cells were characterised 
by a ‘blotchy’ cytoplasmic CD74 staining pattern, and CD74-positive areas could 
also be labelled with antibodies against LAMP1. In H2-Aa-/- B cells CD74 
distribution throughout the cell was similar to CD74 staining patterns in wildtype B 
cells, indicating that CD74 molecules retain their ability to travel into cytoplasmic 
membrane compartments even when they are not associated with MHCII αβ-dimers.  
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Figure 4.13: Subcellular localisation of accumulating CD74  in B 
cells that lack either SPPL2A, MHCII α chains or both 
 
Confocal images of FACS-sorted B cells from Sppl2a+/+, Sppl2a-/-, H2-
Aa-/- and Sppl2a-/-H2-Aa-/- mice, labelled with antibodies against the late 
endosome marker LAMP1 (red) and the N-terminus of CD74 (green). 
The scale bar is 10µm. Data representative of two independent 
experiments. 
Sppl2a-/-H2-Aa-/- 
H2-Aa-/- 
Sppl2a-/- 
CD74 LAMP1 Merge 
Sppl2a+/+ 
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The absence of CD74-MHCII complexes appeared to result in smaller LAMP1+ 
endosomes. In B cells doubly deficient for SPPL2A and MHCII α chains N-terminal 
CD74 staining produced a ‘blotchy’ cytoplasmic pattern, which seem to co-localise 
with LAMP1-endosomal staining and resembled the subcellular localisation pattern 
of CD74 in SPPL2A-singly deficient B cells (Figure 4.13).  
 
This suggests that CD74 molecules that are not associated with MHCII reach 
endosomal membrane compartments in murine B cells. CD74 chaperoning of MHCII 
does not seem to be necessary for CD74 to aggregate in concise cytoplasmic areas of 
SPPL2A-deficient B cells. 
 
If endosomal CD74 aggregation in SPPL2A-deficient B cells is independent of 
MHCII chaperoning by CD74, B cell development in Sppl2a-/-H2-Aa-/- doubly 
deficient mice should still be marred with the Sppl2a-/- survival defect from the 
transitional stage onwards and reduced surface expression of BCRs, BAFFRs and 
other B cell markers. Interestingly, H2-Aa-/- B cells are known to have a similar 
survival defect of their own (Rolink et al., 1999). The current understanding is that 
orphaned MHCII β chains in H2-Aa-/- B cells become entrapped in the ER (Bonnerot 
et al., 1994), retain almost normal MHCII β chain expression levels (Koonce and 
Bikoff, 2004) and exert a toxic effect on B cells when more β than α chains are 
present (Labrecque et al., 1999). Paradoxically the inverted scenario does not 
interfere with B cell survival, as H2-Ab-/- B cells develop normally (Cosgrove et al., 
1991, Markowitz et al., 1993). It would therefore not be surprising to see worsening 
of the SPPL2A-B cell defect when MHCII α chains are additionally removed. To test 
this assumption, B cell development was analysed in wildtype (Sppl2a+/+), Sppl2a-/-, 
H2-Aa-/- and Sppl2a-/-H2-Aa-/- mice. Flowcytometric analysis of B cell subsets in the 
bone marrow is shown in Figure 4.14. Early B cell development up until the 
immature stage in the bone marrow of MHCII α chain deficient and Sppl2a-/-H2-Aa-/- 
doubly deficient mice was normal. Percentages of Pre-Pro, Pro-, Pre- and immature 
early B cell subsets as shown in the 2nd  and 3rd columns, as well as the induction of 
IgM and IgD expression in immature IgDlowIgM+ B cells shown in the 2nd column of 
Figure 4.14 were comparable between all four genotypes examined. Recirculating 
mature B220+IgDhighIgMint B cells were represented at 3-fold lower percentages in 
both Sppl2a-/-and H2-Aa-/- marrows, and they were lowered by about 12-fold in bone 
marrows of Sppl2a-/-H2-Aa-/- mice. IgD surface levels in Sppl2a-/- and               
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Figure 4.14: Early B cell development in SPPL2A-
deficient mice is not affected by additional removal of 
MHC class II α chains 
 
Representative flow cytometric plots and percentages of 
bone marrow B cell subsets isolated from Sppl2a+/+, Sppl2a-/-, 
H2-Aa-/-, and Sppl2a-/-H2-Aa-/- mice. Data are representative 
of at least two independent experiments with 3 to 5 mice per 
group. 
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Sppl2a-/-H2-Aa-/- mature recirculating B cells were clearly reduced, indicating that 
mature B cells in peripheral lymphoid organs of these mice were defective.  
 
The mature B cell defect in peripheral lymphoid organs was confirmed by further 
examination of transitional B cell maturation in the spleen as shown in Figure 4.15. 
Sppl2a-/-H2-Aa-/- B cell subsets in the spleen had a comparable phenotype to Sppl2a-/- 
B cells. The ratio of CD93high immature to CD93low mature B cells was skewed 
towards immature cells and overall CD19+ B cells expressed lower surface levels of 
B220 and IgD as they down-regulate CD93 and IgM respectively (2nd and 3rd column 
Figure 4.15A). Immature transitional T1 cells did not developmentally progress to 
the T2 stage, resembling the B cell survival defect seen in SPPL2A-deficient mice 
and was reflected by comparably reduced numbers of T2, T3 and mature follicular B 
cells in Sppl2a-/-H2-Aa-/- and Sppl2a-/- mice (Figure 4.15B). As previously described 
by Rolink and colleagues, H2-Aa-/- mice had reduced proportions and numbers of 
mature B cells, with reduced IgD surface levels in mature cells and increased IgM 
levels in immature B cells (Rolink et al., 1999). However, those B cell changes in 
MHCII α chain deficient animals were clearly of a lesser degree than in Sppl2a-/-H2-
Aa-/- and Sppl2a-/- mice, as quantified for IgD, IgM, BAFFR and CD23 surface 
expression levels as well as percentage of CD93low mature B cells in Figure 4.16A. 
Sppl2a-/-H2-Aa-/- B cells mirrored the inability of SPPL2A-deficient B cells to 
gradually up-regulate BAFFR and IgD during transitional development, as well as 
the pronounced loss of surface IgM during this process (Figure 4.16B). MHCII α 
chain deficient B cells almost normally up-regulated BAFFR as they progressed 
from T1 to maturity, but did not increase IgD and concomitantly increased IgM 
expression past the T2 stage, indicating that the block in H2-Aa-/- B cell survival 
occurs at a later stage than in B cells that lack SPPL2A. From these data I concluded 
that SPPL2A mediated B cell survival and ability for expression of surface molecules 
is independent of CD74’s function to chaperone MHCII. This was in line with the 
microscopic observation that ‘free’-CD74 in H2-Aa-/- or Sppl2a-/-H2-Aa-/- B cells still 
travelled into the cytoplasm and aggregated, in the same way as it did when MHCII 
αβ-dimers were present in wildtype or SPPL2A-deficient B cells. Therefore, 
production of p8-CD74 by Cathepsin S in the endosomes of SPPL2A-deficient B 
cells does not seem to require p10-MHCII complexes as precursors, as H2-Aa-/- 
Sppl2a-/- doubly deficient B cells present with a similar phenotype as SPPL2A-singly 
deficient cells, indicating that p8-CD74 still accumulates in this situation. 
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Figure 4.15: Developmental defects in peripheral Sppl2a-/- 
B cells are not rescued by removing MHC class II 
 
A. Representative flow cytometric plots of lymphocytes in the 
spleen from mice of the indicated Sppl2a and H2-Aa 
genotypes. Pregates for plots are specified above the 
columns. 
B. Number of cells of the indicated subsets in spleens from 
Sppl2a+/+, H2-Aa-/-, and Sppl2a-/- or Sppl2a-/-H2-Aa-/- mice: 
Lympho, lymphocytes; T1 and T2, transitional B cells stage 1 
and 2; Foll, follicular B cells. Bars show mean, and each dot 
is a single mouse. Data are representative of at least two 
independent experiments with 3 to 5 mice per group. 
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Figure 4.16: Low surface expression of survival 
receptors in peripheral Sppl2a-/- B cells remains 
unchanged upon removal of MHC class II 
 
A. Geometric mean fluorescent intensity (MFI) of staining for 
surface IgD, IgM, BAFFR and CD23 on total CD19+ B cells as 
well as the proportion of mature CD93low B cells in spleens 
from Sppl2a-/-, H2-Aa-/-, Sppl2a-/-H2-Aa-/- and Sppl2a+/+ mice. 
B. MFI of staining for BAFFR, IgD and IgM on the indicated 
developmental B cell subsets in spleens from Sppl2a-/-, H2-
Aa-/-, Sppl2a-/-H2-Aa-/- and wild-type (Sppl2a+/+) mice. Both 
data taken from same experiment as presented in previous 
figures. Data are representative of at least two independent 
experiments with 3 to 5 mice per group. 
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The assumption that free CD74 is the origin of accumulating p8-CD74 fragments in 
Sppl2a-/- B cells implies that Cathepsin S cleavage might not be the penultimate 
CD74 processing step to produce p8. In scenarios of low affinity CD74 –MHCII 
interaction, reminiscent of absent MHCII α chains, p10-CD74 fragments do not 
accumulate when Cathepsin S activity is blocked (Nakagawa and Rudensky, 1999, 
Hsing and Rudensky, 2005). This suggests that small CD74 fragments that are not 
associated with MHCII can be degraded by other endosomal proteases when 
Cathepsin S is inactive. In other words, Cathepsin S has the unique ability to cleave 
p10-CD74 only whilst it is protected by MHCII binding, whereas free CD74 can be 
degraded by more than one protease. As additional MHCII α chain removal in 
SPPL2A deficient B cells did not rescue the phenotype, I predicted that Cathepsin S 
was not responsible for production of the p8-CD74 fragments leading to the B cell 
defect in Sppl2a-/- B cells. This prediction was examined genetically by crossing 
SPPL2A-deficient mice with animals lacking Cathepsin S and then 
flowcytometrically analysing the resulting Sppl2a-/-Ctss-/- doubly deficient offspring 
in comparison with wildtype, Sppl2a-/-, H2-Aa-/-, Ctss-/- and Sppl2a-/-H2-Aa-/- mice. 
Plots in Figure 4.17A show IgD and IgM surface expression on CD19+B220+ B cells 
from the blood from mice with the indicated genotypes. Whilst SPPL2A-deficient 
cells displayed the characteristically low IgD surface expression profile indicative of 
endosomal p8-CD74 fragment accumulation, IgD levels on Sppl2a-/-Ctss-/- B cells 
were increased by comparison (Figure 4.17A and B). However, this increase was not 
significant here, but appears to show that blocking Cathepsin S activity in Sppl2a-/-B 
cells might restore some surface IgD. Figure 4.17B also shows that surface 
expression of IgM, CD23 and MHCII on Sppl2a-/-Ctss-/- B cells in the blood 
remained comparable to levels on SPPL2A-deficient cells. Analysis of early B cell 
development in the bone marrow is depicted in Figure 4.18. As in Sppl2a-/- and Ctss-
/- mice, percentages of IgM-IgD- Pre-Pro, Pro-, Pre- and IgM+ immature early B220+ 
B cell subsets were represented normally in Sppl2a-/-Ctss-/- bone marrows. Mature 
recirculating B220+IgD+ B cell percentages in Sppl2a-/-Ctss-/- animals were about 10-
fold reduced compared to wildtype marrow, thus pointing to defective survival of 
mature B cells in the periphery. Similar to peripheral B cells from the blood, IgD 
surface levels on Sppl2a-/-Ctss-/- recirculating bone marrow cells appeared greater 
than levels on mature SPPL2A-deficient bone marrow B cells. 
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Figure 4.17: Removing Cathepsin S in SPPL2A-deficient 
B cells does not rescue defects 
 
A. Representative IgM and IgD flow cytometric plots gated on 
B cells from the blood of mice with the indicated genotypes. 
Numbers in top right corner are geometric mean fluorescence 
intensity of IgD in IgDhi gate, and other numbers are 
percentage of cells in each!gate. 
B. Bar graphs displaying surface expression, presented as 
geometric MFI, of IgD, IgM, CD23 and MHCII on B cells from 
the blood of mice with genotypes indicated and colour coded 
as in panel A. Data representative of two independent 
experiments with two to 22 mice per genotype. 
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Figure 4.18: Early B cell development in Sppl2a-/-Ctss-/- 
double deficient mice is normal 
 
Representative flow cytometric plots and percentages of B 
cell subsets isolated from bone marrows of mice with the 
indicated genotypes. Data are representative of two 
independent experiments with 3 to 5 mice per group. 
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Analysis of B cell development in spleens from Sppl2a-/-Ctss-/- mice revealed that 
Cathepsin S blockage did not prevent B cell deficiency in mice lacking SPPL2A 
(Figure 4.19 and 4.20A). Despite increasing surface IgD and also increasing B220 
surface levels in CD93low mature Sppl2a-/-Ctss-/- compared to Sppl2a-/- B cells 
(Figure 4.19), the proportion of mature cells, as well as their absolute numbers did 
not rise (Figure 4.19 and 4.20).  
 
The Sppl2a-/-Ctss-/- CD93high transitional B cell compartment consisted 
predominantly of T1 cells, which failed to up-regulate CD23 and developmentally 
progress to T2, alike transitional B cells in SPPL2A-deficient mice. Taken together, 
Cathepsin S mediated CD74 cleavage is not required to interfere with transitional 
and mature B cell survival in Sppl2a-/- B cells, despite increasing surface IgD 
expression. As apart from mildly increased surface IgD levels on Sppl2a-/-Ctss-/- B 
cells their phenotype was reminiscent of that of Sppl2a-/- singly deficient B cells, it 
could be concluded that improving surface IgD levels are not capable to improve 
accumulation of peripheral B cell numbers. This might further support the idea stated 
in Chapter 3.3 that loss of surface IgD is not causative for defects in SPPL2A-
deficient B cells. 
 
Accumulating p8-CD74 fragments cause B cell deficiency and characteristically low 
surface BCR and BAFFR expression in the absence of the CD74 degrading 
intramembrane protease SPPL2A. CD74 is most renown for its role in chaperoning 
MHCII molecules to travel into endosomal antigen presenting compartments. In the 
endosome resident enzymes degrade the luminal CD74-domain in a well-
investigated, stepwise process. The penultimate protease to cleave C-terminally 
truncated p10-CD74 associated to MHCII is Cathepsin S. In the absence of 
Cathepsin S p10-MHCII complexes accumulate and cause severe endosomal 
expansion that surprisingly does not interfere with B cell survival or general surface 
molecule expression. It was assumed that SPPL2A slots into the line-up of CD74 
degrading proteases in the endosome of B cells, by targeting the Cathepsin S 
cleavage product of CD74 as substrate. I hypothesised that in the way p10-CD74 
accumulates in Cathepsin S-deficiency, p8-CD74 would accumulate when SPPL2A 
is absent. In this scenario Cathepsin S is the producer of B cell deficiency by 
generating p8-CD74. The previous analyses have shown that mature Sppl2a-/- B cells 
fail to accumulate even when CD74 cleavage by Cathepsin S and MHCII  
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Figure 4.19: Additional deletion of Cathepsin S in 
Sppl2a-/- mice does not rescue their late B cell 
development 
 
Representative flow cytometric plots and percentatges of 
spleen B cell subsets from Sppl2a+/+, Sppl2a-/-, H2-Aa-I-, 
Ctss-/-, Sppl2a-/-H2-Aa-/- and Sppl2a-/-Ctss-/- mice. Data are 
representative of two independent experiments with 3 to 5 
mice per group. 
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Figure 4.20: As Sppl2a-/- mice, Sppl2a-/-Ctss-/- double 
deficient mice have reduced numbers of mature B cells 
 
A. Bar graph showing absolute number of total, immature and 
mature B cells in spleens from mice with the indicated 
genotypes. Numbers shown are from taken from the same 
experiment as the FACS plots from the previous figures. 
B. Proportion of CD93low mature B cells in the spleens of 
mice with genotypes colour coded per bar as in panel A. Data 
are representative of two independent experiments with 3 to 
5 mice per group. 
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chaperoning are disrupted. If accumulating p8-CD74 is the underlying cause of 
reduced B cell survival, than Sppl2a-/-H2-Aa-/- and Sppl2a-/-Ctss-/- B cells should still 
accumulate excessive amounts of this CD74 fragment. This was tested by 
immunobloting splenic B cell lysates against N-terminal CD74 (N1), thereby 
revealing all accumulating C-terminally degraded CD74 fragments. Figure 4.21 
shows that SPPL2A-deficient B cells indeed amass p8-CD74, regardless of 
additional MHCII α chain or Cathepsin S deletion. It was unexpected to see that 
SPPL2A-deficieny blocked the accumulation of the Cathepsin S substrate p10-CD74 
(Figure 4.21). This suggested that SPPL2A in some way acts up-stream of Cathepsin 
S in the chain of CD74 degrading enzymes. For this analysis I prepared equal 
numbers of B cells as per indicated genotype, allowing for semi-quantitive 
differentiation of the detected N-terminal CD74 protein species.  
 
 
 
In the absence of MHCII α chains (H2-Aa-/-) the amount of full length CD74 protein 
was increased compared to wildtype B cells (Sppl2a+/+), and no shorter N-terminal 
CD74 degradation products were detectable. In SPPL2A-deficient B cells only about 
a fifth of the total N-terminal CD74 protein was at its full length and the remaining 
~80% CD74 protein represented p8-CD74 fragments independent of the presence or 
absence of Cathepsin S or MHCII α chains. This confirmed that p8-CD74 
accumulation in the absence of SPPL2A is independent of MHCII chaperoning and 
that p8-CD74 is generated by other CD74 cleaving enzymes than Cathepsin S. This 
means that SPPL2A probably does not act as an extension of sequential CD74 
processing in the MHCII pathway, but rather cleaves truncated membrane CD74 
fragments that emerge in endosomes from a different process. 
 
To measure the effects MHCII α chain and Cathepsin S deletion had on the 
endosomal phenotype of SPPL2A-deficient CD19+B220+ B cells from the blood, 
combined intracellular staining for N-terminal CD74, MHCII complexes and 
LAMP1 was detected by flowcytometry. Histograms in Figure 4.22A show wildtype 
(Sppl2a+/+) staining levels as grey and measurements in Sppl2a-/- B cells as lime 
green graphs. For comparison H2-Aa-/- and Sppl2a-/-H2-Aa-/-, Ctss-/- and Sppl2a-/-
Ctss-/-, as well as Cd74-/- and Sppl2a-/-Cd74-/- histograms are overlaid as indicated in 
columns one, two and three, respectively. Bar graphs in Figure 4.22B provide  
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Figure 4.21: SPPL2A dependent p8-CD74 accumulation in 
B cells does not require MHC class II or Cathepsin S 
 
Immunoblot analysis of about 20 000 MACS sorted splenic B 
cells from Sppl2a+/+, Sppl2a-/-, Ctss-/-, Sppl2a-/-Ctss-/-, H2-
Aa-/-, Sppl2a-/-H2-Aa-/- mice. Immunoblot membrane was 
probed with IN1 antibody against the CD74 N-terminal tail, 
then stripped and re-probed with antibody against α/β-
Tubulin. Murine p41 and p31 CD74 isoforms as well as p10 
and p8 fragments of CD74 are labelled. Data representative 
of two independent experiments. 
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Figure 4.22: The CD74 dependent endosomal 
enlargement in SPPL2A deficient B cells occurs without 
MHC class II chaperoning or Cathepsin S 
 
A. Representative flow cytometric overlay histograms of total, 
intracellular staining for N-terminal CD74, MHCII and LAMP1 
in B cells from the blood of mice with the indicated 
genotypes. Sppl2a-/- mice were bred with H2-Aa-/-, Ctss-/- or 
CD74-/- mice and for each cross a column of histograms is 
shown as one of the three columns. 
B. Bar graphs showing quantification of intracellular (total) 
staining for the whole experiment from which histograms in 
panel A are displayed. N-terminal CD74, MHCII and LAMP1 
in B cells from the blood of mice with the indicated genotypes 
are presented as geometric mean fluorescent intensity. Data 
are representative of two independent experiments with 3 to 
5 mice per group. 
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quantification of N-terminal CD74, MHCII complexes and LAMP1 in B cells of the 
aforementioned genotypes. Additional removal of MHCII α chain or Cathepsin S 
from Sppl2a-/- B cells did not alter the overall quantity of accumulating N-terminal 
CD74 protein. Flowyctometric quantification also confirmed that CD74 accumulated 
in MHCII α chain deficient B cells (mean MFI 5565 ± 114, n=24) as opposed to 
wildtype B cells (mean MFI 5891 ± 103, n=22), confirming the observation of 
increased full length CD74 in H2-Aa-/- B cell lysates presented in Figure 4.21. B cells 
from the spleen provided comparable results. 
 
As already seen by CD74 immunoblotting in the previous figure, SPPL2A-
deficiency blocked the accumulation of CD74 in the absence of Cathepsin S. Since 
p10-CD74 only accumulates in association with MHCII αβ-dimers, the reduction of 
p10-CD74 in Sppl2a-/-Ctss-/- doubly deficient B cells (see Figure 4.21) was reflected 
in the concomitant decrease of total MHCII from levels seen in Ctss-/- cells to levels 
that matched total MHCII staining in SPPL2A-singly deficient B cells (Figure 4.22).  
 
MHCII levels in the absence of CD74 were indistinguishable between Cd74-/- and 
Sppl2a-/-Cd74-/- B cells and slightly lower than normal overall. Intracellular staining 
with the MHCII αβ-dimer recognising M5/114 clone (Koonce and Bikoff, 2004), 
verified that no MHCII-CD74 complexes could be formed in H2-Aa-/- and Sppl2a-/-
H2-Aa-/- B cells. 
 
At last LAMP1 intracellular flowcytometric analysis provided an objective 
indication of the size of the endosomal membrane compartment in the examined B 
cells (bottom row Figure 4.22). LAMP1 levels in H2-Aa-/-, Cd74-/- and Sppl2a-/-Cd74-
/- B cells were reduced compared to cells from wildtype Sppl2a+/+ mice. This would 
be consistent with the idea that CD74-MHCII complexes exiting the ER are 
responsible for expanding the size of endosomal MHCII containing membrane 
compartments (MIIC). In all investigated situations of SPPL2A-deficiency, such as 
in Sppl2a-/-, Sppl2a-/-Ctss-/- and Sppl2a-/-H2-Aa-/- B cells, LAMP1 levels were 
increased comparably, demonstrating that this effect was indeed caused by SPPL2A-
deficiency alone and independent of MHCII-α chains or Cathepsin S activity.  
 
In summary, this section confirmed that SPPL2A-deficiency causes the accumulation 
of p8-CD74 N-terminal fragments not associated with MHCII; hence p8-CD74 
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persisted when MHCII αβ-dimerisation was disrupted. Accordingly, the B cell 
survival defect associated with accumulation of p8-CD74 also persisted in Sppl2a-/-
H2-Aa-/- B cells. The penultimate CD74 cleaving enzyme in the MHCII antigen 
presentation pathway, Cathepsin S, was not required to produce p8-CD74 in 
SPPL2A-deficient B cells, which is consistent with the previous statement and the 
understanding that CD74 degradation by Cathepsin S is only necessary when CD74 
is chaperoning MHCII αβ-dimers. Since p8-CD74 still accumulated in B cells from 
Sppl2a-/-Ctss-/- mice, mature B cell survival was just as impaired in these animals as 
it was in mice solely lacking SPPL2A. It was also observed that N-terminal CD74 
fragment accumulation could either induce endosomal enlargement in association 
with MHCII and not be harmful for B cell survival in Cathepsin S deficient mice, or 
cause expansion of LAMP1+ endosomes independently of MHCII association and 
interfere with mature B cell survival in Sppl2a-/- mice. I therefore concluded that 
excessive p8-CD74 accumulation expands an endosomal LAMP1+ compartment that 
is distinct from the type of endosomal enlargement induced by p10-MHCII 
complexes in Ctss-/- B cells. 
 
4.4 Kinetics of CD74 turnover in developing B cells 
The observation that Cathepsin S-SPPL2A doubly deficient B cells accumulated less 
p10-CD74, whereas levels of p8-CD74 were similar to SPPL2A-singly deficient B 
cells was unexpected (Figure 4.21). It implied that p10-production does not precede 
the production of p8-CD74, but rather that SPPL2A activity is needed to accumulate 
p10-CD74 in the absence of Cathepsin S. It does not seem logical that SPPL2A 
cleaves CD74 up-stream of Cathepsin S, as the Cathepsin S CD74 substrate p10 is a 
longer molecule than the SPPL2A substrate p8. Yet, SPPL2A mediated CD74 
processing seems to occur before Cathepsin S cleavage of CD74 takes place. The 
explanation to this conundrum could be a question about timing: When does p8-
CD74 accumulate in SPPL2A-deficient B cells? SPPL2A facilitated CD74 cleavage 
could precede Cathepsin S activity not just mechanistically in the same pathway, but 
more likely occur at an earlier time point altogether. Therefore the kinetics of p8-
CD74 production in the absence of SPPL2A were investigated next.  
 
To determine how quickly Sppl2a-/- B cells would produce the accumulating p8-
CD74 fragments equal numbers of splenocytes from wildtype and Sppl2a-/- mice 
were isolated and metabolically labelled for pulse & chase examination of CD74  
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metabolism. To label a cohort of synthetised CD74 protein, splenocytes were 
cultured with with radioactive 35S-methionine. During a two-hour ‘pulse’ label the 
splenocytes were given time to incorporate the radioactive amino acid into all 
methionine containing proteins synthetised during this time period. A proportion of 
cells were continuously pulsed for 16 hours. Another proportion of cells were 
washed and transferred to fresh media that did not contain 35S-methionine any 
longer after 2 hours, to then be cultured and ‘chased’ for another 14 hours. Cell 
samples collected after the initial two-hour pulse, after continuous 16-hour pulse and 
following the 14-hour chase were lysed and immunoprecipitated with anti-N-
terminal CD74 IN1 antibody. Immunoprecipitates (IPs) were boiled to disrupt 
MHCII-CD74 complexes and separated by their molecular weight using gel 
electrophoresis and radiographed to visualise incorporated the radioactive 35S-
methionine label. The resulting radiograph is presented in Figure 4.23 and size 
specific bands of the precipitated p41 and p31 full length CD74 isoforms, p22, p10 
and p8-CD74 N-terminal fragments, as well as the MHCII α and β chains are 
indicated based on their estimated relative molecular weights.  
 
The 2-hour pulse shows a cohort of CD74 protein synthetised during that time 
period. In both, Sppl2a+/+ and Sppl2a-/- cells, p31, p41 were synthetised and CD74 
degradation products p22 and p10 are visible. In Sppl2a-/- splenocyte anti-CD74 
precipitates, traces of p8-CD74 fragments just started to appear, demonstrating that 
within about two hours native CD74 protein is processed to the short p8 fragment 
accumulating in the absence of SPPL2A. After following the labelled cohort of 
CD74 protein over 14 hours, p41, p22 and p10-CD74 protein relative to p31-CD74 
molecules disappeared from Sppl2a+/+ and Sppl2a-/- samples, whereas p8-CD74 
fragments persisted only in Sppl2a-/- cells. Continuous 35S-methionine labelling of 
splenocytes for 16 hours captured the resulting equilibrium of CD74 synthesis and 
degradation during that time. Surprisingly, the relative amount of p8-CD74 that 
accumulated in Sppl2a-/- cells after 16 hours did not reach relative levels compared to 
p31 synthesis expected from previous measurements of total CD74 in SPPL2A-
deficient B cells by flowcytometry (Figure 4.20) and immunoblotting (Figure 4.21). 
This metabolic pulse and chase analysis of CD74 metabolism in SPPL2A-deficient 
splenocytes suggests that p8-CD74 can be generated after about 2 hours from the 
start of full length CD74 synthesis. After 16 hours of CD74 synthesis less than about  
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Figure 4.23: New production of p8-CD74 in peripheral 
Sppl2a-/- B cells detectable after 14 hours 
 
Radiograph of immunoprecipitates from CD74, that were 
prepared from freshly isolated wildtype (Sppl2a+/+) or 
Sppl2a-/- splenocytes following a 2 hour pulse label with 35S-
methionine and 14 hour chase in unlabeled culture medium 
or a 16 hour pulse label with 35S-methionine, analysed after 
boiling by SDS-PAGE. 
p41 
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10% of the persisting CD74 protein was p8-CD74, which was contrasted by about 
70-80% in steady state CD74 protein quantifications of Sppl2a-/- B cells by anti-N-
terminal CD74 immunoblotting (Figure 4.21). Based on these numbers and if 
assuming a linear rate of relative p8 increase, it could be further estimated that 
SPPL2A-deficient B cells takes at least 4.5 days from the onset of CD74 expression 
to reach steady state p8-CD74 fragment accumulation levels. 
 
To test whether B cell activation influences the rate of p8-CD74 accumulation, the 
pulse and chase experiment was repeated as described above. This time Sppl2a+/+ 
and Sppl2a-/- splenocytes were stimulated with anti-IgM and LPS to provoke B cell 
activation (Figure 4.24). Synthesis of CD74 and the appearance of CD74 degradation 
products after 2 hours of 35S-methionine pulse under anti-IgM and LPS stimulation 
or after 4 hours of chase were indistinguishable from CD74-precipitates that were 
isolated from non-activated cells. After 4 hours of chase Sppl2a-/- cells had 
accumulated p8-CD74, regardless of B cell activation.  
 
Thus, cell activation did not seem to influence the fate of synthesised CD74 in 
SPPL2A-deficient B cells. 
 
To address the previously raised question about timing of p8-CD74 accumulation 
during B cell development, total amounts of N-terminal CD74 were measured in 
developing Bc cells. SPPL2A-deficiency causes a survival defect and changes of 
surface molecule expression from the transitional T1 stage onwards. The underlying 
reason for this defect is the accumulation of excessive p8-CD74 fragments. Based on 
these observations one would expect that accumulation of p8-CD74 fragments 
coincide with progression from T1 to T2 during transitional development of Sppl2a-/- 
B cells in the spleen. Plots in Figure 4.25A show flowcytometric staining for total N-
terminal CD74 (IN1) and surface IgM on B220+ B cells in the bone marrow of 
Sppl2a+/+, Sppl2a-/- and Ctss-/- mice. In wildtype bone marrow B cells, total CD74 
expression was induced at the immature IgM+ stage and reached highest levels in 
IgMint recirculating, mature B cells. Expectedly, CD74 protein levels in recirculating, 
mature B cells from the bone marrow of SPPL2A and Cathepsin S-deficient mice are 
higher than in wildtype cells. However, some IgM- and IgM+ immature Sppl2a-/- 
bone marrow B cells did clearly carry increased levels of N-terminal CD74 protein, 
whereas Cathepsin S deficient immature B cells did not. Figure 4.25B presents  
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Figure 4.24: Activation of Sppl2a-/- B cells has no effect 
on p8-CD74 production. 
 
Radiograph of immunoprecipitates from CD74, that were 
prepared from freshly isolated wildtype (Sppl2a+/+) or 
Sppl2a-/- splenocytes following a 2 hour pulse label with 35S-
methionine and 4 hour chase in unlabeled medium, analysed 
after boiling by SDS-PAGE. During the 2 hour pulse 
splenocytes were either activated with anti-IgM and LPS or 
not. 
	   220  
N-term CD74 
0
20
40
60
80
100
0 102 103 104 105 
B 
Sppl2a+/+ 
Sppl2a-/- 
B220+ 
Ctss-/- 
C
el
ls
 (%
) 
IgM+ 
IgD+ 
IgM- 
IgD- 
010
2
103
104
105 5.12 37.1
9.4848.3
9.38 34.7
7.7248.2
19.5 29.9
3.147.5
IgM 
0 102 103 104 105 
A 
N
-te
rm
 C
D
74
 
Sppl2a+/+  Sppl2a-/- Ctss-/- 
0
20000
40000
60000
80000
**** 
**** 
n.s. 
IgD+ IgM- 
IgD- 
IgM+ 
3.97
51.4
5.620
102
103
104
105 26
31.4
2.67
24.5
40.3
8.03
IgM 
0 102 103 104 105 
Ig
D
 
Sppl2a-/- Ctss-/- Sppl2a+/+ 
IgD+ IgM- 
IgD- 
IgM+ IgD+ IgM- 
IgD- 
IgM+ 
Figure 4.25: CD74 begins to accumulate during early B 
cell development in the bone marrow of Sppl2a-/- mice 
 
A. Flow cytometric plots showing surface IgM and total N-
terminal CD74 expression on B220+ B cells isolated from the 
bone marrow of Sppl2a+/+, Sppl2a-/- and Ctss-/- mice with the 
indicated genotypes.  
B. Representative flow cytometric staining presented as 
overlay histograms showing total N-terminal CD74 
expression in B cell precursors (IgM+, IgD+), immature B cells 
(IgM+) and mature recirculating B cells (IgD+) from the bone 
marrow of Sppl2a-/- (green line), Ctss-/- (purple line), and 
Sppl2a+/+ (shaded grey) mice. Gating for these populations 
done as shown in bottom panel C. 
C. Dot graph displaying geometric MFI for total N-terminal 
CD74 expression in IgM+, IgD+ and IgM-IgD- B cell subsets inf 
the bone marrow of mice with the indicated genotypes, as per 
gating strategy shown in bottom panel. One Way ANOVA with 
Bonferroni’s Multiple Comparison post test, **** p<0.0001, 
n.s. p>0.05. Data are representative of two independent 
experiments with 3 to 5 mice per group. 
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overlay histograms for N-terminal CD74 staining in IgM-IgD-B220+ precursors, 
IgM+IgD- immature and IgD+ recirculating, mature B cells from the bone marrow, as 
gated on flowcytometric plots shown in Figure 4.25C. As opposed to Ctss-/- bone 
marrow B cells, a proportion of Sppl2a-/- B cell precursors and all immature Sppl2a-/- 
B cells expressed increased CD74 protein levels. This is quantified in Figure 4.25C. 
The abnormal increase of CD74 protein levels in immature Sppl2a-/- bone marrow B 
cells, but not in Cathepsin S-deficient cells implies that SPPL2A activity is required 
earlier in B cell development than Cathepsin S activity. Thus SPPL2A might act ‘up-
stream’ of Cathepsin S rather in a timely than in a mechanistic fashion.  
 
CD74 accumulation was further followed along the B cell development pathway, 
by intracellular N-terminal CD74 staining in B cell subsets from the spleen (Figure 
4.26). In spleen B cells from wildtype mice CD74 expression was further increased 
as IgM+ immature B cells down-regulate surface IgM (Figure 4.26A and B). 
 
When comparing the expression of CD74 in all IgM+ immature B cells, which would 
include recent bone marrow emigrant T1 cells from spleens of SPPL2A-deficient 
mice, with mature IgD+ B cells from the same mouse, they showed a similar level. 
(Figure 4.26B). This was consistent with immature Sppl2a-/- B cells in the bone 
marrow already accumulating excessive quantities of CD74 fragments. Of Cathepsin 
S-deficient immature IgM+ spleen B cells some had increased CD74 levels and some 
did not, whilst all IgD+ mature cells reached high levels of CD74 protein, indicating 
that p10-MHCII complexes in Cathepsin S deficient B cells accumulate during 
transitional B cell development. Taken together, SPPL2A activity seems to be 
required for CD74 processing just before immature B cell in the bone marrow 
express IgM, whereas Cathepsin S is only required at later stages, during transitional 
B cell development. 
 
The abnormal increase of CD74 protein levels in developing B cells from SPPL2A-
deficient mice correlated well with increasing Cd74 mRNA expression during B cell 
development. The graph in Figure 4.27A plots Cd74 mRNA expression data from the 
ImmGen database (www.immgen.org), to show that Cd74 is first expressed, just as B 
cells reach the immature stage in the bone marrow (Heng et al., 2008). Cd74 is then 
further up regulated to reach highest expression levels in mature follicular B cells. 
Contrastingly, and as already indicated in the previous chapter, Cd74 mRNA  
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Figure 4.26: Immature Sppl2a-/- B cells that have left the 
bone marrow already accumulate high levels of p8-CD74 
at this stage of their development. 
 
A. Flow cytometric plots and percentages of B cells from 
spleens of Sppl2a-/-, Ctss-/-, and Sppl2a+/+ mice showing total 
N-terminal CD74 and surface IgM expression.  
B. Overlay FACS histograms to show total N-terminal CD74 
and total MHCII expression in IgM+ or IgD+ B cell subsets 
from spleens of mice with the indicated genotypes. Data are 
representative of two independent experiments with 3 to 5 
mice per group. 
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Figure 4.27: Sppl2a deficient developing B cells 
accumulate p8-CD74 from the immature bone marrow 
stage onwards, despite shutting down CD74 
transcription 
 
A. ImmGen (www.immgen.org) dataset showing relative 
expression of Cd74 mRNA (arbitrary units, A.U.) in wildtype 
(Sppl2a+/+) B cell developmental subsets: Pre, Pre-B cells; 
Immat, immature B cells; T1 and T2, transitional stage 1 and 
2 B cells; Mat, mature follicular B cells. 
B. Cd74 relative mRNA expressionas arbitrary units (A.U.) in 
FACS sorted splenic T1/T2 immature (CD93high IgMhigh) and 
mature follicular B cells (CD93low IgMlow) from Sppl2a+/+ and 
Sppl2a-/- mice. Dashed lines show mean expression. Two 
tailed t-test, ** p<0.01. 
C. Immunoblot analysis of the indicated FACS sorted B cell 
subsets (as described for panel A) from bone marrow and 
spleen of Sppl2a-/- and Sppl2a+/+ mice. 50 000 cells of each 
subset where loaded per lane. Blots were probed with In-1 
antibody against the CD74 N-terminal tail and then stripped 
and re-probed with antibody to α/β-Tubulin. 
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expression in maturing Sppl2a-/- B cells was decreased to about 70% of the levels 
seen in mature wildtype B cells (Figure 4.27B). This suggests that the accumulation 
of p8-CD74 fragments causes a negative feedback to shuts down its own 
transcription. 
 
To confirm that the flowcytometrically measured increase in total CD74 protein 
during B cell development in the absence of SPPL2A was due to increasing 
accumulation of the p8-CD74 fragment, sorted Pre- and immature B cells from bone 
marrows, as well as transitional T1/T2 and mature B cells from spleens of wildtype 
and Sppl2a-/- mice were analysed by N-terminal CD74 immunoblot analysis (Figure 
4.27C). Lysates from equal numbers of each sorted B cell subset were separated by 
gel electrophoresis and immunoblotted with the IN1 monoclonal antibody to 
visualise all N-terminal CD74 fragments. Wildtype lysates (Sppl2a+/+) only 
contained the full length CD74 isoforms p31 and p41, which were first detectable in 
immature B cells and gradually increasing CD74 protein amounts in transitional and 
mature B cells mirrored the mRNA Cd74 expression pattern shown in Figure 4.27.  
 
In comparison, SPPL2A-deficient B cell samples showed a similar p31 and p41-
CD74 expression pattern, but additionally p8-CD74-fragment accumulation was 
clearly detectable in immature B cells as indicated in Figure 4.27C. P8-CD74 levels 
increased gradually in transitional and again in mature B cells. It also seemed like 
traces of p10-CD74 fragments became detectable from the transitional stage 
onwards, which reflected p10-CD74 bands, that were also visible in previous IN1-
immunoblots of Sppl2a-/- B cell lysates (see Figures 3.27B and 4.21).  
 
From these experiments examining the kinetics of p8-CD74 metabolism in SPPL2A-
deficient B cells, it could be concluded that p8-CD74 accumulation in Sppl2a-/- B 
cells is a matter of days and begins as soon as developing B cells in the bone marrow 
start to express Cd74 mRNA. Therefore SPPL2A activity is needed in B cell 
development from just before the immature bone marrow stage onwards to prevent 
p8-CD74 accumulation. Activity of Cathepsin S for MHCII-bound CD74 removal is 
required at the comparably later transitional stages of B cell development. It also 
seemed like Cathepsin S activity might be blocked in the absence of SPPL2A. These 
findings further supported the view that SPPL2A and Cathepsin S mediated CD74 
degradation are not only mechanistically, but also timely distinct processes. It was 
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also intriguing that immature Sppl2a-/- B cells in the bone marrow accumulated p8-
CD74, whilst a phenotypical B cell defect was only noticeable later in B cell 
development, at the transitional T2 stage. It seemed like immature B cells were 
‘immune’ to p8-CD74 accumulation, whereas T2 and mature Sppl2a-/- B cells were 
not. Different levels of p8-CD74 accumulation at different stages of B cell 
development, or additional requirements of external signals through the BCR are 
other possibilities that might explain why immature Sppl2a-/- B cells develop 
normally, despite p8-accumulation. These possibilities will be explored later in the 
discussion (Chapter 6). 
 
4.5 Aggregates of multilamellar bodies morphologically characterise the 
endosomal membrane compartment in SPPL2A-deficient B cells 
Excessive p8-CD74 build-up in Sppl2a-/- B cells was independent of Cathepsin S 
activity and accumulation of p8 or p10-CD74 fragments in endosomes occurred at 
different developmental stages and had different effects on B cell survival. Increased 
LAMP1 levels in Sppl2a-/- B cells lacking Cathepsin S or MHCII α chains suggested 
that p8-CD74 build-up and distribution in Sppl2a-/- B cells is accompanied by unique 
changes of the endosomal membrane compartment.  
 
Examination of subcellular CD74 distribution in SPPL2A-deficient B cells by 
confocal microscopy showed that CD74 in Sppl2a-/- cells aggregated in patchy, 
LAMP1+ areas in the cytosol, as opposed to relatively homogenous cytosolic CD74 
distribution in wildtype B cells (see Figure 4.2 and 4.13). As described previously, 
CD74 distribution in wildtype B cells was also characterised by strong CD74 
staining of a distinct peri-nuclear area, that was identifiable as ‘nuclear groove’ in 
confocal B cell images that visualised a kidney shaped DAPI-labelled nucleus. This 
‘nuclear groove’ is referred to as peri-centriolar region and contains ER and the 
TGN. Closer examination of CD74 localisation in this region by confocal 
microscopy revealed that the ‘nuclear groove’ (marked by red arrows) in SPPL2A-
deficient B cells poorly labelled for N-terminal CD74 protein (Figure 4.28). A 
commonly used image-processing algorithm known as Sobel operator was applied to 
highlight sharp changes in CD74 signal intensity across confocal images. As a result 
the extent of subcellular CD74 distribution was emphasised and representative 
images in Figure 4.28 show that in Sppl2a-/- B cells CD74 did not reside inside the 
‘nuclear groove’ or peri-centriolar region. Contrastingly, the ‘nuclear groove’ was  
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Figure 4.28: ‘Nuclear groove’ in Sppl2a-/- B cells is devoid 
of CD74 staining  
 
Representative confocal microscopy images of FACS sorted 
B cells from wildtype (Sppl2a+/+), Sppl2a-/- and Ctss-/- mouse 
spleens show staining for N-terminal CD74 (In1-antibody) in 
relation to DAPI labelled nucleus. Image J 1.47v (Rasband 
WS. ImageJ, U.S. National Institutes of Health, Bethesda, 
Maryland, USA, imagej.nih.gov/ij/, 1997-2012) software was 
used to apply Sobel operator for edge detection, by 
highlighting sharp changes in signal intensity across each 
image in the left and middle column. For comparison the 
operator has not been applied to merged images in the right 
column. B cell images that display the groove of a kidney 
shaped nucleus (red arrows) have been selected to show 
CD74 staining in relation to this groove. Data representative 
of two independent experiment. 
Ctss-/- 
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Sppl2a+/+ 
CD74 Merge Nucleus 
	   227 
filled with CD74 label in wildtype and also Cathepsin S deficient B cells. This 
suggests that Sppl2a-/- B cells possess fewer ER and Golgi-resident CD74 molecules, 
which supports the view of distinct effects p8-CD74 accumulation has on the 
endosomal membrane compartment in SPPL2A-deficient B cells. Another possible 
explanation for the absence of ER-resident CD74 in Sppl2a-/- B cells could be the 
SPPL2A-deficiency induced reduction of Cd74 mRNA transcription (Figure 3.34) in 
combination with sequestration of CD74 protein in peripheral vesicles. 
 
Unfortunately visible light limits subcellular resolution of vacuoles and organelles by 
confocal microscopy to structures larger than 200nm. To investigate the 
ultrastructure of the endosomal membrane compartment, Sppl2a-/- B cells were 
sorted from spleens of wildtype and SPPL2A-deficient mice and prepared them for 
transmission electron microscopic imaging (TEM), which allows for resolution of 
membrane structures. Figure 4.29A presents high-resolution TEM images captured 
from Sppl2a+/+ and Sppl2a-/- B cells at three different magnifications, as indicated. 
Electron microscopic B cell images allowed morphological assessment of electron-
translucent vacuolar structures. Three observations that distinguished vacuoles in 
Sppl2a-/- B cells from vacuoles in Sppl2a+/+ cells stood out. Firstly, vacuoles 
appeared to be more abundant in Sppl2a-/- B cells, which was consistent with 
increased B cell granularity mentioned earlier and could be quantified by counting 
vacuoles in B cell TEM sections (Figure 4.29B).  
 
Secondly, vacuoles in Sppl2a-/- B cells seemed to be aggregated in groups, as 
opposed to relatively even distribution of vesicular structures in wildtype B cells. 
This vesicle distribution pattern seemed to reflect the patchy or ‘blotchy’ subcellular 
CD74 distribution in confocal images of SPPL2A-deficient B cells. Thirdly, an 
increased number of vesicles in Sppl2a-/- B cells were morphologically characterised 
by two or more internal membrane sheets, as shown in an exemplary TEM image as 
well as zoomed regional inserts of a Sppl2a-/- B cell in Figure 4.30A. The bar graphs 
in Figure 4.30B quantify that Sppl2a-/- B cells contained on average about 4 vesicles 
with internal membrane sheets per B cell. In wildtype (Sppl2a+/+) B cells usually less 
than 2 vesicles per cell were counted to contain additional internal membrane sheets. 
Vesicles with multiple internal membrane layers are known as multilamellar bodies 
(MLBs) (West et al., 1994, Murk et al., 2004, Stern et al., 2006), and have been  
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Figure 4.29: Sppl2a-/- B cells have ultra-structurally 
increased numbers of vesicles 
 
A. Transmission electron microscopic (TEM) images of 
Sppl2a+/+ and Sppl2a-/- splenic B cells showing their 
ultrastructure at varying magnifications. Bars are either 2µm, 
1µm or 0.5µm.  
B. Semi-quantitive bar graph showing absolute vesicle counts 
per TEM-section of Sppl2a+/+ and Sppl2a-/- splenic B cells. 13 
sections from Sppl2a+/+ and 20 sections from Sppl2a-/- B cells 
were counted, prepared from n=3-4 mice per genotype. Two 
tailed t-test * p<0.05. 
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Figure 4.30: Sppl2a-/- B cells contain vesicles with 
multiple membrane layers 
 
A. Ultrastructural TEM image of splenic Sppl2a-/- B cells 
showing examples of vesicles with multiple discerning 
membranes in inserts I, II and III. Bar in main image is 1µm 
and bars in inserts are 100nm. 
B. Semi-quantitive bar graphs showing absolute counts per 
TEM-section of Sppl2a+/+ and Sppl2a-/- splenic B cells for 
number of vesicles with multiple discerning membranes 
(Multi-Lamellar-Bodies, MLBs) and the proportion of MLBs 
amongst all vesicles in each section. 13 sections from Sppl2a
+/+ and 20 sections from Sppl2a-/- B cells were counted, 
prepared from n=3-4 mice per genotype. Two tailed t-test, **** 
p<0.0001. 
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associated with hyper-mature endosomes, MIIC or autophagy derived, dense vesicle 
structures (Hariri et al., 2000, Lajoie et al., 2005). 
 
Preliminary high-resolution imaging of vesicular membranes by TEM implied that 
p8-CD74 fragments in Sppl2a-/- B cells seem to accumulate in aggregates of vesicles 
with multiple internal membrane sheets that are referred to as multilamellar bodies. 
Whilst it does seem very likely for this assumption to be true, direct evidence of 
CD74 localisation to these MLB aggregates by immune-gold CD74 labelling in 
ultrastructural TEM images would be needed to confirm the exact subcellular 
localisation of accumulating CD74 patches in the cytosol of Sppl2a-/- B cells. 
 
4.6 Accelerated internalisation of surface IgM and IgD in B cells lacking 
SPPL2A  
A hallmark of SPPL2A-deficient B cells is their low surface expression of BCRs and 
other surface B cell markers. In fact, most examined surface molecules, such as 
CD19, B220, IgM, IgD, CD23 and CD21 on Sppl2a-/- B cells showed reduced 
expression levels. Normal or increased MHCII and CD74 surface expression levels 
were exceptions. Surface expression of membrane proteins, like the BCR, is the 
result of a sequence of events that could at every point along the way influence 
resulting surface expression levels. Taking the BCR as an example, the schematic 
drawing in Figure 4.31 shows how BCR mRNA is first transcribed, and then 
transported to the ER for translation and synthesis of the BCR chains. This is 
followed by chaperone helped conformational protein stabilisation and BCR 
assembly, before export along the secretory route. As the BCR passes through the 
Golgi, additional post-translational modifications, such as trimming of sugar side 
chains occurs. At last, the BCR arrives at the cell surface. Surface membrane 
proteins are regularly turned over by recirculation through early endosomal sub-
membrane compartments, or internalisation deeper into the endocytic pathway, 
sometimes carrying cargo from outside the cell into endosomes. Membrane proteins 
targeted for ubiquitin-mediated degradation enter the Multi Vesicular body (MVB) 
pathway, as they travel into endosomes and bud into intra-luminal vesicles bound for 
degradation by lysosome fusion (Babst, 2014). 
 
In SPPL2A-deficient B cells, lowered surface expression of IgD was dependent on 
the presence of excessively accumulating p8-CD74, indicating that p8-CD74  
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fragments were able to interfere with processes controlling IgD surface expression. 
To test whether this effect was dose dependent, IgD surface expression on Sppl2a-/- 
B cells or Cd74 heterozygous Sppl2a-/- B cells with only one instead of two Cd74 
alleles was analysed by flowcytometry. Figure 4.32A shows that halving of Cd74 
transcription in Sppl2a-/- B cells improved IgD surface levels consistent with a dose 
dependent effect (Figure 4.32A). Similar dose dependent effects on phenotypic 
changes associated with heterozygous Cd74+/-Sppl2a-/- mice were observed for 
accumulation of mature CD93low B cells in the periphery overall, and for B cell 
surface CD23 expression (Figure 4.32A). It was then considered that p8-CD74 may 
block IgD, IgM and BAFFR surface expression by reducing their mRNA 
transcription or by stalling transcription of the highly conserved IgD regulating 
splice factor ZFP318. This was found not to be the case following microarray 
measurement of RNA expression coding for each of these proteins in immature and 
mature B cells from both Sppl2a-/- and Sppl2a+/+ mice (Figure 4.32B, see also 
Chapter 3.6). In contrast, p8-CD74 accumulation did seem to directly or indirectly 
interfere with Fcer2a (CD23) transcription, and provided an explanation as to why 
Sppl2a-/- B cells lacked surface CD23 expression (Figure 4.32C). Thus, p8-CD74 
must block surface BCR and BAFFR expression through a post-transcriptional 
mechanism. 
 
Since IgM and IgD expression was induced normally in immature Sppl2a-/- B cells 
(Figure 3.6 and Figure 4.32B), it seemed likely that a considerable pool of BCR 
protein had been synthesised by the time Sppl2a-/- B cells reached the T1/T2 stage of 
development. p8-CD74 increases the size of LAMP1+ membrane compartment, a 
process that might have an effect on BCR turnover. B cells transport BCRs by 
endocytosis from the cell surface, followed by ESCRT mediated movement into 
endosomes (Zhang et al., 2007, Clark et al., 2011, Yuseff and Lennon-Dumenil, 
2013). Steady state surface levels of membrane molecules are the result of the 
balance between molecules reaching the cell surface from the secretory route, or 
recirculation and removal by internalisation and targeting into endosomes. To see 
whether p8-CD74 driven endosomal changes in Sppl2a-/- B cells have an effect on 
surface molecule levels by increasing BCR internalisation and subsequent 
recruitment into the endosomes, surface IgM internalisation was followed on 
wildtype and Sppl2a-/- spleen B cells over time (Figure 4.33). To achieve this, the 
surface cohort of IgM molecules was labelled using the acid sensitive phytoerythrin  
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Figure 4.32: Surface IgD expression is dose dependent on CD74 
accumulation in Sppl2a-/- B cells, but its transcription is normal 
 
A. Flow cytometric B cell surface IgD and CD23 expression on 
CD19+B220+ B cells presented as geometric mean fluorescent intensity 
(MFI), as well as the proportion (%) of mature CD93low B cells in the 
blood from mice with the indicated genotypes. One Way ANOVA with 
Bonferroni’s Multiple Comparison post test, **** p<0.0001, *** p<0.001, 
n.s. p>0.05. Representative of two independent experiments. 
B. Ighm, Ighd, Tnfrsf13c and Zfp318 relative mRNA expression as 
arbitrary units (A.U.) in FACS sorted splenic T1/T2 immature (CD93high 
IgMhigh) (T1/T2) and mature follicular B cells (CD93low IgMlow) (Mat) from 
Sppl2a+/+ and Sppl2a-/- mice. Dashed lines show mean expression. Data 
from microarray shown in Chapter 3.6. 
C. Fcer2a relative mRNA expression in FACS sorted splenic B cells as 
described for panel B. Data from microarray shown in Chapter 3.6. Two 
tailed t-test, ** p<0.01. 
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(PE) fluorochrome and followed at multiple time points up to 50 min for IgM 
internalisation. Remaining PE-labelled IgM molecules on the B cell surface were 
then extinguished by exposure to acid (Figure 4.33A). All internalised PE-labelled 
IgM was protected from the acid treatment and could be measured by flowcytometry 
to quantify IgM internalisation. Starting and stopping of surface molecule 
internalisation was controlled by temperature regulation. Figure 4.33B shows 
histograms of protected IgM-PE-staining after indicated periods of time allowed for 
IgM internalisation. At every time point the present IgM surface pool was counter-
labelled with a separate anti-IgM-fluorochrome pair, confirming that the total surface 
levels of IgM did not change whilst following internalisation of the PE-labelled IgM 
cohort (data not shown). This indicated that a steady state turn over of surface IgM 
was measured in this system. Relative to the total surface IgM pool CD93high 
immature and CD93low mature Sppl2a-/- B cells internalised increased amounts of 
IgM over time when compared to IgM internalisation rates of Sppl2a+/+ cells (Figure 
4.33C). Mature Sppl2a-/- B cells internalised a greater quantity of IgM surface 
molecules from their surface pool than immature cells, whereas the opposite 
relationship was observed for wiltype B cells. These data showed that in the absence 
of SPPL2A B cells internalised an increased number of IgM molecules from their 
existing surface IgM pool. As overall surface IgM levels remained constant, 
internalised IgM molecules must have been replaced by non-PE labelled IgM, which 
could either be derived from newly synthetised IgM or from the recirculating sub-
surface membrane IgM pool. 
 
To put these observations into perspective, a similar approach was used to examine 
internalisation rates of surface IgD molecules, but also BAFFRs, transferrin receptors 
(CD71), surface full length CD74 and MHCII (Figure 4.34). IgD, CD71 and BAFFR 
surface internalisation in splenic B cells was followed over 50min or 70min as 
described for IgM above, whereas CD74 and MHCII internalisation were measured 
by detecting surface remaining molecules from an initially labelled surface pool with 
secondary antibodies. Internalisation rates are shown as percentage of the total 
surface pool for each investigated molecule. Similar to what was seen for surface 
IgM, Sppl2a-/- B cells internalised a greater proportion of their surface membrane 
IgD faster than wildtype B cells, but this was similar for both, immature and mature 
spleen B cells (Figure 4.34A). BAFFR levels appeared to be unchanged over a time 
period of 50min, as all surface BAFFR PE-label could be inactivated with acid   
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Figure 4.34: Increased internalisation of surface IgD and IgM 
molecules is BCR specific 
 
A. Surface IgD internalisation rates on CD93high immature (left 
graph) or CD93low mature B cells (right graph). Presented as 
percentage of a surface labelled IgD cohort that has been 
internalised during various chase durations. Data derived as 
described for previous figure; in brief, surface IgD was labelled 
with PE-conjugated antibodies, and the fraction of internalised IgD 
was followed flowcytometrically over time by inactivating non-
internalised PE with acetic-acid. 
B. Surface internalisation rates of BAFF receptors (BAFFR), 
CD71 (Transferrin receptor), full length CD74 and MHCII 
molecules on splenic CD19+ B cells isolated from wildtype or 
Sppl2a-/- mice. Splenocytes were surface labelled with PE 
conjugated antibodies (BAFFR, CD71), or unconjugated rabbit 
serum (CD74-JV11, MHCII-JV1) on ice and then allowed to regain 
surface membrane activity by incubating them at 37°C for the 
indicated timespans, before ceasing membrane protein movement 
by chilling cells on ice. PE-marked samples were briefly exposed 
to acid, inactivating any non-protected surface bound PE-label. 
Rabbit serum-marked samples were stained with secondary α-
rabbit antibody to detect fraction of remaining surface molecules. 
Samples were then fixed, stained for B cell markers and FACS 
analysis. Data representative of one (B) or two (A) experiments. 
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treatment, regardless of the amount of time allowed for B cells to internalise 
BAFFRs (Figure 4.34B). About half of a PE-labelled cohort of the transferrin 
receptor CD71 was internalised and protected from acid treatment after about 30min 
at 37°C in Sppl2a+/+ and Sppl2a-/- B cells. CD71 is known to recirculate through 
early endosomal compartments back to the surface by clathrin-dependent 
endocytosis (Grant and Donaldson, 2009), which explained why only about half of 
the CD71 surface cohort remained protected between 30-50min of chase, followed 
by loss of CD71-PE protection thereafter as molecules recirculated back to the cell 
surface. Thus surface internalisation and recirculation of CD71 appeared normal in 
Sppl2a-/- B cells. 
 
To assess CD74 and MHCII internalisation kinetics, a surface cohort of CD74 and 
MHCII molecules were marked with anti-CD74 (JV11) and anti-MHCII rabbit sera 
(JV1) to measure their disappearance from the B cell surface over time spent at 
37°C. CD74 and MHCII disappeared from the surface of wildtype and Sppl2a-/- B 
cells at a comparable rates (Figure 4.34B). So similarly to CD71, full-length CD74 
and MHCII surface internalisation rates occurred normally in SPPL2A-deficient B 
cells 
 
Increased internalisation of IgM and IgD, but not MHCII or CD74 was consistent 
with reduced IgM and IgD, but normal or increased MHCII or CD74 surface levels 
on B cells lacking SPPL2A (Figure 4.9). Normal early endosomal recirculation of the 
transferrin receptor CD71 in Sppl2a-/- B cells suggested no disturbances in this sub-
membrane compartment. Tnfrsf13c expression decreases during late B cell 
maturation (Figure 3.33), whereas surface BAFFR levels increase (Figure 3.8B). 
This implied that BAFFR surface expression might not be replenished through new 
synthesis and needs to be maintained on the B cell surface with little to no 
recirculation in order to successfully compete for limiting amounts of BAFF. 
BAFFRs expressed on Sppl2a-/- B cells seemed to be maintained at the surface 
membrane comparably to wildtype B cells. I concluded, that reduced surface IgM 
and IgD expression on SPPL2A-deficient B cells could be explained by increased 
internalisation rates and thus shortened lifespan of surface receptors. I did not test, 
whether internalised IgM and IgD would recirculate back to the surface 50min after 
internalisation, but increased internalisation from the surface would equate with a 
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greater length of time spent in endosomes, and subsequently an increased likelihood 
of IgM and IgD targeting to late endosomes (Hare and Taylor, 1991). 
 
It was then hypothesised that the IgM and IgD molecules missing on the surface, 
might accumulate inside Sppl2a-/- B cells. Since SPPL2A-deficient B cells feature an 
expanded endosomal membrane compartment and increased numbers of vesicles 
with multilamellar morphology, it was an intriguing possibility that a mechanism 
drew IgD or IgM to be trapped in these membrane structures. In order to measure 
this, I fixed and permeabilised spleen B cells from wildtype or Sppl2a-/- mice to 
flowcytometrically detect intracellular IgD (Figure 4.35) or IgM (Figure 4.36). 
Intracellular or total IgD levels did not increase as Sppl2a-/- spleen B cells matured, 
which mirrored the surface IgD expression pattern in these cells (Figure 4.35A). This 
showed that developing SPPL2A-deficient B cells did not accumulate intracellular 
IgD, and that the loss of surface IgD levels was due to an overall loss of IgD, rather 
than being caused by redistribution away from the cell surface. The loss of 
intracellular IgD from Sppl2a-/- B cells was also caused by the presence of CD74, as 
the removal of CD74 in SPPL2A-CD74-doubly deficient B cells rescued total IgD to 
levels indistinguishable from CD74-singly deficient B cells (Figure 4.35B and C). 
Intracellular IgM measurements are shown in the histogram of Figure 4.36A and, 
similarly to IgD, matched the relative surface IgM staining levels, indicating that 
IgM did not accumulate inside SPPL2A-deficient B cells. Normal transcription of 
BCR mRNA in maturing Sppl2a-/- B cells, but complete absence of BCR protein 
overall implies that either BCR synthesis is decreased, or BCR protein degradation is 
increased. Normal onset of IgM and IgD expression and greater surface BCR 
turnover pointed to a possible increase of BCR degradation, but pulse and chase 
analysis of µ-chain synthesis and degradation, analogous to CD74 metabolism (see 
Figure 4.24), did not reveal a difference between wildtype and Sppl2a-/- B cells 
(Figure 4.36B). After 2 hours of metabolic 35S-methionine labelling and 4 hours of 
chase, B cell activation with anti-IgM and LPS did not alter µ synthesis of the 
slightly smaller ~74kD ER-resident protein, but caused a reduction of more heavily 
glycosylated ~78kD mature µ-chains that were likely targeted for endosomal 
degradation in both, wildtype and SPPL2A-deficient samples (Andersson et al., 
1974, Yuan, 1984). 
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Figure 4.35: IgD does not accumulate intracellularly in 
SPPL2A deficient B cells 
 
A. Geometric mean fluorescent intensity (MFI) of surface and 
total intracellular IgD flow cytometric staining in immature 
CD93high (immat) and mature CD93low (mat) B cells from 
spleens of  Sppl2a+/+ and Sppl2a-/- mice. Lines represent 
mean and each dot a single mouse. 
B. FACS plots showing surface and total intracellular IgD 
expression in splenic B220+ B cells from mice of the indicated 
genotypes. 
C. X-Y-plot of geometric mean fluorescent intensity for 
surface and total intracellular flow cytometric IgD staining 
splenic B cells from mice with the indicated genotypes. Data 
are representative of at least two independent experiments 
with one to three mice per genotype. 
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Figure 4.36: Synthesis and degradation of µ heavy 
chains seems to occur at normal rates in SPPL2A 
deficient B cells, regardless of activation 
 
A. Flow cytometric overlay histogram showing total 
intracellular and surface IgM staining in splenic CD19+B220+ 
B cells from mice with the indicated genotypes. 
B. Radiograph showing immunoprecipitates of µ heavy chain. 
Precipitates were prepared from freshly isolated wildtype 
(Sppl2a+/+) or Sppl2a-/- splenocytes following a 2 hour pulse 
label with 35S-methionine and 4 hour chase in unlabeled 
medium. The Precipitates were then analysed after boiling by 
SDS-PAGE. During the 2 hour pulse splenocytes were either 
activated with anti-IgM and LPS or not. 
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The p8-CD74 mediated loss BCRs in SPPL2A-deficient B cells could still be 
connected to specific endosomal changes and the concomitantly increased number of 
multilamellar bodies in these cells. Excessive accumulation of aberrant proteins or 
lipids is a key feature of endo-lysosomal storage diseases (Futerman and van Meer, 
2004, Platt et al., 2012). Lipid rich multilamellar bodies have been noticed to occur 
in Tay-Sachs, Fabry’s and Niemann-Pick lipid storage diseases and autophagy 
inhibition by blocking PI3-Kinase with 3-methyladenine (3-MA) in related disease 
models was able to prevent the formation of MLBs (Hariri et al., 2000, Lajoie et al., 
2005, Platt et al., 2012). Interestingly, spleen B cells isolated from Niemann-Pick C, 
Fabry, but also GM1-gangliosidosis (Sandhoff disease) and GM1-gangliosidosis 
storage disease mouse models had expanded endo-lysosomal membrane 
compartments and β-Hexosaminidase deficient Sandhoff disease B cells were found 
to have reduced surface BCR but not MHCII levels and an increased surface 
internalisation IgM rate (te Vruchte et al., 2010). To test if reduced surface BCR 
expression and multilamellar bodies might be connected processes in the absence of 
SPPL2A, I cultured wiltype and Sppl2a-/- spleen B cells for 8 hours in 3-MA at 
varying concentrations and then flowcytometrically measured surface IgM, IgD and 
CD19 expression (Figure 4.37). Strikingly, treatment of Sppl2a-/- B cells with 3-MA 
completely rescued surface IgM levels to levels seen in wiltype cells. 3-MA 
treatment at a 5mM concentration was most effective to also increase surface IgD 
levels. However, this response was not specific to Sppl2a-/- B cells, as wildtype cells 
also increased surface IgD levels, yet to a relatively lesser degree. Thus, surface IgM 
and IgD levels are at least in parts limited by a 3-MA sensitive process, which seems 
to be overly active in B cells lacking SPPL2A. 
 
4.7 Human B cells with targeted SPPL2A deletion have increased CD74 levels 
Inactivity of the intramembrane protease SPPL2A in murine B cells leads to 
excessive accumulation of small N-terminal CD74 fragments, which in turn cause a 
survival defect of transitional and mature B cells. Mice with an SPPL2A-deficient B 
cell compartment are unable to mount neither T cell dependent nor independent B 
cell responses to form germinal centres and produce specific antibodies. Thus, 
inhibition of SPPL2A potently blocks humoral immunity and B cell survival, but 
otherwise seems to allow normal growth and reproduction of mice. Easily druggable 
proteins required for B lymphocyte survival and immune responses are an emerging 
source of new treatments for autoimmunity and lymphoid malignancy. The existence  
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Figure 4.37: 3-Methyladenine mediated blockage of 
autophagy for 8 hours in Sppl2a-/- B cells recovers some 
loss of surface IgD and IgM expression. 
 
A. FACS plots showing surface expression of IgM and IgD on 
Sppl2a+/+ or Sppl2a-/-  B cells that have been cultured for 8 
hours, either with 5mM 3-MA or without. 
B. Overlay histograms of the same cultured B cell samples 
presented in A, comparing surface IgD and IgM expression. 
C. X-Y graphs displaying surface expression of IgD, IgM and 
CD19 as geometric mean fluorescent intensity (MFI) or fold 
change, as well the proportion of Annexin 5 positive B cells 
from wildtype (Sppl2a+/+) or Sppl2a-/- mice, cultured for 8 
hours at various concentrations of 3-MA. For all data shown 
in this figure, cells were activated by adding 10mg/ml LPS to 
cultures. 
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of pharmacological inhibitors for SPPL (Eder et al., 2007), suggests that SPPL2A 
might be a useful target for protease inhibitor treatment to achieve 
immunosuppression in B cell diseases. SPPL2A-inhibition could be particularly 
desirable in B cell malignancies that often express high levels of CD74 (Stein et al., 
2007). To test whether SPPL2A-blockage could be of use as therapeutic in humans 
and if SPPL2A degrades CD74 in human B cells, analogously to the murine system, 
SPPL2A was deleted in human B cell lines to subsequently assess CD74 
accumulation and phenotypic changes. 
 
To delete SPPL2A in human B cells, the Burkitt lymphoma derived human B cell 
lines Ramos, Raji and Daudi were used as models. Burkitt lymphomas typically arise 
from pre-germinal centre B cells by translocation that brings expression of the pro-
survival and DNA-destabilising factor MYC under control of the immunoglobulin 
heavy or light chain promoter (Klein and Dalla-Favera, 2008). In regards to their 
developmental stage, Burkitt lymphoma cell lines therefore come relatively close to 
represent immortalised mature, naive human B cells that should express CD74, but 
might display a variable surface immunoglobulin phenotype. To test this, Ramos, 
Raji and Daudi B cell lines in comparison with human peripheral blood mononuclear 
cell (PBMC) derived B cells were flowcytometrically analysed for surface IgM and 
IgD expression (Figure 4.38A and B), as well as intracellular N-terminal CD74 
levels (Figure 4.38Cand D). To detect N-terminal CD74 protein, the anti-human N-
terminal CD74 monoclonal PIN1 antibody was used, which is the human analogue 
reagent to murine N-terminal CD74 recognising IN1. Whereas surface IgD 
expression was only detectable on PBMC-derived B cells, IgM surface levels on 
Ramos and Daudi cell lines were comparable to levels on B cells from the blood.  
 
Raji expressed very low levels of IgM. Intracellular N-terminal CD74 staining with 
fluorochrome labelled PIN1 allowed differentiation of CD19+ B cells among 
PBMCs, as well as another SSChigh CD74 expressing cell population, likely to be of 
monocyte/macrophage origin (Figure 4.38C). This demonstrates that intracellular N-
terminal CD74 staining of PBMCs could be used to identify potentially SPPL2A-
deficient individuals, or to monitor mechanistic efficacy of pharmaceutical SPPL2A 
inhibition. N-terminal CD74 protein levels in Ramos (MFI 20896, 83.3% of PBMCs) 
and Daudi B cell lines (MFI 24434, 97.4% of PBMCs) were similar to PBMC 
derived B cells (MFI 25090, 100%), whilst Raji cells (MFI 12354, 49.2% of  
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Figure 4.38: Human Burkitt-Lymphoma B cell lines 
express CD74, but no IgD 
 
A. Flow cytometric plots for IgM and IgD surface expression 
of the Burkitt-Lymphoma human B cell lines Daudi, Raji and 
Ramos, as well as human peripheral blood mononuclear cells 
(PBMC). Plots are pre-gated on live CD19+ singlets. 
B. Overlay FACS histograms for surface IgM and IgD 
expression of the same samples as in panel A and indicated. 
C. FACS plots showing N-terminal intracellular CD74 staining 
in human PBMC sub-populations. 
D. Overlay histogram of intracellular N-terminal CD74 FACS 
staining, comparing CD74 expression in the indicated Burkitt 
lymphoma B cell lines and human PBMC derived B cells. 
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PBMCs) expressed about half of PBMC-B cell CD74 levels (Figure 4.38D). Thus, if 
SPPL2A plays a similar role in human CD74 metabolism as it does in murine B 
cells, inhibition or deletion of SPPL2A in these Burkitt lymphoma lines should block 
ongoing CD74 turnover and result in increased N-terminal CD74 protein levels. 
 
The CRISPR/Cas9 gene editing system is a recent adoption from prokaryotic 
antiviral immune machinery that uses guide RNA for precise direction of Cas9 
nucleases to cut a desired genomic DNA sequence (Mei et al., 2016). To inactivate 
SPPL2A in Burkitt lymphoma cell lines a Cas9-IRES-GFP reporter and genomic 
Sppl2a targeting guide RNA containing vector (Figure 2.1) was introduced into the 
cells by electroporation (Figure 4.39). Successful transfection and Cas9 nuclease 
synthesis was indicated by GFP expression. The guide RNA was designed to direct 
Cas9 cutting and double stranded DNA breakage to Exon 1 of Sppl2a, which 
subsequently relied on DNA repair mechanisms of non-homologous end joining 
(NHEJ) to produce non-sense sequence changes and a premature STOP codon to 
inactivate Sppl2a. GFP+ Cas9 expressing lymphoma cells were single cell sorted, 
cultured to grow into clonal populations and then analysed for changes in CD74 and 
surface IgM expression levels (Figure 4.40). To control for CD74 independent 
effects of Sppl2a targeted CRISPR/Cas9 treatment, the non-CD74 expressing acute T 
cell leukaemia Jurkat cell line was transduced with the same Sppl2a-Cas9-GFP 
vector and analysed GFP+ Jurkat clones in parallel. Electrophoretic or chemical 
transfection of Daudi cells was not successful. Transfection of Jurkat, Raji and 
Ramos cells resulted in 15, 16 and 10 GFP+ clones respectively.  
 
Plotting of surface IgM against intracellular N-terminal CD74 expression levels of 
GFP+ (circles) and non-transfected clones (squares) shows that Sppl2a-Cas9-GFP 
resulted in variable increases of CD74 protein levels amongst GFP+ clones, which 
did not correlate with changes in surface IgM expression (Figure 4.40A). Sppl2a-
Cas9-GFP transfection of Raji, Ramos and Jurkat cells resulted in increased CD74 
protein levels in about 40% of GFP+ Raji and 80% of GFP+ Ramos Burkitt 
lymphoma cell lines. Collectively CD74 levels were increased in GFP+ Burkitt 
lymphoma clones, but not in Jurkat T cells (Figure 4.40B). IgM surface expression 
on Raji and Ramos clones with increased CD74 levels did not decrease as could be 
expected, and CD74 accumulation in Ramos cells (~2-fold) was less pronounced 
than in Raji cells (~3-fold) (Figure 4.40B and C). Thus SPPL2A appeared to  
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Figure 4.40: Deletion of SPPL2A from human Burkitt 
lymphoma B cell lines leads to accumulation of CD74 
 
A. X-Y plot showing geometric mean fluorescent intensity for 
surface IgM and total N-terminal CD74 staining in GFP+ 
CRISPR-Sppl2a treated Ramos and Raji B cell clones, as 
well as treated Jurkat T cell lymphoma cell line derived 
clones. Clones with high levels of CD74 expression are 
labelled with their clone names (e.g. #14, #4). CRISPR 
treated clones are drawn as circular, whereas non transfected 
clones as square symbols. 
B. Column graph presenting fold increase in N-terminal CD74 
expression of CRISPR-Sppl2a treated clones compared to 
non-treated clones of the indicated human B cell and T cell 
lymphoma lines. One Way ANOVA with Bonferroni’s Multiple 
Comparison post test, * p<0.05, n.s. p>0.05. 
C. Overlay FACS histograms of labelled Raji (top panel) and 
Ramos clones (bottom panel) highlighted in panel A, showing 
total N-terminal CD74 and surface IgM expression. 
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mechanistically fulfil a similar role in murine and human B cells, by cleaving and 
aiding degradation of CD74. This conclusion is consistent with observations of 
impaired CD74 processing in a human Epstein-Barr virus transformed cell line from 
patients with SPPL2A-deficiency caused by deletions in chromosome 15 (Moreno-
De-Luca et al., 2011, Schneppenheim et al., 2014). It remains unclear, whether 
aberrant CD74-fragment accumulation in human B cells would have detrimental 
effects on B cell survival and antibody production similar in mouse cells, as 
increased CD74 levels in Burkitt lymphoma cell lines did not seem to induce 
phenotypic or growth and survival defects.  
 
Nevertheless, these results are preliminary work and have to be considered with 
caution, because some important controls still need to be done. The following 
experiments to validate these initial findings should be performed: CD74 
accumulating Raji and Ramos clones should be sequenced to confirm successful 
Sppl2a CRISPR/Cas9 editing that would result in gene inactivation. Also, lysates of 
CD74 accumulating clones should be immunoblotted for N-terminal CD74 
fragments (PIN1) in order to visualise accumulation of small CD74 fragments as 
opposed to overall increased expression of full length CD74 and thus confirm the 
mechanism of blocked SPPL2A mediated CD74 processing. At last, Sppl2a-Cas9-
GFP transfection of Raji and Ramos cells should be repeated in parallel with a non-
Sppl2a targeting or empty CRISPR/Cas9 vector treatment to rule out any unspecific 
effects of the electroporation process on CD74 expression levels. 
 
4.8 Chapter summary 
In this chapter I unexpectedly find that despite its discovered role in CD74 
metabolism, SPPL2A appeared disconnected from the classical sequence of CD74 
proteolytic cleavage steps, as p8-CD74 accumulation and concomitant B cell 
deficiency in Sppl2a-/- mice was independent of Cathepsin S activity and CD74-
MHCII-chaperoning. Additionally, p8-CD74 accumulation occurred already in 
immature Sppl2a-/- B cells from the bone marrow, whereas p10-CD74 accumulated 
only in transitional Ctss-/- B cells, indicating that SPPL2A processes CD74 earlier 
during B cell development than Cathepsin S. 
 
SPPL2A-deficient B cells exhibit abnormal endosomal enlargement, characterised by 
increased granularity, increased intracellular levels of the late endosomal marker 
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protein LAMP1 and increased intracellular MHCII accumulation. Ultrastructurally 
SPPL2A-deficient B cells were characterised by increased numbers of vesicle 
aggregates with multiple internal membrane sheets, known as multilamellar bodies. 
Collectively, these changes suggest expansion of an overly mature MIIC late 
endosomal membrane structure. 
 
Interestingly, endosomal enlargement has been similarly observed in B cells from 
Cathepsin S-deficient mice, which also accumulate a small N-terminal CD74 
degradation product known as p10-CD74. It was found that expansion of the 
LAMP1+ endosomal membrane compartment in Ctss-/- B cells was much more 
severe than in Sppl2a-/- B cells, but despite these more severe endosomal changes 
Cathepsin S-deficient mice exhibited no B cell abnormalities. This discrepancy, 
between p10-CD74 mediated endosome enlargement in normally developing Ctss-/- 
B cells and p8-CD74 induced B cell deficiency illuminates previously unknown 
capabilities of small N-terminal CD74 fragments to not only regulate endosomal 
biology, but also B cell survival. 
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Chapter 5: CD8- DC require CD74 
degradation by SPPL2A to 
develop and function 
 
 
 
 
 
 
Contributions from others:  
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for the data shown in Figures 5.11 and 5.12, as well as all data shown in 
Figures 5.14 to 5.25. The experiments performed for these data where all 
done under the general supervision and expertise of Jose A. Villadangos, in 
his laboratories at the Department of Microbiology and Immunology as well 
as the Bio21 Institute, both University of Melbourne. 
• Debbie Howard provided technical assistance with intravenous injections and 
irradiations for bone marrow chimera experiments in Figure 5.4. 
• Christopher Goodnow made schematic drawing of CD74 degradation 
products in Figure 5.6B. 
• Mehmet Yabas, Nadine Barthel, Anselm Enders and Stephen Daley provided 
some technical help towards flowcytometric sample preparation. 
  
	   251 
5.1 SPPL2A is needed for CD8- dendritic cell development 
Although the intramembrane protease SPPL2A localises to endosomal membranes 
and is ubiquitously expressed throughout the immune system, SPPL2A function does 
not seem to be essential for survival of all immune cells. For instance, it has already 
been shown that SPPL2A function is required by B cells but not by T cells. We were 
interested to determine which other immune cells may also require SPPL2A function 
for survival. My earlier studies demonstrated that B cells require SPPL2A activity to 
degrade 8kD N-terminal CD74 transmembrane fragments, as without SPPL2A 
activity there was excessive accumulation of p8-CD74 that interfered with B cell 
survival and expression of surface survival receptors. This implied that SPPL2A 
activity was important for cell survival in immune cells that express high levels of 
CD74 and require efficient removal of the protein from endosomal compartments. 
Thus, to identify other immune cells that might require SPPL2A for survival the 
mRNA expression database ImmGen was used to explore Cd74 mRNA expression 
levels across several immune cell subsets as shown in Figure 5.1A (Heng et al., 
2008). As expected, follicular B cells expressed high Cd74 levels, whereas CD4+ and 
CD8+ T cell subsets did not express Cd74. Consistent with CD74’s role in MHCII 
chaperoning, Cd74 levels were also high in antigen presenting cells, such as 
conventional dendritic cell (cDC), Langerhans cells and MHCII expressing 
monocyte and macrophage subsets. This suggested that CD74-expressing cells of the 
myeloid or dendritic cell compartment may also require SPPL2A for survival. Cd74 
mRNA quantities were intermediate to low in non-MHCII expressing monocytes, 
plasmacytoid dendritic cells (pDC) and macrophages, whilst Neutrophils and NK 
cells did not express Cd74.  
 
To explore the prediction that CD74-expressing cells of the myeloid or dendritic cell 
compartment may also require SPPL2A for survival, it was investigated whether 
SPPL2A-deficient mice exhibited abnormalities in these cell compartments 
consistent with poor cell survival. Spleen cells were isolated from wildtype and 
Sppl2a-/- mice and CD11c and CD11b expressing cell subsets analysed by flow 
cytometry (Figure 5.1B). It appeared that Sppl2a-/- mice lacked CD11chigh CD11bhigh 
dendritic cell subsets prompting a more detailed examination of dendritic cell 
populations in the spleen (Figure 5.2), followed by monocyte and macrophage 
populations later in this chapter.  SPPL2A-deficient mice had lower percentages of 
CD11c+ cDC overall and reduced proportions in the CD4+ and CD4- CD8- double  
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Figure 5.1: SPPL2A is critical for dendritic cells 
 
A. Bar graph showing Cd74 relative mRNA expression 
(arbitrary units, A.U.) in the indicated immune cell subsets. 
Graph prepared from Immunological Genome Project 
database (Heng, Nature Immunology, 2008; 
www.immgen.org) 
B. Flow cytometric plots of collagenase digested spleen 
single cell suspensions isolated from Sppl2a+/+ and Sppl2a-/- 
mice, showing CD11c and CD11b surface expression. Data 
are representative of at least three independent experiments 
with three or more mice per genotype. 
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Figure 5.2: SPPL2A is required for CD8- DC development 
 
A. Flow cytometric plots and percentages of dendritic cell (DC) 
subsets in the spleens of wildtype (Sppl2a+/+), heterozygous 
Sppl2a deficient (Sppl2a+/-) and Sppl2a-/- mice. Pregating strategy 
for plots are indicated above each column. Lin, Lineage. 
B. Overlay histograms showing CD11c surface expression of Lin- 
and CD8 expression on CD11c+CD43- dendritic cell spleen 
subsets in mice with the indicated genotype. 
C. Bar graph presenting absolute cell numbers of indicated DC 
subsets in spleens of Sppl2a+/+, Sppl2a+/- and Sppl2a-/- mice. cDC, 
conventional DCs; pDC, plasmacytoid DCs; DN, CD4- and CD8- 
double negative DCs; CD43+, pre-DCs gated as per middle 
column plots in A. Bars show mean, and each symbol represents 
a single mouse. Data are representative of at least three 
independent experiments with three or more mice per genotype. 
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negative (DN) cDC subsets, which was contrasted by a relative increase of CD8+ 
cDC (Figure 5.2A). Less surface CD11c was expressed on all B220- DC and CD8 
surface levels on CD43-CD8+ cDC were also reduced (Figure 5.2B). The changes in 
spleen DC subset ratios were reflected in reduced absolute cDC numbers (12% of 
normal CD4+ and CD8- CD4- DN DC numbers), but normal CD8+ DC numbers in 
spleens from SPPL2A-deficient mice (Figure 5.2C). Sppl2a-/- mice seemed to have 
greater numbers of pDC, but absolute pDC counts were often variable between 
animals.  
 
As opposed to the lowered surface CD11c and CD8 expression, CD11b expression 
levels on Sppl2a-/- CD4+, CD8- CD4- DN and CD8+ cDC spleen subsets appeared 
normal (Figure 5.3 A). MHCII surface levels were increased only on CD4+ and CD8- 
CD4- DN cDC, but not on CD8+ cDC (Figure 5.3B). Flowcytometric staining with an 
antibody (JV11) to the full-length CD74 C-terminal domain revealed that the 
absence of SPPL2A caused an approximate 10-fold increase in CD74 surface 
expression levels on CD8+ cDCs and increases of surface CD74 on CD8- cDC 
subsets, albeit of lesser magnitude (Figure 5.3C). The DC intrinsic requirement for 
SPPL2A was then tested by analysis of mixed bone marrow chimeric Ly5a-mice, 
reconstituted with 65% Ly5b-Sppl2a-/- and 35% Ly5ab- Sppl2a+/+ marrow to assess 
competitive dendritic cell development in the absence of SPPL2A (Figure 5.4). 
Whilst SPPL2A-deficient T cell reconstitution was reminiscent of the seeded bone 
marrow ratios, SSChigh myeloid lineage cells were unexpectedly overrepresented in 
the blood 10 weeks after irradiation and bone marrow transplantation (Figure 5.4 A). 
In the spleen Sppl2a-/- cDCs overall reconstituted almost at normal percentages 
(56.9%), whereas pDCs, similar to the myeloid compartment in the blood, were also 
represented at increased proportions (Figure 5.4 B). However, by further 
differentiating SPPL2A-deficient cDC subset reconstitution in the spleen it was 
found that of the 65% Sppl2a-/--donor marrow contribution,  the CD4+ cDC 
proportion was reduced to 30.6% and DN cDC had reconstituted at 54%, whilst 
CD8+ cDC were overrepresented at 91.2% (Figure 5.4C). This showed that the 
requirement for SPPL2A in CD8- DC development was cell intrinsic. It was 
intriguing that the absence of SPPL2A seemed to provide a competitive advantage 
for developing myeloid cells, pDC and CD8+ cDC, however this finding requires 
further investigation. 
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Figure 5.3: Sppl2a-/- DC subsets have increased levels of surface MHC 
class II and CD74 molecules 
 
A. Overlay flow cytometric histograms of CD4+, CD8+ or DN (double 
negative) spleen DC subsets isolated from Sppl2a+/+ and Sppl2a-/- mice, 
showing CD11b surface expression. 
B and C. Surface expression of MHC class II on splenic DC subsets as in A 
(B), and on CD4+ T cells, B220+ B cells or CD11c+ dendritic cells from 
spleens of mice as indicated (C). 
D. Surface FACS expression of full length CD74 molecules in spleen DC 
subsets described for panel A (D). CD74 was detected with rabbit serum 
(JV11) raised against a murine CD74 epitope in the cytosolic or 
extracellular C-terminus of this type 2, single-pass, transmembrane protein.  
E. Surface C-terminal CD74 staining (JV11) on splenic CD4+ T cells as 
MHCII- control, B220+ B cells or CD11c+ DC from mice with the indicated 
genotypes. Data are representative of at least three independent 
experiments with three or more mice per genotype. 
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Figure 5.4: Dendritic cell subset deficiency in the spleen 
of mice lacking SPPL2A is cell intrinsic 
 
A. Stacked bar graph showing proportions of reconstitution 
for T cells and Myeloid cells in the blood in congenitally 
marked Ly5a host-mice (Sppl2a+/+), that have been sub-
lethally irradiated and injected with a 65%-35% mixture of 
Ly5ab-Sppl2a+/+ (white bars) and Ly5b-Sppl2a-/- (black bars) 
donor bone marrow to generate hematopoietic mouse 
chimera. 10 weeks were allowed for reconstitution of the 
indicated immune cell subsets before FACS analysis. 
B and C. Bar graph stacks illustrating reconstitution ratios of 
the indicated spleen DC subsets derived from Sppl2a+/+ or 
Sppl2a-/- donor marrow. Panel B shows proportions of 
reconstitution in plasmacytoid (pDC) and conventional 
dendritic cell compartments (cDC), whereas Panel C 
differentiates between cDC subsets; DN, CD4- and CD8- 
double negative DCs. Panel A, B and C were prepared from 
the same chimeric recipient mice. Numbers above columns 
are mean percentages and standard deviation of Sppl2a-/- 
derived cell proportion. 
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Findings in chapter 3.4 of this thesis showed that reduced B cell survival in SPPL2A-
deficient mice could be ameliorated by constitutively over expressing the anti-
apoptotic protein BCL2. However, SPPL2A dependent loss of surface molecules was 
independent of survival. To see whether the loss of CD8- cDC in SPPL2A deficient 
mice could also be rescued by constitutive expression of anti-apoptotic BCL2, 
Sppl2a-/- Vav-Bcl2 mice were generated and their DCs analysed by flowcytometry 
(Figure 5.5). In these animals BCL2 overexpression did not correct lowered surface 
expression (Figure 5.5A and B), and, in contrast to what was observed in B cells, it 
also did not seem to increase the numbers of CD8- cDC accumulating in spleens of 
SPPL2A-deficient mice (Figure 5.5C). These preliminary data were obtained from 
few animals and need to be verified; yet they indicated that Sppl2a-/- DC 
abnormalities were not rescued by factors that block intrinsic apoptosis.  
 
Taken together, I concluded that SPPL2A was not only required for B cell survival, 
but also was critical for the development of antigen-presenting DC key populations 
in the spleen. 
 
5.2 Complete CD74 proteolysis in dendritic cells requires SPPL2A and is 
independent of MHCII chaperoning 
Studies presented in chapter 3.5 of this thesis demonstrated that the intracellular 
accumulation of small CD74 transmembrane-fragments was responsible for blocked 
survival and surface molecule loss in Sppl2a-/- B cells. As DCs express high levels of 
CD74, it was reasoned that these cells might also depend on SPPL2A activity for 
processing of residual CD74 molecules, and therefore the absence of SPPL2A would 
likely also cause excessive accumulation of unprocessed CD74 residues. To measure 
whether SPPL2A-deficienct DCs accumulate small CD74 fragments, sorted spleen 
DC lysates from wildtype and Sppl2a-/- mice were immunoblotted using the IN1 
antibody to detect N-terminal CD74 fragments (Figure 5.6A). B cell lysates were 
included as a control. This immunoblot revealed that Sppl2a-/- spleen DC also 
accumulated 8- and 12-kD CD74 N-terminal fragments, which corresponded to the 
predicted sizes for the penultimate p8 and p10 cleavage products produced by 
Cathepsin S in DCs and B cells (Figure 5.6A and B). Because the DC lysates 
contained high CD74 protein levels, in order to resolve the intermediate CD74 
degradation products Figure 5.6B, it was necessary to load as few as 35 000 cells per 
sample for both DCs and B cells. By using similar cell numbers in both cell types,  
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Figure 5.5: Overexpression of antiapoptotic BCL2 does 
not rescue DC defect in Sppl2a-/- mice 
 
A. Flow cytometric plots and percentages of dendritic cell 
subsets in the spleens of Bcl2 transgenic (Tg) Sppl2a+/+ and 
Sppl2a-/- mice. Pre-gates of plots are indicated above 
columns.  
B. FACS overlay histogram of CD11c surface expression in 
live, lymphocyte and granulocyte lineage depleted (Lin-) 
splenocytes isolated from mice with the indicated genotype. 
C. Bar graph showing absolute numbers of indicated DC 
subsets in spleens from Sppl2a+/+ and Sppl2a-/- mice, either 
transgenic for Vav-Bcl2 or not. cDC, conventional DCs; pDC, 
plasmacytoid DCs; DN, CD4- and CD8- double negative DCs; 
CD43+, pre-DCs. Bars show mean, and each symbol is a 
single mouse.  
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Figure 5.6: Proteolytic processing of CD74 in dendritic 
cells requires SPPL2A 
 
A. Immunoblot analysis of FACS sorted splenic dendritic 
cells, B cells and the non-DC / non-B cell (Non) fraction from 
Sppl2a-/- and Sppl2a+/+ mice. Blots were probed with IN1 
antibody against the CD74 N-terminal tail and then stripped 
and re-probed with antibody to α/β-Tubulin. p41 and p31 
isoforms of CD74 are indicated. About 35 000 cells were 
loaded per lane. 
B. Schematic diagram of CD74 processing steps and 
products, showing estimated molecular weights and 
proteases involved. TM, transmembrane. Data are 
representative of at least three independent experiments. 
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this immunoblot provided a comparison of the overall CD74 fragment quantities 
present in DCs relative to B cells per cell. Low numbers B cells and the small B cell 
cytoplasm relative to DCs appear to be the most likely explanations for exceeding 
the detection limits of tubulin in B cell samples. The immense accumulation of p8-
CD74 penultimate cleavage products in Sppl2a-/- DC lysates confirmed that SPPL2A 
activity is not only responsible for CD74-peptide cleavage in B cells, but also in 
dendritic cells. 
 
To verify, if the excessive build-up of CD74 peptides in Sppl2a-/- DC was 
responsible for loss of CD8- cDC in mice lacking SPPL2A, p8-CD74 accumulation 
was prevented by crossing SPPL2A deficient mice with CD74-deficient mice (Cd74-
/-). It was also tested whether the build-up of p8-peptides was dependent on CD74-
MHCII chaperoning in dendritic cells, by analysing Sppl2a-/- H2-Aa-/- doubly 
deficient DCs, which are unable to form CD74-MHCII complexes by removing full 
length MHCII α chains (Koonce and Bikoff, 2004). Plots in Figure 5.7 show the 
flowcytometric analysis and absolute cell numbers of spleen dendritic cell subsets 
from wildtype, Cd74-/-, H2-Aa-/-, Sppl2a-/-, Sppl2a-/- Cd74-/- and Sppl2a-/- H2-Aa-/- 
mice.  
 
Deletion of CD74 in SPPL2A-deficient animals rescued the DC defect observed in 
the absence of SPPL2A. SPPL2A-CD74-doubly deficient CD8- cDC were present at 
percentages and numbers comparable to CD74-singly deficient DC, indicating that 
the accumulation of p8-CD74 fragments in DC lacking SPPL2A causes a defect in 
these DC subsets. Variably increased pDC numbers in Sppl2a-/- mice also appeared 
to be a result of CD74 accumulation. However, this observation needs to be further 
investigated as it differed between mice, which indicating that other unknown and 
experimentally uncontrolled factors appear to interact with SPPL2A-deficiency in 
pDCs. Blockage of MHCII chaperoning by CD74 through the removal of full length 
MHCII α chains did not increase CD8- cDC numbers, demonstrating that p8-CD74 
accumulation was not dependent on MHCII chaperoning. Interestingly, disruption of 
CD74-MHCII chaperoning did reduce CD8+ cDC numbers in SPPL2A-deficient 
mice.  
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Figure 5.7: Accumulating CD74 is causative for Sppl2a-/- 
DC defect, which cannot be rescued by remov l of MHCII 
α chain 
 
A. Flow cytometric plots and percentages of dendritic cell 
subsets from spleens of mice with the indicated genotypes. 
Pre-gating is given above each column. Lin, lineage. 
B. Absolute cell numbers of dendritic cell subsets isolated 
from gradient cut, light density spleen fractions of mice with 
the genotypes shown. DN, CD4 and CD8 double negative; 
pDC, plasmacytoid dendritic cells. 
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DCs from the above mouse crosses were then examined in more detail to determine 
whether excessive accumulation of CD74 was also responsible for the changes in 
surface molecule expression observed on SPPL2A deficient DCs, such as  
reduced expression of CD11c. Additional deletion of CD74 in Sppl2a-/- DCs 
completely corrected the reduced expression of CD11c, whereas the removal of 
MHCII α chains did not (Figure 5.8A). Furthermore, flowcytometric examination of 
surface molecules on SPPL2A-deficient dendritic cell subsets revealed normal 
CD11b levels on CD8- cDCs, indicating that loss of surface CD11c was a selective 
and not generalised feature of DC integrins (Figure 5.8B). Similar to SPPL2A-
deficient B cells, MHCII surface levels were overall increased on cDCs lacking 
SPPL2A (Figure 5.8C). This increase in cDCs overall was caused by the Sppl2a-/- 
CD4+ cDC subset, which accumulated twice the normal amount of MHCII-dimers on 
the cell surface; DN and CD8+ cDC maintained MHCII levels comparable to 
wildtype cells (Figure 5.8C and D). Unexpectedly, the expression levels of MHCII 
molecules on the surface of SPPL2A-deficient cDC subsets did not correlate with 
those of full length CD74, as determined by  flowcytometric staining for the C-
terminal CD74-domain (JV11) (Figure 5.9). Despite only a small increase in full-
length CD74 p31 and p41 proteins detectable by immunoblotting (Figure 5.6), 
overall staining for C-terminal full-length CD74 revealed a large accumulation on 
the cell surface of SPPL2A-deficient CD11c+ DC, which was the result of a striking 
10-fold increase in surface CD74 expression on the CD8+ cDC subset (Figure 5.9A 
and B). A pathway that required MHCII chaperoning by CD74 drove this transport 
and accumulation of full-length CD74 molecules on the surface of SPPL2A-deficient 
CD8+ DCs, as removal of MHCII α chains in Sppl2a-/- H2-Aa-/- CD8+ DCs corrected 
CD74 surface surface expression to levels seen in wildtype DC subsets (Figure 5.9B 
and C). This finding, considered with that of differing levels of CD74 and MHCII 
surface expression, suggests that CD74-MHCII complexes may dissociate after 
reaching the cell surface together, and thereafter could undergo different rates of 
ubiquitinylation dependent removal from the plasma membrane. 
 
N-terminal CD74 immunoblotting of sorted spleen dendritic cell lysates in 
comparison to B cell lysates from wildtype (Sppl2a+/+), Sppl2a-/-, Sppl2a-/- H2-Aa-/-, 
H2-Aa-/- and Ctss-/- mice confirmed that SPPL2A-deficiency related DC defects were 
caused by accumulating p8-CD74 N-terminal fragments (Figure 5.10). p8, but not 
p10-CD74 accumulated in SPPL2A-MHCII α chain doubly deficient DCs. This  
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Figure 5.8: Removal of C 74 from SPPL2a deficient DC 
rescues surface phenotype, whereas removal of MHCII α 
chain does not. 
 
A. Overlay histogram showing surface CD11c FACS staining 
on lineage depleted (Lin-), spleen light density fraction from   
Sppl2a+/+, Sppl2a-/-, CD74-/-, Sppl2a-/-CD74-/-, H2-Aa-/- and 
Sppl2a-/-H2-Aa-/- mice. 
B. Column graph showing geometric mean fluorescent 
intensity (MFI) of surface CD11b staining on spleen DC 
subsets of the displayed genotype. 
C. FACS histogram overlaying surface MHCII staining on 
CD11c+ DC in spleens of mice with the indicated genotypes. 
D. MFI graph quantifying surface MHCII expression in spleen 
DC subsets of Sppl2a+/+, Sppl2a-/-, CD74-/- and Sppl2a-/-
CD74-/- mice. DN, CD4 and CD8 double negative; pDC, 
plasmacytoid dendritic cells. 
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Figure 5.9: Excessive movement of CD74 to the cell 
surface in Sppl2a-/- CD8+ DC is dependent on MHCII α 
chain 
 
A. Flow cytometric plots and percentages of CD8+ and CD8- 
dendritic cell subsets from spleens of mice with the indicated 
genotypes showing their full length, surface CD74 
expression, measured by C-terminal CD74 staining (JV11). 
B. Overlay FACS histogram showing surface C-terminal 
CD74 staining using rabbit serum (JV11) that was raised 
against a murine C-terminal CD74 epitope. Lineage depleted 
CD11c+ light density cells from spleens of mice with the 
indicated genotypes were stained. 
C. Column graph showing geometric mean fluorescent 
intensity (MFI) of surface C-terminal CD74 staining (JV11) in 
splenic CD4+, CD8+, CD4 and CD8 double negative (DN) or 
plasmacytoid dendritic cells (pDC) from mice with the 
indicated genotypes. 
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showed that persistence of p8-CD74 did not require MHCII chaperoning, whereas 
the p10-CD74 Cathepsin S substrate that also accumulated in Ctss-/- DC, did rely on 
MHCII-chaperoning and therefore did not persist in Sppl2a-/- H2-Aa-/- DCs. The 
same was true for a larger ~18 kD CD74 N-terminal intermediate peptide in these 
cells. Equal numbers of sorted DCs were lysed and prepared for N-terminal CD74 
immunoblotting to allow comparison of CD74 full-length p31 and p41 quantities 
between the indicated cell types. In the absence of MHCII α chains, increased 
amounts of p31 and p41 CD74 protein were observed in both, B cells and DCs. 
 
In the absence of Cathepsin S, DCs accumulated a small 10kD CD74 fragment 
known as p10, and appeared biochemically very similar to p8-amassing SPPL2A-
deficient DCs (Figure 5.10). Consistent with published observations of normal DC 
development in the absence of Cathepsin S (Driessen et al., 1999), the CD8- spleen 
DC subsets from Cathepsin S-deficient mice seemed undiminished, and did not 
resemble the defects seen in the SPPL2A-deficinet DC compartment (Figure 5.11). 
However, these data are preliminary from a single Cathepsin S-deficient mouse and 
need to be repeated. Taken together, the apparent persistence of CD8- DCs in Ctss-/- 
mice despite p10-accumulation, and the MHCII-chaperoning dependent loss of p10 
in DC-defective Sppl2a-/- H2-Aa-/- mice, confirmed that accumulation of p8-CD74 
but not p10-CD74, led to the loss of CD8- cDCs and other phenotypical DC changes 
observed in SPPL2A-deficient mice. 
 
To visualise how CD74 molecules were distributed inside Sppl2a-/- DCs, 
CD11c+MHCII+ cells were flow cytometrically sorted from spleens of SPPL2A-
deficient, wildtype and Cathepsin S-deficient mice and the subcellular CD74, 
LAMP1 and MHCII localisation patterns compared by confocal microscopy (Figure 
5.12). Whilst CD74 molecules in wildtype DCs (Sppl2a+/+) were mostly congregated 
in the peri-centriolar region, an ER and TGN containing groove formed by the 
kidney shaped nucleus, this region was completely devoid of CD74 staining in 
SPPL2A-deficient DCs, thus mirroring observations made in Sppl2a-/- B cells as 
shown in chapter 4.5. However, unlike Sppl2a-/- B cells, the cytosolic CD74 staining 
in Sppl2a-/- DCs was spread in a granulated pattern throughout the cytoplasm, rather 
than patchy in aggregates. Similar to wildtype DCs, and unlike Sppl2a-/- DCs,  the 
‘nuclear groove’ and cytoplasm were occupied by CD74 in p10-accumulating 
Cathepsin S-deficient DCs. 
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Figure 5.10: SPPL2A dependent p8-CD74 accumulation in 
DCs does not require MHC class II chaperoning 
 
Immunoblot analysis of about 50 000 FACS sorted splenic B 
cells and CD11c+ MHCII+ dendritic cells from Sppl2a+/+, 
Sppl2a-/-, Sppl2a-/-H2-Aa-/-, H2-Aa-/- and Ctss-/- mice. 
Immunoblot membrane was probed with IN1 antibody against 
the CD74 N-terminal tail, then stripped and re-probed with 
antibody against α/β-Tubulin. Murine p41 and p31 CD74 
isoforms as well as p22, p18, p10 and p8 fragments of CD74 
are labelled. Data representative of three independent 
experiments. 
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Flow cytometric plots and percentages of dendritic cell 
subsets from spleens of mice with the indicated genotypes. 
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Figure 5.12: Subcellular localisation of CD74 in Sppl2a-/- 
DC spares nuclear groove and is distinct from Cathepsin 
S deficient DC. 
 
Confocal images of FACS-sorted CD11c+ MHCII+ dendritic 
cells from Sppl2a+/+, Sppl2a-/-, and Ctss-/- mice, labelled with 
antibodies against the late endosome marker Lamp1 (A) or 
MHCII (B) (red) and the N-terminus of CD74 (green). The 
scale bar is 5µm. Data representative of two independent 
experiments. 
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Co-staining with LAMP1 marked late endosomal membrane structures and 
suggested that CD74 molecules in SPPL2A and Cathepsin S-deficient DC were 
localised in the same subcellular areas as endosomes (Figure 5.12A). In wildtype 
DCs most CD74 resided in the peri-nuclear grove, which did not stain for LAMP1. 
Contrastingly, in SPPL2A-deficient DC, this area was LAMP1+, whilst CD74 
staining was absent (Figure 5.12A). As expected, MHCII labelling was largely 
reminiscent of the CD74 vesicular distribution pattern in the examined DCs from all 
three, wildtype, SPPL2A-deficient, and Cathepsins-deficient mice, indicative of 
CD74’s association with MHCII (Figure 5.12B). 
 
Whilst N-terminal CD74 immunoblotting showed exactly which proportions of 
CD74 peptides were present in Sppl2a-/- DCs, and confocal imaging provided 
information about subcellular CD74 distribution, neither of these methods allowed 
objective measurement of how much CD74 actually accumulated. Therefore 
intracellular flowcytometric staining was used to asses total N-terminal CD74 protein 
levels, as well as intracellular LAMP1 labelling to quantify endosomal membrane 
compartment expansion (Figure 5.13). Total N-terminal CD74 levels were 
approximately 4-fold increased in CD8- DCs and pDCs, and 7-fold increased in 
CD8+ cDCs. Greater CD74 levels were accompanied by almost a doubling of 
intracellular LAMP1 staining in CD8- and CD8+ DCs with slightly lesser increases of 
LAMP1 levels in pDCs (Figure 5.13A and B). By comparison, reduced levels of 
intracellular CD11c showed that the loss of surface CD11c (presented in Figure 5.8) 
was not due to intracellular sequestration of this molecule in endosomes (Figure 
5.13C). 
 
Metabolic labelling of sorted spleen DC from wildtype and Sppl2a+/-, Sppl2a-/- mice 
with radioactive 35S-methionine was used to assess the amount of time SPPL2A-
deficient DCs take to produce p8-CD74 and its association with MHCII (Figure 5.14 
and Figure 5.15). After allowing 30 min of pulse for newly synthetised proteins to 
incorporate radioactive 35S-methionine, the DCs were washed to remove 35S-
methionine and returned to culture for 1.5 or 4 hours to chase the fate of the cohort of 
proteins labelled during the 30 min pulse. After the pulse and each chase time, 
aliquots of cultured DC were lysed, normalised for incorporated radioactivity and 
immunoprecipitated using a serum against N-terminal CD74 (JV5) or MHCII α 
chains (JV1).  
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Figure 5.13: In Sppl2a-/- mice the CD8+ spleen DC subset 
accumulates the highest amount of intracellular CD74 
protein 
 
A. Overlay FACS histograms showing intracellular N-terminal 
CD74 (IN1) and LAMP1 staining in CD8+, CD8- and pDC 
subsets from spleens of wildtype (Sppl2a+/+) or Sppl2a-/- mice. 
Grey vertical line of dots marks peak fluorescence levels of 
wildtype CD8+ DC sample. 
B. MFI graphs displaying geometric mean fluorescent intensity 
of N-terminal CD74 and LAMP1 intracellular staining in the 
indicated splenic DC subsets from Sppl2a+/+ (white circles) and 
Sppl2a-/- (green circles) mice. 
C. MFI graph showing total CD11c staining in splenic DC 
samples as described for panel B. Data are representative of 
two independent experiments with three mice per genotype. 
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Figure 5.14: Slowed degradation of CD74 fragments in 
Sppl2a-/- DC is not detectable after 4 hours 
 
Radiograph of immunoprecipitates from CD74 using rabbit 
serum raised against an N-terminal epitope of murine CD74 
(JV5). Precipitates were prepared from freshly isolated 
wildtype (Sppl2a+/+) Sppl2a+/- or Sppl2a-/- MACS sorted 
splenic dendritic cells following a 30min pulse label with 35S-
methionine and 1.5 or 4 hour chase in unlabeled culture 
medium, analysed after boiling by SDS-PAGE. The quantities 
of lysates used for immunoprecipitation were normalised for 
equal amounts of incorporated radioactivity. 
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Figure 5.15: Degradation of MHCII associated CD74 is 
delayed in Sppl2a-/- DC 
 
Radiograph of radioactively labelled, immunoprecipitated 
MHC class II molecules from freshly isolated Sppl2a+/+ 
Sppl2a+/- or Sppl2a-/- MACS sorted splenic dendritic cells 
following a 30min pulse label with 35S-methionine and 1.5 or 
4 hour chase in unlabeled culture medium, analysed after 
boiling by SDS-PAGE.  To precipitate MHCII, rabbit serum 
raised against an epitope of murine MHCII was used (JV1). 
The quantities of lysates used for immunoprecipitation were 
normalised for equal amounts of incorporated radioactivity. 
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The resulting immunoprecipitates were separated by molecular weight using gel 
electrophoresis. Subsequently, the gels were radiographed to detect incorporated 
radioactivity and to produce the images shown for CD74-IP in Figure 5.14 and for 
the MHCII-IP in Figure 5.15. CD74 isoforms p31 and p41, smaller degradation 
intermediates p22, p10 and p8 and MHCII α and β chains are indicated based on 
estimated molecular weights. Immunoprecipitation of a N-terminal CD74 protein 
cohort synthetised after 30min showed that p31, p41, p22 and p10 were produced in 
SPPL2A-deficient DCs within this time period. Relative persistence of p22 and p10-
CD74 degradation products after 1.5 and 4 hours of chase indicated that CD74 
degradation in the absence of SPPL2A in DC was slower than normal. Whilst in B 
cells lacking SPPL2A radioactively labelled p8-CD74 started to appear after 2 hours 
of 35S-methionine pulse, first traces of p8-CD74 in DCs were only detectable after 4 
hours of chase, suggesting that p8 production in DCs took 4.5 hours, or about twice 
as long as it did in SPPL2A-deficient B cells (Figure 5.14). Immunoprecipitation of 
MHCII using JV1 serum against α chains confirmed that MHCII associated CD74 
turnover was delayed in Sppl2a-/- DCs, as p22 and p10 fragments relative to p31 
bands persisted after 1.5 and 4 hours of chase (Figure 5.15). This observation may 
explain, why SPPL2A-deficient DCs not only accumulated p8-CD74 fragments, but 
also produced significant amounts of Cathepsin S and MHCII-chaperoning 
dependent p10 (Figure 5.10). Overall, the results from these pulse-chase studies 
demonstrate that SPPL2A was required in DCs, as previously also shown for B cells, 
to fully degrade CD74 protein. In the absence of SPPL2A, N-terminal p8-CD74 
fragments accumulated in DCs independently of MHCII-chaperoning and caused a 
loss of CD8- cDCs that seemed mechanistically related to Sppl2a-/- B cell deficiency. 
However, it was intriguing that DC subsets (CD8-, CD8+ and pDC), in Sppl2a-/- mice 
seemed to respond differently to accumulation of CD74 fragments, highlighting stark 
dissimilarities in how these subsets handle CD74 and MHCII metabolism and 
trafficking. 
 
5.3 SPPL2A-deficient Flt3-L bone marrow cultures unexpectedly produce 
normal DC populations 
Dendritic cells are a difficult to isolate and rare immune cell subset in mouse spleens, 
and comprise less than 1% of all cells in this organ. SPPL2A-deficient mice harbour 
even fewer DC numbers than normal, and the low surface CD11c expression levels 
made differentiation of this cell subset difficult. Therefore, I set out to generate 
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greater numbers of dendritic cells in vitro by culturing mouse bone marrow in the 
presence of FMS-Like Tyrosine Kinase 3 Ligand (Flt3-L or FL) (Brasel et al., 2000, 
Naik et al., 2005). Naik and colleagues showed that this 9-day-FL-DC culture system 
produced larger quantities of CD11c+MHCII+ DC, which were both phenotypically 
and functionally reminiscent of murine spleen DC subsets, and of sufficient purity. 
However, FL-DC CD8+ and CD8- spleen DCs are identified by CD24 and Sirp-α 
instead of CD4 and CD8, as CD4 and CD8 expression could only be elicited in FL-
DC by intra vivo adoptive transfers. To verify whether SPPL2A-deficient FL-DC 
subsets mirror the DC deficits observed in SPPL2A-deficient ex vivo spleen DC, day 
9 Flt3-L bone marrow cultures from wildtype, heterozygous Sppl2a+/- and Sppl2a-/- 
mice were analysed by flow cytometry (Figure 5.16). Unexpectedly, SPPL2A-
deficient Flt3-L bone marrow cultures produced normal proportions of CD11c+ 
CD8+ and CD8- cDC equivalent CD24+ and Sirp-α+ cDC subsets, as well as 
CD45RA+ pDC (Figure 5.16A). CD11c surface expression levels on Sppl2a-/- FL-DC 
were normal and the development of CD11c+ cells in bone marrow cultures over 
time was comparable to DC development in wildtype cultures (Figure 5.16B and C). 
Compared to spleen derived DC subsets, SPPL2A-deficient FL-DCs therefore 
seemed to either manage CD74-fragment accumulation by avoiding toxic side 
effects, or may not amass p8-CD74 altogether. 
 
To test whether Sppl2a-/- FL-DC accumulated small CD74 degradation products by 
N-terminal CD74 immunoblotting, FL-DC cultures were prepared from wildtype and 
SPPL2A-deficient bone marrow in parallel with Cathepsin S-deficient marrow to 
serve as control for p10 accumulation (Figure 5.17). All day 9 Flt3-L bone marrow 
cultures produced similar proportions of CD45RA+ pDC, as well as CD24+ and Sirp-
α+ cDC subsets, yet MHCII surface expression was increased in Sppl2a-/- FL-DCs 
(Figure 5.17A and B), overall verifying that Cathepsin S as well as SPPL2A 
deficiency did not interfere with DC development in Flt3-L cultures. Lysates from 
Sppl2a+/+, Sppl2a-/- and Ctss-/- FL-DCs, as well as splenocyte lysates from wildtype 
and Sppl2a-/- mice were then prepared for N-terminal CD74 immunoblotting using 
IN1 antibody (Figure 5.17C). Despite seemingly normal development in Flt3-L bone 
marrow cultures, SPPL2A-deficient FL-DC did produce the expected small CD74 N-
terminal fragments p8 and to a lesser degree p10. P10 was equivalently accumulated 
in Cathepsin S deficient FL-DC lysates. 
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Figure 5.16: Flt3-Ligand driven differentiation of DC in 
bone marrow cultures does not depend on SPPL2A. 
 
A. FACS plots and percentages of dendritic cell subsets 
found in bone marrow Flt3-Ligand cultures prepared from 
Sppl2a+/+, Sppl2a+/- and Sppl2a-/- mice after incubation at 
37°C and 10% CO2 for 9 days. 
B. Flow cytometric CD11c surface expression as overlay 
histogram of live cells from day 9 Sppl2a+/+, Sppl2a+/- and 
Sppl2a-/- Flt3-Ligand bone marrow cultures.  
C. Percentage of CD11c+ DC among all live cells in Flt3-
Ligand bone marrow cultures over time, prepared from 
Sppl2a+/+, Sppl2a+/- and Sppl2a-/- mice. Data are 
representative of at least three independent experiments. 
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Figure 5.17: Flt3-Ligand bone marrow culture derived 
Sppl2a-/- DC (FLDC) also accumulate p8-CD74 fragments 
 
A. FACS plots and percentages of dendritic cell subsets 
found in bone marrow Flt3-Ligand (FL) cultures prepared 
from Sppl2a+/+, Sppl2a-/- and Ctss-/- mice after incubation at 
37°C and 10% CO2 for 9 days. 
B. X-Y-graph showing proportion of CD11c+ DC in Flt3L 
marrow cultures from panel A over time. 
C. Immunoblot analysis of day 9 FLDC bone marrow cultures 
derived from marrow of Sppl2a+/+, Sppl2a-/-, and Ctss-/- mice 
(lanes 3, 4 and 5), shown in panel A. For comparison 
splenocytes from wildtype (Sppl2a+/+) and Sppl2a-/- mice were 
lysed and loaded onto lanes 1 and 2. The immunoblot was 
probed with anti-N-terminal CD74 antibody (IN1). p8- and 
p10-CD74 fragments are labelled. 
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It was intriguing that SPPL2A-deficient FL-DC seemed to develop normally, 
whereas their in vivo counterparts did not. Both types of DCs required SPPL2A 
activity to degrade p8-CD74 fragments, but p8-CD74 accumulation only seemed to 
affect spleen DCs, and not FL-DCs grown in bone marrow cultures over 9 days. In B 
cells it was found (Chapter 4.4) that timing of p8-CD74 accumulation during B cell 
development was important and showed that immature and T1 B cells already 
accumulated p8 during the early developmental stages, yet the survival defect was 
only detectable from the T2 stage onwards. This observation, as well as the described 
persistence of CD8+ and pDC subsets in SPPL2A-deficient mice, indicates that p8-
CD74 accumulation could exist without disrupting cell survival. It was therefore 
hypothesised that timing of p8 accumulation could explain why developing Sppl2a-/- 
FL-DCs could survive in culture. To test this hypothesis FL-DC bone marrow 
cultures were prepared from Sppl2a+/+, Sppl2a-/-, Sppl2a-/- H2-Aa-/-, H2-Aa-/- and 
Ctss-/- mice, and DC percentages, absolute DC numbers and intracellular N-terminal 
CD74 accumulation measured by flowcytometry and IN1 immunoblotting on days 4, 
6, 7, 8, 9 and 10 (Figures 5.18 to 5.20). From the literature it is known that the 
presence of Flt3-L drives development of CD11c+MHCII+ DC from whole bone 
marrow preparations over a period of 9 days. Furthermore, in day 9 cultures the 
percentage of CD11c+ DCs reaches up to 80%, after which DCs become overly 
mature and begin to die off (Brasel et al., 2000, Naik et al., 2005, Naik et al., 2007). 
By following an Flt3-L driven cohort of developing DCs from day 4 to day 10, it was 
anticipated to learn when, during DC development, CD74 fragments would 
accumulate and how this CD74 build-up would affect DC survival. Flowcytometric 
measurement of accumulating N-terminal CD74 protein provided an objective 
quantification of this process and revealed that developing Sppl2a-/- FL-DC cultures, 
regardless of MHCII α chain expression, progressively lost N-terminal CD74high cells 
(Figure 5.18A). This was contrasted by increasing proportions of N-terminal 
CD74high cells in Cathepsin S deficient maturing cultures and reflected the 
continually increasing N-terminal CD74 levels as cultures progressed from day 4 to 
day 10 (Figure 5.18B). The absence of MHCII α chain expression also resulted in 
greater proportions of CD74 accumulating cells, which could be seen in increased N-
terminal CD74 levels of H2-Aa-/- bone marrow cultures from day 8 onwards. 
 
The x-y-plots in Figure 5.19A quantify the percentages and absolute DC 
concentrations in Flt3-L bone marrow cultures of the indicated genotypes over time.  
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Figure 5.18: In Flt3-Ligand bone marrow cultures no 
Sppl2a-/- DC with high levels of intracellular CD74 persist 
 
A. Flow cytometric plots and percentages showing total, 
intracellular N-terminal CD74 (IN1) and surface CD11c 
staining in live BST2- Flt3-L bone marrow cultures prepared 
from mice with the indicated genotypes and were sampled on 
days 4, 6, 7, 8, 9 and 10, fixed and analysed on the same 
day. Cells were cultured at 37°C and 10% CO2. 
B. X-Y MFI graphs displaying geometric mean fluorescent 
intensity of intracellular N-terminal CD74 (IN1) staining on live 
BST2- Flt3-L bone marrow culture cells shown in panel A over 
time. Culture genotypes of graphs shown as colour coded. 
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Figure 5.19: p8-CD74 accumulates early in developing 
Sppl2a-/- DC of Flt3-Ligand bone marrow cultures 
 
A. X-Y MFI graph of absolute CD11c+ cDC cell counts and 
percentages developing in Flt3-L marrow cultures over time. 
Cultures were seeded at 1.5x106 bone marrow cells/ml on 
day 0. The genotypes represented in the graphs can be 
identified using the colour coded legend. 
B. Immunoblot for N-terminal CD74 (IN1) on 25 000 cell 
aliquots collected of day 4, 6, 7, 8 and 9 Flt3-L bone marrow 
cultures prepared from wildtype (Sppl2a+/+) or Sppl2a-/- mice. 
Membrane was stripped and re-probed with antibody against 
α/β-Tubulin. Samples for this blot were isolated from the 
same experiment presented in the previous and following 
figure. 
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Wildtype bone marrow developed as expected and produced around 500 000 CD11c+ 
DCs per ml of culture media peaking on day 9, whilst SPPL2A-deficient marrow 
only reached ~350 000DCs/ml.  
 
Sppl2a-/- H2-Aa-/-, H2-Aa-/- and Ctss-/- marrows were also less capable of generating 
DCs compared to wildtype marrow. These differences in absolute DC numbers were 
not reflected in CD11c+ DC percentages, indicating that the overall capability to 
generate cellular material  in gene deficient Flt3-L bone marrow cultures was 
reduced in comparison to wildtype cultures. 
 
To follow the production of CD74-N-terminal peptides in developing Sppl2a-/- FL-
DCs, equal cell number aliquots from all bone marrow cultures mentioned above on 
day 4, 5, 6, 7, 8 and 9 were collected and prepared as lysates for side by side N-
terminal CD74 immunoblotting (Figure 5.19B and Figure 5.20). To allow relative 
cross-comparison between immunoblots, a reference sample of the same day 9 
Sppl2a-/- FL-DC lysate was included in all blots. Wildtype FL-DCs expressed p31 
from culture day 4 onwards, whilst a p10-CD74 degradation product gradually 
appeared as cultures matured, indicating that from at least culture day 4 onwards, the 
developing cohort of Flt3-L receptive FL-DCs synthetise full-length p31, which is 
subjected to degradation as the FL-DCs mature and presumably begin trafficking 
CD74 into proteolytic vesicles (Figure 5.19B). By comparison Sppl2a-/- Flt3-L bone 
marrow cultures on day 4 already contained significant amounts of p8-CD74, 
whereas p31 and p10 were present in much lesser quantities and progressively 
increased from day 4 through until day 7. From day 8 onwards p31, p41 and p10 
suddenly became more abundant, which also saw p8 bands noticeably increasing in 
size. Thus N-terminal CD74 immunoblotting of developing Sppl2a-/- FL-DC cultures 
showed, that p8-CD74 was present from as early as day 4 during DC development. 
Overall CD74 abundance saw a sudden increase from day 7 to day 8, which 
coincided with the loss of N-terminal CD74high cells in these cultures (Figure 5.18A). 
Additional removal of MHCII α chains in Sppl2a-/- H2-Aa-/- bone marrow cultures 
did not change this CD74 expression pattern, aside from the loss of accumulating 
p22-CD74 intermediates (Figure 5.20). Noticeably, p10-CD74 persisted in the 
absence of MHCII α chains, even when SPPL2A was functional in H2-Aa-/- FL-DC 
cultures. Lysates from these cultures also displayed more pronounced p31 and p41-
CD74 from day 6 onwards, which was consistent with increasing total N-terminal  
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Figure 5.20: Early accumulation of p8-CD74 in 
developing Sppl2a-/- DC of Flt3-L bone marrow cultures is 
independent of MHCII and similar to p10-CD74 
accumulation in developing Ctss-/- DC 
 
Immunoblots for N-terminal CD74 (IN1) on 25 000 cell 
aliquots collected of day 4, 6, 7, 8 and 9 Flt3-L bone marrow 
cultures that have been prepared from mice of the indicated 
genotypes. Membrane was stripped and re-probed with 
antibody against α/β-Tubulin. Samples for these blots were 
isolated from the same experiment presented in the previous 
two figures. 
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CD74 levels measured by flowcytometry (Figure 5.18B). Cathpesin S-deficient Flt3-
L bone marrow cultures produced strongly increasing amounts of p10 from day 4 
onwards, with increasing band sizes for p31, p41, p22 and p18, following a 
progressively increasing pattern from day 4 to day 9  (Figure 5.20), reflecting 
increasing CD74 levels overall (Figure 5.18B). Since equal cell numbers were used 
for each aliquot and the percentage of developing DCs was comparable between 
genotypes (Figure 5.19A), these CD74-immunoblots provided a good approximation 
of relative CD74 metabolism on a per cell basis in each culture. 
 
Taken together, SPPL2A was required for cDC development in vivo, but 
unexpectedly Flt3-L dependent FL-DCs generated from bone marrow cultures in 
vitro developed normally in the absence of SPPL2A. This occurred in spite of p8-
CD74 fragment accumulation in Sppl2a-/- FL-DCs, something that was previously 
shown to be causative of B cell (Chapter 3.5) and DC deficiency (Chapter 5.2) in 
mice lacking SPPL2A. Quantification of total N-terminal CD74 protein in 
developing Sppl2a-/- FL-DC cultures showed that cells accumulating high levels of 
CD74 were lost from SPPL2A-deficient bone marrow cultures. Whilst these findings 
are preliminary and require further investigation, they did indicate that the toxic 
effects of accumulating p8-CD74 might have been dose or maturation-stage 
dependent, and selected for development of more immature Sppl2a-/- FL-DCs with 
lower p8 levels to persist in this system.  
 
5.4 SPPL2A deficiency in dendritic cells hinders antigen presentation on 
MHC class II  
SPPL2A-deficient mice exhibited profound humoral immunodeficiency and were 
unable to produce antibody responses following immunisation with T cell-dependent 
model antigens. Dendritic cells are necessary to initiate CD4+ T cell help, by 
processing and presenting antigen on MHCII molecules (Heath and Carbone, 2009, 
Roche and Furuta, 2015). Sppl2a-/- mice were characterised by a B cell survival 
defect, inability to form germinal centres, and a lessened ability for B cells to 
activate, suggesting that SPPL2A-deficient B cells were unable to develop into 
antibody producing plasma cells. However, SPPL2A-deficient mice also exhibited 
dendritic cell defects, specifically of the CD8- cDC subsets known to be more 
efficient antigen presenters on MHCII molecules as opposed to the more effectively 
cross presenting CD8+ DC subset (Pooley et al., 2001, Schnorrer et al., 2006). 
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Therefore, DC defects and their ability to elicit T cell help by antigen presentation 
could contribute to humoral immunodeficiency in Sppl2a-/- mice, prompting an 
analysis of the antigen processing and presentation ability of DCs in these animals. 
 
To test whether the accumulation of p8-CD74 fragments in endosomal membrane 
structures in SPPL2A-deficient DCs interfered with their ability to present antigen 
and thus to fulfil their role as antigen presenting cells, mixed T cell-DC cultures were 
prepared and incubated in the presence of model antigens. To use the established 
ovalbumin recognising OT-I and OT-II T cell transgenic antigen presentation system 
(Schnorrer et al., 2006), soluble ovalbumin (sOVA), cell associated antigen (OVA 
coated splenocytes, OCS) or MHCI (OVA257-264 OT-I peptide) and MHCII (OVA323-
339  OT-II peptide) presentable ovalbumin peptides were used as antigens in this 
model, as shown in Figure 5.21.  
 
Presentation of ovalbumin (OVA) to OTI or OT-II transgenic T cells requires DCs to 
endocytosis and proteolyse the sOVA protein. DCs then load OVA derived peptides 
onto MHCII or MHCI and present peptide-MHC complexes with the right co-
stimulation on the cell surface to OTI or OT-II transgenic T cells. To test whether 
p8-CD74 fragments in endosomal membrane structures in SPPL2A-deficient DC 
interfered with presentation of OVA, dendritic cells were sorted flowcytometrically 
from the spleens of wildtype or Sppl2a-/- mice and co-cultured with proliferation dye 
carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled TCR-transgenic T 
cells, that recognised the chicken-OVA epitopes either in the context of MHCI (OT-I 
CD8+ T cells) or MHCII (OT-II CD4+ T cells). Thus OVA was added as model 
antigen to the cultures, which allowed testing of OVA processing and presentation of 
the OT-I peptide on MHCI or presentation of OT-II peptide on MHCII to OT-I or 
OT-II transgenic T cells respectively. If dendritic cells presented antigen 
successfully, T cells would respond with vigorous proliferation within 60 hours. 
Therefore OT-I or OT-II T cell CFSE-dilution was used to measure proliferation and 
to calculate the number of proliferated T cells as readout of how effectively DCs in 
the cultures presented antigen. The methodology of this OT I or OT-II transgenic T 
cell based assay to test the capacity of DCs to present antigen in vitro is explained in 
more detail in Chapter 2.4.4.. 
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The graphs in Figure 5.22 show measurements of OT-I and OT-II transgenic T cell 
proliferation in cultures with sorted CD11c+MHCII+ spleen DC from wildtype or 
Sppl2a-/- mice and soluble OVA, OVA coated splenocytes (OCS) and OT-I or OT-II 
OVA peptides that can be presented directly. SPPL2A-deficient spleen DCs had a 
similar capacity to induce CD8+ OT-I T cell proliferation as wildtype DCs (Figure 
5.22A). Sppl2a-/- DCs were able to induce normal proliferation of MHCI-OT-I-
peptide recognising CD8+ OT-I T cells using soluble protein (OVA), cell membrane 
associated antigen (OCS) or small soluble OT-I peptides as the source of antigen. 
Since OT-I T cells only recognise peptide bound to MHCI molecules, this 
observation showed that Sppl2a-/- DC could internalise exogenous antigen along the 
endocytic pathway for proteolysis and transfer resulting peptides across to MHCI 
molecules, indicating that p8-CD74 accumulation did not interfere with soluble 
antigen cross-presentation. In contrast, Sppl2a-/- DCs could not process soluble or 
cell associated OVA for loading onto CD74-chaperoned MHCII molecules and 
present OT-II peptides to CD4+ OT-II TCR transgenic T cells (Figure 5.22B and C). 
As direct loading of surface MHCII did result in OT-II T cell proliferation (Figure 
5.22B), it appeared that Sppl2a-/- DCs could provide T cell co-stimulation, but were 
unable to internalise, process or transport antigen. These data revealed that SPPL2A-
deficiency in DCs interferes with their ability to process and present antigen on 
MHCII molecules, but not with cross-presentation of exogenous antigen on MHCI. 
 
It is important to analyse the different DC subpopulations individually because they  
are known to have different abilities to activate antigen specific T cells, depending 
on the type of antigen presentation. CD8+ DCs are thought to be particularly good at 
cross-presenting exogenous antigen on MHCI, whereas both CD8+ and CD8- DCs 
efficiently present exogenous antigen on MHCII (Joffre et al., 2012). Since p8-CD74 
accumulation in these lymphoid resident DC subsets caused a loss of CD8-, but not 
CD8+ DCs, it was examined whether the blockage of MHCII antigen presentation by 
the lack of SPPL2A was restricted only to CD8- DCs. Flowcytometrically sorted 
CD8+ and CD8- CD11c+MHCII+ DC subsets from spleens of wildtype or Sppl2a-/- 
mice were tested for their ability to present antigen and induce T cell proliferation 
(Figure 5.23). Sppl2a-/- CD8+ DCs were able to cross-present soluble protein to CD8+ 
OT-I T cells, by processing exogenous soluble OVA and then presenting OT1-
peptide-MHCI on the cell surface, driving T cell proliferation over a range of antigen 
concentrations (Figure 5.23A).  
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Figure 5.22: SPPL2A is required by dendritic cells for 
antigen presentation on MHC II, but not MHC I 
 
A. Graphs show number of proliferated OT-I transgenic CD8+ 
T cells after 60h co-culture with either FACS sorted wildtype 
(Sppl2a+/+, black circles) or Sppl2a-/- (green circles) CD11c
+MHCII+ cDC in the presence of titrated quantities of soluble 
ovalbumin (sOVA), OVA-coated MHCI-deficient splenocytes 
(OCS) or SIINFEKL OT-I-peptide as source of the model 
antigen. Graphs are mean with SD-bars. 
B. Graphs show the number of proliferated OT-II transgenic 
CD4+ T cells after 60h co-culture with cDC in the presence of 
titrated quantities of sOVA, OVA-coated MHCII-deficient 
splenocytes (OCS) or OT-II peptide as source of antigen. 
Graphs are mean with SD-bars. 
C. FACS histograms illustrating CFSE dilution of proliferated 
OT-II CD4+ T cells co-cultured 60 h with either wildtype 
(Sppl2a+/+) or Sppl2a-/- CD11c+MHCII+ cDC in the presence of 
31.25ng/ml soluble OVA. Data taken from same analysis 
shown in panel B. 
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Figure 5.23: Both conventional spleen DC subsets, CD8+ 
and CD8- DC require SPPL2A to present antigen on 
MHCII 
 
A. Graphs show the number of proliferated OT-I CD8+ T cells 
after 60h co-culture with FACS sorted Sppl2a+/+ (black 
circles) or Sppl2a-/- (green circles) CD8+ cDC in the presence 
of titrated quantities of soluble OVA or SIINFEKL peptide as 
antigen source. Graphs are mean with SD-bars. 
B and C. Graphs show the number of proliferated OT-II CD4+ 
T cells after 60h co-culture with CD8+ (B) or CD8- (C) cDC 
subset of the indicated genotype in the presence of titrated 
quantities of soluble OVA or OT-II-peptide as antigen source. 
Graphs are mean with SD-bars. 
D. FACS histograms illustrating CFSE dilution of proliferated 
OT-II CD4+ T cells co-cultured 60 h with Sppl2a+/+ or Sppl2a-/- 
CD8+ cDC in the presence of 0.25mg/ml soluble OVA. Data 
taken from same analysis shown in panel B. 
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Although CD8+ DCs retained their ability to cross present when SPPL2A was 
absent,they did not induce proliferation of MHCII recognising OT-II CD4+ T cells 
following a pulse with titrated concentrations of soluble OVA (Figure 5.23B). The 
same was true for Sppl2a-/- CD8- DCs, which showed a reduced ability to drive 
antigen specific CD4+ T cell proliferation, however, they were normally competent 
to do so, when OT-II peptide was provided for direct presentation on a pre-existing 
surface MHCII pool (Figure 5.23C). Sppl2a-/- CD8+ DCs could not drive peptide-
MHCII dependent CD4+ T cell proliferation to the extent observed when wildtype 
CD8+ DC were co-cultured with OT-II T cells. The difference of CFSE-dilution in 
proliferating OT-II T cells during co-culture with OVA-pulsed CD8+ DC from either 
wildtype of SPPL2A-deficient mice is shown in Figure 5.23D. These results 
confirmed that SPPL2A-deficent DCs were impaired MHCII antigen presenters, 
which was true for both CD8+ and CD8- cDC subsets. 
 
The generally normal levels of T cell proliferation following specific antigenic 
peptide exposure in the presence of SPPL2A-deficient DC suggested that activation 
and co-stimulation necessary for MHCII antigen presentation to T cells was 
functional. Yet, a deficit in this regard might have existed in Sppl2a-/- CD8+ DCs. To 
test if CD8+ DCs require SPPL2A for normal cell activation, cDC equivalent CD24+ 
(CD8+) and Sirp-α+ (CD8-) subsets from Flt3-L bone marrow cultures were 
generated to ensure sufficient cell numbers for in vitro DC activation cultures. Plots 
in Figure 5.24 show that CD24+ and Sirp-α+ Sppl2a-/- FL-DCs normally up-regulated 
surface levels of CD69, CD103 and MHCII following 24 hours of treatment with 
GM-CSF, LPS or CpG, suggesting that SPPL2A-deficient DCs responded normally 
to these stimuli. However, given the differences between Sppl2a-/- spleen cDCs and 
FL-DC, normal DC activation in the absence of SPPL2A needs to be further verified 
by using spleen derived DCs and also by measuring levels of other surface molecules 
necessary to form functional immunological synapses at the DC-T cell interface, 
such as CD40, ICAM1 and CD80/CD86 (Huppa and Davis, 2003). 
 
Sppl2a-/- DCs appeared competent in presenting peptides directly to CD4+ T cells, 
but the processes necessary for peptide-MHCII expression on the DC surface were 
impaired. Peptide-MHCII expression on the DC surfaces, requires uptake of antigen 
into acidified endosomes and activation of endo-/lysosomal enzymes to generate a 
repertoire of presentable peptides (Figure 5.25A). The resulting peptide pool is  
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Figure 5.24: SPPL2A deficient FL-DC normally up-
regulate CD69, CD103 and MHCII following stimulation 
 
A and B. Surface CD69, CD103 and MHCII histograms of 
day 9 Flt3-L bone marrow culture derived CD24+ (A) or   
Sirpα+ (B) DC of the indicated genotype, that have been 
stimulated for 24h with GM-CSF, LPS or CpG. 
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consistently sampled by MHCII-CLIP complexes, which rely on the help of H2-M to 
replace CLIP and load peptide. At last peptide-MHCII is transported to the cell 
surface for presentation to CD4+ T cells via formation of endosomal-lysosomal 
membrane tubes and vesicles to fuse with the surface membrane (Roche and Furuta, 
2015). Here it was examined whether Sppl2a-/- DC were able to execute the early 
steps in the process of antigen uptake in preparation for presentation on MHCII 
(Figure 5.25). To test if Sppl2a-/- DC were able to normally endocytose soluble 
antigen through the unspecific process of macropinocytosis, CD11c+MHCII+ 
wildtype or Sppl2a-/- spleen DCs were cultured in media with OVA that was labelled 
with the pH-resistant fluorescent dye Alexa-488 (A488). After 30 minutes at 37°C, 
flowcytometric analysis of DCs that were allowed to endocytose OVA-A488 in 
comparison to cells that were kept on ice and therefore were unable to endcytose 
OVA-A488 showed that wildtype and Sppl2a-/- DCs had internalised similar amounts 
of OVA-A488 (Figure 5.25B). 
 
This same approach was then employed to test other aspects of early antigen uptake 
and processing. OVA was used as carrier protein and linked with different types of 
fluorescent dyes to allow measurement of increasing endosomal acidification (FITC) 
and proteolytic breakdown of endocytosed antigen (DQ-OVA). FITC fluorescence is 
pH sensitive and is lost with decreasing pH. Feeding FITC-labelled OVA to DCs 
showed that over 4 hours of chase FITC-fluorescence was lost at similar rates in 
wildtype and Sppl2a-/- DCs, and indicated that SPPL2A-deficient DCs were able to 
acidify endocytic vesicles (Figure 5.25C).  
 
Differentiation of spleen DCs in their subsets CD8+ and CD8-, confirmed that 
antigen uptake with OVA-A488 was functional in both SPPL2A-deficient subsets 
(Figure 5.25D). The same was true for endocytic acidification required to initiate 
proteolytic activity and degradation of endocytosed antigen in DCs pulsed with DQ-
conjugated OVA (Figure 5.25E). DQ-OVA is a self-quenching conjugate, which 
releases fluorescence following proteolytic break down of the molecule and thus 
provides a functionally relevant measure of endocytic acidification and proteolysis.  
 
These experiments suggest that SPPL2A-deficient DCs, despite clear disturbances in 
CD74-metabolism, were capable of endocytosis and proteolytic degradation of 
internalised protein antigen. Since early steps in antigen processing appeared to  
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function normally in Sppl2a-/- DCs, and considering that p8-CD74 accumulation 
alters the membrane structure of the MIIC, it is likely that SPPL2A-deficiency 
interferes with H2-M dependent MHCII peptide loading in this membrane 
compartment. The ability of Sppl2a-/- DCs to normally form peptide-MHCII 
complexes could be tested by assessing the presence of SDS-stable peptide-MHCII 
in non-heated MHCII-immunoprecipitates from SPPL2A-deficient DC lysates. 
 
5.5 Sppl2a-/- steady state monocyte and macrophage populations develop 
normally 
As shown in Figure 5.1A, monocytes and macrophages are other antigen presenting 
cells aside from B cells and DCs that express considerable levels of Cd74 mRNA. 
Thus, it seemed likely that at least MHCII expressing monocytes and macrophages 
would also require SPPL2A activity to successfully degrade CD74-transmembrane 
fragments and successfully populate lymphoid organs. To test whether the steady-
state myeloid cell compartment in SPPL2A-deficient mice was normally developed, 
bone marrow and spleen cells were isolated from wildtype, Sppl2a+/- and Sppl2a-/- 
mice and flowcytometrically separated into CD11b+ granulocyte, monocyte and 
macrophage subsets (Figure 5.26 and 5.27). Plots in Figure 5.26A show that Sppl2a-/- 
bone marrow contained normal proportions of Ly6GhiGr1hiSSCint neutrophils, 
Ly6CintGr1intSSChi eosinophils, and Ly6Clo-negGr1lo-negSSClo non-classical or 
Ly6ChiGr1hiSSClo classical monocytes and macrophages, with no changes in surface 
MHCII and full length C-terminal CD74 expression (Figure 5.26B). These myeloid 
cell populations also existed with normal percentages in SPPL2A-deficient spleen 
cell suspensions (Figure 5.27A), likewise expressing surface MHCII and CD74 
comparably to wildtype counterparts (Figure 5.27B).  Phenotypically normal 
myeloid cells in the spleen and bone marrow of Sppl2a-/- mice suggested that 
SPPL2A was not required for the maintenance of macrophage and monocyte 
populations. Nonetheless, the macrophage and monocyte system is known: to be of 
great plasticity; to variedly respond to infections or injuries; and to generate 
overlapping tissue resident and recirculating cells that seed inflamed or damaged 
tissues (Lavin et al., 2015). In response to environmental cues, monocytes and 
macrophages adopt distinct macrophage or dendritic cell-like characteristics and it 
might only be under these environmental conditions that a requirement for SPPL2A 
emerges. The slowly unravelling diversity of this innate phagocytic cell system  
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Figure 5.26: SPPL2A is dispensable for development of 
myeloid cells in the bone marrow 
 
A. Flow cytometric plots and percentages of myeloid cell 
subsets in the bone marrow of wildtype (Sppl2a+/+), 
heterozygous Sppl2a deficient (Sppl2a+/-) and Sppl2a-/- mice. 
In the second and third column four myeloid cell populations 
can be distinguished: 1.) Ly6GhiGr1hiSSCint neutrophils, 2.) 
Ly6CintGr1intSSChi eosinophils, 3.) Ly6Clo-negGr1lo-negSSClo 
non-classical or  4.) Ly6ChiGr1hiSSClo classical monocytes 
and macrophages. Pre-gating strategies are above columns. 
B. Overlay histograms showing MHCII and C-terminal CD74 
(JV11) surface expression on Ly6Clo-negGr1lo-negSSClo and  
Ly6ChiGr1hiSSClo myeloid cell subsets in the bone marrow of 
mice with the indicated Sppl2a genotype. 
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Figure 5.27: SPPL2A is not required to maintain myeloid 
cell populations other than DC in the spleen 
 
A. Flow cytometric plots and percentages of myeloid cell 
subsets in spleens of wildtype (Sppl2a+/+), heterozygous 
Sppl2a deficient (Sppl2a+/-) and Sppl2a-/- mice. In the second 
and third column four myeloid cell populations can be 
distinguished: 1.) CD11bhiCD11cnegLy6Ghi-intGr1hiSSCint 
neutrophils, 2.) CD11bhiCD11cnegLy6CintGr1intSSChi 
eosinophils, 3.) CD11bintCD11cintLy6Clo-negGr1lo-negSSClo non-
classical or 4.) CD11bhi-intCD11cnegLy6ChiGr1intSSClo classical 
monocytes and macrophages. Pre-gating strategies are 
provided above each column. 
B. Overlay histograms showing MHCII and C-terminal CD74 
(JV11) surface expression on Ly6Clo-negGr1lo-negSSClo and  
Ly6ChiGr1hiSSClo myeloid cell subsets in spleens of mice with 
the indicated Sppl2a genotype. 
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suggests that further investigations into the potential roles of SPPL2A in 
macrophages and monocytes are certainly warranted. 
 
5.6 Chapter summary  
In summary, this chapter showed that the intramembrane protease SPPL2A was 
required for both DC development and their ability to present antigen on MHC class 
II. SPPL2A-deficient mice had normal CD11b+ macrophage and monocyte 
populations, but the DC compartment was abnormal. Specifically, SPPL2A-deficient 
mice lacked CD8- cDCs and had increased numbers of pDCs, yet  CD8+ cDCs were 
present at normal numbers. Both cDC types were characterised by low CD11c 
surface expression, whilst CD8- cells had increased sMHCII, and CD8+ cells had 
high CD74 surface levels. Additional deletion of the MHCII α chain reduced surface 
expression of CD74 on Sppl2a-/- CD8+ cDCs to normal levels and thus further 
highlighted a differential roles for MHCII in CD74 trafficking in CD8+ and CD8- 
cDC subsets. The underlying cause for DC-deficiency in the absence of SPPL2A was 
the excessive endosomal accumulation of small 8kD CD74 membrane fragments, as 
SPPL2A-CD74-doubly deficient DCs had restored CD11c levels and CD8- subset 
numbers, and DCs developed indistinguishably from CD74-singly deficient DCs. 
The loss of MHCII α chains did not correct p8-CD74 accumulation and low CD8- 
DC numbers overall, demonstrating that p8-CD74 production was independent of 
CD74-MHCII chaperoning and that the DC-deficiency had mechanistic similarities 
to Sppl2a-/- B cells loss. 
 
Sppl2a-/- bone Flt3-L bone marrow cultures are known to produce CD8+ and CD8- 
cDC equivalent FL-DC subsets. Sppl2a-/- FL-DC cultures produced fewer DCs, but 
unexpectedly had normal CD11c, CD24 and Sirp-α expression and all subsets 
developed at normal proportions, despite p8-CD74 peptide accumulation. Selective 
loss of FL-DC with high intracellular CD74 accumulation levels from these cultures 
could explain the relatively normal phenotype of remaining Sppl2a-/- DCs. 
 
Functionally, SPPL2A-deficiency interfered with the ability of spleen DCs to process 
and present antigen on MHC class II to CD4+ T cells, but not with MHCI associated 
cross-presentation of exogenous antigen to CD8+ T cells. SPPL2A was critical for 
key populations of antigen-presenting DCs and therefore, the DC deficit likely 
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contributed to the profound humoral immunodeficiency observed in mice lacking 
SPPL2A activity. 
 
Finally, with these findings I show that the non-redundant cell survival requirement 
for CD74 proteolysis by SPPL2A extends beyond B cells to include DCs. SPPL2A 
was also necessary for successful MHCII antigen presentation in DCs. Thus, I 
discovered a critical role for regulated intramembrane proteolysis across multiple 
levels of humoral immunity. 
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Chapter 6: General Discussion 
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6.1 Key findings in relation to aims of this study 
B cell development is crucial to achieve antibody-mediated immunity and is one of 
the most thoroughly investigated cell-developmental systems in mammals, yet our 
understanding of this process is still far from complete (Nutt and Kee, 2007, Bryder 
and Sigvardsson, 2010). This study set out by focussing on three aims to understand 
SPPL2A-deficiency as a previously unknown mechanism to interfere with B cell 
development. The first aim was to characterise B cell deficiency in mice with an 
ENU-mutagenesis induced inactivating splice-site mutation in Sppl2a. SPPL2A-
deficient mice exhibited profound humoral immunodeficiency and specifically 
lacked transitional T2 and mature B cells, as well as CD8- DCs. Residual mature B 
cells in these mice were characterised by low surface IgM, IgD and BAFFR 
expression. Mature B cell survival but not low surface BAFFR and BCR expression 
could be rescued by over-expression of the pro-apoptotic protein BCL2. 
 
The second aim could be resolved by identifying the causative mechanism 
responsible for the observed lack of mature B cells and DCs in SPPL2A-deficient 
mice. The findings in this thesis revealed SPPL2A as the previously unknown 
intramembrane protease responsible for the final cleavage of CD74 (Lipp and 
Dobberstein, 1986a). The absence of CD74-cleaving SPPL2A caused an intracellular 
accumulation of ~8kD N-terminal CD74 membrane fragments. This build-up of p8-
CD74 fragments was responsible for the cellular phenotype of B cells and DCs in 
Sppl2a-/- mice, as additional deletion of CD74 in these animals reconstituted mature 
B cell and DC numbers to levels seen in mice solely lacking CD74, and also restored 
surface expression of BAFFRs and BCRs.  
 
The third aim was to use the Sppl2a-/- mouse model in order to expand our 
understanding of B cell biology and crosses with Cathepsin S or MHCII α chain-
deficient mice provided insights into a potential role for SPPL2A. Despite the 
discovered role for SPPL2A in CD74 metabolism, the intramembrane protease 
seemed disconnected from the classically known sequence of step-wise CD74 
degradation in B cells, because p8-CD74 build-up was independent of Cathepsin S 
activity and CD74 chaperoning with MHC class II αβ dimers. Cathepsin S did not 
contribute to the production of p8-CD74 fragments, which persisted at unchanged 
levels in B cells from Sppl2a-/-Ctss-/- mice. It was also found that immature bone 
marrow B cells from Sppl2a-/- mice already accumulated p8-CD74. In contrast, 
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T1/T2 transitional spleen B cells, but not immature bone marrow B cells from 
Cathepsin S-deficient mice accumulated increased CD74 levels This indicating that 
CD74 processing by SPPL2A occurs before Cathepsin S during B cell development 
and could explain why Cathepsin S is not required to produce p8-CD74 fragments. 
The finding that p8-CD74 accumulates in Sppl2a-/- B cells at an earlier 
developmental stage than the occurrence of mature B cell loss from T2 onwards, 
indicates that the previously unknown capability of CD74 to cause cell survival 
defects might be linked to BCR driven processes, as explained later in the discussion. 
Apart from functions in B cells, SPPL2A-deficiency further revealed a cell biological 
situation that produces differences in the handling of CD74 and MHCII trafficking 
between cross-presenting dominant CD8+ and MHCII presentation dominant CD8- 
DC subsets. 
 
Taken together, the characterisation of an ENU-mutagenesis derived SPPL2A-
deficient mouse model in this thesis revealed an unprecedented in vivo role for the 
intramembrane protease SPPL2A in the survival of developing B cells and CD8- 
DCs. In this study CD74 was identified as a new SPPL2A in vivo substrate and a 30-
year old proposition for a role of intramembrane proteolysis in CD74 biology (Lipp 
and Dobberstein, 1986a) as well as a suspected relevance for this process in 
developing B cells was resolved. 
 
6.2 SPPL2A is required for B cell survival 
SPPL2A-deficient B cells were characterised by low surface expression of BCR and 
BAFFR. BCR and BAFFR signalling are both required for survival and 
accumulation of mature B cells in peripheral lymphoid organs as B cells with 
impaired BCR or BAFFR signal fail to survive. This suggested that low BCR and 
BAFFR could reduce tonic survival signalling in T2 and mature B cells needed to 
suppress intrinsic apoptosis, and as a result SPPL2A-deficient B cells might succumb 
to a survival defect, rather than a developmentally programmed arrest. This 
assumption was tested by forced overexpression of the anti-apoptotic protein BCL2, 
which is needed to block the intrinsic mitochondrial apoptosis pathway by inhibiting 
BAX and BAK in B cells (Takeuchi et al., 2005, Youle and Strasser, 2008, Tait and 
Green, 2010). Forced overexpression of BCL2 resulted in a specific rise of CD93-
IgM-CD62L+ mature B cell numbers, notably also in lymph nodes, which thus 
increased the ratio of mature cells to immature CD93+IgM+CD62L- B cells in 
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Sppl2a-/-Vav-Bcl2 mice. The numbers of Sppl2a-/-Vav-Bcl2 mature B cells were 
greater than in non-transgenic wildtype, but nevertheless lower than in wildtype Vav-
Bcl2 mice, which implied that rescue of B cell accumulation by BCL2 did not render 
the B cells independent of the need for SPPL2A activity. BCL2 is known to slow, 
but not completely block BAX/BAK-induced apoptosis in B cells when relevant 
survival signals are withheld, as BAFFR-deficiency (Rahman and Manser, 2004), 
BAFF-blockade (Tardivel et al., 2004) or loss of the BCR (Lam et al., 1997) all 
lessen the accumulation of mature B cells in Bcl2 transgenic mice. These studies also 
showed that BCL2 did not substitute for maturation signals delivered by the BCR 
and BAFFR, resulting in the persistence of an immature B cell phenotype. This could 
explain why CD93-IgM-CD62L+ mature B cell numbers in in Sppl2a-/-Vav-Bcl2 mice 
were still lower than mature B cell numbers in wildtype transgenics. Taken together, 
these results confirmed that SPPL2A-deficient mature B cells were lost due to a 
survival defect, rather than a developmental block, as BCL2 overexpression rescued 
the survival of Sppl2a-/- B cells that would have otherwise died. The interpretation 
that the absence of SPPL2A did not block a genetic developmental program, but 
rather interfered with B cell survival was confirmed by microarray measurements of 
transcriptionally normal regulation for key transitional B cell maturation genes, such 
as Zfp318, Cr2, Tnfrsf13c and Nfkb2. Despite the Vav-Bcl2 transgenes ability to 
improve Sppl2a-/- B cell survival, surface expression of IgM, IgD and BAFFR 
remained low, which additionally demonstrated that activation of the intrinsic 
BAX/BAK mitochondrial apoptosis pathway was not responsible for diminished 
BCR and BAFFR surface expression. 
 
6.3 Low surface expression of BCR and BAFFR in Sppl2a-/- B cell survival 
Based on these conclusions it is tempting to hypothesise that low BCR and BAFFR 
levels were indeed responsible for B cell deficiency in Sppl2a-/- mice, and therefore, 
if BCR or BAFFR signals could be re-instated than SPPL2A-deficient B cells should 
survive and mature normally. It has been found that the BCR signalling pathway in 
SPPL2A-deficient B cells is inhibited (Huttl et al., 2015), which could be due to an 
unknown intrinsic block of signal transduction, or simply the result of reduced BCR 
stimulation due to reduced surface BCR expression. Both, the BCR (Kurosaki, 1999, 
Pasparakis et al., 2002b, Siebenlist et al., 2005, Srinivasan et al., 2009, Werner et al., 
2010, Rickert, 2013) and the BAFFR (Senftleben et al., 2001, Claudio et al., 2002, 
Kayagaki et al., 2002, Mackay and Schneider, 2009, Baracho et al., 2011, Jellusova 
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et al., 2013) engage downstream pathways mediated by PI3K and AKT to suppress 
pro-apoptotic FOXO1 transcription, as well as IKK regulated NFκB transcription of 
pro-survival factors, including BCL2. Experimental systems that ablate critical BCR 
or BAFFR pathway components and then reconstitute activity of either PI3K or 
NFκB signalling downstream of these receptors were able to show that enforced 
PI3K-pathway activity compensated for the deficiency of BCR and BAFFR 
(Srinivasan et al., 2009, Jellusova et al., 2013), whilst activation of canonical IKK 
driven NFκB signal only corrected the loss of BAFFR, but not that of the BCR 
(Sasaki et al., 2006, Srinivasan et al., 2009). On one hand BAFFR mimicking NFκB 
signal would therefore seem necessary for mature B cell survival, but not sufficient 
to sustain B cell maturation on its own. On the other hand PI3K activity could 
perhaps be sufficient to support B cell maturation in the absence of the BCR and 
BAFFR. Analogous to this experimental approach, reconstitution of critical PI3K 
and/or canonical NFκB signal in Sppl2a-/- developing B cells would clearly 
demonstrate whether low BCR and BAFFR expression were mechanistically 
responsible for B cell deficiency in Sppl2a-/- mice. Whilst time limitations deferred 
the analysis of Sppl2a-/- mice with B cell specific expression of either a constitutively 
active P110α* subunit of PI3K (Srinivasan et al., 2009) or constitutively active 
IKKβ* (Sasaki et al., 2006) into the future, several results in this thesis still provided 
indications for the answer to the preceding question:  
 
Firstly, retroviral transduction of constitutively active IKK* (Rossi et al., 2011, 
Mercurio et al., 1997) into cultured Sppl2a-/- B cells did unexpectedly fail to facilitate 
proliferation, survival and induction of the NFκB target CD25 (Figure 3.24), which 
was consistent with the inability of LPS or α-IgM activated Sppl2a-/- B cells to 
respond with CD25 up-regulation (Figure 3.17). These observations suggest that 
SPPL2A is required for B cell responsiveness to canonical NFκB activation and that 
the absence of SPPL2A might generally block NFκB signals either from the BAFFR 
or the BCR, regardless whether they are present on the B cell surface or not. This 
interpretation would be consistent with similar B cell or CD8- DC deficiency in 
Sppl2a-/- mice and previously described mice with various types of blocked NFκB 
transcription (Franzoso et al., 1997, Wu et al., 1996, Grossmann et al., 1999, 
Grossmann et al., 2000, Claudio et al., 2002). 
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Secondly, immature and mature Sppl2a-/- B cells in the HEL-BCR transgenic model 
of B cell anergy responded with normal down-regulation of surface IgM upon BCR-
engagement with the soluble model self-antigen HEL (Figure 3.18 and 3.19). This 
implied that SPPL2A did not block BCR responsiveness required for B cell anergy 
and that at least some form of BCR signal must therefore still be functional in 
SPPL2A-deficient B cells. In fact, inactivation of PI3K is though to be a key 
determinant in the induction of anergic B cells (Browne et al., 2009, Yarkoni et al., 
2010), suggesting that Sppl2a-/- B cells exhibit sufficiently active BCR-PI3K signal 
to respond to inappropriate BCR-self-antigen binding by reducing BCR 
responsiveness and converting into PI3K-inhibited anergic cells (Zikherman et al., 
2012). As could be seen in immature CD93high Sppl2a-/- B cells that recognised the 
soluble model-self-antigen HEL (Figure 3.19), the IgM down-regulating anergy 
program was induced during an early stage of transitional B cell development, before 
SPPL2A-deficiency affected the B cell phenotype and their survival. This shows that 
the induction of anergy in developing Sppl2a-/- B cells occurred normally and implies 
that anergic Sppl2a-/- B cells would have successfully inactivated PI3K-BCR 
signalling as a result. Anergic B cells normally survive despite reduced PI3K-
signalling (Browne et al., 2009, Yarkoni et al., 2010), rendering them seemingly less 
dependent on PI3K signal to survive. If SPPL2A-deficient B cells fail to survive due 
to a lack of PI3K signalling, then it could be expected that anergic Sppl2a-/- B cells 
with reduced dependence on PI3K-signalling survive better. This should be 
measurable by increased relative survival of anergic Sppl2a-/- B cell proportions in 
mixed bone marrow chimeric mice (Figure 3.18 and 3.19). However, this was not the 
case, as induction of B cell anergy did not improve the survival of SPPL2A-deficient 
B cells, relative to non-anergic B cells (Figure 3.19). It could therefore be concluded 
that BCR signalling, or the reduced need for BCR signalling in anergic B cells, may 
not be capable to facilitate survival and maturation of SPPL2A-deficient B cells. 
 
Thirdly, global microarray analysis of gene expression profiles in resting Sppl2a-/- B 
cells did not reveal any changes in groups of genes that would be expected to show 
abnormal expression when BCR or BAFFR surface expression is lost during 
transitional B cell development (Figure 3.35 and 3.36), supporting a view of 
irrelevance for BCR and BAFFR expression in regards to SPPL2A dependent B cell 
deficiency. Nevertheless, it was unexpected to find no changes in BCR or BAFFR 
driven gene signatures of SPPL2A-deficient B cells considering the reduced surface 
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levels of BCR and BAFFR. This could be due to relatively mild signals through 
these receptors in resting B cells and repeating gene signature measurements in 
surface BCR and BAFFR stimulated B cells should reveal defects in Sppl2a-/- 
compared to wildtype B cells. 
 
Collectively, these results indicate that low surface BCR and BAFFR expression may 
not be responsible for B cell deficiency in Sppl2a-/- mice. It seems more likely that 
the loss of mature SPPL2A-deficient B cells is caused by an unknown patho-
mechanism related to endosomal accumulation of p8-CD74 fragments. Low BCR 
and BAFFR expression on Sppl2a-/- B cells thus appear to be a symptom of the p8-
CD74-related underlying problem and likely irrelevant for SPPL2A-deficient B cell 
survival. Consequently, it could be predicted that bypassing the need for surface 
BCR and BAFFR by constitutive activation of PI3K and canonical NFκB signalling 
in Sppl2a-/- B cells would not restore normal B cell maturation. This experimental 
approach should be able to resolve this ‘hen or egg’ conundrum of what is cause and 
what is symptom in SPPL2A-deficient B cells: Low surface BCR and BAFFR may 
cause a B cell survival defect, or a B cell survival defect may cause low surface BCR 
and BAFFR expression. 
 
6.4 CD74 intramembrane processing in B cell survival 
One of the central findings from this project was the discovery of CD74 as a new 
substrate for the endosomal intramembrane protease SPPL2A. Previously an in vivo 
role for SPPL2A was unknown, but as shown in this thesis SPPL2A must cleave 
small CD74 membrane fragments to ensure B cell and CD8- DC survival. In the 
absence of SPPL2A B cells and DCs accumulated 5-fold increased quantities of 
CD74 protein overall, of which around 80% consisted of small ~8kD N-terminal 
fragments (Figure 5.10). Consistent with the endosomal localisation of SPPL2A 
(Friedmann et al., 2006, Kirkin et al., 2007, Martin et al., 2008, Behnke et al., 2011), 
this demonstrated that SPPL2A is a crucial protease for endosomal membrane CD74 
processing and is normally responsible to degrade small 8kD N-terminal CD74 
fragments in B cells and DCs. 30 years ago Lipp and Dobberstein proposed that the 
CD74 transmembrane domain is potentially cleaved by an intramembrane protease 
(Lipp and Dobberstein, 1986a). This proposal was explored later in an attempt to 
explain a putative MHCII-chaperoning independent requirement of CD74 for B cell 
development (Matza et al., 2002b). The labile 42 amino acid cytosolic fragment of 
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CD74 that results from intramembrane cleavage of p8-CD74 has been suggested to 
serve as a transcriptional co-activator for NFκB signaling and B cell maturation 
(Becker-Herman et al., 2005), analogous to the final cleavage of the Notch 
intracellular domain (ICD) by γ-secretase (Aster et al., 2008, Selkoe and Kopan, 
2003). However, a conclusion that SPPL2A might act as reverse signalling 
intramembrane protease to release CD74 derived cytosolic pro-survival factors can 
be ruled out for several reasons: Firstly, the loss of T2 transitional B cells in 
SPPL2A-deficient B cells was greater than in the absence of CD74, indicating that 
the loss of the entire CD74 molecule is less problematic than the putative blockage of 
p8-CD74 cleavage in the absence of SPPL2A. Secondly, the additional removal of 
CD74 rescued the accumulation of T2 and mature B cells, as well as recovering 
surface B cell BCR and BAFFR expression in SPPL2A-deficient mice, rendering 
them indistinguishable from mice singly CD74-deficient (Figure 3.28 and 3.29) 
(Schneppenheim et al., 2013, Beisner et al., 2013). This demonstrated that the loss of 
SPPL2A protease activity accounted for the loss of mature B cells via accumulation 
of unprocessed p8-CD74, rather than SPPL2A providing a co-transcriptional B cell 
survival signal via the release of cytoplasmic CD74 fragments. Thirdly, it has been 
shown that B cell deficiency in CD74-lacking mice could be corrected by 
additionally removing MHCII β chains or all classical MHCII molecules (Benlagha 
et al., 2004, Maehr et al., 2004), or if the B cells carried an MHC II haplotype that is 
less dependent on CD74 chaperone activity (Zimmermann et al., 1999). This 
confirmed that unchaperoned MHCII is responsible for B cell deficiency in the 
absence of CD74, but not failure to release cytosolic CD74-N-terminal NFκB co-
transactivator by intrammebrane proteolysis. Nevertheless, despite the irrelevance of 
a putative N-terminal CD74 cytosolic fragment itself for B cell development, the 
SPPL2A mediated intramembrane cleavage step of CD74 is essential for B cell and 
DC survival. 
 
6.5 p8-CD74 accumulation causes B cell deficiency in Sppl2a-/- mice 
The key to understand the biological relevance of intramembrane proteases such as 
SPPL2A, is to know which substrates they target, where in the cell they access 
substrates and what the physiological or pathophysiological consequences of 
substrate processing are (Strisovsky, 2015). In this thesis CD74 has been identified 
as a new in vivo substrate for SPPL2A, but other type II transmembrane protein 
substrates for SPPL2A have been found in vitro, of which TNF-α(Fluhrer et al., 
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2006, Friedmann et al., 2006) and membrane FASL processing by SPPL2A (Kirkin 
et al., 2007) may be the most likely nominees to play a role in developing B cells. 
Additionally, other unknown SPPL2A substrates might have an effect on developing 
SPPL2A-deficient B cells as well. One of these candidates could be CD38, which 
has been identified here as a potential SPPL2A B cell substrate based on a 
transitional B cell specific expression pattern similar to CD74 and has also been 
shown by others to play a role in transitional and mature B cell survival (Rodriguez-
Alba et al., 2008). Nonetheless, TNF-α, FASL or CD38 degradation in SPPL2A-
deficient B cells has not been assessed during this study. Whilst impaired cleavage 
and subsequently blocked reverse signaling with accumulation of non-processed 
TNF-α and FASL protein fragments in Sppl2a-/- B cells seems likely, the biological 
relevance for compromised intramembrane proteolysis of these or any yet to be 
identified SPPL2A substrate to explain B cell deficiency in Sppl2a-/- mice is 
questionable. This view is based on the striking resemblance of the B cell phenotypes 
seen in CD74 singly deficient and SPPL2A-CD74 doubly deficient mice. 
Throughout this project and as investigated by others, Sppl2a-/-CD74-/- B cells were 
indistinguishable from Cd74-/- B cells and whenever tested, no CD74-independent 
defects that would suggest a role for other SPPL2A-substrates in developing B cells 
were noticed (Schneppenheim et al., 2013, Beisner et al., 2013). Whilst it was 
therefore concluded that the endosomal accumulation of p8-CD74 membrane 
fragments in Sppl2a-/- B cells was the sole reason for B cell defects observed in 
SPPL2A-defcient mice, this has not been formally shown and needs to be considered 
as one of the limitations for this project. Recent identification of CD74’s molecular 
determinants for SPPL2A intramembrane cleavage (Huttl et al., 2016), will now 
permit to overexpress modified p8-CD74 fragments that cannot be cleaved by 
SPPL2A in B cells to deliver proof, as to whether overabundant p8 fragments can 
recapitulate the phenotype of SPPL2A-deficient B cells. Uncleavable p8 
overexpression in T cells or expression of CD74 in SPPL2A-deficient T cells would 
further allow to test whether p8 requires presence of the MIIC and BCR dependent 
antigen processing machinery to cause endosomal changes, loss of surface molecules 
and survival defects, or if these effects are linked to more universal and possibly 
unknown mechanisms that control membrane protein homeostasis. 
 
6.6 A two-step hypothesis: p8-accumulation causes endosome expansion, 
which causes B cell deficiency 
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B cell deficiency in Sppl2a-/- mice is caused by the failure to remove small 8kD N-
terminal CD74 endosomal membrane fragments through SPPL2A mediated 
intramembrane proteolysis, but how does accumulating p8-CD74 cause B cell 
deficieny? Apart from discovering p8 accumulation, a second key finding of this 
study was the detection of endosomal enlargement in SPPL2A-deficient B cells. It 
was therefore hypothesised, that p8 accumulation is connected with endosomal 
enlargement and that interferences with intracellular trafficking and endosomal 
biology may be responsible for the B cell defects observed in Sppl2a-/- mice. In other 
words, p8 might cause B cell deficieny in a two-step process: Firstly, p8-CD74 
accumulation causes endosomal changes, and secondly, these endosomal changes are 
then responsible for Sppl2a-/- B cell defects. 
 
To help understand why p8 accumulation could cause endosomal expansion and lead 
to the endosomal changes seen in this study, a brief review of the endocytic 
pathway’s general working principles and mechanism of normal membrane protein 
degradation are described. Endocytosed material, which can include membrane-
associated molecules, enters the endocytic pathway at the cell surface through 
various internalisation modes, which include actin dependent phagocytosis and 
membrane ruffling, clathrin-dependent endocytosis or clathrin-indpendent caveolae 
and STEM formation or yet other non-clathrin dependent endocytosis mechanisms 
(Maxfield and McGraw, 2004). Thereafter, the endocytic pathway can be divided 
into three interdigitating systems that organise transport of endocytosed cargo from 
the cell surface deeper into the cell and ultimately facilitates degradation, storage and 
recycling of nutrients and building blocks that sustain cellular life. Near the cell 
surface an early endosomal recycling machinery facilitates sorting and quality 
control of plasma membrane derived cargo, whilst a unidirectional ‘feeder system’ of 
gradually growing and morphologically evolving endosomes carries cargo towards 
the peri-nuclear lysosomal degradation machinery (Huotari and Helenius, 2011). 
Many additional vesicle transport pathways connected to this classical endocytic 
system exist and include direct exchange routes between the endocytic route and the 
trans-Golgi network (TGN) or feeding of cytoplasmic or organelle derived 
autophagosomes into endo-lysosomes relevant for antigen presentation (Huotari and 
Helenius, 2011, Roche and Furuta, 2015). 
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The cargo conveying and constantly maturing late endosomal vesicle system that 
connects the early recycling endosomes with the macromolecule digesting lysosomal 
‘stomachs’ of the cell undergoes dramatic changes to essentially convert early 
endosomes into safe membrane compartments that guard the interface of highly 
destructive subcellular spaces. These changes of maturing endosomes involve 
acquisition of new membrane and lysosomal components, increased acidification, 
enzyme activation and digestive activity, as well as formation of intraluminal 
vesicles (ILVs) that characterise the morphology of endosomes as constantly 
growing multivesicular bodies (MVBs) (Huotari and Helenius, 2011). ILVs fission in 
maturing endosomes is mediated by endosomal sorting complexes required for 
transport (ESCRT) (Hurley and Hanson, 2010). ILV formation is important for the 
degradation of membrane proteins and lipid membranes, but is also involved in 
regulation of signalling receptors (Sorkin and von Zastrow, 2009), such as the BCR. 
Degradation of endosomal membrane proteins typically occurs via ubiquitin-
dependent or independent sequestration into ILVs and subsequent lipid and 
glycoprotein modification to remove a protective glycocalix and permit lysis of the 
entire ILV inside the endo-lysosomal lumen (Piper and Katzmann, 2007, Piper and 
Luzio, 2007, Schulze et al., 2009, Li et al., 2015a). Finally, lysosomes represent the 
endpoint of the endocytic pathway and act as storage compartments for nutrients or 
re-usable enzymes and often contain multilamellar membrane structures thought to 
represent slowly degrading intraluminal membranes (Huotari and Helenius, 2011). 
 
In APCs, such as B cells and DCs, this classical endocytic pathway has evolved 
further to facilitate antigen presentation and allow sampling of sub-terminally 
degraded material for MHC loading and presentation to T cells. As explained in the 
introduction, many of these endosomal modifications are facilitated by specific 
sequences in CD74’s N-terminal cytoplasmic tail and help the biogenesis of a 
specialised endosomal MHC II containing antigen processing compartment referred 
to as MIIC (Landsverk et al., 2009). One of the most important CD74-driven 
adaptions of the endocytic pathway is slowing of the endosomal maturation and 
acidification process by inducing the formation of large intracellular vesicles in order 
to delay processing of endocytosed material when endosomes reach the lysosomal 
degradation system (Bakke and Dobberstein, 1990, Gedde-Dahl et al., 1997, 
Lagaudriere-Gesbert et al., 2002, Landsverk et al., 2009, Landsverk et al., 2011, 
Pieters et al., 1993, Romagnoli and Germain, 1994, Romagnoli et al., 1993, 
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Arunachalam et al., 1994, Gorvel et al., 1995, Stang and Bakke, 1997, Bakke and 
Nordeng, 1999, Boes et al., 2005). This is required to load peptides from the luminal 
digestive content onto MHCII molecules and to ensure the effective presentation of a 
diverse epitope-repertoire from the processed material. A second modification of the 
endocytic pathway is the prevention of ILV degradation. This is important, because 
H2-M mediated MHC class II loading with peptides seems to predominantly occur 
on intraluminal membranes, from which peptide-MHCII complexes are sorted back 
into the limiting MIIC-membrane and transported to the cell surface, through a 
process known as ‘backfusion’ (Zwart et al., 2005, van der Goot and Gruenberg, 
2006, Neefjes et al., 2011). However a contrasting view exists, by which all ILV 
associated MHCII, representing about 50% of the entire MHCII pool, is targeted for 
degradation (ten Broeke et al., 2011, ten Broeke et al., 2013). If peptide-MHCII from 
the ILV would be utilised for presentation by backfusion, there would need to be an 
ILV stabilising mechanism to prevent intraluminal ILV lysis and consequently loss 
of MHCII-peptide complexes, as proposed by ten Broeke and colleagues (ten Broeke 
et al., 2011). 
 
High CD74 expression levels in B cells and DCs suggest that large quantities of 
CD74 are constantly poured into the endocytic pathway (Figure 5.1)(Heng et al., 
2008). Considering that CD74 has the ability to profoundly slow late endosomal 
maturation and at the same time expand the MIIC compartment (Bakke and 
Dobberstein, 1990, Gedde-Dahl et al., 1997, Lagaudriere-Gesbert et al., 2002, 
Landsverk et al., 2009, Landsverk et al., 2011, Pieters et al., 1993, Romagnoli and 
Germain, 1994, Romagnoli et al., 1993, Arunachalam et al., 1994, Gorvel et al., 
1995, Stang and Bakke, 1997, Bakke and Nordeng, 1999, Boes et al., 2005), it seems 
likely that CD74-activity needs to be kept in check by an efficient removal 
mechanism. Here it was found that SPPL2A mediated removal of CD74 from 
endosomal membranes is critical for the survival of B cells and CD8- DCs. SPPL2A-
deficient B cells had increased SSC granularity (Figure 3.30), increased levels of 
intracellular LAMP1 staining (Figure 4.4 and 4.22) and ultrastructurally contained a 
greater number of vesicles (Figure 4.29) (Schneppenheim et al., 2013). Additional 
deletion of CD74 from B cells lacking SPPL2A reduced LAMP1-staining levels in 
Sppl2a-/-Cd74-/- doubly deficient B cells below levels seen in wiltype B cells and thus 
demonstrated that late endosomal changes represented by LAMP1 abundance in 
SPPL2A-singly deficient mice were indeed caused by accumulating p8-CD74 
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(Figure 4.22). Contrastingly, increased SSC granularity in IgD+ mature Sppl2a-/- B 
cells was not reduced in Sppl2a-/-Cd74-/- B cells analogous to diminished LAMP1 
levels (Figure 3.30). This can be explained by aggregates of unchaperoned MHCII 
known to accumulate in abnormal ER-cis-Golgi membrane compartments when 
CD74 is absent and are likely to increase cellular granularity (Bikoff et al., 1993, 
Viville et al., 1993, Elliott et al., 1994). Indistinguishably increased SSC and at the 
same time abnormally reduced LAMP1-protein levels in Sppl2a-/-Cd74-/- and Cd74-/- 
B cells showed that the absence of CD74 on one hand increased granularity of non-
endosomal membrane structures, likely the ER, whereas on the other hand the 
presence of CD74 was required to maintain a normally sized LAMP1+ late 
endosomal system. This finding emphasises the dose dependent regulatory influence 
that CD74 has on the endocytic pathway under steady state conditions in vivo. The 
increased counts of vesicle structures that were detectable by transmission electron 
microscopy (TEM) in Sppl2a-/- B cells sections, see Figure 4.29 and (Schneppenheim 
et al., 2013), have been shown by others to be dependent on CD74 expression as well 
(Schneppenheim et al., 2013). Taken together, this indicates that increased SSC 
granularity, LAMP1-protein levels and ultrastructural vesicle counts in Sppl2a-/- B 
cells were caused by the presence of abnormally accumulating p8-CD74 fragments.  
 
The interpretation that the accumulation of small N-terminal CD74 membrane 
fragments in the absence of SPPL2A is capable of expanding the size and membrane 
quantity of maturing late endosomes was further supported by findings in B cells 
lacking the CD74 cleaving endosomal protease Cathepsin S. Ctss-/- B cells 
accumulated excessive quantities of ~10kD sized N-terminal p10-CD74 fragments, 
which similar to Sppl2a-/- B cells caused increased intracellular LAMP1-protein 
levels. Boes and colleagues observed that endosomal expansion in Ctss-/- B cells 
could be reversed by additional deletion of CD74 in Ctss-/-Cd74-/- B cells (Boes et al., 
2005). Endosomal expansion in Ctss-/- B cells even seemed to affect B cell size 
overall, as increased FSC measurements for naive Ctss-/- B cells from the blood were 
found here (Figure 4.5C), whilst Boes and co-workers detected increased cell size of 
LPS stimulated Ctss-/- B cell blasts in culture (Boes et al., 2005). Mechanistically, it 
seemed that the expansion of the endosomal compartment in SPPL2A-deficient B 
cells was caused by p8-mediated slowing of endosomal maturation, inhibition of 
proteolysis and overshooting growth of the MIIC due to increased presence of N-
terminal CD74 fragments in endosomal membranes. Partial inhibition of Cathpesin S 
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by delayed or reduced endosomal maturation could explain co-accumulation of 
slightly larger p10-CD74 fragments along with p8 in B cells and more so in DCs, 
when SPPL2A was absent (Figure 5.10). From these observations it was concluded, 
that the first step of the hypothesised two-step process by which p8 might cause B 
cell deficiency in Sppl2a-/- mice was experimentally supported: p8-CD74 
accumulation in SPPL2A-deficient B cells causes enlargement of the endosomal 
membrane compartment. Quantities of N-terminal CD74 fragments in the endocytic 
pathway have to be kept in check by SPPL2A, similar to what has been proposed 
before for Cathepsin S (Boes et al., 2005), in order to prevent overshot slowing and 
growth of maturing endosomes. 
 
Whilst SPPL2A dependent p8 accumulation and endosomal changes seem to be 
connected, the second part of the two-step hypothesis, suggesting that p8-induced 
endosomal changes go on to cause Sppl2a-/- B cell defects, is less clear. If increasing 
intracellular quantities of N-terminal CD74 fragments are capable of enlarging 
LAMP1+ endosomal compartments excessively and if these changes would be able 
to cause survival defects in B cells, than Cathepsin S-deficient B cells should 
struggle to survive and fail to accumulate as mature cells in peripheral lymphoid 
organs. In this thesis and as suggested by others (Shi et al., 1999, Nakagawa et al., 
1999), it was shown that Ctss-/- B cells develop surprisingly normal. This was 
observed in Ctss-/- B cells despite endosomal expansion and p10-CD74 
accumulation, which was comparable to accumulating p8-CD74 levels in SPPL2A-
deficient B cells. The contradiction of this finding suggested that CD74-mediated 
endosomal expansion is not harmful for developing B cells and that p8-CD74 
induced endosomal changes in SPPL2A-deficient B cells were irrelevant for B cell 
survival. However, observations of reduced surface membrane protein expression 
levels, increased plasma membrane BCR internalisation rates, alterations of 
phosphatidylserine (PS) membrane lipid composition and increased numbers of 
vesicles with multilamellar membrane sheets in SPPL2A-deficient B cells imply an 
underlying factor that interferes with membrane biology of the endocytic pathway. 
Since p8-CD74 accumulation causes both, endosomal enlargement as well as B cell 
deficiency, and CD74 is a well established factor that profoundly modifies the 
endocytic pathway in B cells, it seems unlikely that p8-CD74 induced endosomal 
changes and B cell deficiency are independent of each other. 
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It nevertheless remains puzzling why the B cell compartment in Cathepsin S-
deficient mice develops normally whereas Sppl2a-/- mice lack mature B cells. N-
terminal CD74 fragments accumulating in Sppl2a-/- and Ctss-/- B cells were slightly 
different in that the smaller SPPL2A-dependent p8-CD74 fragment lacks the CLIP 
sequence and was not associated with MHC class II, whereas Cathepsin S-dependent 
p10 actually required association with MHCII to persist in Sppl2a-/- B cells (Figure 
4.21). Therefore differences in the endosomal changes induced by the loss of either 
SPPL2A or Cathepsin S could explain why Sppl2a-/- mice are B cell deficient and 
Ctss-/- mice are not. Indeed, flowcytometric comparison of the endosomal 
compartment in Sppl2a-/- and Ctss-/- B cells suggested that endosomes in Ctss-/- B 
cells were larger than in Sppl2a-/- B cells, as SSC granularity and intracellular 
LAMP1-protein and MHCII levels were about twice as high in the absence of 
Cathepsin S compared to SPPL2A-deficient B cells (Figure 4.5). Consistent with 
p10’s MHCII association, N-terminal CD74 protein levels of Cathepsin S-deficient B 
cells correlated with increasing levels of MHCII and LAMP1, whereas Sppl2a-/- B 
cells could increase N-terminal CD74 levels in the absence of concomitant MHCII 
accumulation (Figure 4.11). It seems likely that increases of total MHCII staining in 
Sppl2a-/- B cells is due to MHCII pairing with p10-fragments that also accumulate at 
low levels in these cells (Figure 3.27 and Figure 5.10), indicating that total MHCII 
levels in naive Sppl2a-/- and Ctss-/- B cells are a flowcytometric measure of p10-
MHCII complexes accumulating in the MIIC compartment when Cathepsin S 
activity is reduced or absent. This is supported by published TEM images of 
endosomal structures with immuno-gold labelling for MHCII in Ctss-/- B cells, that 
show enlarged late endosomes caused by p10 accumulation and that surprisingly 
lacked intravesicular membrane structures in the form of ILVs, exhibiting restricted 
MHCII distribution to the limiting membrane of late endosomes (Boes et al., 2005). 
These observations were contrasted by TEM images of Sppl2a-/- B cells, that 
revealed vesicle aggregates with endosomes filled with intravesicular multilamellar 
membrane sheets (Figure 4.30). It is therefore possible that restriction of p10-MHCII 
complexes to the limiting MIIC membrane targets vesicle membrane expanding 
CD74-properties to the outer endosomal membrane, whereas p8-CD74 might be 
found on intravesicular membranes (Schneppenheim et al., 2013), and thus causes 
expansion or persistence of membrane structures inside the endosome, leading to 
increased numbers of multilamellar bodies in Sppl2a-/- B cells (Figure 4.30). In other 
words, p10-MHCII might cause expansion of the endosomal diameter, whilst p8 
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causes sequestration of intravesicular membrane sheets. Taken together, the 
hypothesis of p8-induced endosomal changes causing B cell deficiency in Sppl2a-/- 
mice may still be valid and the aforementioned differences of the endocytic pathway 
in Sppl2a-/- and Ctss-/- B cells could provide starting points to investigate the 
mechanism by which p8 specifically regulates the endocytic pathway and is able to 
disrupt B cell survival. 
 
The finding of overly abundant multilamellar bodies (MLBs) in Sppl2a-/- B cells and 
the related endosomal observations in this thesis, discussed above, may lead to the 
following model explaining why SPPL2A has evolved to fulfil a non-redundant role 
in CD74 intramembrane proteolysis of B cells. The proteolytic MHCII antigen 
presenting compartment (MIIC) is a multivesicular version of a late endo-lysosome 
that has been modified by factors including CD74 to facilitate slowed processing and 
endosomal pooling of antigenic cargo. Slowly degraded cargo creates a 
representative array of peptides fit for loading onto intravesicular membrane bound 
MHCII molecules (Neefjes et al., 2011). Considering that the membrane lipid and 
protein composition of ILVs in maturing endosomes is typically modified to permit 
their intraluminal degradation (Piper and Katzmann, 2007, Schulze et al., 2009), and 
the observation that ILVs seem to be the predominant site for MHCII peptide loading 
(Zwart et al., 2005, Neefjes et al., 2011), suggest that internal membranes of the 
MIIC need to be protected from degradation to safeguard MHCII-peptide complexes. 
CD74 and particularly residual N-terminal CD74 fragments released after C-terminal 
CD74 processing could fulfil this role of a membrane stabilising agent, by preventing 
the complex modifications normally required to permit lysis of intravesicular 
membranes. If CD74-membrane stubs are used as a blocking agent for the major 
pathway of endosomal intramembrane protein and lipid degradation, SPPL2A could 
have evolved to disarm this inhibitory CD74 dependent mechanism and facilitate 
eventual removal of intraluminal membranes along with proteins and lipids in 
antigen presenting cells. Persistence of MLBs in Sppl2a-/- B cells and the general 
notion that MLBs are a more mature version of the multivesicular type of MIIC that 
contain internal membranes enriched with C-terminally processed CD74 membrane 
stubs (Stern et al., 2006), support the proposed theory.  
 
At last this model would require an extension to provide a testable hypothesis that 
could explain how p8-driven endosomal changes and the possible persistence of p8-
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studded membranes cause B cell defects. Human endo-lysosomal storage diseases 
with disturbances in lipid metabolism often accumulate multilamellar bodies and 
may suggest pathomechanisms, such as lysosomal leakage of hydrolases into the 
cytosol and subsequent activation of apoptosis, secondary inhibition of other 
lysosomal functions or other clues that help understand the underlying mechanism by 
which p8 blocks B cell survival (Yang et al., 1998, Futerman and van Meer, 2004, 
van Nierop et al., 2006, Platt et al., 2012). The finding of reduced phosphatidylserine 
(PS) in the outer plasma membrane leaflet of SPPL2A-deficient B cells despite 
normal flippase activity (Figure 3.25) could provide another clue to explain 
membrane associated mechanisms, by which p8 may cause B cell deficiency. 
Calcium-dependent scramblease activity greatly contributes to mixing the 
phospholipid distribution between the outer and inner plasma membrane leaflets of 
haematopoietic cells (Williamson, 2015). Considering the observation that PS-
flipping from the outer to the inner leaflet occured at a normal rate in Sppl2a-/- B 
cells (Figure 3.25), scramblease activity to bring PS back to the outer membrane 
leaflet could be reduced. Thus one possibility is that p8-CD74 accumulation 
interferes with endo-lysosomal calcium homeostasis (Morgan et al., 2011) to cause 
reduced intracellular calcium levels and reduced scramblease activity. A second, 
distant possibility is that reduced outer leaflet plasma membrane PS levels in Sppl2a-
/- B cells somehow reflect p8-mediated disturbances of the lipid sorting processes 
that occur at ESCRT-driven membrane fission sites during budding of ILVs from 
limiting endosomal membranes (Piper and Katzmann, 2007, Piper and Luzio, 2007, 
Schulze et al., 2009, Hurley and Hanson, 2010, Li et al., 2015a). 
 
Despite the long-standing history of research into the multiple roles of CD74, it 
should be an exciting endeavour to take up the leads identified in this study and 
resolve how p8-induced endosomal changes cause B cell deficiency, which cannot 
simply be explained by the long known ability of CD74 to expand the endosomal 
compartment. Discovery of the effects of p8-CD74 on B cells exposed an element of 
CD74 function, which has not been known before. The identification of molecular 
CD74 determinants capable to modify the endocytic pathway and B cell survival 
promise to reveal new insights into functioning of the endocytic route, B cell biology 
and antigen presentation. Understanding of how p8 regulates endosomal membrane 
biology and causes B cell defects could also provide a tool to modify the endocytic 
pathway, which might prove useful for membrane impermeable drug or nucleic acid 
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delivery in gene therapy applications and modification of viral immunity or immune 
responses to phagosomal pathogens, such as M. tuberculosis. 
 
6.7 The generation of p8-CD74 in Sppl2a-/- B cells 
Non-MHCII associated p8-CD74 fragments accumulating in B cells were 
responsible for B cell deficiency in Sppl2a-/- mice. It seems clear that p8 
accumulates, because intramembrane proteolysis of pre-degraded p8-CD74 does not 
occur in the absence of SPPL2A, but where do these detrimental p8-CD74 fragments 
come from in the first place and how does SPPL2A fit into the sequence of CD74 
processing proteases? Our current understanding of CD74 proteolytical processing is 
connected to the MHCII antigen presenting pathway (Neefjes et al., 2011), whereby 
CD74 is synthetised as a single-pass type 2 transmmebrane protein in excess of 
MHCII in the ER. Then CD74 chaperones MHCII assembly and guides CD74-
MHCII nonameric complexes along the secretory route from the ER through the 
Golgi, predominantly via the cell surface to enter the endocytic pathway and arrive in 
endosomes for peptide loading (Landsverk et al., 2009). Whilst transporting MHCII 
through the endocytic route, CD74 is exposed to an increasingly proteolytic luminal 
environment and as a result is C-terminally degraded in a stepwise or sequential 
fashion. Cathepsin S executes the penultimate CD74 cleavage step, consistent with 
p10 accumulation in the absence of Cathepsin S (Riese et al., 1996, Shi et al., 1999, 
Nakagawa et al., 1999, Boes et al., 2005). By cutting CD74 on the N-terminal side of 
the MHCII-binding CLIP peptide, Cathepsin S thus releases MHCII-CLIP 
complexes for transport onto internal MIIC membranes and peptide loading, as well 
a CLIP-devoid p8-CD74 N-terminal membrane fragment. Thus p8-CD74 should at 
least in parts be produced by Cathepsin S activity. Since SPPL2A-deficient B cell 
defects were dependent on the dose of expressed CD74, additional deletion of 
Cathepsin S was expected to increase the number of mature accumulating B cells in 
Sppl2a-/-Ctss-/- mice. However, side by side analysis of wildtype, Sppl2a-/-, Ctss-/-, 
Sppl2a-/-Ctss-/- B cells showed that inhibition of Cathepsin S activity could not rescue 
p8 accumulation (Figure 4.21) and B cell deficiency in Sppl2a-/- mice (Figure 4.19 
and 4.20), whilst SPPL2A-deficiency reduced the accumulation of p8 in the absence 
of Cathepsin S (Figure 4.21). These results suggest that Cathepsin S activity 
contributes little or nothing towards the production of p8 in Sppl2a-/- B cells. Even 
more so, SPPL2A-deficiency was able to reduce the accumulation of p10 that is 
normally seen in the absence of Cathepsin S by more than ~80% (Figure 4.21), 
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indicating that SPPL2A was surprisingly required for the accumulation of p10 in the 
absence of Cathepsin S. Why is p10-CD74 lost from Sppl2a-/-Ctss-/- B cells, whereas 
p8 is able to persist? 
 
Persistence of p8 in Sppl2a-/-Ctss-/- B cells could be explained as follows. It is known 
that p10 C-terminal processing exclusively depends on Cathepsin S only when p10 is 
protected from access by other luminal proteases by association with MHCII. In 
situations of Cathepsin S deficiency where CD74 binding to MHCII is of low 
affinity, p10 cannot bind MHCII sufficiently and as a result is non-specifically 
degraded even in the absence of Cathepsin S (Villadangos et al., 1997, Nakagawa 
and Rudensky, 1999, Hsing and Rudensky, 2005). The dependence of p10 
accumulation on MHCII-chaperoning was also seen best in Sppl2a-/-H2-Aa-/- DCs, 
which lost minor p10 bands in anti-N-terminal CD74 immunoblots when compared 
to lysates from singly SPPL2A-deficient DCs (Figure 5.10). It was further shown 
that transport and processing of CD74 to produce p8 in Sppl2a-/- B cells did not 
depend on MHCII-chaperoning (Figure 4.21 and 5.10). Since CD74 is synthetised in 
excess of MHCII, a major proportion of CD74 would exist freely or is associated 
with other non-MHCII molecules. It therefore seems likely that non-specific aspartic 
or cysteine proteases present in the endosome lumen are able to act as sheddases for 
SPPL2A, which C-terminally pre-degrade CD74 to produce p8-membrane fragments 
whenever CD74 is not bound to MHCII. The slightly smeared, or broader bands of 
the estimated ~8kD small CD74 fragments visible in anti-N-terminal CD74 
immunoblots of SPPL2A-deficient B cells and DCs suggest that those p8-fragments 
are in fact a mixed group of peptides of different lengths (Figure 3.27, 4.21 and 
5.10). This indicates that intraluminal proteases, other than Cathepsin S, are able to 
C-terminally trim CD74 right down to the luminal leaflet of the endosomal 
membrane, thereby creating a mixture of p8-fragments, that should probably more 
accurately be addressed as p5-9 rather than p8. Additionally, it has been proposed 
that excess, non-MHCII associated CD74 can be removed from the ER by an 
autophagy or ER-phagy related pathway that bypasses glycosylation of CD74 in the 
golgi and directly transports ER-derived CD74 to LAMP1+ endosomal compartments 
(Lotteau et al., 1990, Sant and Miller, 1994, Chervonsky and Sant, 1995). This 
pathway could be entirely separate from the classical transport and processing 
mechanisms that normally degrade CD74 and may supply a cohort of MHCII-free 
CD74 molecules that is trimmed independently of Cathepsin S to produce p8 and 
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requires SPPL2A cleavage to eventually allow lysis of the mature autophagosome. 
Collectively, the findings in this thesis suggest that non-specific luminal endosome 
proteases trim CD74 to produce p8, whilst Cathepsin S is not required for this 
process. 
 
Regarding the loss of p10-CD74 in Sppl2a-/-Ctss-/- B cells, two possible mechanisms 
could contribute to this observation. One possibility is that the accumulation of p8 
somehow limits the levels of p10 that can accumulate in the endosome by 
destabilising p10-MHCII association and allowing access of non-Cathepsin S 
proteases to cleave p10. Another possibility is that SPPL2A-deficiency diminishes 
the supply of CD74-MHCII complexes entering the endocytic pathway, thus 
reducing CD74-MHCII available for processing into stable p10-MHCII complexes. 
This explanation is supported by the following findings. SPPL2A-deficiency in 
developing B cells caused increased intracellular CD74 levels already at the 
immature developmental stage in IgM+ IgD- B cells from the bone marrow (Figure 
4.25 and 4.27), whereas Cathepsin S deficient B cells only increased CD74 levels at 
the T1/T2 stage (Figure 4.25 and 4.26), later during B cell development. 
Collectively, this indicates that Cathepsin S normally processes CD74 later than 
SPPL2A during B cell development. This finding further implied that SPPL2A-
deficiency causes an accumulation of p8 that pre-exists once Cathepsin S activity 
would normally kick in to prevent p10 build up. Pre-existing p8 in SPPL2A-deficient 
could then slow delivery of CD74-MHCII deeper into the endocytic pathway, which 
is suggested by slowed kinetics of p10 production in pulse and chase analysis of 
CD74 processing in Sppl2a-/- spleeocytes (Figure 4.23). At last it was noted here that 
Sppl2a-/- mature B cells seem to respond to p8-CD74 accumulation with reduced 
transcription of Cd74 mRNA, as measured by microarray (Figure 4.27B). These 
changes in CD74 metabolism of SPPL2A-deficient B cells possibly contribute to 
reduce the supply of CD74-MHCII that would be necessary to enter the endocytic 
pathway in order to accumulate p10 in Sppl2a-/-Ctss-/- B cells. 
 
6.8 p8-CD74 production is independent of MHCII-chaperoning 
Disruption of CD74-MHCII chaperoning in developing Sppl2a-/- B cells by 
additional deletion of MHCII α chains, neither corrected B cell deficiency (Figure 
4.15), nor did it reduce N-terminal CD74 protein accumulation (Figure 4.22) and the 
specific production of p8-CD74 fragments (Figure 4.21 and 5.10). These results 
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indicated that nascent CD74 molecules in B cells reached endosomes and 
subsequently underwent processing in that compartment, independently of MHCII 
chaperoning.  
 
This interpretation was challenged by measurements of increased full length CD74 
protein levels in MHCII α chain singly deficient B cells by flowcytometry (Figure 
4.22) and immunoblotting (Figure 4.21), suggesting ER accumulation of unprocessed 
CD74. However, confocal microscopy revealed that CD74 molecules in H2-Aa-/- B 
cells could still traffic into peripheral membrane compartments (Figure 4.13), which 
was comparable to what was seen in wildtype B cells. From these observations, it 
could therefore be concluded that CD74-MHCII-chaperoning greatly facilitates ER 
export of CD74 in murine B cells, so that MHCII-dimer disruption has a measurable 
effect on full-length CD74 accumulation, likely in the ER. Nonetheless, putative 
CD74-ER retention of molecules not associated with MHCII was not absolute. 
MHCII-free CD74 could still exit the ER in sufficient quantities to supply endosomal 
p8-CD74 production in Sppl2a-/-H2-Aa-/- B cells (Figure 4.21). Numerous reports of 
CD74 surface trafficking in association with other molecules (Naujokas et al., 1993, 
Leng et al., 2003, Shi et al., 1999, Bernhagen et al., 2007, Gore et al., 2008, Schwartz 
et al., 2009, Zwart et al., 2010), subcellular CD74 distribution in Sppl2a-/-H2-Aa-/- B 
cells (Figure 4.13) and persistence of relatively normal surface CD74 levels on H2-
Aa-/- DCs (Figure 5.9) confirm the existence of MHCII-independent pathways for 
CD74 to exit the ER. Therefore, disruption of MHCII-CD74 chaperoning in Sppl2a-/- 
B cells is unable to rescue p8-CD74 production and B cell deficiency, as MHCII-
chaperoning appeared helpful but not necessary for murine CD74 to traffic from the 
ER to the endosome. 
 
A less likely alternative explanation of persistent mature B cell loss and reduced 
surface IgD expression in Sppl2a-/-H2-Aa-/- B cells could be that rescued SPPL2A-
deficiency in Sppl2a-/-H2-Aa-/- mice was masked by the toxic effects of accumulating 
MHCII β chains in the ER when MHCII α chains were absent (Labrecque et al., 
1999, Koonce and Bikoff, 2004). Results in this thesis confirmed that H2-Aa-/- B 
cells have reduced surface IgD levels (Figure 4.15 and 4.16) and shortened survival 
lifespan (Rolink et al., 1999), which are throught to be caused by toxic ER 
accumulation of MHCII β chains (Labrecque et al., 1999). Despite similarities in this 
regard between Sppl2a-/- and H2-Aa-/- B cells, there were also clear differences, 
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indicating that the mechanism underlying B cell defects in Sppl2a-/- and H2-Aa-/- 
mice were dissimilar. Reduction of B cell surface IgD, IgM, BAFFR and CD23, as 
well as overall accumulating B cell numbers were much lower in Sppl2a-/- mice, 
whilst B cells from Sppl2a-/-H2-Aa-/- mice resembled this phenotype (Figure 4.15 and 
4.16). This suggested that removal of MHCII α chains did not improve the B cell 
defect caused by SPPL2A-deficiency, strongly suggesting that the persistently 
accumulating p8-CD74 fragments in Sppl2a-/-H2-Aa-/- B cells remain responsible for 
B cell deficiency. Additionally, there did not seem to be an interaction of 
accumulating β chains in the ER and p8 storage in endosomes, which would have 
been expected to cause worsened B cell deficiency in Sppl2a-/-H2-Aa-/- mice as 
opposed to Sppl2a-/- mice. This was not the case (Figure 4.15 and 4.16), thus 
implying distinct mechanistic effects caused by MHCII β chain or p8-CD74 
accumulation in B cells, and provides indirect evidence for endosomal as opposed to 
ER accumulation of p8-CD74 fragments in SPPL2A-deficient B cells.  
 
The assessment of MHCII’s role in delivering CD74 to SPPL2A accessed membrane 
compartments could further be hindered by residual truncated MHCII α chains that 
are known to persist almost at wildtype levels in H2-Aa-/- mutant mice used in this 
study or by orphaned β chains, as described above (Kontgen et al., 1993, Koonce and 
Bikoff, 2004). Whilst the truncated α chains are unable to dimerise with β and thus 
disrupt chaperoning of CD74 with MHCII in H2-Aa-/- mice (Koonce and Bikoff, 
2004), Sppl2a-/-H2-Aa-/- double deficiency only functionally removes MHCII from 
SPPL2A mediated CD74 processing, as truncated α chain protein persists along with 
MHCII β chain aggregates. To definitely test whether p8-CD74 production and B 
cell deficiency in the absence of SPPL2A is completely independent of MHCII, 
Sppl2a-/- mice should be crossed with mice that lack all MHCII subunits (Madsen et 
al., 1999). 
 
6.9 Loss of surface BCR due to endosomal changes 
One prominent observation in SPPL2A-deficient B cells was the characteristically 
low expression of surface BCRs, particularly IgD (Figure 3.8 and 3.9). Since the 
BCR is an important survival receptor and required for B cell development (Lam et 
al., 1997), it was of interest to understand how SPPL2A-deficiency caused low 
surface BCR levels in B cells. Since surface IgD levels were dose dependent on 
intracellular CD74 quantities accumulating in Sppl2a-/- B cells (Figure 4.32A), it 
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appeared that reduced surface BCR expression was caused by a p8-CD74 driven 
process. To determine where in the live cycle of a surface membrane protein (Figure 
4.31) SPPL2A-deficient B cells loose BCRs, mRNA expression, surface 
internalisation and intracellular BCR levels were examined. mRNA expression levels 
of BCR heavy chains were normal in developing Sppl2a-/- B cells, indicating normal 
production of the BCR. This was supported by normal synthesis rates of IgM protein 
in metabolic pulse and chase labelling experiments (Figure 4.36). BCRs reaching the 
cell surface were internalised at an increased rate by Sppl2a-/- B cells (Figure 4.33 
and 4.34)(Huttl et al., 2015), suggesting that the balance between surface molecule 
internalisation and recirculation that helps to maintain surface receptor levels (Blery 
et al., 2006) might be skewed. Interestingly, increased internalisation rates were a 
specific observation for BCRs, but not other surface molecules tested (Figure 4.34), 
indicating that BCR internalisation is induced by CD74-linked BCR trafficking 
mechanisms from the surface to the endosomes and related endosomal changes 
(Barois et al., 1997, Kim et al., 2006, Siemasko et al., 1998, Vascotto et al., 2007, 
Yuseff et al., 2013, Avalos and Ploegh, 2014) that appear to commence during 
transitional B cell development, and are further discussed below in section 6.10. 
 
Increased BCR internalisation rates suggested that missing surface receptors might 
reside in an intracellular pool, but this was not the case. Intracellular flowcytometric 
measurements of BCR levels showed, that there was no increased amount of BCRs 
sequestered inside Sppl2a-/- B cells (Figure 4.35 and 4.36). These observations imply 
that SPPL2A-deficient B cells normally produce BCRs, expose them on the surface, 
but then loose their receptors following rapid surface internalisation by an unknown 
degradation mechanism. This assumption is supported by the idea that the likelihood 
of degradation for surface molecules increases the longer they reside in sub-plasma 
membrane, early endosomal compartments following internalisation (Hare and 
Taylor, 1991). 
 
Treatment of Sppl2a-/- B cells with 3-MA for 6 hours in culture increased surface 
levels of IgD and IgM compared to untreated cells (Figure 3.37), suggesting that 3-
MA inhabitable autophagy could be a mechanism by which surface BCRs were 
degraded in Sppl2a-/- B cells. However, this finding was not specific to SPPL2A-
deficient B cells, as a similar effect of a lesser extent was also observed in wildtype 
B cells. Two possible processes could explain this observation.  
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Firstly, 3-MA treatment could block a proposed alternative pathway of non-MHCII 
chaperoned CD74 transport directly from the ER to endosomes via autophagy 
(Lotteau et al., 1990, Sant and Miller, 1994, Chervonsky and Sant, 1995), and thus 
limit supply of endosomal CD74 that is involved in BCR trafficking to the endosome 
(Vascotto et al., 2007). Secondly, 3-MA treatment could directly interfere with 
sequestration of internalised BCRs into degrading endosomes. p8-CD74 
accumulation might trigger a compensatory mechanism to remove excessive 
quantities of membrane proteins via autophagy, similar to what has been described in 
the ER (Adolph et al., 2013, Schuck et al., 2014) or via conventional membrane 
protein degradation pathways (Schulze et al., 2009, Babst, 2014, Li et al., 2015a). 
This idea would be supported by the observation of increased BCR internalisation in 
β-Hexosaminidase-deficient mouse B cells, a model for a GM1-gangliosidosis 
lysosomal storage disease (te Vruchte et al., 2010). Excessive accumulation of lipids 
and proteins in other murine endosomal storage disease models causes enlargement 
of endo-lysosomes and formation of multilamellar bodies, which could be inhibited 
by 3-MA treatments (Hariri et al., 2000, Lajoie et al., 2005, Platt et al., 2012). 
Inclusion and sorting of recirculating surface IgM and IgD molecules into membrane 
degrading vesicles could shift the balance from recirculation to more rapid 
internalisation and subsequent degradation of surface BCRs. 3-MA could therefore 
block increased IgM and IgD degradation triggered by p8 accumulation along the 
endocytic route, which then resulted in a relative increase of surface IgM and IgD 
levels on Sppl2a-/- B cells. This interpretation certainly requires experimental 
validation and could easily be challenged by the lack of detected changes in classical 
autophagy related gene expression in microarray analysis (Figure 3.41) and a 
seemingly normal rate of IgM degradation in metabolic pulse and chase experiments 
(Figure 4.36). To date, direct 3-MA sensitive, autophagy related surface membrane 
protein removal pathways seem to be unknown, and other secondary effects of 3-MA 
treatment might have been observed here. 
 
Taken together, it appears that low surface BCR levels on SPPL2A-deficient B cells 
is somehow caused by accumulating intracellular p8-CD74 fragments. Normal BCR 
mRNA expression, increased surface BCR internalisation and a lack of intracellular 
BCR accumulation suggest a loss of surface BCR due to increased degradation of 
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internalised receptors. However, the exact mechanism by which p8 might cause this 
process remains to be revealed in the future. 
 
6.10 Blocked transitional B cell survival despite pre-existing p8 accumulation 
in immature bone marrow B cells 
If the presence of accumulating p8 is responsible for B cell defects in Sppl2a-/- mice, 
why do bone marrow derived immature B cells increasingly amass intracellular p8 
without compromising immature or T1 B cell numbers? B cell survival in Sppl2a-/- 
mice is compromised from the T1 to T2 transitional stage onwards, when developing 
B cells already contain high levels of p8. It is also at the T1/T2 B cell developmental 
stage at which Cathepsin S-deficient B cells start to accumulate increasing quantities 
of intracellular CD74, but as opposed to Sppl2a-/- mice not at earlier stages. This 
suggests an event occurring during T1 to T2 B cell development that drives p8-
dependent disruption of B cell survival, as well as the accumulation of p10 in Ctss-/- 
B cells. This event could be the initiation of BCR signalling that normally occurs 
during transitional B cell development (Chung et al., 2003). 
 
In mature B cells, most MHCII and full-length CD74 is normally found on the cell 
surface until the BCR is engaged by antigen, at which time signals from the BCR 
induce association between CD74 and myosin light chain kinase to activate the 
convergence of BCR-antigen complexes and MHCII molecules in large, perinuclear, 
MIIC compartments (Barois et al., 1997, Kim et al., 2006, Siemasko et al., 1998, 
Vascotto et al., 2007, Yuseff et al., 2013, Avalos and Ploegh, 2014). Kim and 
colleagues showed that BCR stimulation of spleen B cells from HEL recognising 
BCR-transgenic mice with oligovalent HEL was able to induce this endosomal 
reorganisation response (Kim et al., 2006). BCR dependent endosomal changes 
seemed to be dose dependent, as weak BCR stimulation with monomeric HEL-
induced endosomal reorganisation at lower levels (Kim et al., 2006, Avalos and 
Ploegh, 2014). Components of the BCR signalling pathway are functionally 
connected during transitional B cell development and thus from the T1/T2 stage 
onwards a successfully assembled BCR signalsome would likely facilitate BCR-
driven endosomal reorganisation (Su and Rawlings, 2002, Chung et al., 2003, 
Cobaleda et al., 2007, Khan, 2009). This assumption is supported by the observation 
that T1/T2 B cells are able to present antigen (Chung et al., 2003), and thus are likely 
subjected to BCR-driven endosomal changes to facilitate antigen presentation 
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(Vascotto et al., 2007, Yuseff et al., 2013). Weak BCR signalling in transitional 
spleen B cells also causes the adaptive down-regulation of IgM that occurs during 
the development of IgMhiIgDlow T1 B cells into mature IgMlowIgDhi follicular B cells 
(Goodnow et al., 1988, Zikherman et al., 2012), whilst retaining high steady state 
IgD levels on the cell surface through rapid cycles of endocytosis and recycling 
(Blery et al., 2006). Since SPPL2A-deficieny caused B cell abnormalities during the 
T1 to T2 transition, BCR promoted effects on CD74 trafficking and the endocytic 
pathway could explain why pre-existing p8 accumulation in immature B cells only 
interferes with B cell survival once BCR signalling in transitional B cells is 
established. In other words, the accumulation of p8-CD74 fragments in the absence 
of BCR signalling may not cause B cell defects. Thus a model could be proposed, by 
which p8 accumulates in SPPL2A-deficient B cells as soon as CD74 is expressed 
during B cell development at the Pre-B cell to immature stage (Figure 3.26). p8-
CD74 fragments are able to persist without any effect, until successful assembly of 
the BCR-signalsome during transitional B cell development produces a weak BCR 
signal that is able to drive p8-CD74-dependent endosomal reorganisation (Kim et al., 
2006, Vascotto et al., 2007, Avalos and Ploegh, 2014), and subsequently leads to loss 
of T2 and mature B cells. The idea that BCR signalling during transitional B cell 
development is responsible for the induction of p8-dependent B cell loss is supported 
by observations in Ctss-/- B cells and measurements of cell granularity in SPPL2A-
deficient B cells.  
 
Firstly, in the absence of Cathepsin S increased intracellular CD74 levels occurred 
mostly at the T2 stage, when IgM-down-regulation marked the transition from 
immature to mature B cells (Figure 4.25 and 4.26). This indicates that only from this 
phase of B cell development onwards CD74-MHCII complexes enter the endocytic 
pathway and can persist as p10-MHCII complexes on enlarged endosomal 
membranes. Thus the same weak BCR signal that appears coincidentally responsible 
for production of p10 in Ctss-/- B cells may drive the induction of B cell defects that 
occur in transitional SPPL2A-deficient B cells with pre-existing levels of p8-CD74. 
 
Secondly, side scatter (SSC) was selectively increased in IgD+IgMlow, but not in 
IgDlowIgM+ SPPL2A-deficient B cells (Figure 3.30). Using flow cytometry to 
determine the SSC of laser light in peripheral blood B cells provided a measure of 
intracellular vacuolation. Low levels of vacuolation in IgM+ immature and increased 
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levels of vacuolation in IgMlow mature Sppl2a-/- B cells suggests that abnormal 
endosomal reorganisation occurs during the transition from immature to mature 
Sppl2a-/- B cells, marked by the down-regulation of IgM. 
 
The interpretation of BCR-driven effects on accumulated p8-CD74 provides an 
opposing perspective about the role of BCR signalling in SPPL2A-deficiency. Whilst 
low surface BCR levels suggest that Sppl2a-/- B cells are deprived of BCR signal, it 
might well be the other way around. BCR signalling could be the underlying cause of 
p8-CD74 mediated B cell deficiency and enforced BCR signalling in Sppl2a-/- B 
cells with constitutively active PI3-Kinase (Srinivasan et al., 2009), would be 
expected to worsen the effect of accumulating p8-CD74 on B cell survival. 
 
6.11 CD8- but not CD8+ DCs require SPPL2A mediated CD74 processing for 
survival 
The intramembrane protease SPPL2A is ubiquitously expressed throughout the 
immune system (Figure 1.6)(Heng et al., 2008), but mice with an inactivating 
mutation in Sppl2a specifically lacked B lymphocytes whilst T cells developed 
normally (Figure 3.13). Defective intramembrane processing of CD74 and 
subsequent p8-CD74 fragment accumulation was the underlying cause of B cell 
deficiency in these mice. Differential expression of CD74 in B cells but not in T cells 
could explain why B cells were affected by SPPL2A-deficiency and T cells were not. 
Other CD74-expressing cell types, such as macrophages, monocytes and dendritic 
cell subsets seemed to develop normally in Sppl2a-/- mice, except for CD8- cDCs. 
SPPL2A-deficiency caused increased intracellular CD74 levels in pDCs, CD8+ and 
CD8- DC subsets and accumulation of p8-CD74 fragments in CD11c+MHCII+ spleen 
DCs overall. Other phenotypes of Sppl2a-/- DCs included low surface CD11c and 
CD8 expression, as well as high surface MHCII levels on CD8- DCs as opposed to 
high full-length CD74 expression on CD8+ DCs. Similar to B cells, the CD8- DC 
defect was rescued in Sppl2a-/-Cd74-/- mice, showing that accumulating CD74 
fragments caused it. SPPL2A-deficiency also interfered with MHCII antigen 
presentation, but not with cross-presentation of exogenous antigen on MHCI. These 
findings raise several questions. 
 
Why does the lack of SPPL2A and subsequent p8-CD74 accumulation only interfere 
with the peripheral accumulation of CD8- DCs, but not with CD8+ DCs, as both 
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subsets express CD74 at comparable levels? The basis for the specific loss of CD8- 
DCs as opposed to CD8+ DCs is obscure, but there are three possible aspects that 
could explain this observation. Firstly, it is known that CD8+ DCs have a faster turn 
over in the spleen than CD8- DCs (Kamath et al., 2002), and thus there might not be 
enough time for CD8+ DCs to succumb to the effects of p8-CD74 accumulation. 
CD8+ spleen DCs were found to be turned over in 3 days, whereas the CD8- DC 
population took around 9-12 days to be completely replaced by successors from the 
bone marrow (Kamath et al., 2002). If the aforementioned B cell estimate to reach 
steady state p8 levels of 4.5 days is applied, then it could be possible, that CD8+ DCs 
are replaced before reaching high enough p8 levels, whereas CD8- DCs could be lost 
before they would normally be replaced. However, flowytometric intracellular CD74 
measurements did not support this hypothesis, as CD74 levels were 4-fold greater in 
CD8+ DCs as opposed to CD8- DCs, indicating that CD8+ DCs might be more 
resilient to p8 accumulation. 
 
A second possibility to explain the difference in CD8+ and CD8- DC susceptibility to 
the loss of SPPL2A is that p8 accumulation or SPPL2A-deficiency might block a 
pathway that is specifically required by CD8- but not by CD8+ DCs. TRAF6 , RELB, 
IRF2 and IRF4, as well as other factors are known to be selectively required for the 
development and survival of CD8- DCs and could provide starting points to further 
investigate whether they are connected to effects mediated by the loss of SPPL2A 
(Steinman and Idoyaga, 2010). 
 
The third and more likely explanation for the different responses of CD8+ and CD8- 
DCs to SPPL2A-deficiency could be differences in the control of CD74, endosomes 
and trafficking, which allow CD8+ DCs to survive p8 accumulation better than the 
CD8- subset. One of the quests in the field of DC biology is to resolve differences in 
the antigen presenting pathways between CD8+ and CD8- DCs in order to identify 
potential cross-presentation machinery in CD8+ DCs that could explain why this 
subset is better at cross-presentation than the other (Villadangos and Schnorrer, 
2007, Lin et al., 2008). CD8+ DCs are known for their superior ability over CD8- 
DCs to cross-present soluble exogenous antigen that could be internalised equally 
well by both subsets, showing that cross-presenting capabilities of CD8+ DCs are the 
result of a specialised intracellular machinery or mechanistic differences in antigen 
handling that may yet need to be revealed (Schnorrer et al., 2006, Shortman and 
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Heath, 2010, Lin et al., 2008, Segura and Villadangos, 2011, Neefjes and Sadaka, 
2012). Disturbance of CD74 metabolism in SPPL2A-deficient DCs seems to bring 
such a difference to the forefront. Surface MHCII levels on Sppl2a-/- CD8- DCs were 
increased as opposed to a 10-fold MHCII-chaperoning dependent increase of CD74 
predominantly on the surface of Sppl2a-/- CD8+ DCs. Overall intracellular CD74 
quantities were also greater in both, Sppl2a-/- and wildtype CD8+ than in CD8- DCs. 
If the underlying effect of SPPL2A-deficieny is equal in CD8+ and CD8- DCs, and 
since mRNA expression levels of Cd74 are similar in both DC subsets, the resulting 
response in CD74 and MHCII distribution demonstrate that CD8+ and CD8- DCs 
handle those molecules differently. Such differences in CD74 and MHCII handling 
likely point towards prevailing endosomal pathways in one or the other cDC subset 
and could help to reveal DC subset intrinsic capabilities that help explain the 
superior cross-presenting prowess of CD8+ DCs, as well as the increased 
susceptibility of CD8- DCs to SPPL2A-deficieny. 
 
The nature of these differences in trafficking pathways between CD8+ and CD8- DCs 
will be discussed next and are purely hypothetical. It is assumed that differences in 
CD74 trafficking between CD8+ and CD8- DCs depend on variations in the use of 
transport routes that CD74 could follow through the cell. In a simplified model, 
CD74 can travel from the ER to the TGN and from there either via the cell surface or 
directly to the endosome (Neefjes et al., 2011). Alternatively CD74 could travel 
directly from the ER to endosomes (Chervonsky and Sant, 1995), which might be 
facilitated by connections between the ER and endosome that have been identified as 
possible pathway for ER-derived MHCI to meet processed antigen for cross-
presentation (Segura and Villadangos, 2011, Basha et al., 2012). In MHCII antigen 
presentation focussed CD8- DCs the CD74-MHCII transport pathway to the cell 
surface might prevail. This would ensure the presence of MHCII molecules along the 
entire proteolytic peptide spectrum of the endocytic route. By contrast, cross-
presentation proficient CD8+ DCs might predominantly employ the direct CD74 
transport from the ER to endosomes, particularly to transport MHCI rather than 
MHCII to a pool of exogenous peptides (Basha et al., 2012). Endosomal p8-CD74 
accumulation in Sppl2a-/- CD8+ DCs might then deflect this direct CD74 transport 
pathway to the cell surface instead and cause the increase of CD74 molecules at the 
plasma membrane. The ability to overflow CD74 to the cell surface might also 
explain why CD8+ DCs were more resistant to SPPL2A-deficieny than their CD8- 
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counterparts. CD74 surface overflow was dependent on MHCII α chain expression 
(Figure 5.9) and blockage of CD74-MHCII chaperoning in Sppl2a-/-H2-Aa-/- mice 
caused a reduction of spleen CD8+ DC numbers (Figure 5.7), indicating that this 
escape mechanism was helping to keep CD8+ DCs alive. Still, more obvious 
questions remain and require experimental refinement of this mouse model in the 
future: Why do Sppl2a-/- CD8+ DCs have increased surface levels of CD74, but 
normal MHCII expression at the plasma membrane, particularly if surface CD74 
transport is dependent on CD74-MHCII chaperoning? If a cross-presentation 
relevant difference in CD8+ DCs is disturbed by SPPL2A-deficiency, why does 
cross-presentation of soluble OVA to CD8+ OT-I T cells still seem to occur 
normally? Which escape mechanism is employed by pDCs to persists in SPPL2A-
deficient mice, despite intracellular accumulation of CD74-protein in this subset? Is 
p8-interference with H2-M dependent peptide MHCII loading on ILVs the post-
endocytic inhibition of MHCII antigen presentation in Sppl2a-/- DCs? In conclusion, 
differences in CD74 and MHCII trafficking that were observed in SPPL2A-deficient 
CD8+ and CD8- DCs could explain why CD8+ are more resilient to the loss of CD74 
intramembrane processing by SPPL2A and might also provide a new approach to 
investigate why CD8+ DCs are more capable cross-presenters than CD8- DCs. 
 
6.12 Limitations 
This study has limitations and requires alleviating future experimentation, some of 
which have already been suggested. Non-exhaustively these include the lack of 
formal demonstration for p8-CD74 accumulation to be able to cause B cell and DC 
defects. Although the results presented here very much imply this central conclusion, 
formal proof would require isolated overexpression of non-cleavable p8 fragments in 
B cells or non-B cells to replicate phenotypes similar to SPPL2A-deficient B cells 
and DCs. These types of experiments should allow identification of already known 
or unknown causative molecular CD74 determinants that are likely part of the N-
terminal cytoplasmic tail.  
 
It has not been shown where exactly p8-CD74 membrane stubs accumulate inside 
SPPL2A-deficient B cells and DCs, as there are likely to be telling differences, 
particularly between CD8+ and CD8- DCs. The assumption made here that p8-CD74 
accumulates in endosomal membranes is based on three observations: Firstly, the 
demonstration by others, that the p8-CD74 cleaving enzyme SPPL2A localises to 
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endosomal membranes (Friedmann et al., 2006, Kirkin et al., 2007, Martin et al., 
2008, Behnke et al., 2011). Secondly, measurements in this study that SPPL2A-
deficient B cells have increased intracellular levels of the late endosomal marker 
LAMP1 and thirdly, confocal microscopic images from Sppl2a-/- B cells and DCs 
showing that N-terminal CD74 staining seems to label the same subcellular areas that 
are marked by antibodies to LAMP1. The exact subcellular localisation of p8 in 
SPPL2A-deficiency needs to be confirmed, but differentiation of p8 from full-length 
CD74 molecules and expected abnormalities of intracellular membrane structures 
provide challenges. Sub-cellular fractionation, combined with metabolic labelling 
and subsequent N-terminal CD74 immunoblotting, or alternatively, TEM imaging 
with immuno-gold counter staining of the CD74 N- and C-terminus could be 
successful experimental approaches to resolve this limitation. 
 
Low surface expression of Sppl2a-/- B cell and DC surface markers, including IgM, 
IgD and CD11c, posed limitations to differentiate and compare similar cell subsets, 
which may have confound flowcytometric and other experimental readouts. In some 
experimental settings it might have been difficult to determine, whether Sppl2a-/- cell 
subsets were present, or whether they simply could not be detected due to low 
surface marker expression levels. Assessment of B cell responses to anti-BCR 
stimulation were likely also biased by low surface IgM and IgD levels. For example, 
it did not seem surprising to measure reduced Sppl2a-/- B cell activation, following 
anti-IgM treatment in vitro, because surface IgM levels were reduced and therefore 
stimulatory input at the B cell surface would have been reduced as well. To assess 
whether BCR signalling is indeed disrupted by SPPL2A-deficiency, experimental 
approaches that can activate BCR downstream pathways whilst bypassing the 
involvement of low surface BCR levels should be used, alike the experimental 
suggestions at the beginning of this discussion. Therefore, low surface molecule 
expression on Sppl2a-/- B cells and DCs, data analysis and interpretation required 
attention. Despite these clear limitations, most of the critical markers used for B cell 
and DC differentiation in Sppl2a-/- mice were expressed lower than normal, but still 
adequately for careful separation of the targeted cell population. 
 
6.13 Summary 
In summary, this project has revealed the intramembrane protease SPPL2A as a new 
factor that is required for B cell and CD8- cDC survival as well as CD74 metabolism 
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in mice. With these findings CD74 was discovered as the first in vivo substrate for 
SPPL2A, highlighting a biological role for SPPL2A in multiple aspects of humoral 
immunity. Small, pre-degraded ~8kD CD74 membrane fragments accumulated in 
enlarged endosomal vesicle clusters of B cells when failing to be degraded in the 
absence of SPPL2A. Accumulating p8-CD74 membrane stubs caused expansion of 
the endosomal membrane compartment and blocked surface BCR and BAFFR 
expression, as well as the survival of transitional T2 and mature B cells. Deletion of 
CD74 in SPPL2A-deficient mice rescued these B cell defects and revealed a 
previously unknown capability of CD74 to alter endosomal biology in a way that 
likely interfered with cell survival. Despite its requirement for ultimate 
intramembrane cleavage in CD74 metabolism, SPPL2A seemed disconnected from 
the classical sequence of endosomal CD74 degradation steps, as p8-CD74 production 
did neither require penultimate processing by Cathepsin S nor MHCII-chaperoning. 
p8-CD74 accumulation occurred already at the immature B cell stage in SPPL2A-
deficient mice, which was before Cathepsin S mediated CD74 processing was 
required during B cell development. 
 
Out of other CD74-expressing immune cells, only CD8- DCs required p8-CD74 
cleavage by SPPL2A for their survival. CD8+ DCs and pDCs accumulated increased 
CD74-protein levels, but persisted in normal numbers, whilst macrophage and 
monocyte lineage cells were present at normal proportions. CD8- DCs showed 
greater surface levels of MHCII, whilst CD8+ DCs were characterised by an MHCII-
chaperoning dependent 10-fold increase of full length CD74 molecules on the cell 
surface, which highlighted differences in the wiring of MHCII and CD74 trafficking 
responses from these DC subsets. Functionally, SPPL2A-inactivation inhibited the 
ability of spleen DCs to present endocytosed antigen on MHC class II molecules to 
CD4+ T cells, whilst cross-presentation of exogenous antigen on MHC class I to 
could still induce proliferation of antigen specific CD8+ T cells. 
 
Besides providing new insights for developing B cells and DCs, this project 
unusually links the fields of CD74 controlled antigen presentation with, proteolysis, 
quality control and turnover mechanisms for endosmal membrane proteins, endo-
lysosomal biology and intracellular trafficking, possibly offering a model for rare 
membrane protein storage disorders. After the discovery of SPPL2A and CD74 
metabolism as important factors for humoral immunity, APC survival and endosomal 
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integrity in mice, future will show whether these factors may serve as previously 
unknown causes for immunodeficiency or as avenues for disease treatments in 
humans. 
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